No O
significant O
correlations O
were O
found O
between O
tumor B
beta I
2 I
- I
M I
expression O
and O
several O
histologic O
attributes O
such O
as O
type O
, O
histologic O
and O
nuclear O
grades O
, O
mitotic O
index O
, O
necrosis O
, O
vascular O
invasion O
, O
and O
lymphocytic O
infiltration O
. O

However O
, O
there O
was O
a O
significantly O
positive O
association O
between O
tumor B
beta I
2 I
- I
M I
expression O
and O
the O
degree O
of O
lymphocytic O
infiltration O
in O
the O
tumor O
tissue O
. O

Although O
some O
of O
the O
highest O
values O
had O
been O
obtained O
in O
women O
with O
larger O
( O
T4 O
) O
primary O
tumors O
, O
the O
authors O
failed O
to O
detect O
any O
statistical O
relationship O
between O
beta O
2 O
- O
M O
expression O
in O
the O
tumor O
with O
serum O
levels O
or O
between O
serum B
beta I
2 I
- I
M I
and O
the O
above O
histologic O
, O
laboratory O
, O
and O
clinical O
factors O
. O

[ O
Preliminary O
observation O
of O
level O
free B
- I
form I
E I
receptor I
levels O
in O
serum O
of O
normal O
childbearing O
- O
aged O
and O
pregnant O
women O
] O

In O
137 O
cases O
of O
childbearing O
- O
aged O
and O
pregnant O
women O
, O
free B
form I
E I
receptor I
levels O
( O
sE O
) O
in O
serum O
were O
measured O
by O
ELISA O
. O

Transcriptional O
activation O
of O
the O
human O
interleukin O
- O
2 O
( O
IL O
- O
2 O
) O
gene O
, O
like O
induction O
of O
the O
IL O
- O
2 O
receptor O
alpha O
( O
IL O
- O
2R O
alpha O
) O
gene O
and O
the O
type O
1 O
human O
immunodeficiency O
virus O
( O
HIV O
- O
1 O
) O
, O
is O
shown O
to O
be O
modulated O
by O
a O
kappa B
B I
- I
like I
enhancer I
element I
. O

Mutation O
of O
a O
kappa B
B I
core I
sequence I
identified O
in O
the O
IL O
- O
2 O
promoter O
( O
- O
206 O
to O
- O
195 O
) O
partially O
inhibits O
both O
mitogen O
- O
and O
HTLV O
- O
I O
Tax O
- O
mediated O
activation O
of O
this O
transcription O
unit O
and O
blocks O
the O
specific O
binding O
of O
two O
inducible B
cellular I
factors I
. O

These O
kappa B
B I
- I
specific I
proteins I
( O
80 O
to O
90 O
and O
50 O
to O
55 O
kilodaltons O
) O
similarly O
interact O
with O
the O
functional O
kappa O
B O
enhancer O
present O
in O
the O
IL O
- O
2R O
alpha O
promoter O
. O

These O
data O
suggest O
that O
these O
kappa B
B I
- I
specific I
proteins I
have O
a O
role O
in O
the O
coordinate O
regulation O
of O
this O
growth O
factor O
- O
growth O
factor O
receptor O
gene O
system O
that O
controls O
T O
cell O
proliferation O
. O

Novel O
region O
within O
the O
V B
kappa I
gene I
promoter I
is O
responsible O
for O
tissue O
and O
stage O
- O
specific O
expression O
of O
immunoglobulin O
genes O
in O
human O
lymphoid O
neoplasms O
. O

Immunoglobulin B
gene I
- I
specific I
transacting I
factors I
have O
been O
shown O
to O
play O
a O
role O
in O
lymphoid O
tissue O
- O
specific O
expression O
of O
immunoglobulin O
genes O
. O

Different O
fragments O
of O
unrearranged B
human I
variable I
region I
of O
immunoglobulin B
kappa I
gene I
( O
V B
kappa I
) O
were O
used O
for O
cell O
- O
free O
in O
vitro O
transcription O
and O
DNA O
mobility O
shift O
assays O
. O

Previously O
described O
enhancement O
of O
in O
vitro O
transcription O
that O
was O
only O
seen O
with O
nuclear O
extracts O
derived O
from O
B O
- O
cell O
neoplasms O
corresponding O
to O
the O
late O
stages O
of O
B O
- O
cell O
differentiation O
was O
shown O
to O
be O
dependent O
on O
the O
actions O
of O
these O
factor O
( O
s O
) O
on O
the O
DNA O
region O
within O
the O
V B
kappa I
gene I
promoter I
. O

[ O
Determination O
of O
the O
sensitivity O
to O
glucocorticoids B
in O
vitro O
] O

The O
principal O
distinction O
of O
the O
method O
is O
standardization O
by O
the O
lymphocyte O
count O
in O
a O
sample O
( O
1 O
mln O
) O
and O
the O
labeled O
hormone B
concentration O
. O

Examinations O
of O
70 O
children O
aged O
4 O
to O
15 O
suffering O
from O
the O
nephrotic O
form O
of O
glomerulonephritis O
have O
made O
it O
possible O
to O
distinguish O
two O
groups O
of O
patients O
: O
with O
relatively O
high O
values O
of O
specific O
binding O
X O
= O
6820 O
. O
1 O
+ O
/ O
- O
530 O
. O
0 O
( O
n O
= O
30 O
, O
p O
= O
0 O
. O
95 O
, O
t O
= O
2 O
. O
04 O
) O
, O
this O
corresponding O
to O
a O
clinical O
form O
of O
hormone B
- O
sensitive O
glomerulonephritis O
, O
and O
with O
relatively O
low O
values O
of O
specific O
binding O
X O
= O
1815 O
. O
2 O
+ O
/ O
- O
302 O
. O
8 O
( O
n O
= O
40 O
, O
p O
= O
0 O
. O
95 O
, O
t O
= O
1 O
. O
96 O

) O
, O
that O
corresponds O
to O
hormone B
- O
resistant O
glomerulonephritis O
. O

These O
results O
permit O
regarding O
the O
specific O
binding O
value O
as O
a O
prognostic O
criterion O
in O
the O
assessment O
of O
corticosteroid B
therapy O
; O
this O
allows O
a O
wide O
employment O
of O
the O
described O
method O
in O
practical O
nephrology O
. O

The O
B O
- O
cell O
- O
type O
specificity O
of O
the O
immunoglobulin O
( O
Ig O
) O
heavy O
- O
chain O
and O
light O
- O
chain O
promoters O
is O
mediated O
by O
an O
octanucleotide B
( I
OCTA I
) I
element I
, O
ATGCAAAT O
, O
that O
is O
also O
a O
functional O
component O
of O
other O
RNA O
polymerase O
II O
promoters O
, O
such O
as O
snRNA O
and O
histone O
H2B O
promoters O
. O

Two O
nuclear O
proteins O
that O
bind O
specifically O
and O
with O
high O
affinity O
to O
the O
OCTA B
element I
have O
been O
identified O
. O

NF B
- I
A1 I
is O
present O
in O
a O
variety O
of O
cell O
types O
, O
whereas O
the O
presence O
of O
NF B
- I
A2 I
is O
essentially O
confined O
to O
B O
cells O
, O
leading O
to O
the O
hypothesis O
that O
NF B
- I
A2 I
activates O
cell O
- O
type O
- O
specific O
transcription O
of O
the O
Ig B
promoter I
and O
NF B
- I
A1 I
mediates O
the O
other O
responses O
of O
the O
OCTA B
element I
. O

Extracts O
of O
the O
B O
- O
cell O
line O
, O
BJA O
- O
B O
, O
contain O
high O
levels O
of O
NF B
- I
A2 I
and O
specifically O
transcribe O
Ig B
promoters I
. O

In O
contrast O
, O
extracts O
from O
HeLa O
cells O
transcribed O
the O
Ig B
promoter I
poorly O
. O

Surprisingly O
, O
addition O
of O
either O
affinity O
- O
enriched O
NF O
- O
A2 O
or O
NF O
- O
A1 O
to O
either O
a O
HeLa O
extract O
or O
a O
partially O
purified O
reaction O
system O
specifically O
stimulates O
the O
Ig B
promoter I
. O

This O
suggests O
that O
the O
constitutive O
OCTA B
- I
binding I
factor I
NF I
- I
A1 I
can O
activate O
transcription O
of O
the O
Ig B
promoter I
and O
that O
B O
- O
cell O
- O
specific O
transcription O
of O
this O
promoter O
, O
at O
least O
in O
vitro O
, O
is O
partially O
due O
to O
a O
quantitative O
difference O
in O
the O
amount O
of O
OCTA B
- I
binding I
protein I
. O

Because O
NF B
- I
A1 I
can O
stimulate O
Ig O
transcription O
, O
the O
inability O
of O
this O
factor O
to O
activate O
in O
vivo O
the O
Ig B
promoter I
to O
the O
same O
degree O
as O
the O
snRNA B
promoters I
probably O
reflects O
a O
difference O
in O
the O
context O
of O
the O
OCTA B
element I
in O
these O
two O
types O
of O
promoters O
. O

Identification O
of O
a O
putative O
regulator O
of O
early B
T I
cell I
activation I
genes I
. O

Molecules O
involved O
in O
the O
antigen O
receptor O
- O
dependent O
regulation O
of O
early B
T I
cell I
activation I
genes I
were O
investigated O
with O
the O
use O
of O
functional O
sequences O
of O
the O
T B
cell I
activation I
- I
specific I
enhancer I
of O
interleukin O
- O
2 O
( O
IL O
- O
2 O
) O
. O

As O
a O
first O
step O
towards O
understanding O
the O
mechanism O
of O
thyroid O
hormone O
action O
in O
man O
we O
have O
characterized O
T3 B
binding I
sites I
in O
nuclei O
of O
the O
human O
lymphoblastoid O
line O
, O
IM O
- O
9 O
cells O
. O

In O
whole O
cell O
experiments O
at O
37 O
degrees O
C O
, O
nuclear O
binding O
of O
[ B
125I I
] I
T3 I
was O
saturable O
( O
Kd O
34 O
+ O
/ O
- O
6 O
pmol O
/ O
l O
) O
and O
of O
finite O
capacity O
( O
approximately O
equal O
to O
350 O
sites O
/ O
cell O
) O
. O

Separation O
of O
bound O
from O
free O
[ B
125I I
] I
T3 I
in O
the O
extracts O
was O
achieved O
using O
the O
calcium O
phosphate O
matrix O
, O
hydroxyapatite O
at O
a O
concentration O
of O
0 O
. O
3 O
ml O
of O
a O
150 O
g O
/ O
l O
slurry O
. O

Under O
these O
conditions O
T3 B
binding I
sites I
in O
the O
nuclear O
extracts O
were O
present O
at O
a O
concentration O
of O
22 O
. O
4 O
+ O
/ O
- O
8 O
. O
6 O
fmol O
/ O
mg O
protein O
and O
showed O
an O
affinity O
of O
( O
Kd O
, O
room O
temperature O
) O
140 O
+ O
/ O
- O
10 O
pmol O
/ O
l O
. O

These O
results O
suggest O
that O
the O
T3 B
binding I
sites I
present O
in O
human O
IM O
- O
9 O
lymphocyte O
nuclei O
and O
extracts O
thereof O
are O
thyroid O
hormone O
receptors O
. O

Definition O
of O
T B
- I
cell I
specific I
DNA I
- I
binding I
factors I
that O
interact O
with O
a O
3 B
' I
- I
silencer I
in O
the O
CD4 B
+ I
T I
- I
cell I
gene I
Rpt I
- I
1 I
. O

Analysis O
of O
the O
region O
3 O
' O
to O
the O
CD4 B
+ I
T I
- I
cell I
gene I
Rpt I
- I
1 I
( O
encoding O
regulatory O
protein O
T B
- I
lymphocyte I
1 I
) O
led O
to O
the O
definition O
of O
a O
silencer B
element I
that O
inhibits O
heterologous O
gene O
expression O
in O
certain O
CD4 O
+ O
T O
- O
cell O
lines O
but O
not O
in O
B O
- O
cell O
or O
non O
- O
lymphoid O
cell O
lines O
. O

Functional O
silencer O
activity O
in O
vivo O
was O
associated O
with O
the O
presence O
of O
a O
specific O
silencer B
- I
DNA I
- I
protein I
complex I
in O
electrophoretic O
mobility O
shift O
assays O
with O
T O
- O
cell O
extracts O
. O

Formation O
of O
this O
complex O
was O
selectively O
inhibited O
by O
the O
region O
in O
HIV B
- I
1 I
containing O
a O
silencer B
element I
. O

We O
discuss O
the O
possibility O
that O
DNA B
- I
binding I
factors I
may O
coregulate O
HIV O
- O
1 O
and O
Rpt O
- O
1 O
gene O
expression O
through O
a O
common O
transcriptional B
silencer I
element I
. O

Coordinate O
regulation O
of O
HLA B
class I
II I
gene I
expression O
during O
development O
and O
coinduction O
of O
class O
II O
genes O
by O
soluble O
factors O
suggests O
that O
common O
trans O
- O
acting O
factor O
( O
s O
) O
control O
expression O
of O
these O
genes O
. O

Further O
studies O
show O
that O
genes O
governing O
the O
expression O
of O
class B
II I
antigens I
fall O
into O
at O
least O
three O
complementation O
groups O
; O
two O
of O
these O
were O
previously O
unidentified O
in O
mutant O
cell O
lines O
generated O
in O
vitro O
. O

In O
addition O
, O
we O
report O
the O
identification O
of O
two O
discrete O
complexes O
, O
NFX1 B
. I
1 I
and O
NFX1 B
. I
2 I
, O
that O
bind O
to O
the O
DRA B
X I
consensus I
element I
. O

Though O
the O
mutation O
in O
at O
least O
one O
mutant O
line O
generated O
in O
vitro O
( O
RJ2 O
. O
2 O
. O
5 O
) O
affects O
products O
functioning O
via O
interaction O
with O
the O
X O
box O
, O
clear O
alterations O
in O
either O
NFX1 B
. I
1 I
or O
NFX1 B
. I
2 I
are O
not O
found O
in O
any O
of O
the O
mutant O
cell O
lines O
. O

Estradiol B
receptors I
in O
the O
cytosol O
of O
peripheral O
blood O
mononuclear O
cells O
and O
the O
effects O
of O
interferon O
- O
alpha O
( O
IFN O
- O
alpha O
) O
on O
estradiol B
receptors I
were O
studied O
in O
asymptomatic O
hepatitis O
B O
virus O
( O
HBV O
) O
carriers O
, O
patients O
with O
chronic O
hepatitis O
B O
and O
normal O
controls O
. O

The O
level O
of O
estradiol B
receptors I
in O
the O
cytosol O
of O
mononuclear O
cells O
was O
significantly O
lower O
in O
asymptomatic O
HBV O
carriers O
and O
patients O
with O
chronic O
hepatitis O
B O
, O
compared O
to O
normal O
controls O
. O

This O
low O
level O
of O
cytosol O
estradiol B
receptors I
in O
patients O
with O
chronic O
hepatitis O
B O
was O
increased O
by O
the O
administration O
of O
IFN O
- O
alpha O
. O

In O
addition O
, O
when O
peripheral O
blood O
mononuclear O
cells O
from O
patients O
with O
chronic O
hepatitis O
B O
were O
incubated O
with O
IFN O
- O
alpha O
in O
vitro O
, O
the O
level O
of O
cytosol O
estradiol B
receptors I
also O
increased O
by O
increasing O
the O
concentration O
of O
IFN O
- O
alpha O
. O

We O
previously O
reported O
that O
the O
response O
of O
mononuclear O
cells O
to O
estrogen O
is O
impaired O
in O
HBV O
carriers O
, O
and O
our O
present O
results O
suggested O
that O
this O
may O
be O
due O
to O
the O
low O
level O
of O
estradiol B
receptors I
in O
the O
cytosol O
of O
mononuclear O
cells O
. O

The O
thermal O
stability O
of O
GR O
and O
thermal O
activation O
of O
cytosolic B
receptors I
in O
both O
patients O
were O
found O
to O
be O
normal O
. O

Octamer O
transcription O
factors O
1 O
and O
2 O
each O
bind O
to O
two O
different O
functional B
elements I
in O
the O
immunoglobulin O
heavy O
- O
chain O
promoter O
. O

Immunoglobulin B
heavy I
- I
chain I
genes I
contain O
two O
conserved B
sequence I
elements I
5 O
' O
to O
the O
site O
of O
transcription O
initiation O
: O
the O
octamer O
ATGCAAAT O
and O
the O
heptamer O
CTCATGA O
. O

Both O
of O
these O
elements O
are O
required O
for O
normal B
cell I
- I
specific I
promoter I
function O
. O

The O
present O
study O
demonstrates O
that O
both O
the O
ubiquitous B
and I
lymphoid I
- I
cell I
- I
specific I
octamer I
transcription I
factors I
( O
OTF O
- O
1 O
and O
OTF O
- O
2 O
, O
respectively O
) O
interact O
specifically O
with O
each O
of O
the O
two O
conserved B
sequence I
elements I
, O
forming O
either O
homo B
- I
or I
heterodimeric I
complexes I
. O

However O
, O
OTF B
interaction O
with O
the O
heptamer B
sequence I
appeared O
to O
require O
the O
presence O
of O
an O
intact O
octamer O
motif O
and O
occurred O
with O
a O
spacing O
of O
either O
2 B
or I
14 I
base I
pairs I
between O
the O
two O
elements O
, O
suggesting O
coordinate O
binding O
resulting O
from O
protein O
- O
protein O
interactions O
. O

Identification O
of O
a O
novel O
lymphoid B
specific I
octamer I
binding I
protein I
( O
OTF B
- I
2B I
) O
by O
proteolytic O
clipping O
bandshift O
assay O
( O
PCBA O
) O
. O

The O
octamer O
sequence O
ATGCAAAT O
is O
found O
in O
the O
promoters O
of O
immunoglobulin B
( I
Ig I
) I
heavy I
and I
light I
chain I
genes I
and O
in O
the O
heavy B
chain I
enhancer I
and O
is O
a O
major O
determinant O
of O
the O
cell O
type O
specific O
expression O
of O
Ig O
genes O
in O
B O
cells O
. O

An O
apparent O
paradox O
is O
that O
the O
same O
sequence O
serves O
as O
an O
upstream B
promoter I
or I
enhancer I
element I
in O
a O
variety O
of O
housekeeping O
genes O
such O
as O
the O
histone B
H2B I
and I
U I
snRNA I
genes I
. O

The O
lymphoid B
cell I
specific I
octamer I
binding I
protein I
of O
60 O
kd O
( O
OTF B
- I
2A I
) O
specifically O
stimulates O
Ig B
promoters I
which O
consist O
essentially O
of O
a O
TATA O
- O
box O
and O
an O
octamer O
sequence O
upstream O
of O
it O
. O

Here O
we O
present O
evidence O
for O
yet O
another O
B B
cell I
specific I
octamer I
binding I
protein I
of O
75 O
kd O
( O
OTF B
- I
2B I
) O
. O

From O
several O
findings O
, O
including O
the O
absence O
of O
OTF B
- I
2B I
( O
but O
not O
OTF B
- I
2A I
) O
from O
a O
lymphocyte O
line O
that O
can O
not O
respond O
to O
the O
IgH O
enhancer O
, O
we O
propose O
a O
role O
of O
the O
novel B
octamer I
factor I
in O
the O
long O
range O
activation O
by O
the O
IgH O
enhancer O
. O

This O
analysis O
indicates O
that O
the O
75 O
kd O
- O
species O
OTF B
- I
2B I
is O
closely O
related O
to O
the O
60 B
kd I
species I
OTF I
- I
2A I
. O

A O
complete O
inhibition O
of O
DNA O
synthesis O
by O
dexamethasone O
( O
Dx O
) O
could O
be O
observed O
when O
IL O
2 O
- O
depleted O
cultures O
of O
CTL O
were O
either O
incubated O
for O
6 O
h O
with O
the O
hormone B
prior O
to O
the O
addition O
of O
IL O
2 O
or O
treated O
simultaneously O
with O
Dx O
and O
a O
low O
concentration O
of O
IL O
2 O
. O

The O
action O
of O
these O
hormones B
possibly O
involves O
the O
synthesis O
of O
an O
inhibitory O
protein O
( O
s O
) O
, O
since O
the O
presence O
of O
cycloheximide O
during O
the O
incubation O
with O
Dx O
prevented O
the O
inhibition O
of O
DNA O
synthesis O
. O

Our O
results O
indicate O
that O
these O
hormones B
may O
also O
affect O
T O
cell O
proliferation O
by O
inhibiting O
IL O
2 O
activity O
. O

Identification O
and O
purification O
of O
a O
human B
immunoglobulin I
- I
enhancer I
- I
binding I
protein I
( O
NF O
- O
kappa O
B O
) O
that O
activates O
transcription O
from O
a O
human B
immunodeficiency I
virus I
type I
1 I
promoter I
in O
vitro O
. O

The O
enhancer B
- I
binding I
factor I
NF I
- I
kappa I
B I
, O
which O
is O
found O
only O
in O
cells O
that O
transcribe O
immunoglobulin B
light I
chain I
genes I
, O
has O
been O
purified O
from O
nuclear O
extracts O
of O
Namalwa O
cells O
( O
human O
Burkitt O
lymphoma O
cells O
) O
by O
sequence O
- O
specific O
DNA O
affinity O
chromatography O
. O

The O
purified O
NF O
- O
kappa O
B O
has O
been O
identified O
as O
a O
51 B
- I
kDa I
polypeptide I
by O
UV O
- O
crosslinking O
analysis O
. O

` O
` O
Footprint O
' O
' O
and O
methylation O
- O
interference O
analyses O
have O
shown O
that O
purified O
NF O
- O
kappa O
B O
has O
a O
binding O
activity O
specific O
for O
the O
kappa B
light I
chain I
enhancer I
sequence I
. O

The O
purified O
factor O
activated O
in O
vitro O
transcription O
of O
the O
human B
immunodeficiency I
virus I
type I
I I
promoter I
by O
binding O
to O
an O
upstream O
NF O
- O
kappa O
B O
- O
binding O
site O

Lymphocyte O
glucocorticoid B
receptor I
binding O
in O
depression O
: O
normal O
values O
following O
recovery O
. O

Identification O
and O
purification O
of O
a O
human B
lymphoid I
- I
specific I
octamer I
- I
binding I
protein I
( O
OTF O
- O
2 O
) O
that O
activates O
transcription O
of O
an O
immunoglobulin O
promoter O
in O
vitro O
. O

The O
octamer O
sequence O
5 O
' O
- O
ATGCAAAT O
, O
in O
either O
orientation O
, O
serves O
as O
an O
upstream B
element I
in O
a O
variety O
of O
promoters O
and O
also O
occurs O
as O
a O
modular B
enhancer I
element I
. O

It O
is O
of O
particular O
interest O
in O
immunoglobulin O
genes O
since O
it O
is O
found O
in O
the O
upstream B
regions I
of O
all O
heavy B
and I
light I
chain I
promoters I
and O
in O
the O
heavy B
chain I
enhancer I
, O
both O
of O
which O
are O
known O
to O
be O
necessary O
for O
cell O
- O
specific O
expression O
. O

We O
report O
here O
the O
chromatographic O
separation O
of O
ubiquitous B
and I
B I
cell I
- I
specific I
octamer I
- I
binding I
proteins I
. O

The O
specific O
DNA O
binding O
activity O
of O
the O
pure O
B O
cell O
- O
specific O
factor O
was O
indistinguishable O
from O
that O
of O
the O
affinity B
- I
purified I
ubiquitous I
factor I
. O

This O
B B
cell I
- I
specific I
octamer I
- I
binding I
factor I
, O
in O
pure O
form O
, O
activated O
transcription O
from O
a O
kappa B
light I
chain I
promoter I
in O
vitro O
, O
thus O
demonstrating O
that O
it O
is O
indeed O
a O
B O
cell O
- O
specific O
transcription O
factor O
for O
this O
gene O
. O

In O
addition O
to O
the O
ubiquitous B
and I
B I
cell I
- I
specific I
octamer I
- I
binding I
factors I
, O
we O
identified O
several O
additional O
proteins O
, O
one O
of O
which O
is O
B O
cell O
- O
specific O
, O
that O
interact O
with O
the O
kappa B
promoter I
. O

Decreased O
deoxyribonucleic O
acid O
binding O
of O
glucocorticoid B
- I
receptor I
complex I
in O
cultured O
skin O
fibroblasts O
from O
a O
patient O
with O
the O
glucocorticoid O
resistance O
syndrome O
. O

DNA O
binding O
of O
the O
GR B
complex I
after O
temperature O
- O
induced O
activation O
was O
lower O
in O
the O
patient O
than O
in O
normal O
subjects O
. O

Nuclear O
translocation O
of O
GR B
complexes I
from O
the O
patient O
was O
also O
slightly O
decreased O
. O

These O
results O
suggest O
that O
the O
patient O
' O
s O
glucocorticoid O
resistance O
was O
due O
to O
a O
decrease O
in O
the O
affinity O
of O
the O
receptor O
for O
glucocorticoids O
and O
a O
decrease O
in O
the O
binding O
of O
the O
GR B
complex I
to O
DNA O
. O

We O
show O
that O
1 O
, O
25 O
- O
dihydroxyvitamin O
D3 O
( O
1 O
, O
25 O
[ O
OH O
] O
2D3 O
) O
, O
the O
most O
hormonally O
active O
metabolite O
of O
vitamin O
D3 O
, O
modulates O
sensitively O
and O
specifically O
both O
the O
protein O
and O
messenger O
RNA O
accumulation O
of O
the O
multilineage B
growth I
factor I
granulocyte O
- O
macrophage O
colony O
- O
stimulating O
factor O
( O
GM O
- O
CSF O
) O
. O

In O
contrast O
, O
cells O
from O
a O
HTLV O
- O
1 O
transformed O
T O
lymphocyte O
line O
( O
Ab O
- O
VDR O
) O
established O
from O
a O
patient O
with O
vitamin O
D O
- O
resistant O
rickets O
type O
II O
with O
undetectable O
1 B
, I
25 I
( I
OH I
) I
2D3 I
cellular I
receptors I
are O
resistant O
to O
the O
action O
of O
1 O
, O
25 O
( O
OH O
) O
2D3 O
. O

Inhibition O
of O
GM O
- O
CSF O
expression O
by O
1 O
, O
25 O
( O
OH O
) O
2D3 O
can O
occur O
independently O
of O
interleukin O
2 O
regulation O
and O
is O
probably O
mediated O
through O
cellular B
1 I
, I
25 I
( I
OH I
) I
2D3 I
receptors I
. O

Treatment O
of O
NK O
effectors O
with O
a O
monoclonal B
anti I
- I
human I
corticosteroid I
- I
binding I
globulin I
( I
CBG I
) I
antibody I
produced O
an O
enhancement O
of O
the O
spontaneous O
NK O
activity O
and O
a O
partial O
suppression O
of O
cortisol O
- O
mediated O
effects O
. O

Since O
the O
effect O
of O
cortisol O
was O
additive O
to O
that O
of O
PgE2 O
and O
was O
not O
changed O
by O
phosphodiesterase B
inhibitors O
, O
it O
is O
conceivable O
that O
the O
hormone O
acts O
at O
a O
level O
different O
from O
the O
adenylate O
cyclase O
- O
phosphodiesterase B
system O
. O

Data O
obtained O
with O
the O
use O
of O
antiglucocorticoids O
and O
the O
anti B
- I
CBG I
antibody I
are O
compatible O
with O
a O
role O
both O
of O
high O
- O
affinity O
glucocorticoid O
receptors O
and O
of O
CBG B
in O
mediating O
cortisol O
action O
on O
the O
human O
NK O
cell O
activity O
. O

Interaction O
of O
cell B
- I
type I
- I
specific I
nuclear I
proteins I
with O
immunoglobulin B
VH I
promoter I
region I
sequences I
. O

All O
human B
and I
murine I
immunoglobulin I
heavy I
chain I
variable I
region I
( I
VH I
) I
genes I
contain O
the O
sequence O
ATGCAAAT O
approximately O
70 O
nucleotides O
5 O
' O
from O
the O
site O
of O
transcription O
initiation O
. O

This O
octanucleotide O
, O
in O
reverse O
orientation O
, O
is O
also O
found O
in O
all O
light B
chain I
variable I
region I
( I
VL I
) I
genes I
, O
and O
in O
the O
immunoglobulin B
heavy I
chain I
transcriptional I
enhancer I
. O

Octamer B
- I
containing I
fragments I
have O
been O
reported O
to O
bind O
a O
factor O
present O
in O
nuclear O
extracts O
of O
human O
cell O
lines O
; O
however O
, O
identical O
binding O
activity O
was O
detected O
in O
both O
B O
lymphoid O
and O
non O
- O
lymphoid O
cells O
. O

Here O
we O
establish O
that O
nuclear O
extracts O
from O
distinct O
cell O
types O
differ O
in O
their O
ability O
to O
interact O
with O
octamer B
- I
containing I
fragments I
. O

Preferential O
transcription O
of O
HTLV O
- O
I O
LTR O
in O
cell O
- O
free O
extracts O
of O
human O
T O
cells O
producing O
HTLV B
- I
I I
viral I
proteins I
. O

The O
promoters O
of O
the O
adenovirus B
2 I
major I
late I
gene I
, O
the O
mouse B
beta I
- I
globin I
gene I
, O
the O
mouse B
immunoglobulin I
VH I
gene I
and O
the O
LTR O
of O
the O
human O
T O
- O
lymphotropic O
retrovirus O
type O
I O
were O
tested O
for O
their O
transcription O
activities O
in O
cell O
- O
free O
extracts O
of O
four O
cell O
lines O
; O
HeLa O
, O
CESS O
( O
Epstein O
- O
Barr O
virus O
- O
transformed O
human O
B O
cell O
line O
) O
, O
MT O
- O
1 O
( O
HTLV O
- O
I O
- O
infected O
human O
T O
cell O
line O
without O
viral O
protein O
synthesis O
) O
, O
and O
MT O
- O
2 O
( O
HTLV O
- O
I O
- O
infected O
human O

A O
nuclear O
factor O
that O
binds O
to O
a O
conserved O
sequence O
motif O
in O
transcriptional B
control I
elements I
of O
immunoglobulin O
genes O
. O

Trans O
- O
acting O
factors O
that O
mediate O
B O
- O
cell O
specific O
transcription O
of O
immunoglobulin O
genes O
have O
been O
postulated O
based O
on O
an O
analysis O
of O
the O
expression O
of O
exogenously O
introduced O
immunoglobulin B
gene I
recombinants I
in O
lymphoid O
and O
non O
- O
lymphoid O
cells O
. O

Two O
B O
- O
cell O
- O
specific O
, O
cis B
- I
acting I
transcriptional I
regulatory I
elements I
have O
been O
identified O
. O

One O
element O
is O
located O
in O
the O
intron O
between O
the O
variable O
( O
V O
) O
and O
constant O
( O
C O
) O
regions O
of O
both O
heavy B
and I
kappa I
light I
- I
chain I
genes I
and O
acts O
as O
a O
transcriptional O
enhancer O
. O

The O
second O
element O
is O
found O
upstream O
of O
both O
heavy B
and I
kappa I
light I
- I
chain I
gene I
promoters I
. O

This O
element O
directs O
lymphoid O
- O
specific O
transcription O
even O
in O
the O
presence O
of O
viral B
enhancers I
. O

We O
report O
here O
the O
identification O
of O
a O
human B
B I
- I
cell I
nuclear I
factor I
( O
IgNF B
- I
A I
) O
that O
binds O
to O
DNA O
sequences O
in O
the O
upstream B
regions I
of O
both O
the O
mouse B
heavy I
and I
kappa I
light I
- I
chain I
gene I
promoters I
and O
also O
to O
the O
mouse B
heavy I
- I
chain I
gene I
enhancer I
. O

This O
sequence O
- O
specific O
binding O
is O
probably O
mediated O
by O
a O
highly O
conserved O
sequence O
motif O
, O
ATTTGCAT O
, O
present O
in O
all O
three O
transcriptional B
elements I
. O

Interestingly O
, O
a O
factor O
showing O
similar O
binding O
specificity O
to O
IgNF B
- I
A I
is O
also O
present O
in O
human O
HeLa O
cells O
. O

The O
ratios O
of O
nuclear O
to O
cytosolic B
hormone I
- I
receptor I
- I
complexes I
and O
of O
cytosolic O
activated O
to O
unactivated B
receptor I
complexes I
in O
intact O
cells O
are O
similar O
to O
Old O
World O
primates O
. O

Thus O
, O
unlike O
Old O
World O
primates O
, O
cortisol O
in O
New O
World O
primates O
has O
only O
weak O
sodium O
- O
retaining O
potency O
because O
the O
aldosterone B
receptor I
has O
a O
low O
affinity O
for O
cortisol O
. O

We O
conclude O
that O
contact O
with O
fibrinogen B
- I
derived I
proteins I
may O
contribute O
to O
mononuclear O
phagocyte O
activation O
by O
signaling O
through O
CD11b O
/ O
CD18 O
, O
resulting O
in O
selective O
activation O
of O
transcriptional O
regulatory O
factors O
, O
including O
NF O
- O
kappa O
B O
. O

OBJECTIVE O
: O
To O
identify O
and O
characterize O
estrogen B
receptor I
( I
ER I
) I
transcripts I
expressed O
in O
immune O
cells O
of O
patients O
with O
systemic O
lupus O
erythematosus O
( O
SLE O
) O
and O
healthy O
donors O
. O

There O
were O
no O
notable O
differences O
in O
the O
ER B
transcripts I
between O
patients O
and O
healthy O
controls O
. O

Whether O
the O
detected O
transcripts O
are O
translated O
into O
functional B
receptor I
proteins I
remains O
to O
be O
determined O
. O

We O
report O
that O
activation O
of O
the O
two O
transcription B
factors I
NF I
- I
kappa I
B I
and I
AP I
- I
1 I
is O
crucially O
involved O
in O
FasL O
expression O
induced O
by O
etoposide O
, O
teniposide O
, O
and O
UV O
irradiation O
. O

A O
nondegradable B
mutant I
of O
I O
kappa O
B O
blocked O
both O
FasL O
expression O
and O
apoptosis O
induced O
by O
DNA O
damage O
but O
not O
Fas O
ligation O
. O

Mutations O
in O
the O
relevant O
NF B
- I
kappa I
B I
and I
AP I
- I
1 I
binding I
sites I
eliminated O
these O
responses O
. O

Minimal O
residual O
disease O
in O
acute O
myelogenous O
leukemia O
with O
PML O
/ O
RAR O
alpha O
or O
AML1 B
/ I
ETO I
mRNA I
and O
phenotypic O
analysis O
of O
possible O
T O
and O
natural O
killer O
cells O
in O
bone O
marrow O
. O

The O
implication O
of O
protein B
tyrosine I
kinase I
( I
s I
) I
, O
protein O
kinase O
A O
and O
/ O
or O
protein O
kinase O
C O
was O
highlighted O
by O
the O
abrogation O
of O
the O
ManLAM O
- O
mediated O
activation O
of O
HIV O
- O
1 O
LTR O
- O
driven O
gene O
expression O
using O
herbimycin O
A O
and O
H7 O
. O

In O
particular O
, O
naturally O
occurring O
sequence O
variation O
impacted O
transcription O
factor O
binding O
to O
an O
activating B
transcription I
factor I
/ O
cAMP B
response I
element I
binding I
( O
ATF O
/ O
CREB O
) O
binding O
site O
( O
located O
between O
the O
LEF O
- O
1 O
and O
distal O
NF O
- O
kappaB O
transcription O
factor O
binding O
sites O
) O
that O
we O
identified O
in O
previous O
studies O
of O
the O
HIV O
- O
1 O
LTR O
. O

HMG B
box I
containing I
transcription I
factors I
in O
lymphocyte O
differentiation O
. O

These O
insights O
in O
the O
molecular O
events O
that O
are O
involved O
in O
TCF B
/ I
LEF I
function O
in O
these O
organisms O
may O
eventually O
lead O
to O
the O
understanding O
of O
the O
function O
of O
these O
HMG O
box O
proteins O
in O
lymphoid O
development O

Transcriptional O
regulation O
by O
C B
/ I
EBP I
alpha I
and I
- I
beta I
in O
the O
expression O
of O
the O
gene O
for O
the O
MRP14 B
myeloid I
calcium I
binding I
protein I
. O

Transcriptional O
regulation O
of O
the O
gene O
for O
the O
myeloid B
calcium I
binding I
protein I
, O
MRP14 O
, O
was O
investigated O
in O
human O
monocytic O
leukemia O
cell O
lines O
. O

The O
MRP14 B
gene I
was O
not O
expressed O
in O
monoblastic O
ML O
- O
1 O
cells O
, O
promonocytic O
U O
- O
937 O
cells O
, O
or O
promyelocytic O
HL O
- O
60 O
cells O
. O

Among O
several O
known O
transcription B
factor I
binding I
motifs I
, O
nuclear B
protein I
( I
s I
) I
of O
VD3 O
- O
treated O
HL O
- O
60 O
cells O
and O
THP O
- O
1 O
cells O
bound O
to O
the O
CCAAT B
/ I
enhancer I
binding I
protein I
( I
C I
/ I
EBP I
) I
- I
binding I
motif I
that O
was O
located O
in O
the O
upstream O
region O
of O
the O
MRP14 B
gene I
( O
- O
81 O
) O
, O
as O
evidenced O
by O
the O
competitive O
gel O
mobility O
- O
shift O
assay O
. O

An O
anti B
- I
C I
/ I
EBP I
delta I
antibody I
had O
no O
effect O
on O
the O
complex O
in O
either O
cell O
. O

Thus O
, O
it O
was O
concluded O
that O
C B
/ I
EBP I
alpha I
and I
- I
beta I
were O
able O
to O
bind O
to O
the O
C O
/ O
EBP O
motif O
, O
and O
that O
C O
/ O
EBP O
alpha O
bound O
to O
the O
motif O
in O
THP O
- O
1 O
cells O
and O
C O
/ O
EBP O
beta O
bound O
to O
that O
in O
the O
VD3 O
- O
treated O
HL O
- O
60 O
cells O
. O

Furthermore O
, O
to O
examine O
the O
transcriptional O
activity O
of O
the O
C O
/ O
EBP O
motif O
, O
we O
transfected O
several O
constructed O
luciferase B
reporter I
DNAs I
into O
HL O
- O
60 O
cells O
and O
THP O
- O
1 O
cells O
. O

The O
C O
/ O
EBP O
motif O
in O
the O
MRP14 B
gene I
was O
confirmed O
to O
function O
as O
a O
regulatory O
region O
in O
VD3 O
- O
treated O
HL O
- O
60 O
cells O
and O
THP O
- O
1 O
cells O
by O
the O
assay O
. O

Appropriate O
sized O
transcripts O
were O
detected O
in O
both O
cultured O
and O
fresh O
peripheral O
lymphocytes O
for O
CYP11A B
, O
CYP17 B
, O
HSD11L B
( O
11beta B
- I
hydroxysteroid I
dehydrogenase I
I I
) O
, O
HSD17B1 B
( O
17beta B
- I
hydroxysteroid I
dehydrogenase I
type I
I I
) O
and O
SRD5A1 B
( O
5alpha B
- I
reductase I
I I
) O
. O

B O
- O
LCL O
, O
but O
not O
T O
and O
B O
cells O
, O
expressed O
CYP11B B
. O

There O
was O
minimal O
expression O
of O
HSD3B1 B
and O
HSD3B2 B
( O
3beta B
- I
hydroxysteroid I
dehydrogenase I
I I
and I
II I
) O
in O
B O
- O
LCL O
and O
T O
cells O
. O

Transcripts O
for O
CYP19 B
and O
HSD11K B
were O
not O
detected O
. O

Corresponding O
enzymatic O
activity O
was O
detectable O
only O
for O
17 B
- I
hydroxysteroid I
dehydrogenase I
and O
5alpha B
- I
reductase I
, O
respectively O
producing O
testosterone O
and O
5alpha O
- O
dihydrotestosterone O
. O

It O
is O
a O
pterin B
4alpha I
- I
carbinolamine I
dehydratase I
that O
is O
involved O
in O
the O
regeneration O
of O
the O
cofactor B
tetrahydrobiopterin I
during O
the O
phenylalanine O
hydroxylase O
- O
catalyzed O
hydroxylation O
of O
phenylalanine O
. O

Deficiencies O
in O
the O
gene O
for O
this O
dual B
functional I
protein I
result O
in O
hyperphenylalaninemi O
. O

Here O
we O
report O
for O
the O
first O
time O
that O
the O
PCD B
/ I
DCoH I
mRNA I
is O
present O
in O
human O
white O
blood O
cells O
and O
hair O
follicles O
. O

Biochemical O
characterization O
of O
the O
NF B
- I
Y I
transcription I
factor I
complex I
during O
B O
lymphocyte O
development O
. O

In O
this O
report O
the O
biochemical O
properties O
of O
the O
heterotrimeric B
NF I
- I
Y I
complex I
have O
been O
characterized O
during O
stage O
- O
specific O
B O
- O
cell O
development O
, O
and O
in O
several O
class O
II O
- O
mutant O
B O
- O
cell O
lines O
, O
which O
represent O
distinct O
bare O
lymphocyte O
syndrome O
class O
II O
genetic O
complementation O
groups O
. O

The O
NF B
- I
Y I
complex I
derived O
from O
class O
II O
+ O
mature O
B O
- O
cells O
bound O
with O
high O
affinity O
to O
anion B
exchangers I
, O
and O
eluted O
as O
an O
intact O
trimeric B
complex I
, O
whereas O
, O
NF O
- O
Y O
derived O
from O
class O
II O
- O
plasma O
B O
- O
cells O
, O
and O
from O
bare O
lymphocyte O
syndrome O
group O
II O
cell O
lines O
, O
RJ2 O
. O
2 O
. O
5 O
and O
RM3 O
, O
dissociated O
into O
discrete O
NF B
- I
YA I
and O
NF B
- I
YB I
: I
C I
subunit B
fractions I
. O

Recombination O
of O
the O
MPC11 B
plasma I
B I
- I
cell I
derived I
NF I
- I
Y I
A I
: I
B I
: I
C I
complex I
with O
the O
low O
molecular O
mass O
protein O
fraction O
, O
NF B
- I
Y I
- I
associated I
factors I
( O
YAFs B
) O
, O
derived O
from O
mature O
A20 O
B O
- O
cell O
nuclei O
, O
conferred O
high O
affinity O
anion O
exchange O
binding O
to O
NF O
- O
Y O
as O
an O
intact B
trimeric I
complex I
. O

Recombination O
of O
the O
native B
NF I
- I
YA I
: I
B I
: I
C I
complex I
with O
the O
transcriptional B
cofactor I
, O
PC4 O
, O
likewise O
conferred O
high B
affinity I
NF I
- I
Y I
binding O
to O
anion B
exchangers I
, O
and O
stabilized O
NF O
- O
Y O
interaction O
with O
CCAAT B
- I
box I
DNA I
motifs I
in O
vitro O
. O

Interaction O
between O
PC4 O
and O
NF O
- O
Y O
was O
mapped O
to O
the O
C O
- O
terminal O
region O
of O
PC4 O
, O
and O
the O
subunit B
interaction I
subdomain I
of O
the O
highly B
conserved I
DNA I
binding I
- I
subunit I
interaction I
domain I
( O
DBD O
) O
of O
NF B
- I
YA I
. O

This O
arrest O
is O
manifested O
at O
a O
molecular O
level O
as O
a O
reduction O
in O
mRNA O
levels O
of O
secretory O
immunoglobulin O
gene O
products O
such O
as O
mu O
( O
s O
) O
and O
J O
chain O
as O
well O
as O
the O
loss O
of O
the O
transcriptional B
regulator I
BLIMP B
- I
1 I
. O

Furthermore O
, O
the O
inhibition O
of O
B O
cell O
differentiation O
by O
CD40 O
engagement O
could O
not O
be O
overcome O
by O
either O
mitogens O
or O
cytokines O
, O
but O
could O
be O
reversed O
by O
antibodies O
that O
interfere O
with O
the O
CD40 O
/ O
gp39 B
interaction O
. O

OBJECTIVE O
: O
Carrier O
identification O
in O
X O
- O
linked O
immunodeficiency O
disorders O
can O
be O
based O
on O
the O
demonstration O
of O
non O
- O
random O
X O
inactivation O
( O
NRXI O
) O
in O
affected O
blood O
cell O
lineages O
when O
growth O
is O
impaired O
in O
cells O
expressing O
the O
abnormal B
gene I
. O

METHODOLOGY O
: O
A O
polymerase O
chain O
reaction O
- O
based O
method O
was O
used O
to O
amplify O
a O
polymorphic O
CAG B
repeat I
in O
the O
first O
exon O
of O
the O
androgen O
receptor O
gene O
after O
selective O
digestion O
of O
the O
active B
X I
chromosome I
with O
a O
methylation B
- I
sensitive I
enzyme I
, O
HpaII B
to O
distinguish O
between O
the O
paternal B
and I
maternal I
alleles I
and O
to O
identify O
their O
methylation O
status O
. O

As O
anticipated O
, O
NRXI O
could O
be O
demonstrated O
in O
all O
lymphoid O
cells O
studied O
from O
obligate O
carriers O
of O
XSCID O
and O
an O
obligate O
carrier O
of O
XLH O
but O
not O
on O
a O
carrier O
of O
X O
- O
linked O
immunodeficiency O
with O
hyper B
- I
IgM I
. O

We O
addressed O
the O
role O
of O
hyperglycemia O
in O
leukocyte O
- O
endothelium O
interaction O
under O
flow O
conditions O
by O
exposing O
human O
umbilical O
vein O
endothelial O
cells O
for O
24 O
h O
to O
normal O
( O
5 O
mM O
) O
, O
high O
concentration O
of O
glucose O
( O
30 O
mM O
) O
, O
advanced O
glycosylation O
end O
product B
- I
albumin I
( O
100 O
microg O
/ O
ml O
) O
, O
or O
hyperglycemic O
( O
174 O
- O
316 O
mg O
/ O
dl O
) O
sera O
from O
patients O
with O
diabetes O
and O
abnormal O
hemoglobin O
A1c O
( O
8 O
. O
1 O
+ O
/ O
- O
1 O
. O
4 O
% O
) O
. O

Functional O
blocking O
of O
E O
- O
selectin O
, O
intercellular B
cell I
adhesion I
molecule I
- I
1 I
, O
and O
vascular O
cell O
adhesion O
molecule O
- O
1 O
on O
endothelial O
cells O
with O
the O
corresponding O
mouse B
mAb I
significantly O
inhibited O
glucose O
- O
induced O
increase O
in O
leukocyte O
adhesion O
( O
67 O
+ O
/ O
- O
16 O
, O
83 O
+ O
/ O
- O
12 O
, O
62 O
+ O
/ O
- O
8 O
versus O
144 O
+ O
/ O
- O
21 O
cells O
/ O
mm2 O
) O
. O

Confocal O
fluorescence O
microscopy O
studies O
showed O
that O
30 O
mM O
glucose O
induced O
an O
increase O
in O
endothelial O
surface O
expression O
of O
E O
- O
selectin O
, O
intercellular B
cell I
adhesion I
molecule I
- I
1 I
, O
and O
vascular O
cell O
adhesion O
molecule O
- O
1 O
. O

Treatment O
of O
HUVEC O
exposed O
to O
high O
glucose O
with O
the O
NF B
- I
kB I
inhibitors I
pyrrolidinedithiocar O
( O
100 O
microM O
) O
and O
tosyl O
- O
phe O
- O
chloromethylketone O
( O
25 O
microM O
) O
significantly O
reduced O
( O
P O
< O
0 O
. O
05 O
) O
leukocyte O
adhesion O
in O
respect O
to O
HUVEC O
treated O
with O
glucose O
alone O
. O

When O
HUVEC O
were O
treated O
with O
specific O
antisense O
oligodesoxynucleotid O
against O
PKCalpha B
and I
PKCepsilon I
isoforms I
before O
the O
addition O
of O
30 O
mM O
glucose O
, O
a O
significant O
( O
P O
< O
0 O
. O
05 O
) O
reduction O
in O
the O
adhesion O
was O
also O
seen O
. O

Advanced O
glycosylation O
end O
product B
- I
albumin I
significantly O
increased O
the O
number O
of O
adhering O
leukocytes O
in O
respect O
to O
native B
albumin I
used O
as O
control O
( O
110 O
+ O
/ O
- O
16 O
versus O
66 O
+ O
/ O
- O
7 O
, O
P O
< O
0 O
. O
01 O
) O
. O

Here O
we O
review O
the O
role O
of O
Ikaros O
, O
the O
founding O
member O
of O
a O
unique O
family O
of O
zinc B
finger I
transcription I
factors I
in O
this O
developmental O
process O
. O

Differences O
in O
the O
phenotypes O
of O
a O
null O
and O
a O
dominant B
negative I
( I
DN I
) I
Ikaros I
mutation I
provide O
insight O
into O
a O
regulatory O
network O
through O
which O
Ikaros O
proteins O
exert O
their O
effects O
in O
development O
. O

In O
addition O
a O
comparative O
analysis O
of O
the O
hemopoietic O
stem O
cell O
and O
precursor O
compartment O
resulting O
from O
the O
two O
Ikaros B
mutations I
reveals O
a O
profound O
yet O
not O
absolute O
requirement O
for O
Ikaros O

Induction O
of O
early B
B I
cell I
factor I
( O
EBF O
) O
and O
multiple B
B I
lineage I
genes I
by O
the O
basic B
helix I
- I
loop I
- I
helix I
transcription I
factor I
E12 O
. O

Moreover O
, O
we O
show O
that O
ectopic O
expression O
of O
the O
E2A O
protein O
E12 O
in O
this O
macrophage O
line O
results O
in O
the O
induction O
of O
many B
B I
lineage I
genes I
, O
including O
EBF O
, O
IL7Ralpha B
, O
lambda5 O
, O
and O
Rag O
- O
1 O
, O
and O
the O
ability O
to O
induce O
kappa O
light O
chain O
in O
response O
to O
mitogen O
. O

Our O
data O
demonstrate O
that O
, O
in O
the O
context O
of O
this O
macrophage O
line O
, O
E12 O
induces O
expression O
of O
EBF O
and O
together O
these O
transcription O
factors O
coordinately O
regulate O
numerous O
B B
lineage I
- I
associated I
genes I
. O

Activation O
- O
induced O
down O
- O
regulation O
of O
retinoid B
receptor I
RXRalpha I
expression O
in O
human O
T O
lymphocytes O
. O

A O
5 B
. I
4 I
- I
kilobase I
mRNA I
, O
the O
expression O
of O
which O
is O
down O
- O
regulated O
after O
treatment O
of O
human O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
) O
with O
various O
T O
cell O
- O
activating O
agents O
, O
was O
isolated O
using O
an O
mRNA O
differential O
display O
method O
. O

Nucleotide O
sequence O
analysis O
identified O
the O
5 O
' O
end O
of O
this O
RNA O
as O
human B
retinoid I
receptor I
RXRalpha I
mRNA I
. O

Here O
, O
we O
report O
the O
nucleotide O
sequence O
of O
3 B
. I
6 I
kilobases I
of O
this O
RNA O
, O
which O
represents O
the O
3 O
' O
end O
of O
RXRalpha B
mRNA I
, O
the O
sequence O
of O
which O
has O
not O
been O
previously O
described O
. O

Activated O
PBMCs O
also O
expressed O
lower O
levels O
of O
RXRalpha B
protein O
, O
and O
a O
DNA O
binding O
assay O
showed O
that O
the O
activation O
- O
induced O
loss O
of O
RXRalpha B
mRNA I
and O
protein O
expression O
correlated O
with O
the O
loss O
of O
DNA O
binding O
activity O
of O
this O
protein O
. O

We O
present O
evidence O
that O
the O
transition O
from O
G0 O
/ O
G1 O
to O
S O
phase O
of O
the O
cell O
cycle O
results O
in O
the O
down O
- O
regulation O
of O
RXRalpha B
expression O
and O
that O
cell O
cycle O
inhibitors O
, O
which O
block O
the O
cells O
in O
G1 O
phase O
, O
prevent O
this O
down O
- O
regulation O
. O

The O
decrease O
in O
the O
levels O
of O
RXRalpha B
mRNA I
was O
found O
to O
be O
regulated O
at O
the O
post O
- O
transcriptional O
level O
and O
involved O
new O
protein O
synthesis O
. O

These O
observations O
indicate O
that O
the O
levels O
of O
RXRalpha B
expression O
in O
T O
lymphocytes O
are O
coupled O
to O
cell O
cycle O
progression O
, O
and O
there O
is O
tight O
regulatory O
control O
of O
RXRalpha B
expression O
during O
the O
transition O
from O
G0 O
/ O
G1 O
to O
S O
phase O
of O
the O
cell O
cycle O
. O

Specific O
forms O
of O
HIV O
- O
associated O
NHL O
are O
linked O
to O
expression O
of O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
- I
latent I
proteins I
; O
the O
newly O
described O
DNA O
virus O
, O
Karposi O
' O
s O
sarcoma O
- O
associated O
herpesvirus O
/ O
human O
herpesvirus O
- O
8 O
( O
KSHV O
/ O
HHV O
- O
8 O
) O
; O
and O
perhaps O
HIV O
. O

Matrix B
metalloproteinase I
expression O
in O
human O
breast O
cancer O
: O
an O
immunohistochemical O
study O
including O
correlation O
with O
cathepsin B
D I
, O
type B
IV I
collagen I
, O
laminin B
, O
fibronectin O
, O
EGFR O
, O
c B
- I
erbB I
- I
2 I
oncoprotein I
, O
p53 O
, O
steroid O
receptors O
status O
and O
proliferative O
indices O
. O

Matrix B
metalloproteinase I
s O
( O
MMPs B
) O
are O
a O
group O
of O
enzymes O
thought O
to O
be O
responsible O
for O
both O
normal O
connective O
tissue O
matrix O
remodelling O
and O
accelerated O
breakdown O
associated O
with O
tumour O
development O
. O

The O
current O
study O
aimed O
to O
investigate O
the O
immunohistochemical O
expression O
of O
matrix B
metalloproteinase I
3 I
( O
MMP B
- I
3 I
, O
stromelysin B
- I
1 I
) O
in O
correlation O
with O
the O
expression O
of O
Basement B
Membrane I
( I
BM I
) I
antigen I
( O
type B
IV I
collagen I
, O
laminin B
) O
, O
fibronectin O
, O
cathepsin B
D I
, O
p53 O
, O
c B
- I
erbB I
- I
2 I
, O
proliferative O
activity O
( O
Ki O
- O
67 O
, O
PCNA O
) O
, O
steroid O
receptor O
content O
as O
well O
as O
to O
the O
other O
conventional O
clinicopathological O
parameters O
in O
breast O
cancer O
. O

This O
study O
was O
performed O
on O
a O
series O
of O
frozen O
and O
paraffin O
sections O
from O
84 O
breast O
cancer O
specimens O
by O
immunohistochemistry O
using O
the O
monoclonal B
antibody I
MMP I
- I
3 I
( O
Ab B
- I
1 I
) O
. O

Stromelysin B
- I
1 I
( O
ST1 B
) O
was O
observed O
in O
about O
10 O
% O
of O
epithelial O
cells O
in O
the O
control O
groups O
( O
cases O
of O
fibrocystic O
and O
benign O
proliferative O
breast O
disease O
) O
, O
while O
expression O
( O
> O
10 O
% O
of O
expression O
) O
was O
detected O
in O
89 O
. O
7 O
% O
of O
tumours O
. O

The O
expression O
of O
ST1 B
in O
carcinoma O
cells O
was O
strongly O
associated O
with O
its O
presence O
in O
the O
stroma O
( O
p O
< O
0 O
. O
001 O
) O
. O

A O
significantly O
positive O
correlation O
was O
found O
between O
ST1 B
expression O
, O
and O
p53 O
tumour O
suppressor O
gene O
product O
( O
p O
= O
0 O
. O
004 O
) O
, O
and O
a O
relationship O
with O
c B
- I
erbB I
- I
2 I
protein O
and O
progesterone O
receptor O
status O
was O
also O
indicated O
. O

These O
findings O
suggest O
that O
ST1 B
expression O
in O
breast O
cancer O
tissue O
is O
irrespective O
of O
the O
expression O
of O
the O
extracellular O
matrix O
component O
, O
the O
proteolytic B
enzyme I
cathepsin B
D I
and O
the O
growth O
fraction O
of O
the O
tumour O
, O
and O
that O
it O
could O
be O
a O
potential O
new O
prognostic O
marker O
in O
breast O
cancer O
. O

Patients O
with O
ALD O
also O
have O
decreased O
protective B
factors I
for O
cellular O
oxidative O
injury O
. O

Manganous B
superoxide I
dismutase I
( O
MnSOD B
) O
is O
an O
antioxidant B
protective I
factor I
. O

The O
objectives O
of O
these O
studies O
were O
to O
investigate O
mechanisms O
for O
induction O
of O
an O
injurious B
factor I
( O
IL O
- O
8 O
) O
and O
a O
protective B
factor I
( O
MnSOD B
) O
in O
the O
HepG2 O
human O
hepatoma O
cell O
line O
. O

In O
the O
first O
set O
of O
experiments O
, O
IL B
- I
8 I
gene I
reporter I
constructs I
were O
used O
to O
transiently O
transfect O
a O
derivative O
( O
MVh2E1 O
- O
9 O
) O
of O
the O
HepG2 O
cell O
line O
which O
expresses O
P B
- I
4502E1 I
and O
metabolizes O
ethanol O
. O

Inactivation O
of O
the O
NF B
- I
kappaB I
and I
3 I
' I
NF I
- I
IL I
- I
6 I
DNA I
binding I
sites I
decreased O
IL O
- O
8 O
gene O
transcriptional O
activation O
in O
response O
to O
TNF O
while O
inactivation O
of O
the O
5 B
' I
NF I
- I
IL I
- I
6 I
binding I
site I
increased O
IL O
- O
8 O
gene O
transcriptional O
activity O
in O
response O
to O
TNF O
. O

Both O
TNF O
and O
ethanol O
increased O
HepG2 O
cell O
MnSOD B
activity O
in O
short O
- O
term O
( O
72 O
hr O
) O
cultures O
with O
ethanol O
. O

However O
, O
after O
long O
- O
term O
( O
10 O
weeks O
) O
culture O
with O
ethanol O
, O
there O
was O
no O
induction O
of O
MnSOD B
by O
ethanol O
and O
there O
was O
a O
diminished O
induction O
of O
MnSOD B
in O
response O
to O
TNF O
. O

Further O
studies O
are O
needed O
to O
assess O
the O
effect O
of O
this O
diminished O
induction O
of O
MnSOD B
with O
chronic O
ethanol O
culture O
on O
HepG2 O
cell O
susceptibility O
to O
TNF O
cytotoxicity O
. O

We O
conclude O
that O
transfected O
liver O
cell O
lines O
can O
be O
used O
to O
evaluate O
mechanisms O
for O
increased O
injurious B
factors I
and O
decreased O
protective B
factors I
in O
alcoholic O
liver O
injury O
. O

Tissue O
factor O
transcription O
driven O
by O
Egr O
- O
1 O
is O
a O
critical O
mechanism O
of O
murine B
pulmonary I
fibrin I
deposition O
in O
hypoxia O
. O

We O
have O
demonstrated O
previously O
that O
in O
a O
murine O
model O
of O
normobaric O
hypoxia O
pulmonary O
fibrin O
deposition O
is O
a O
result O
of O
expression O
of O
tissue O
factor O
, O
especially O
in O
oxygen B
- I
deprived I
mononuclear I
phagocytes I
( O
MPs B
) O
. O

We O
now O
show O
that O
transcription B
factor I
early I
- I
growth I
- I
response I
gene I
product I
( O
Egr O
- O
1 O
) O
is O
rapidly O
activated O
in O
hypoxia O
, O
both O
in O
vitro O
and O
in O
vivo O
, O
and O
is O
responsible O
for O
transcription O
and O
expression O
of O
tissue O
factor O
in O
hypoxic O
lung O
. O

MPs B
and O
HeLa O
cells O
subjected O
to O
hypoxia O
( O
pO2 O
approximately O
13 O
torr O
) O
had O
increased O
levels O
of O
tissue B
factor I
transcripts I
( O
approximately O
18 O
- O
fold O
) O
and O
an O
increased O
rate O
of O
transcription O
( O
approximately O
15 O
- O
fold O
) O
, O
based O
on O
nuclear O
run O
- O
on O
analysis O
. O

Gel O
- O
shift O
analysis O
of O
nuclear O
extracts O
from O
hypoxic B
MPs I
and O
HeLa O
cells O
demonstrated O
increased O
DNA O
- O
binding O
activity O
at O
the O
serum B
response I
region I
( O
SRR O
; O
- O
111 O
/ O
+ O
14 O
bp O
) O
of O
the O
tissue B
factor I
promoter I
at O
Egr B
- I
1 I
motifs I
. O

Transient O
transfection O
of O
HeLa O
cells O
with O
chimeric B
plasmids I
containing O
wild B
- I
type I
or I
mutant I
SRR I
from O
the O
tissue B
factor I
promoter I
showed O
that O
intact B
Sp1 I
sites I
are O
necessary O
for O
basal O
promoter O
activity O
, O
whereas O
the O
integrity O
of O
Egr B
- I
1 I
sites I
was O
required O
for O
hypoxia O
- O
enhanced O
expression O
. O

A O
central O
role O
for O
Egr O
- O
1 O
in O
hypoxia O
- O
mediated O
tissue O
factor O
expression O
was O
confirmed O
by O
experiments O
with O
homozygous O
Egr O
- O
1 O
null O
mice O
; O
wild O
- O
type O
mice O
subjected O
to O
oxygen B
deprivation I
expressed I
tissue I
factor I
and O
showed O
fibrin O
deposition O
, O
but O
hypoxic O
homozygous O
Egr O
- O
1 O
null O
mice O
displayed O
neither O
tissue O
factor O
nor O
fibrin O
. O

Here O
we O
have O
analysed O
the O
kinetics O
and O
nature O
of O
cytokine O
production O
in O
human O
peripheral O
blood O
- O
derived O
T O
lymphoblasts O
stimulated O
with O
anti O
- O
CD3 O
antibodies O
or O
Lens B
culinaris I
lectin I
( O
LCL B
) O
. O

Anti O
- O
CD3 O
- O
restimulated O
T O
cells O
( O
mainly O
CD8 O
+ O
) O
produced O
IL O
- O
2 O
, O
interferon O
- O
gamma O
( O
IFN O
- O
gamma O
) O
and O
tumour O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
and O
low O
levels O
of O
IL B
- I
4 I
and I
IL I
- I
10 I
transcripts I
and O
proteins O
. O

Anti O
- O
CD3 O
- O
stimulated O
IL O
- O
2 O
gene O
expression O
was O
down O
- O
regulated O
by O
protein O
synthesis O
inhibitor O
, O
whereas O
IL B
- I
10 I
, I
IFN I
- I
gamma I
and I
TNF I
- I
alpha I
genes I
were O
readily O
induced O
independent O
of O
ongoing O
protein O
synthesis O
. O

T O
- O
cell O
receptor O
stimulation O
also O
induced O
a O
very O
rapid O
expression O
of O
c B
- I
jun I
, I
c I
- I
fos I
and I
NFATc1 I
( I
NFATc I
) I
genes I
, O
the O
gene O
products O
of O
which O
are O
involved O
in O
cytokine O
gene O
expression O
. O

Molecular O
mechanisms O
of O
promoter O
regulation O
of O
the O
gp34 B
gene I
that O
is O
trans O
- O
activated O
by O
an O
oncoprotein B
Tax I
of O
human O
T O
cell O
leukemia O
virus O
type O
I O
. O

We O
investigated O
the O
molecular O
mechanism O
of O
transcriptional O
activation O
of O
the O
gp34 B
gene I
by O
the O
Tax B
oncoprotein I
of O
human O
T O
cell O
leukemia O
virus O
type O
I O
( O
HTLV O
- O
I O
) O
. O

gp34 B
is O
a O
type B
II I
transmembrane I
molecule I
belonging O
to O
the O
tumor O
necrosis O
factor O
family O
and O
is O
constitutively O
expressed O
on O
HTLV O
- O
I O
- O
producing O
cells O
but O
not O
normal O
resting O
T O
cells O
. O

The O
transcriptional O
regulatory O
region O
of O
the O
gp34 B
gene I
was O
activated O
by O
HTLV O
- O
I O
Tax O
in O
the O
human O
T O
cell O
line O
Jurkat O
, O
in O
which O
endogenous O
gp34 B
is O
induced O
by O
Tax O
. O

Sequence O
analysis O
demonstrated O
that O
two O
NF B
- I
kappaB I
- I
like I
elements I
( O
1 O
and O
2 O
) O
were O
present O
in O
the O
regulatory O
region O
. O

Both O
NF B
- I
kappaB I
- I
like I
elements I
were O
able O
to O
bind O
to O
NF O
- O
kappaB O
or O
its O
related O
factor O
( O
s O
) O
in O
a O
Tax O
- O
dependent O
manner O
. O

Chloramphenicol O
acetyltransferase O
assays O
indicated O
that O
NF B
- I
kappaB I
- I
like I
element I
1 I
was O
Tax O
- O
responsive O
, O
although O
the O
activity O
was O
lower O
than O
that O
the O
native O
promoter O
. O

NF O
- O
kappaB O
- O
like O
element O
2 O
elevated O
promoter O
activity O
when O
combined O
with O
NF B
- I
kappaB I
- I
like I
element I
1 I
, O
indicating O
cooperative O
function O
of O
the O
elements O
for O
maximum O
promoter O
function O
. O

Unlike O
typical O
NF B
- I
kappaB I
elements I
, O
the O
NF B
- I
kappaB I
- I
like I
elements I
in O
gp34 B
were O
not O
activated O
by O
treatment O
of O
Jurkat O
cells O
with O
phorbol O
ester O
despite O
induction O
of O
the O
NF O
- O
kappaB O
- O
like O
binding O
activity O
. O

Chloramphenicol O
acetyltransferase O
reporter O
assays O
using O
the O
region O
upstream O
of O
the O
NF B
- I
kappaB I
- I
like I
elements I
identified O
an O
upstream O
region O
that O
reduced O
transcription O
from O
cognate B
and I
noncognate I
core I
promoters I
in O
a O
Tax O
- O
independent O
manner O
. O

Our O
results O
imply O
complex O
regulation O
of O
expression O
of O
the O
gp34 B
gene I
and O
suggest O
implication O
of O
gp34 B
in O
proliferation O
of O
HTLV O
- O
I O
infected O
T O
cells O
. O

beta B
- I
Amyloid I
fibrils I
activate O
parallel O
mitogen O
- O
activated O
protein O
kinase O
pathways O
in O
microglia O
and O
THP1 O
monocytes O
. O

Fibrillar B
forms I
of O
beta B
- I
amyloid I
( O
Abeta B
) O
, O
which O
are O
the O
primary O
constituents O
of O
senile O
plaques O
, O
have O
been O
shown O
to O
activate O
tyrosine O
kinase O
- O
dependent O
signal O
transduction O
cascades O
, O
resulting O
in O
inflammatory O
responses O
in O
microglia O
. O

However O
, O
the O
downstream O
signaling O
pathways O
mediating O
Abeta B
- O
induced O
inflammatory O
events O
are O
not O
well O
characterized O
. O

We O
report O
that O
exposure O
of O
primary O
rat O
microglia O
and O
human O
THP1 O
monocytes O
to O
fibrillar B
Abeta I
results O
in O
the O
tyrosine O
kinase O
- O
dependent O
activation O
of O
two O
parallel O
signal O
transduction O
cascades O
involving O
members O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
( I
MAPK I
) I
superfamily I
. O

Abeta B
stimulated O
the O
rapid O
, O
transient O
activation O
of O
extracellular B
signal I
- I
regulated I
kinase I
1 I
( O
ERK1 O
) O
and O
ERK2 O
in O
microglia O
and O
ERK2 O
in O
THP1 O
monocytes O
. O

A O
second O
superfamily B
member I
, O
p38 O
MAPK O
, O
was O
also O
activated O
with O
similar O
kinetics O
. O

Scavenger B
receptor I
and O
receptor B
for I
advanced I
glycated I
end I
products I
( O
RAGE B
) O
ligands O
failed O
to O
activate O
ERK O
and O
p38 O
MAPK O
in O
the O
absence O
of O
significant O
increases O
in O
protein O
tyrosine O
phosphorylation O
, O
demonstrating O
that O
scavenger B
receptors I
and O
RAGE B
are O
not O
linked O
to O
these O
pathways O
. O

Importantly O
, O
the O
stress O
- O
activated O
protein O
kinases O
( O
SAPKs O
) O
were O
not O
significantly O
activated O
in O
response O
to O
Abeta B
. O

Downstream O
effectors O
of O
the O
MAPK O
signal O
transduction O
cascades O
include O
MAPKAP B
kinases I
, O
such O
as O
RSK1 B
and O
RSK2 B
, O
as O
well O
as O
transcription O
factors O
. O

Exposure O
of O
microglia O
and O
THP1 O
monocytes O
to O
Abeta B
resulted O
in O
the O
activation O
of O
RSK1 B
and O
RSK2 B
and O
phosphorylation O
of O
cAMP O
response O
element O
- O
binding O
protein O
at O
Ser133 O
, O
providing O
a O
mechanism O
for O
Abeta B
- O
induced O
changes O
in O
gene O
expression O

Regulation O
of O
cellular B
retinoic I
acid I
binding I
protein I
( O
CRABP B
II I
) O
during O
human O
monocyte O
differentiation O
in O
vitro O
. O

Cellular B
retinoic I
acid I
binding I
proteins I
( O
CRABP B
) O
are O
low B
molecular I
weight I
proteins I
whose O
precise O
function O
remains O
unknown O
. O

Whereas O
CRABP B
I I
is O
ubiquitously O
expressed O
, O
CRABP B
II I
is O
mainly O
detected O
in O
various O
cell O
types O
of O
the O
skin O
. O

By O
representative O
difference O
analysis O
we O
found O
that O
CRABP B
II I
is O
also O
strongly O
expressed O
in O
human O
monocyte O
- O
derived O
macrophages O
( O
MAC O
) O
but O
not O
in O
freshly O
isolated O
monocytes O
( O
MO O
) O
. O

The O
CRABP B
II I
mRNA I
was O
gradually O
upregulated O
during O
differentiation O
from O
MO O
to O
MAC O
in O
the O
presence O
of O
2 O
% O
serum O
. O

Adherence O
, O
which O
is O
important O
for O
MO O
differentiation O
, O
induced O
CRABP B
II I
expression O
, O
but O
the O
addition O
of O
10 O
( O
- O
7 O
) O
M O
retinoic O
acid O
inhibited O
the O
upregulation O
of O
CRABP B
II I
expression O
during O
MO O
/ O
MAC O
differentiation O
. O

As O
MO O
can O
differentiate O
along O
the O
classical O
pathway O
not O
only O
to O
MAC O
but O
also O
to O
dendritic O
cells O
we O
analyzed O
the O
expression O
of O
CRABP B
II I
in O
MO O
- O
derived O
dendritic O
cells O
cultured O
with O
10 O
% O
FCS B
, O
IL O
- O
4 O
, O
and O
GM O
- O
CSF O
. O

In O
contrast O
to O
MAC O
, O
MO O
- O
derived O
dendritic O
cells O
showed O
an O
extremely O
low O
expression O
of O
CRABP B
II I
. O

Transcription B
factor I
B I
- I
cell I
- I
specific I
activator I
protein I
( O
BSAP O
) O
is O
differentially O
expressed O
in O
B O
cells O
and O
in O
subsets O
of O
B O
- O
cell O
lymphomas O
. O

Mitogen O
and O
growth O
factor O
- O
induced O
activation O
of O
a O
STAT B
- I
like I
molecule I
in O
channel O
catfish O
lymphoid O
cells O
. O

This O
article O
describes O
the O
identification O
of O
a O
putative B
STAT I
molecule I
in O
the O
channel O
catfish O
( O
Ictalurus O
punctatus O
) O
, O
the O
first O
report O
of O
such O
a O
molecule O
in O
a O
' O
lower O
' O
vertebrate O
. O

A O
monoclonal O
antibody O
against O
human B
STAT6 I
recognizes O
an O
approximately O
100 B
kDa I
molecule I
that O
becomes O
activated O
and O
translocates O
to O
the O
nucleus O
upon O
both O
growth O
factor O
and O
mitogen O
stimulation O
of O
catfish O
leukocytes O
. O

This O
presumed O
catfish B
STAT I
binds O
the O
mammalian B
interferon I
- I
gamma I
activation I
site I
, O
a O
known O
motif O
of O
mammalian O
STAT O
binding O
, O
as O
shown O
by O
electromobility O
shift O
assays O
. O

Purification O
of O
the O
proteins O
present O
in O
these O
DNA B
complexes I
confirms O
that O
the O
catfish O
reactive O
molecule O
binds O
to O
the O
interferon B
- I
gamma I
activation I
site I
sequence I
. O

These O
results O
suggest O
that O
STAT B
molecules I
have O
been O
highly O
conserved O
in O
vertebrate O
evolution O
. O

Isolation O
and O
analysis O
of O
a O
T O
cell O
clone O
variant O
exhibiting O
constitutively O
phosphorylated B
Ser133 I
cAMP I
response I
element I
- I
binding I
protein I
. O

In O
driving O
T O
cell O
proliferation O
, O
IL O
- O
2 O
stimulates O
a O
new O
program O
of O
gene O
expression O
that O
includes O
proliferating B
cell I
nuclear I
antigen I
( O
PCNA O
) O
, O
a O
requisite O
processivity O
factor O
for O
DNA B
polymerase I
delta I
. O

PCNA O
transcription O
is O
regulated O
in O
part O
through O
tandem O
CRE B
sequences I
in O
the O
promoter B
and I
CRE I
binding I
proteins I
; O
IL O
- O
2 O
stimulates O
CREB O
phosphorylation O
in O
the O
resting O
cloned O
T O
lymphocyte O
, O
L2 O
. O

Elevated O
expression O
of O
differentiation B
inhibitory I
factor I
nm23 I
mRNA I
in O
monoblastic O
crisis O
of O
a O
patient O
with O
chronic O
myelogenous O
leukemia O
. O

Differentiation B
inhibitory I
factor I
nm23 O
gene O
has O
been O
found O
to O
be O
expressed O
in O
high O
quantities O
in O
acute O
myelogenous O
leukemia O
( O
AML O
) O
, O
especially O
in O
acute O
monocytic O
leukemia O
( O
AML O
- O
M5 O
) O
and O
is O
suggested O
as O
a O
new O
prognostic O
factor O
in O
AML O
- O
M5 O
. O

We O
report O
an O
example O
of O
elevated O
expression O
of O
nm23 B
mRNA I
in O
a O
patient O
with O
chronic O
myelogenous O
leukemia O
( O
CML O
) O
who O
developed O
monoblastic O
crisis O
. O

Relative O
levels O
of O
nm23 B
- I
H1 I
and I
- I
H2 I
mRNA I
extracted O
from O
the O
patient O
' O
s O
peripheral O
blood O
mononuclear O
cells O
and O
bone O
marrow O
mononuclear O
cells O
were O
measured O
by O
quantitative O
reverse O
transcriptase O
polymerase O
chain O
reaction O
. O

The O
level O
of O
nm23 B
- I
H1 I
mRNA I
in O
CML O
cells O
at O
the O
chronic O
phase O
was O
as O
high O
as O
that O
in O
bone O
marrow O
cells O
from O
healthy O
volunteers O
. O

At O
blastic O
crisis O
, O
however O
, O
expression O
of O
both O
nm23 B
- I
H1 I
and I
- I
H2 I
mRNA I
was O
elevated O
to O
about O
three O
to O
nine O
times O
of O
that O
at O
the O
chronic O
phase O
. O

Proliferated O
blastic O
cells O
were O
positive O
for O
non B
- I
specific I
esterase I
, O
and O
the O
serum O
lysozyme O
level O
was O
elevated O
and O
diagnosed O
as O
monoblastic O
crisis O
. O

Increased O
transcription O
decreases O
the O
spontaneous O
mutation O
rate O
at O
the O
thymidine B
kinase I
locus I
in O
human O
cells O
. O

In O
our O
TK6i O
- O
G3 O
and O
G9 O
tk O
heterozygous O
cell O
lines O
, O
the O
active O
tk B
allele I
is O
linked O
to O
an O
inducible O
promoter O
element O
. O

Tk B
mRNA I
is O
induced O
following O
treatment O
with O
estrogen O
. O

Immunoglobulin B
( I
Ig I
) I
genes I
are O
hypermutated O
in O
B O
lymphocytes O
that O
are O
the O
precursors O
to O
memory O
B O
cells O
. O

The O
mutations O
are O
linked O
to O
transcription O
initiation O
, O
but O
non B
- I
Ig I
promoters I
are O
permissible O
for O
the O
mutation O
process O
; O
thus O
, O
other O
genes O
expressed O
in O
mutating O
B O
cells O
may O
also O
be O
subject O
to O
somatic O
hypermutation O
. O

Significant O
mutations O
were O
not O
observed O
in O
c B
- I
MYC I
, I
S14 I
, I
or I
alpha I
- I
fetoprotein I
( I
AFP I
) I
genes I
, O
but O
BCL O
- O
6 O
was O
highly O
mutated O
in O
a O
large O
proportion O
of O
memory O
B O
cells O
of O
normal O
individuals O
. O

Analysis O
of O
the O
nuclear B
c I
- I
Rel I
protein I
indicated O
that O
after O
anti O
- O
CD3 O
+ O
anti O
- O
CD28 O
stimulation O
the O
level O
of O
c O
- O
Rel O
was O
higher O
in O
CD45RA O
+ O
cells O
. O

Biochemical O
characterization O
of O
MIP B
- I
1 I
alpha I
nuclear I
protein I
. O

A O
family O
of O
hematopoietic O
specific O
transcription O
factors O
, O
MIP B
- I
1 I
alpha I
nuclear I
protein I
( I
MNP I
) I
family I
, O
has O
recently O
been O
identified O
. O

They O
are O
intimately O
involved O
in O
regulating O
the O
transcription O
of O
the O
huMIP B
- I
1 I
alpha I
gene I
in O
monocytes O
, O
T O
- O
cells O
, O
and O
transformed O
B O
- O
cells O
. O

A O
third O
member O
of O
the O
family O
( O
MNP B
- I
3 I
) O
is O
expressed O
in O
PMA O
induced O
HL60 O
cells O
and O
probably O
has O
a O
role O
in O
monocyte O
differentiation O
. O

Bcl O
- O
3 O
is O
a O
proto O
- O
oncogene O
involved O
in O
the O
chromosomal O
translocation O
t B
( I
14 I
; I
19 I
) I
found O
in O
some O
patients O
with O
chronic O
lymphocytic O
leukemia O
. O

It O
shares O
structural O
similarities O
with O
and O
is O
a O
member O
of O
the O
IkappaB B
family I
of O
proteins O
. O

Overexpression O
of O
Bcl O
- O
3 O
in O
TF O
- O
1 O
cells O
by O
transient O
transfection O
along O
with O
the O
NF B
- I
kappaB I
factors I
p50 I
or I
p52 I
resulted O
in O
significant O
induction O
of O
an O
human B
immunodeficiency I
virus I
- I
type I
1 I
( I
HIV I
- I
1 I
) I
kappaB I
- I
TATA I
- I
luceriferase I
reporter I
plasmid I
, O
demonstrating O
that O
Bcl O
- O
3 O
has O
a O
positive O
role O
in O
transactivation O
of O
kappaB B
- I
containing I
genes I
in O
erythroid O
cells O
. O

Bcl O
- O
3 O
in O
nuclear O
extracts O
of O
TF O
- O
1 O
cells O
bound O
to O
a O
kappaB B
enhancer I
in O
the O
c B
- I
myb I
promoter I
together O
with O
NF O
- O
kappaB2 O
/ O
p52 O
and O
this O
binding O
activity O
was O
enhanced O
by O
GM O
- O
CSF O
stimulation O
. O

Furthermore O
, O
cotransfection O
of O
Bcl O
- O
3 O
with O
p52 O
or O
p50 O
in O
TF O
- O
1 O
cells O
resulted O
in O
significant O
activation O
of O
a O
c B
- I
myb I
kappaB I
- I
TATA I
- I
luceriferase I
reporter I
plasmid I
. O

These O
findings O
suggest O
that O
Bcl O
- O
3 O
may O
participate O
in O
the O
transcriptional O
regulation O
of O
certain O
kappaB B
- I
containing I
genes I
involved O
in O
hematopoiesis O
, O
including O
c O
- O
myb O
. O

5 O
- O
Lipoxygenase O
compartmentalization O
in O
granulocytic O
cells O
is O
modulated O
by O
an O
internal B
bipartite I
nuclear I
localizing I
sequence I
and O
nuclear B
factor I
kappa I
B I
complex I
formation O
. O

A O
region O
of O
basic O
amino O
acids O
spanning O
residues B
639 I
- I
656 I
in O
the O
human B
5 I
- I
lipoxygenase I
sequence I
resembles O
a O
consensus B
bipartite I
nuclear I
localizing I
sequence I
. O

A O
synthetic O
peptide O
consisting O
of O
the O
Kaposi B
fibroblast I
growth I
factor I
signal I
sequence I
fused O
to O
the O
5 B
- I
lipoxygenase639 I
- I
656 I
bipartite I
nuclear I
localizing I
sequence I
has O
a O
prominent O
inhibitory O
effect O
on O
5 O
- O
lipoxygenase O
catalysis O
in O
granulocytic O
HL O
- O
60 O
cells O
activated O
by O
calcium O
ionophor O
A23187 O
. O

5 B
- I
Lipoxygenase I
protein I
was O
detected O
in O
nuclear B
factor I
kappaB I
( I
NF I
- I
kappaB I
) I
p65 I
subunit I
immunoprecipitate O
fractions O
prepared O
from O
HL O
- O
60 O
cell O
lysates O
. O

The O
amount O
of O
5 B
- I
lipoxygenase I
protein I
coimmunoprecipitated O
by O
NF O
- O
kappaB O
antiserum O
was O
increased O
following O
A23187 O
stimulation O
. O

Our O
results O
implicate O
an O
internal B
bipartite I
nuclear I
localizing I
sequence I
as O
a O
regulatory O
domain O
that O
modulates O
5 O
- O
lipoxygenase O
redistribution O
and O
catalysis O
in O
granulocytic O
cells O
. O

Inhibition O
of O
CD28 O
/ O
CD3 O
- O
mediated O
costimulation O
of O
naive O
and O
memory O
human O
T O
lymphocytes O
by O
intracellular O
incorporation O
of O
polyclonal O
antibodies O
specific O
for O
the O
activator B
protein I
- I
1 I
transcriptional I
complex I
. O

Cells O
scraped O
off O
poly O
- O
L O
- O
lysine O
in O
the O
presence O
of O
Ig B
FITC I
efficiently O
incorporated O
Ig O
, O
with O
relatively O
uniform O
fluorescence O
. O

The O
intracellular O
incorporation O
of O
Abs O
specific O
for O
c B
- I
Fos I
and I
c I
- I
Jun I
family I
members I
by O
scrape O
loading O
inhibited O
the O
production O
and O
intracellular O
accumulation O
of O
IL O
- O
2 O
within O
6 O
h O
of O
costimulation O
with O
PMA O
/ O
ionomycin O
, O
or O
costimulation O
by O
CD28 O
and O
CD3 O
ligation O
. O

Differential O
expression O
of O
Nur77 B
family I
members I
in O
human O
T O
- O
lymphotropic O
virus O
type O
1 O
- O
infected O
cells O
: O
transactivation O
of O
the O
TR3 B
/ I
nur77 I
gene I
by O
Tax O
protein O
. O

We O
analyzed O
the O
differential O
expression O
and O
regulation O
of O
three O
members O
of O
the O
Nur77 B
transcription I
factor I
family I
by O
the O
human O
T O
- O
lymphotropic O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
Tax O
protein O
. O

We O
have O
demonstrated O
that O
in O
both O
HTLV O
- O
1 O
- O
infected O
cells O
and O
Tax O
- O
expressing O
JPX O
- O
9 O
cells O
, O
TR3 B
/ I
nur77 I
is O
highly O
expressed O
, O
whereas O
neither O
NOR O
- O
1 O
nor O
NOT O
expression O
is O
detectable O
. O

Transient O
transfection O
analysis O
further O
confirmed O
the O
Tax O
transactivation O
of O
the O
TR3 B
/ I
nur77 I
promoter O
but O
not O
the O
NOR B
- I
1 I
promoter I
in O
different O
cell O
types O
. O

Furthermore O
, O
expression O
of O
a O
luciferase O
reporter O
gene O
driven O
by O
the O
NGFI B
- I
B I
( I
rat I
homolog I
of I
TR3 I
/ I
Nur77 I
) I
response I
element I
( O
NBRE B
) O
provided O
evidence O
that O
Tax O
- O
mediated O
transactivation O
resulted O
in O
the O
induction O
of O
a O
functional O
protein O
. O

Cotransfection O
assays O
with O
the O
TR3 B
/ I
nur77 I
promoter I
sequence I
or O
the O
NBRE B
binding O
motif O
together O
with O
a O
series O
of O
Tax O
mutants O
have O
shown O
that O
Tax O
- O
induced O
TR3 B
/ I
nur77 I
expression O
is O
mediated O
by O
CREB B
/ I
ATF I
- I
related I
transcription I
factors I
. O

Negative O
regulation O
of O
the O
heat O
shock O
transcriptional O
response O
by O
HSBP1 B
. O

In O
response O
to O
stress O
, O
heat O
shock O
factor O
1 O
( O
HSF1 O
) O
acquires O
rapid O
DNA O
binding O
and O
transient O
transcriptional O
activity O
while O
undergoing O
conformational O
transition O
from O
an O
inert O
non B
- I
DNA I
- I
binding I
monomer I
to O
active O
functional O
trimers O
. O

Attenuation O
of O
the O
inducible O
transcriptional O
response O
occurs O
during O
heat O
shock O
or O
upon O
recovery O
at O
non O
- O
stress O
conditions O
and O
involves O
dissociation O
of O
the O
HSF1 B
trimer I
and O
loss O
of O
activity O
. O

We O
have O
used O
the O
hydrophobic B
repeats I
of O
the O
HSF1 O
trimerization O
domain O
in O
the O
yeast O
two O
- O
hybrid O
protein O
interaction O
assay O
to O
identify O
heat B
shock I
factor I
binding I
protein I
1 I
( O
HSBP1 B
) O
, O
a O
novel O
, O
conserved O
, O
76 B
- I
amino I
- I
acid I
protein I
that O
contains O
two O
extended O
arrays O
of O
hydrophobic B
repeats I
that O
interact O
with O
the O
HSF1 B
heptad I
repeats I
. O

HSBP1 B
is O
nuclear O
- O
localized O
and O
interacts O
in O
vivo O
with O
the O
active O
trimeric O
state O
of O
HSF1 O
that O
appears O
during O
heat O
shock O
. O

During O
attenuation O
of O
HSF1 O
to O
the O
inert O
monomer O
, O
HSBP1 B
associates O
with O
Hsp70 O
. O

HSBP1 B
negatively O
affects O
HSF1 O
DNA O
- O
binding O
activity O
, O
and O
overexpression O
of O
HSBP1 B
in O
mammalian O
cells O
represses O
the O
transactivation O
activity O
of O
HSF1 O
. O

To O
establish O
a O
biological O
role O
for O
HSBP1 B
, O
the O
homologous O
Caenorhabditis B
elegans I
protein I
was O
overexpressed O
in O
body O
wall O
muscle O
cells O
and O
was O
shown O
to O
block O
activation O
of O
the O
heat O
shock O
response O
from O
a O
heat B
shock I
promoter I
- I
reporter I
construct I
. O

Alteration O
in O
the O
level O
of O
HSBP1 B
expression O
in O
C O
. O
elegans O
has O
severe O
effects O
on O
survival O
of O
the O
animals O
after O
thermal O
and O
chemical O
stress O
, O
consistent O
with O
a O
role O
for O
HSBP1 B
as O
a O
negative O
regulator O
of O
the O
heat O
shock O
response O
. O

Most O
studies O
on O
the O
control O
of O
cytokine O
gene O
expression O
have O
involved O
the O
functional O
analysis O
of O
proximal B
promoters I
. O

Recent O
work O
has O
identified O
distal B
elements I
that O
mediate O
long O
- O
range O
cytokine O
gene O
regulation O
and O
has O
implicated O
chromatin O
reorganization O
in O
regulation O
of O
cytokine B
gene I
loci I
. O

Stimulation O
of O
T O
lymphocytes O
results O
in O
a O
rapid O
increase O
in O
intracellular O
calcium O
concentration O
( O
[ O
Ca2 O
+ O
] O
i O
) O
that O
parallels O
the O
activation O
of O
Ca2 O
+ O
- O
calmodulin O
- O
dependent O
protein O
kinase O
IV O
( O
CaMKIV O
) O
, O
a O
nuclear B
enzyme I
that O
can O
phosphorylate O
and O
activate O
the O
cyclic B
adenosine I
monophosphate I
( I
cAMP I
) I
response I
element I
- I
binding I
protein I
( O
CREB O
) O
. O

A O
stable O
and O
stoichiometric O
complex O
of O
CaMKIV O
with O
protein B
serine I
- I
threonine I
phosphatase I
2A I
( O
PP2A O
) O
was O
identified O
in O
which O
PP2A O
dephosphorylates O
CaMKIV O
and O
functions O
as O
a O
negative O
regulator O
of O
CaMKIV O
signaling O
. O

These O
findings O
reveal O
an O
intracellular O
signaling O
mechanism O
whereby O
a O
protein B
serine I
- I
threonine I
kinase I
( O
CaMKIV O
) O
is O
regulated O
by O
a O
tightly O
associated O
protein B
serine I
- I
threonine I
phosphatase I
( O
PP2A O
) O
. O

Hypoxia O
down O
- O
regulated O
TNF B
- I
alpha I
- I
induced I
MCP I
- I
1 I
mRNA I
and O
protein O
production O
by O
ovarian O
cancer O
cells O
. O

Nuclear O
factor O
kappa O
B O
( O
NF O
kappa O
B O
) O
controls O
transcription O
of O
inflammation B
genes I
. O

OBJECTIVE O
: O
The O
redox B
- I
sensitive I
transcription I
factor I
nuclear I
factor I
- I
kappa I
B I
( O
NF O
- O
kappa O
B O
) O
is O
believed O
to O
contribute O
to O
late O
diabetic O
complications O
. O

PCNSL O
associated O
frequently O
( O
50 O
. O
0 O
% O
) O
with O
mutations O
of O
BCL B
- I
6 I
5 I
' I
noncoding I
regions I
, O
which O
are O
regarded O
as O
a O
marker O
of O
B O
- O
cell O
transition O
through O
the O
germinal O
center O
( O
GC O
) O
. O

Notably O
, O
among O
AIDS O
- O
related O
PCNSL O
, O
expression O
of O
BCL O
- O
6 O
was O
mutually O
exclusive O
with O
expression O
of O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
- I
encoded I
latent I
membrane I
protein I
( I
LMP I
) I
- I
1 I
and O
, O
with O
few O
exceptions O
, O
also O
of O
BCL O
- O
2 O
. O

Protein O
kinase O
C O
( O
PKC O
) O
has O
been O
suggested O
to O
regulate O
PMA O
- O
induced O
adhesion O
molecule O
expression O
by O
post O
- O
transcriptional O
stabilization O
of O
adhesion B
molecule I
mRNA I
. O

Binding O
of O
human O
immunodeficiency O
virus O
type O
1 O
to O
CD4 B
and I
CXCR4 I
receptors I
differentially O
regulates O
expression O
of O
inflammatory O
genes O
and O
activates O
the O
MEK O
/ O
ERK O
signaling O
pathway O
. O

In O
the O
present O
study O
, O
we O
demonstrate O
that O
HIV B
- I
1 I
envelope I
glycoproteins I
of O
both O
T O
- O
cell O
- O
tropic O
and O
macrophagetropic O
strains O
rapidly O
activate O
the O
ERK O
/ O
mitogen O
- O
activated O
protein O
( O
MAP O
) O
kinase O
pathway O
and O
the O
binding O
of O
nuclear O
transcription O
factors O
( O
AP O
- O
1 O
, O
NF O
- O
kappaB O
, O
and O
C O
/ O
EBP O
) O
and O
stimulate O
expression O
of O
cytokine B
and I
chemokine I
genes I
. O

Binding O
of O
the O
natural O
ligand O
stromal B
cell I
- I
derived I
factor I
1 I
( O
SDF B
- I
1 I
) O
to O
CXCR4 O
, O
which O
inhibits O
entry O
of O
T O
- O
cell O
- O
tropic O
HIV O
- O
1 O
, O
activates O
also O
the O
ERK O
/ O
MAP O
kinase O
pathway O
. O

However O
, O
SDF B
- I
1 I
did O
not O
affect O
the O
CD4 O
- O
mediated O
expression O
of O
cytokine B
and I
chemokine I
genes I
. O

These O
results O
provide O
firm O
molecular O
evidence O
that O
binding O
of O
HIV B
- I
1 I
envelope I
glycoproteins I
to O
CD4 O
receptor O
initiates O
a O
signaling O
pathway O
( O
s O
) O
independent O
of O
the O
binding O
to O
the O
chemokine O
receptor O
that O
leads O
to O
the O
aberrant O
expression O
of O
inflammatory O
genes O
and O
may O
contribute O
significantly O
to O
HIV O
- O
1 O
replication O
as O
well O
as O
to O
deregulation O
of O
the O
immune O
system O
. O

The O
bcl B
- I
6 I
proto I
- I
oncogene I
encodes O
a O
POZ O
/ O
zinc O
finger O
transcriptional O
repressor O
expressed O
in O
germinal O
center O
( O
GC O
) O
B O
and O
T O
cells O
and O
required O
for O
GC O
formation O
and O
antibody O
affinity O
maturation O
. O

Deregulation O
of O
bcl O
- O
6 O
expression O
by O
chromosomal O
rearrangements O
and O
point O
mutations O
of O
the O
bcl B
- I
6 I
promoter I
region I
are O
implicated O
in O
the O
pathogenesis O
of O
B O
- O
cell O
lymphoma O
. O

This O
signaling O
pathway O
may O
be O
crucial O
for O
the O
control O
of O
B O
- O
cell O
differentiation O
and O
antibody O
response O
and O
has O
implications O
for O
the O
regulation O
of O
other O
POZ B
/ I
zinc I
finger I
transcription I
factors I
in O
other O
tissues O
. O

Cytosolic B
glucocorticoid I
receptor I
( O
GR O
) O
binding O
studies O
on O
immune O
tissues O
demonstrate O
that O
the O
thymus O
exhibits O
three O
to O
four O
times O
higher O
levels O
of O
GR B
protein I
than O
the O
spleen O
. O

To O
address O
these O
inconsistencies O
, O
GR B
protein I
was O
assessed O
in O
immune O
cells O
and O
tissues O
using O
cytosolic O
radioligand O
binding O
. O

Functional O
replacement O
of O
the O
mouse O
E2A O
gene O
with O
a O
human B
HEB I
cDNA I
. O

The O
mammalian B
E2A I
, I
HEB I
, I
and I
E2 I
- I
2 I
genes I
encode O
a O
unique O
class O
of O
basic O
helix O
- O
loop O
- O
helix O
( O
bHLH O
) O
transcription O
factors O
that O
are O
evolutionarily O
conserved O
and O
essential O
for O
embryonic O
and O
postnatal O
development O
. O

While O
the O
structural O
and O
functional O
similarities O
among O
the O
gene O
products O
are O
well O
demonstrated O
, O
it O
is O
not O
clear O
why O
deletion O
of O
E2A O
, O
but O
not O
HEB O
or O
E2 B
- I
2 I
, O
leads O
to O
a O
complete O
arrest O
in O
B O
- O
lymphocyte O
development O
. O

To O
understand O
the O
molecular O
basis O
of O
the O
functional O
specificity O
between O
E2A O
and O
HEB O
/ O
E2 B
- I
2 I
in O
mammalian O
development O
, O
we O
generated O
and O
tested O
a O
panel O
of O
E2A O
knockin O
mutations O
including O
subtle O
mutations O
in O
the O
E12 B
and I
E47 I
exons I
and O
substitution O
of O
both O
E12 B
and I
E47 I
exons I
with O
a O
human B
HEB I
cDNA I
. O

We O
find O
that O
the O
alternatively O
spliced O
E12 B
and I
E47 I
bHLH I
proteins I
of O
the O
E2A O
gene O
play O
similar O
and O
additive O
roles O
in O
supporting O
B O
lymphopoiesis O
. O

Further O
, O
we O
find O
that O
HEB O
driven O
by O
the O
endogenous B
E2A I
promoter I
can O
functionally O
replace O
E2A O
in O
supporting O
B O
- O
cell O
commitment O
and O
differentiation O
toward O
completion O
. O

Biased O
dependency O
of O
CD80 O
versus O
CD86 O
in O
the O
induction O
of O
transcription O
factors O
regulating O
the O
human B
IL I
- I
2 I
promoter I
. O

To O
further O
characterize O
the O
consequences O
of O
this O
biased O
co O
- O
stimulatory O
dependency O
, O
we O
employed O
a O
well O
- O
defined O
system O
of O
transfected O
CHO O
cells O
expressing O
human B
MHC I
class I
II I
together O
with O
CD80 O
, O
CD86 O
or O
CD80 O
and O
CD86 O
. O

To O
analyze O
IL O
- O
2 O
transcriptional O
activity O
in O
CD80 O
and O
CD86 O
co O
- O
stimulated O
T O
cells O
we O
used O
Jurkat O
T O
cells O
transfected O
with O
luciferase B
reporter I
gene I
constructs I
. O

Furthermore O
, O
the O
activity O
of O
transcription O
factors O
regulating O
the O
IL B
- I
2 I
promoter I
- I
enhancer I
region I
including O
activation O
protein O
- O
1 O
, O
CD28 O
response O
element O
and O
nuclear O
factor O
kappaB O
were O
4 O
- O
8 O
times O
higher O
after O
CD80 O
compared O
to O
CD86 O
ligation O
. O

Duplication O
of O
the O
DR3 B
gene I
on O
human B
chromosome I
1p36 I
and O
its O
deletion O
in O
human O
neuroblastoma O
. O

The O
human B
DR3 I
gene I
, O
whose O
product O
is O
also O
known O
as O
Wsl B
- I
1 I
/ I
APO I
- I
3 I
/ I
TRAMP I
/ I
LARD I
, O
encodes O
a O
tumor B
necrosis I
factor I
- I
related I
receptor I
that O
is O
expressed O
primarily O
on O
the O
surface O
of O
thymocytes O
and O
lymphocytes O
. O

We O
report O
here O
that O
the O
DR3 B
gene I
locus I
is O
tandemly O
duplicated O
on O
human B
chromosome I
band I
1p36 I
. I
2 I
- I
p36 I
. I
3 I
and O
that O
these O
genes O
are O
hemizygously O
deleted O
and O
/ O
or O
translocated O
to O
another O
chromosome O
in O
neuroblastoma O
( O
NB O
) O
cell O
lines O
with O
amplified O
MYCN O
. O

Duplication O
of O
at O
least O
a O
portion O
of O
the O
DR3 B
gene I
, O
including O
the O
extracellular O
and O
transmembrane O
regions O
but O
not O
the O
cytoplasmic O
domain O
, O
was O
demonstrated O
by O
both O
fluorescence O
in O
situ O
hybridization O
and O
genomic O
Southern O
blotting O
. O

In O
most O
NB O
cell O
lines O
, O
both O
the O
DR3 B
and I
the I
DR3L I
sequences I
are O
simultaneously O
deleted O
and O
/ O
or O
translocated O
to O
another O
chromosome O
. O

Finally O
, O
DR3 B
/ I
Wsl I
- I
1 I
protein I
expression O
is O
quite O
variable O
among O
these O
NB O
cell O
lines O
, O
with O
very O
low O
or O
undetectable O
levels O
in O
7 O
of O
17 O
NB O
cell O
lines O

Cycloheximide O
, O
a O
reversible O
protein O
synthesis O
inhibitor O
, O
is O
thought O
to O
block O
DNA O
replication O
in O
normal O
cells O
by O
preventing O
synthesis O
of O
a O
labile B
protein I
. O

Results O
were O
the O
same O
when O
the O
amount O
of O
dexamethasone O
bound O
per O
milligram O
of O
cell B
protein I
was O
measured O
. O

Our O
results O
indicate O
that O
cell O
cycle O
changes O
in O
dexamethasone O
binding O
are O
not O
simply O
related O
to O
changes O
in O
cell B
protein I
or O
cell O
volume O
during O
the O
cell O
cycle O
. O

It O
is O
suggested O
that O
the O
presence O
of O
steroid B
- I
inducible I
GS I
in O
ALL O
cells O
may O
prove O
to O
be O
a O
marker O
for O
functional B
receptor I
sites I
. O

These O
included O
inhibition O
of O
the O
proliferative O
responses O
to O
the O
T O
- O
cell O
mitogens O
concanavalin B
A I
and O
phytohaemagglutinin O
and O
an O
enhanced O
accumulation O
of O
immunoglobulin O
secreting O
cells O
in O
pokeweed O
mitogen O
- O
stimulated O
cultures O
. O

Human O
chronic O
lymphocytic O
leukemia O
( O
CLL O
) O
cells O
like O
prothymocytes O
and O
immunoactivated O
T O
- O
lymphocytes O
are O
readily O
lysed O
in O
vitro O
by O
pharmacological O
concentrations O
of O
glucocorticoids O
such O
as O
cortisol O
, O
whereas O
peripheral O
blood O
lymphocytes O
and O
thymocytes O
are O
unaffected O
by O
the O
hormone B
. O

However O
, O
30 O
min O
of O
incubation O
with O
cortisol O
at O
either O
37 O
degrees O
or O
4 O
degrees O
followed O
by O
the O
removal O
of O
the O
hormone B
was O
still O
sufficient O
to O
induce O
the O
lytic O
process O
. O

Ultrastructural O
studies O
demonstrated O
sequential O
changes O
in O
the O
cytoplasm O
, O
including O
swelling O
of O
mitochondria O
and O
cytoplasmic O
decompartmentalizati O
, O
followed O
by O
loss O
of O
surface O
microvilli O
with O
the O
appearance O
of O
` O
` O
holes O
' O
' O
in O
the O
cell O
membrane O
, O
and O
subsequent O
condensation O
of O
nuclear B
chromatin I
. O

The O
large O
holes O
in O
the O
membrane O
appearing O
after O
6 O
hr O
of O
incubation O
with O
the O
hormone B
may O
be O
the O
cause O
for O
the O
penetration O
of O
the O
viable O
stain O
into O
the O
dead O
cells O
, O
as O
seen O
by O
light O
microscopy O
. O

In O
Specimens O
of O
115 O
patients O
with O
breast O
cancer O
4 O
tumorparameters O
( O
tumorsize O
, O
tumorboder O
, O
nucleargrade O
, O
lymphocytic O
stromal O
reaction O
) O
3 O
features O
of O
regional O
lymphnodes O
( O
sinushistiocytosis O
, O
T O
- O
cellreaction O
, O
lymphnode O
metastases O
) O
and O
estrogen B
and I
progesteron I
receptors I
were O
determined O
. O

Aldosterone B
- I
receptor I
deficiency O
in O
pseudohypoaldosteron O
. O

We O
have O
investigated O
this O
syndrome O
for O
the O
possibility O
of O
abnormal B
Type I
I I
or O
` B
` I
mineralocorticoid I
- I
like I
' I
' I
receptors I
, O
which O
have O
intrinsic O
steroid O
specificity O
indistinguishable O
from O
that O
of O
renal B
mineralocorticoid I
receptors I
and O
are O
found O
in O
many O
tissues O
and O
cells O
, O
including O
mononuclear O
leukocytes O
. O

Glucocorticoid O
inhibition O
of O
urokinase B
- I
like I
plasminogen I
activators I
in O
cultured O
human O
lymphoblasts O
. O

Both O
cell O
types O
secrete O
a O
urokinase B
( I
UK I
) I
- I
like I
plasminogen I
activator I
( O
PA B
) O
. O

Treatment O
of O
both O
HMy2 O
and O
GM4672A O
cells O
with O
Dex O
for O
1 O
- O
4 O
days O
inhibits O
extracellular O
PA B
activity O
in O
a O
concentration O
- O
dependent O
manner O
, O
being O
half O
- O
maximal O
at O
approximately O
1 O
X O
10 O
( O
- O
9 O
) O
M O
. O

Inhibition O
of O
PA B
in O
both O
cell O
types O
is O
specific O
for O
active O
glucocorticoids O
, O
and O
this O
specificity O
parallels O
the O
ability O
of O
various O
steroids O
to O
bind O
to O
glucocorticoid O
receptors O
. O

HMy2 O
cell O
PA B
is O
fully O
suppressible O
by O
Dex O
, O
whereas O
up O
to O
one O
third O
of O
the O
activator O
expressed O
by O
GM4672A O
cells O
is O
resistant O
to O
glucocorticoid O
inhibition O
. O

Mixing O
experiments O
using O
a O
UK O
standard O
and O
conditioned O
media O
from O
Dex O
- O
treated O
cells O
suggest O
an O
absence O
of O
glucocorticoid B
- I
inducible I
inhibitors I
to O
UK B
or O
plasmin B
in O
both O
cell O
types O
. O

Thus O
, O
low O
levels O
of O
glucocorticoid B
- I
inducible I
inhibitors I
may O
contribute O
to O
, O
but O
can O
not O
fully O
account O
for O
, O
Dex O
inhibition O
of O
GM4672A B
PA I
activity O
. O

Glucocorticoid B
- I
inducible I
inhibitors I
in O
HMy2 O
cells O
are O
either O
totally O
absent O
or O
are O
present O
at O
undetectable O
levels O
. O

Thus O
, O
regulation O
of O
UK B
- I
like I
PAs I
in O
HMy2 O
and O
GM4672A O
cells O
differs O
with O
respect O
to O
the O
extent O
to O
which O
glucocorticoids O
inhibit O
constitutively B
expressed I
activator I
levels O
, O
as O
well O
as O
the O
possible O
contribution O
of O
glucocorticoid B
- I
inducible I
inhibitors I
to O
the O
regulatory O
process O
in O
GM4672A O
cells O
. O

Mineralocorticoid B
and I
glucocorticoid I
receptors I
in O
circulating O
mononuclear O
leukocytes O
of O
patients O
with O
primary O
hyperaldosteronism O
. O

Mineralocorticoid B
and I
glucocorticoid I
receptors I
were O
measured O
in O
circulating O
mononuclear O
leukocytes O
in O
5 O
patients O
affected O
by O
Conn O
' O
s O
syndrome O
( O
3 O
cases O
of O
bilateral O
adrenal O
hyperplasia O
and O
2 O
cases O
of O
adenoma O
plus O
unilateral O
hyperplasia O
) O
. O

Lymphocytes O
from O
adult O
, O
neonatally O
DES O
- O
treated O
female O
mice O
have O
a O
reduced O
mitogen O
response O
to O
ConA B
and O
LPS B
( O
T B
and I
B I
cell I
mitogen I
) O
and O
the O
delayed O
type O
hypersensitivity O
response O
is O
depressed O
. O

This O
alteration O
was O
scarcely O
modified O
by O
incubation O
with O
theophylline B
, O
which O
increases O
cellular O
concentration O
of O
cAMP O
. O

Serum O
sex O
steroid O
and O
peptide O
hormone O
concentrations O
, O
and O
endometrial O
estrogen O
and O
progestin O
receptor O
levels O
during O
administration O
of O
human B
leukocyte I
interferon I
. O

Five O
normally O
cycling O
healthy O
women O
were O
given O
daily O
subcutaneous O
injections O
of O
human B
leukocyte I
interferon I
( O
3 O
X O
10 O
( O
6 O
) O
units O
/ O
day O
) O
from O
the O
3rd O
through O
23rd O
day O
of O
the O
menstrual O
cycle O
, O
and O
serum O
steroid O
and O
peptide O
hormone O
concentrations O
monitored O
at O
3 O
- O
day O
intervals O
during O
the O
treatment O
and O
the O
preceding O
control O
cycle O
. O

Concentrations O
of O
cytosol B
and I
nuclear I
estrogen I
receptors I
( O
ERC B
and O
ERN B
, O
respectively O
) O
and O
progestin B
receptors I
( O
PRC B
and O
PRN B
) O
were O
also O
measured O
from O
endometrial O
biopsies O
taken O
on O
the O
24th O
day O
of O
the O
control O
and O
treatment O
cycle O
. O

No O
significant O
changes O
were O
observed O
in O
the O
serum O
peptide O
hormone O
concentrations O
measured O
( O
FSH O
, O
LH O
, O
prolactin O
, O
insulin O
, O
growth O
hormone O
and O
TSH O
) O
; O
neither O
were O
the O
levels O
of O
endometrial B
ERC I
, I
ERN I
, I
PRC I
and I
PRN I
affected O
by O
interferon O
administration O
. O

Moreover O
, O
an O
increasing O
tendency O
in O
the O
activities O
of O
serum B
alkaline I
phosphatase I
and O
gamma B
- I
glutamyltransferase I
during O
the O
interferon O
therapy O
shows O
that O
interferon O
may O
slightly O
interfere O
with O
the O
liver O
function O
. O

Distinct O
increase O
in O
amount O
of O
the O
leukocyte B
glucocorticoid I
receptors I
was O
found O
in O
patients O
with O
poisoning O
by O
dichlorethane O
and O
hypnotic O
drugs O
under O
conditions O
of O
acute O
myocardial O
infarction O
. O

In O
acute O
pancreatitis O
content O
of O
the O
leukocyte B
receptors I
was O
not O
altered O
as O
compared O
with O
controls O
. O

But O
in O
the O
patients O
with O
acute O
pancreatitis O
the O
decrease O
in O
content O
of O
leukocyte B
glucocorticoid I
receptors I
was O
not O
observed O
although O
there O
was O
an O
increase O
in O
cortisol O
concentration O
in O
blood O
. O

Interleukin O
2 O
receptor O
( O
Tac B
antigen I
) O
expression O
in O
HTLV O
- O
I O
- O
associated O
adult O
T O
- O
cell O
leukemia O
. O

Resting O
T O
- O
cells O
do O
not O
express O
IL O
- O
2 O
receptors O
, O
but O
receptors O
are O
rapidly O
expressed O
on O
T O
- O
cells O
following O
interaction O
of O
antigens O
, O
mitogens O
, O
or O
monoclonal O
antibodies O
with O
the O
antigen B
- I
specific I
T I
- I
cell I
receptor I
complex I
. O

Using O
anti B
- I
Tac I
, O
a O
monoclonal O
antibody O
that O
recognizes O
the O
IL O
- O
2 O
receptor O
, O
the O
receptor O
has O
been O
purified O
and O
shown O
to O
be O
a O
Mr O
33 O
, O
000 O
peptide O
that O
is O
posttranslationally O
glycosylated O
to O
a O
Mr O
55 O
, O
000 O
mature O
form O
. O

Normal O
resting O
T O
- O
cells O
and O
most O
leukemic O
T O
- O
cell O
populations O
do O
not O
express O
IL O
- O
2 O
receptors O
; O
however O
, O
the O
leukemic O
cells O
of O
the O
11 O
patients O
examined O
who O
had O
human O
T O
- O
cell O
lymphotropic O
virus O
- O
associated O
adult O
T O
- O
cell O
leukemia O
expressed O
the O
Tac B
antigen I
. O

In O
human O
T O
- O
cell O
lymphotropic O
virus O
- O
I O
infected O
cells O
, O
the O
Mr O
42 O
, O
000 O
long O
open B
reading I
frame I
protein I
encoded O
in O
part O
by O
the O
pX B
region I
of O
this O
virus O
may O
act O
as O
a O
transacting B
transcriptional I
activator I
that O
induces O
IL B
- I
2 I
receptor I
gene I
transcription O
, O
thus O
providing O
an O
explanation O
for O
the O
constant O
association O
of O
IL O
- O
2 O
receptor O
expression O
with O
adult O
T O
- O
cell O
lymphotropic O
virus O
- O
I O
infection O
of O
lymphoid O
cells O
. O

Two O
patients O
with O
Tac O
- O
positive O
adult O
T O
- O
cell O
leukemia O
have O
been O
treated O
with O
the O
anti B
- I
Tac I
. O

One O
of O
the O
patients O
had O
6 O
- O
and O
3 O
- O
mo O
remissions O
of O
his O
leukemia O
following O
two O
courses O
of O
therapy O
with O
this O
monoclonal O
antibody O
directed O
toward O
this O
growth B
factor I
receptor I
. O

Structure O
and O
regulation O
of O
the O
glucocorticoid B
hormone I
receptor I
. O

The O
glucocorticoid O
receptor O
is O
an O
intracellular B
protein I
which O
possesses O
three O
distinct O
domains O
, O
one O
that O
binds O
agonist O
and O
antagonist O
steroids O
, O
one O
that O
binds O
DNA O
, O
and O
one O
that O
binds O
anti B
- I
receptor I
antibodies I
and O
is O
required O
for O
glucocorticoid O
modulation O
of O
gene O
expression O
. O

Some O
of O
these O
factors O
appear O
to O
exert O
their O
effect O
by O
controlling O
critical O
receptor O
properties O
such O
as O
ATP O
- O
dependent O
phosphorylation O
, O
integrity O
of O
thiol B
groups I
, O
and O
exposure O
of O
key B
amino I
acid I
residues I
. O

Glucocorticoid O
antagonists O
are O
steroids O
that O
interact O
with O
the O
receptor O
but O
either O
fail O
to O
produce O
a O
stable B
complex I
or O
produce O
a O
stable B
but I
inefficient I
complex I
. O

The O
transformed B
receptor I
then O
interacts O
with O
chromatin O
( O
state O
D O
) O
. O

Dissociation O
of O
the O
steroid O
and O
oxidation O
of O
receptor B
thiol I
group I
( O
s O
) O
lead O
to O
the O
inactive O
receptor O
form O
( O
state O
E O
) O
. O

Cell O
cycle O
- O
related O
changes O
in O
number O
of O
T B
- I
lymphocyte I
receptors I
for O
glucocorticoids O
and O
insulin O
. O

Few O
but O
significant O
numbers O
of O
glucocorticoid O
receptors O
( O
2700 O
/ O
cell O
) O
and O
no O
insulin B
receptors I
( O
- O
1 O
/ O
cell O
) O
were O
found O
in O
the O
resting O
( O
G0 O
) O
phase O
. O

Based O
on O
these O
findings O
, O
it O
is O
concluded O
that O
both O
receptor O
types O
( O
cell B
membrane I
and I
cytoplasmic I
receptors I
) O
are O
being O
formed O
and O
increased O
at O
G1 O
phase O
prior O
to O
cell O
proliferation O
, O
indicating O
the O
importance O
of O
G1 O
phase O
in O
immunoregulation O
. O

DEX O
almost O
completely O
inhibited O
TPA O
activation O
of O
the O
following O
macrophage O
functions O
: O
adherency O
to O
the O
culture O
plate O
, O
expression O
of O
lysosomal B
enzymes I
, O
Fc B
and I
C3 I
receptors I
, O
and O
stimulation O
of O
phagocytosis O
. O

The O
conclusions O
from O
these O
findings O
are O
: O
( O
a O
) O
the O
inhibition O
of O
mitogenic O
stimulation O
by O
1 O
, O
25 O
( O
OH O
) O
2D3 O
is O
mediated O
by O
specific B
functional I
receptors I
to O
the O
hormone O
; O
and O
( O
b O
) O
the O
receptors O
for O
1 O
, O
25 O
( O
OH O
) O
2D3 O
in O
mononuclear O
cells O
are O
probably O
controlled O
genetically O
by O
the O
same O
mechanisms O
as O
the O
effector O
system O
in O
well O
- O
characterized O
target O
organs O
of O
the O
hormone O
, O
such O
as O
intestine O
and O
kidney O
. O

The O
inhibitory O
effect O
on O
B O
- O
cell O
function O
can O
be O
observed O
both O
as O
decreased O
serum O
levels O
of O
immunoglobulins B
and O
as O
impaired O
binding O
of O
antibodies O
and O
complement O
to O
the O
cellular O
surface O
. O

Reduced O
T O
- O
cell O
function O
indicated O
by O
impaired O
stimulation O
by O
PHA O
and O
porkweed B
as O
well O
as O
by O
impaired O
lymphokinin O
effects O
on O
leukocyte O
migration O
inhibition O
has O
been O
reported O
. O

Identification O
of O
human B
leukemic I
glucocorticoid I
receptors I
using O
affinity O
labeling O
and O
anti B
- I
human I
glucocorticoid I
receptor I
antibodies I
. O

Antisera O
raised O
against O
human B
lymphoid I
glucocorticoid I
receptors I
were O
used O
in O
combination O
with O
the O
glucocorticoid O
receptor O
affinity O
label O
[ O
3H O
] O
dexamethasone O
21 O
- O
mesylate O
[ O
( O
3H O
] O
DM O
) O
to O
identify O
the O
glucocorticoid O
receptors O
of O
the O
human O
B O
- O
lymphoblastoid O
cell O
line O
IM O
- O
9 O
and O
the O
human O
T O
- O
cell O
leukemic O
cell O
line O
CEM O
- O
C7 O
. O

Antisera O
were O
obtained O
following O
immunization O
of O
New O
Zealand O
White O
rabbits O
with O
[ B
3H I
] I
triamcinolone I
acetonide I
[ I
( I
3H I
] I
TA I
) I
- I
glucocorticoid I
receptor I
complexes I
partially O
purified O
by O
two O
- O
stage O
DNA O
- O
cellulose O
chromatography O
. O

The O
presence O
of O
anti B
- I
human I
glucocorticoid I
receptor I
antibodies I
was O
verified O
by O
: O
( O
a O
) O
adsorption O
of O
[ B
3H I
] I
TA I
- I
receptor I
- I
antibody I
complexes I
to O
Protein B
A I
; O
( O
b O
) O
a O
shift O
to O
higher O
apparent O
molecular O
weight O
in O
the O
elution O
position O
from O
Sephacryl O
S300 O
of O
[ B
3H I
] I
TA I
- I
receptor I
complexes I
incubated O
with O
immune O
serum O
; O
and O
( O
c O
) O
the O
ability O
of O
immune O
serum O
to O
displace O
[ B
3H I
] I
TA I
- I
receptor I
complexes I
on O
sucrose O
gradients O
. O

These O
antibodies O
also O
recognized O
rat O
liver O
and O
murine B
S49 I
cell I
glucocorticoid I
receptors I
. O

Thus O
, O
the O
combination O
of O
affinity O
labeling O
and O
anti B
- I
human I
glucocorticoid I
receptor I
antibodies I
is O
capable O
of O
providing O
direct O
physical O
identification O
of O
human B
lymphoid I
glucocorticoid I
receptors I
. O

Specific B
high I
- I
affinity I
receptors I
for O
1 O
, O
25 O
- O
dihydroxyvitamin O
D3 O
in O
human O
peripheral O
blood O
mononuclear O
cells O
: O
presence O
in O
monocytes O
and O
induction O
in O
T O
lymphocytes O
following O
activation O
. O

Moderate O
- O
to O
- O
severe O
intraductal O
epithelial O
hyperplasias O
were O
more O
often O
associated O
with O
immunoglobulin B
G I
localization O
that O
were O
other O
benign O
lesions O

Breast O
carcinomas O
were O
examined O
by O
the O
immunoperoxidase O
technique O
using O
antisera O
specific O
for O
lymphocyte O
subsets O
, O
monocytes O
, O
NK O
cells O
and O
major B
histocompatibility I
antigens I
( O
HLA B
- I
A I
, O
- O
B O
, O
- O
C O
; O
Ia B
- I
like I
) O
. O

Some O
of O
the O
T O
cells O
had O
the O
Ia B
antigen I
and O
were O
thus O
probably O
activated O
. O

A O
few O
monocytes O
were O
heterogeneous O
according O
to O
their O
markers O
( O
OKM B
I I
and O
acid O
phosphatase O
) O
. O

In O
6 O
cases O
only O
there O
was O
a O
strong O
infiltration O
of O
mononuclear O
cells O
positive O
for O
acid B
phosphatase I
. O

There O
was O
a O
positive O
correlation O
between O
the O
inflammatory O
infiltration O
and O
the O
presence O
of O
HLA B
class I
- I
I I
antigens I
on O
tumor O
cell O
s O
. O

A O
study O
of O
the O
receptors O
for O
dihydrotestosterone O
in O
fibroblasts O
of O
genital O
and O
nongenital O
skin O
showed O
a O
normal O
concentration O
of O
receptors O
in O
genital O
skin O
; O
5 B
- I
alpha I
- I
reductase I
activity O
in O
fibroblasts O
of O
the O
genital O
skin O
was O
low O
, O
but O
the O
plasma O
relationship O
testosterone O
/ O
dihydrotestosterone O
under O
HCG O
stimulation O
was O
normal O
. O

The O
proliferative O
response O
of O
murine O
spleen O
and O
thymus O
cells O
to O
antigen B
but O
not O
to O
lectin O
was O
inhibited O
by O
the O
active O
metabolite O
of O
vitamin O
D3 O
, O
1 O
, O
25 O
- O
( O
OH O
) O
2D3 O
. O

1 O
, O
25 O
- O
( O
OH O
) O
2D3 O
failed O
, O
however O
, O
to O
inhibit O
the O
activation O
of O
the O
T O
cell O
hybridomas O
by O
lectin O
or O
by O
an O
anti B
- I
Thy I
- I
1 I
antibody I
. O

It O
was O
shown O
that O
GC B
receptors I
in O
donors O
' O
lymphocytes O
could O
be O
distributed O
into O
two O
different O
classes O
similarly O
to O
the O
pattern O
seen O
in O
skin O
fibroblasts O
. O

Human O
lymphocytes O
are O
an O
adequate O
object O
for O
studying O
genetically O
determined O
variability O
of O
GC B
receptors I
and O
its O
clinical O
importance O
. O

Specific O
estrogen B
binding I
sites I
in O
human O
lymphoid O
cells O
and O
thymic O
cells O
. O

Scatchard O
' O
s O
analysis O
of O
[ O
3H O
] O
- O
moxestrol O
( O
R2858 O
) O
and O
[ O
3H O
] O
- O
estradiol O
binding O
proves O
the O
existence O
of O
a O
single O
class O
of O
receptor B
sites I
having O
a O
dissociation O
constant O
of O
0 O
. O
18 O
- O
2 O
. O
4 O
X O
10 O
( O
- O
9 O
) O
M O
. O

Administration O
of O
fibroblast B
interferon I
to O
patients O
with O
advanced O
breast O
cancer O
: O
possible O
effects O
on O
skin O
metastasis O
and O
on O
hormone O
receptors O
. O

Eleven O
patients O
with O
metastasized O
breast O
cancer O
received O
8 O
intramuscular O
injections O
of O
6 O
x O
10 O
( O
6 O
) O
units O
of O
human B
fibroblast I
interferon I
over O
a O
period O
of O
40 O
days O
. O

Glucocorticoid O
receptor O
concentrations O
and O
terminal O
transferase B
activity O
as O
indicators O
of O
prognosis O
in O
acute O
non O
- O
lymphocytic O
leukaemia O
. O

Activity O
of O
terminal O
deoxynucleotidyl O
transferase O
( O
TdT B
) O
, O
adenosine O
deaminase O
, O
and O
5 B
' I
nucleotidase I
and O
the O
cellular O
concentration O
of O
glucocorticoid B
( I
dexamethasone I
) I
receptor I
were O
determined O
in O
25 O
patients O
with O
acute O
non O
- O
lymphocytic O
leukaemia O
. O

Increased O
activity O
of O
TdT B
( O
greater O
than O
0 O
. O
1 O
unit O
/ O
microgram O
DNA O
) O
was O
found O
in O
11 O
patients O
. O

Adenosine O
deaminase O
and O
5 B
' I
nucleotidase I
activities O
both O
varied O
within O
two O
orders O
of O
magnitude O
. O

These O
results O
show O
that O
measurements O
of O
TdT B
activity O
and O
the O
glucocorticoid O
receptor O
concentration O
yield O
valuable O
prognostic O
information O
in O
acute O
non O
- O
lymphocytic O
leukaemia O

On O
DEAE O
- O
cellulose O
chromatography O
, O
[ B
3H I
] I
CVZ I
- I
receptor I
complexes I
show O
a O
shift O
from O
high O
( O
0 O
. O
25 O
M O
KP O
) O
to O
low O
salt O
( O
0 O
. O
09 O
M O
KP O
) O
eluting O
forms O
upon O
activation O
. O

The O
receptor O
concentration O
of O
the O
low O
affinity O
site O
( O
0 O
. O
30 O
pmol O
/ O
mg O
protein O
) O
was O
approximately O
twice O
that O
of O
the O
high B
affinity I
site I
( O
0 O
. O
14 O
pmol O
/ O
mg O
protein O
) O
. O

In O
cytosol O
from O
a O
glucocorticoid O
- O
resistant O
cell O
line O
with O
virtually O
no O
[ O
3H O
] O
DEX O
binding O
, O
[ O
3H O
] O
CVZ O
detected O
a O
single O
high O
affinity O
binding O
site O
that O
was O
similar O
in O
dissociation O
constant O
( O
0 O
. O
8 O
nM O
) O
and O
receptor O
concentration O
( O
0 O
. O
13 O
pmol O
/ O
mg O
protein O
) O
to O
the O
high B
affinity I
site I
detected O
in O
the O
glucocorticoid O
- O
sensitive O
cell O
line O
C7 O
. O

A O
controlled O
pore O
glass O
bead O
assay O
for O
the O
measurement O
of O
cytoplasmic B
and I
nuclear I
glucocorticoid I
receptors I
. O

An O
assay O
for O
the O
quantitation O
of O
cytoplasmic B
and I
nuclear I
glucocorticoid I
receptors I
in O
lymphoid O
tissue O
has O
been O
developed O
using O
controlled O
pore O
glass O
( O
CPG O
) O
beads O
. O

Soluble O
receptor B
- I
- I
3H I
- I
steroid I
complex I
( O
cytosol O
or O
nuclear O
extract O
) O
is O
adsorbed O
quantitatively O
within O
the O
crevasses O
of O
porous O
glass O
beads O
. O

Excess O
labeled O
steroid O
as O
well O
as O
most O
non O
- O
specifically O
bound O
steroid O
is O
easily O
washed O
away O
, O
leaving O
the O
hormone B
- I
receptor I
complex I
retained O
by O
the O
beads O
. O

A O
comparison O
of O
the O
CPG O
assay O
to O
dextran O
coated O
charcoal O
and O
a O
whole O
cell O
assay O
demonstrates O
that O
CPG O
and O
dextran O
coated O
charcoal O
give O
equivalent O
measurements O
of O
cytosolic B
receptor I
concentration O
, O
while O
the O
CPG O
and O
whole O
cell O
assays O
provide O
equivalent O
values O
for O
total O
receptor O
content O
. O

Evolution O
of O
a O
case O
of O
chronic O
lymphocytic O
leukemia O
( O
CLL O
) O
into O
blast O
crisis O
was O
found O
to O
be O
characterized O
by O
three O
unusual O
features O
( O
1 O
) O
the O
phenotype O
of O
the O
emerging O
blast O
cells O
was O
that O
of O
pre O
- O
plasmacytoid O
cells O
as O
shown O
by O
plasma O
cell O
morphology O
and O
an O
immunological O
phenotype O
corresponding O
partially O
with O
CLL O
- O
or O
intermediate O
B O
- O
cells O
, O
partially O
with O
plasma O
cells O
( O
terminal B
transferase I
- O
, O
common O
acute B
lymphocytic I
leukemia I
antigen I
- O
, O
Ia B
+ I
, O
surface B
immunoglobulin I
heavy I
chains I
- O
, O
surface B
kappa I
light I
chains I
+ O
, O

intracytoplasmic B
immunoglobulin I
A I
+ I
and I
G I
+ I
, O
BA B
- I
1 I
+ I
, O
polyclonal O
gammaglobulin O
production O
) O
; O
( O
2 O
) O
cytogenetic O
analysis O
of O
spontaneous O
metaphases O
revealed O
that O
in O
addition O
to O
the O
typical O
CLL O
abnormality O
, O
trisomy O
12 O
, O
in O
all O
of O
the O
cells O
, O
an O
additional O
translocation O
between O
chromosomes B
14 I
and I
17 I
was O
present O
in O
40 O
% O
with O
a O
presumptive O
breakpoint O
on O
chromosome O
14 O
( O
q12 O
- O
3 O
) O
never O
described O
before O
( O
commonly O
q32 O
) O
and O
( O
3 O
) O
the O
progression O
of O
the O
disease O
was O
associated O
with O
a O

striking O
increase O
in O
the O
expression O
by O
the O
transformed O
cells O
of O
specific O
binding O
sites O
for O
estradiol O
( O
E2 O
) O
due O
to O
an O
actual O
increase O
in O
total O
cellular B
receptor I
proteins I
and O
not O
to O
a O
change O
in O
receptor O
affinity O
for O
E2 O
. O

The O
functional O
status O
of O
the O
steroid O
receptors O
was O
confirmed O
by O
nuclear O
transfer O
of O
the O
cytoplasmic B
hormone I
- I
receptor I
complex I
upon O
temperature O
activation O
. O

Since O
the O
rise O
in O
E2 B
- I
receptor I
display O
paralleled O
a O
large O
increase O
in O
the O
proliferative O
activity O
of O
the O
cells O
as O
well O
as O
a O
change O
in O
their O
maturation O
status O
the O
question O
was O
raised O
as O
to O
whether O
the O
E2 B
- I
receptor I
should O
be O
considered O
as O
a O
physiological O
marker O
of O
growth O
rate O
or O
of O
cellular O
differentiation O
. O

This O
suggests O
the O
association O
of O
E2 B
- I
receptor I
expression O
with O
control O
of O
growth O
rather O
than O
cell O
maturation O
. O

Multiple O
forms O
and O
fragments O
of O
cytosolic B
glucocorticoid I
receptors I
from O
human O
leukemic O
cells O
and O
normal O
lymphocytes O
. O

The O
objectives O
of O
this O
study O
were O
to O
determine O
whether O
there O
are O
intrinsic O
structural O
differences O
among O
the O
glucocorticoid O
receptors O
in O
various O
types O
of O
leukemic O
cells O
and O
normal O
lymphocytes O
and O
to O
investigate O
the O
role O
of O
endogenous B
peptidases I
in O
receptor O
degradation O
. O

In O
hypertonic O
, O
molybdate O
- O
free O
buffer O
, O
these O
oligomeric B
complexes I
were O
dissociated O
into O
subunits O
with O
Rs O
of O
5 O
. O
9 O
+ O
/ O
- O
0 O
. O
3 O
nm O
( O
n O
= O
12 O
) O
and O
a O
/ O
b O
of O
11 O
to O
12 O
, O
as O
observed O
previously O
for O
other O
receptors O
. O

Fragmentation O
of O
the O
oligomer O
and O
the O
subunit B
was O
evident O
in O
some O
cytosols O
. O

High O
activities O
of O
peptidases B
of O
various O
specificities O
were O
detected O
in O
leukemic O
cell O
cytosols O
, O
as O
in O
other O
cytosols O
, O
by O
fluorometric O
assays O
with O
derivatives O
of O
7 O
- O
amino O
- O
4 O
- O
methylcoumarin O
. O

Receptor O
cleavage O
by O
these O
and O
other O
endogenous B
enzymes I
may O
account O
for O
previous O
observations O
of O
` O
` O
abnormal O
' O
' O
receptors O
in O
cytosols O
from O
some O
leukemic O
specimens O
. O

Covalent O
labeling O
of O
rat O
thymocyte O
and O
human B
lymphoid I
glucocorticoid I
receptor I
. O

Smaller B
moieties I
were O
also O
identified O
by O
competition O
experiments O
; O
these O
may O
represent O
proteolytic B
fragments I
of O
the O
Mr O
approximately O
equal O
to O
95 O
, O
000 O
receptor O
. O

The O
association O
of O
cytosol O
oestrogen B
and I
progesterone I
receptors I
with O
histological O
features O
of O
breast O
cancer O
and O
early O
recurrence O
of O
disease O
. O

Two O
hundred O
and O
eighty O
- O
eight O
primary O
breast O
tumours O
were O
examined O
for O
the O
presence O
or O
absence O
of O
oestrogen B
( I
REc I
) I
and I
progesterone I
( I
RPc I
) I
receptors I
. O

There O
were O
significant O
associations O
between O
epithelial O
cellularity O
, O
stromal O
fibrosis O
and O
the O
value O
of O
REc B
in O
those O
tumours O
in O
which O
the O
receptor O
was O
present O
. O

By O
contrast O
, O
neither O
the O
presence O
or O
absence O
nor O
the O
value O
of O
RPc B
could O
be O
related O
to O
cellularity O
or O
fibrosis O
. O

The O
value O
of O
REc B
and O
RPc B
analysis O
as O
an O
indicator O
of O
prognosis O
was O
examined O
in O
a O
sub O
- O
group O
of O
175 O
patients O
receiving O
no O
additional O
treatment O
following O
mastectomy O
. O

Overall O
relapse O
- O
free O
survival O
( O
RFS O
) O
was O
no O
different O
for O
those O
patients O
with O
receptors O
compared O
to O
those O
without O
them O
( O
REc B
P O
= O
0 O
. O
11 O
, O
RPc O
P O
= O
0 O
. O
7 O
) O
. O

Intracytoplasmic B
corticosteroid I
- I
specific I
receptors I
appear O
to O
be O
an O
important O
common O
pathway O
for O
steroid O
- O
induced O
changes O
, O
but O
variations O
of O
receptor O
parameters O
do O
not O
account O
for O
the O
multifaceted O
effects O
on O
the O
immune O
system O
. O

The O
cytoplasmic B
receptors I
of O
leukaemia O
and O
lymphoblastoid O
lines O
appeared O
to O
contain O
both O
proteinaceous O
and O
phospholipid O
components O
. O

Cytoplasmic B
steroid I
- I
receptor I
complexes I
exhibited O
a O
wide O
range O
of O
sedimentation O
coefficients O
( O
8 O
. O
5 O
- O
11 O
. O
3S O
) O
in O
low O
ionic O
strength O
buffer O
but O
there O
was O
no O
correlation O
with O
cell O
line O
type O
or O
glucocorticoid O
sensitivity O
. O

The O
resistance O
to O
cytolethal O
effects O
can O
not O
be O
ascribed O
to O
a O
failure O
of O
cells O
to O
take O
up O
and O
bind O
steroid O
or O
to O
significant O
differences O
in O
the O
molecular O
species O
of O
cytoplasmic B
receptors I
present O
. O

Analysis O
of O
the O
nuclear B
c I
- I
Rel I
protein I
indicated O
that O
after O
anti O
- O
CD3 O
+ O
anti O
- O
CD28 O
stimulation O
the O
level O
of O
c O
- O
Rel O
was O
higher O
in O
CD45RA O
+ O
cells O
. O

Here O
we O
review O
the O
role O
of O
Ikaros O
, O
the O
founding O
member O
of O
a O
unique O
family O
of O
zinc B
finger I
transcription I
factors I
in O
this O
developmental O
process O
. O

Cotransfection O
of O
both O
c O
- O
Jun O
and O
c O
- O
Fos O
substitutes O
for O
B7 O
- O
1 O
costimulation O
in O
driving O
an O
activation B
protein I
- I
1 I
response I
element I
but O
not O
for O
the O
IL O
- O
2 O
promoter O
. O

Overexpression O
of O
Rel O
proteins O
demonstrated O
that O
p65 O
- O
expressing O
Jurkat O
cells O
transcribed O
equally O
well O
a O
nuclear B
factor I
kappabeta I
reporter I
construct I
when O
costimulated O
with O
B7 O
- O
1 O
or O
LFA O
- O
3 O
, O
but O
transcription O
of O
IL O
- O
2 O
promoter O
or O
CD28 B
response I
element I
( I
CD28RE I
) I
- I
driven I
reporters I
was O
superior O
in O
B7 O
- O
1 O
- O
costimulated O
cells O
. O

Combined O
expression O
of O
c O
- O
Jun O
and O
p65 O
induced O
vigorous O
transcription O
of O
IL B
- I
2 I
promoter I
- I
and I
CD28RE I
- I
driven I
reporter I
constructs I
in O
both O
LFA O
- O
3 O
- O
and O
B7 O
- O
1 O
- O
costimulated O
Jurkat O
cells O
. O

Mutating O
the O
CD28RE O
but O
not O
the O
upstream B
nuclear I
factor I
kappabeta I
- I
binding I
site I
in O
the O
IL O
- O
2 O
promoter O
reduced O
B7 O
- O
1 O
- O
driven O
transcription O
> O
90 O
% O
. O

Activation O
of O
Jun O
N O
- O
terminal O
kinase O
or O
stress B
- I
activated I
kinase I
( O
JNK O
or O
SAPK O
) O
and O
mitogen O
- O
activated O
protein O
kinase O
( O
MAPK O
) O
and O
the O
induction O
of O
the O
transcription O
factor O
NF B
- I
ATc1 I
and I
egr I
- I
1 I
genes I
was O
normal O
. O

Despite O
the O
reduced O
Ca2 O
+ O
mobilization O
, O
translocation O
of O
cytoplasmic B
NF I
- I
ATc I
to O
the O
nucleus O
was O
normal O
, O
reflecting O
that O
the O
lower O
levels O
of O
Ca2 O
+ O
in O
vav O
- O
/ O
- O
cells O
were O
still O
sufficient O
to O
activate O
calcineurin O
. O

To O
assess O
HUVEC O
activation O
, O
E O
- O
selectin O
expression O
was O
measured O
by O
enzyme O
- O
linked O
immunosorbent O
assay O
( O
ELISA O
) O
, O
Northern O
blot O
analysis O
for O
E B
- I
selectin I
- I
specific I
mRNA I
, O
and O
electrophoretic O
gel O
mobility O
shift O
assay O
( O
EMSA O
) O
for O
NF O
- O
kappa O
B O
, O
a O
transcription O
factor O
necessary O
for O
E O
- O
selectin O
gene O
activation O
. O

Inhibition O
of O
TNFalpha O
- O
induced O
NF O
- O
kappaB O
activation O
using O
the O
antioxidant O
N O
- O
acetylcysteine O
( O
NAC O
) O
resulted O
in O
increased O
apoptosis O
in O
both O
U937 O
and O
U9 O
- O
IIIB O
cells O
, O
while O
preactivation O
of O
NF O
- O
kappaB O
with O
the O
non B
- I
apoptotic I
inducer I
IL I
- I
1beta I
caused O
a O
relative O
decrease O
in O
apoptosis O
. O

TNFalpha O
plus O
NAC O
treatment O
resulted O
in O
a O
marked O
decrease O
in O
Bcl O
- O
2 O
protein O
levels O
in O
HIV O
- O
1 O
- O
infected O
cells O
, O
coupled O
with O
an O
increase O
in O
Bax B
protein I
compared O
to O
uninfected O
cells O
, O
suggesting O
that O
the O
difference O
in O
susceptibility O
to O
TNFalpha O
- O
induced O
apoptosis O
may O
relate O
to O
the O
differences O
in O
relative O
levels O
of O
Bcl O
- O
2 O
and O
Bax O
. O

The O
protective O
role O
of O
NF O
- O
kappaB O
in O
blocking O
TNFalpha O
- O
and O
HIV O
- O
1 O
- O
induced O
apoptosis O
was O
supported O
by O
studies O
in O
Jurkat O
T O
cells O
engineered O
to O
express O
IkappaB B
alpha I
repressor I
mutants I
( O
TD B
- I
IkappaB I
) O
under O
the O
control O
of O
a O
tetracycline B
- I
responsive I
promoter I
. O

Cells O
underwent O
apoptosis O
in O
response O
to O
TNFalpha O
only O
when O
NF O
- O
kappaB O
activation O
was O
inhibited O
by O
TD B
- I
IkappaB I
expression O
. O

Human O
normal O
peripheral O
blood O
B O
- O
lymphocytes O
are O
deficient O
in O
DNA O
- O
dependent O
protein O
kinase O
activity O
due O
to O
the O
expression O
of O
a O
variant O
form O
of O
the O
Ku86 B
protein I
. O

The O
heterodimeric O
Ku B
protein I
, O
which O
comprises O
a O
86 B
kDa I
( I
Ku86 I
) I
amd O
a O
70 B
kDa I
( I
Ku70 I
) I
subunits I
, O
is O
an O
abundant O
nuclear O
DNA O
- O
binding O
protein O
which O
binds O
in O
vitro O
to O
DNA B
termini I
without O
sequence O
specificity O
. O

Ku O
is O
the O
DNA B
- I
targeting I
component I
of O
the O
large O
catalytic B
sub I
- I
unit I
of O
the O
DNA B
- I
dependent I
protein I
kinase I
complex I
( O
DNA O
- O
PK O
[ O
CS O
] O
) O
, O
that O
plays O
a O
critical O
role O
in O
mammalian O
double O
- O
strand O
break O
repair O
and O
lymphoid O
V O
( O
D O
) O
J O
recombination O
. O

By O
using O
electrophoretic O
mobility O
shift O
assays O
, O
we O
demonstrated O
that O
in O
addition O
to O
the O
major B
Ku I
x I
DNA I
complex I
usually O
detected O
in O
cell O
line O
extracts O
, O
a O
second O
complex O
with O
faster O
electrophoretic O
mobility O
was O
observed O
in O
normal O
peripheral O
blood O
lymphocytes O
( O
PBL O
) O
extracts O
. O

Western O
blot O
analysis O
revealed O
that O
B O
cells O
express O
a O
variant O
form O
of O
the O
Ku86 B
protein I
with O
an O
apparent O
molecular O
weight O
of O
69 O
kDa O
, O
and O
not O
the O
86 B
kDa I
- I
full I
- I
length I
protein I
. O

Although O
the O
heterodimer B
Ku70 I
/ I
variant I
- I
Ku86 I
binds O
to O
DNA B
- I
ends I
, O
this O
altered O
form O
of O
the O
Ku B
heterodimer I
has O
a O
decreased O
ability O
to O
recruit O
the O
catalytic B
component I
of O
the O
complex O
, O
DNA O
- O
PK O
( O
CS O
) O
, O
which O
contributes O
to O
an O
absence O
of O
detectable O
DNA O
- O
PK O
activity O
in O
B O
cells O
. O

Phosphorylation O
of O
the O
cAMP B
- I
response I
element I
binding I
protein I
CREB I
within O
1 O
h O
of O
CD2 O
but O
not O
CD3 O
cross O
- O
linking O
of O
human O
PBMC O
was O
recently O
demonstrated O
. O

Therefore O
, O
P O
- O
CREB O
was O
evaluated O
following O
co O
- O
stimulation O
of O
human O
PBMC O
through O
the O
IL B
- I
2 I
and I
CD2 I
or I
CD3 I
receptors I
. O

Although O
all O
the O
cells O
in O
an O
organism O
contain O
the O
same O
genetic O
information O
, O
differences O
in O
the O
cell O
phenotype O
arise O
from O
the O
expression O
of O
lineage B
- I
specific I
genes I
. O

In O
particular O
, O
the O
transcription B
factor I
PU I
. I
1 I
has O
a O
critical O
role O
in O
this O
process O
. O

Transcription B
factor I
LKLF I
is O
sufficient O
to O
program O
T O
cell O
quiescence O
via O
a O
c O
- O
Myc O
- O
- O
dependent O
pathway O
. O

T O
lymphocytes O
circulate O
in O
a O
quiescent O
state O
until O
they O
encounter O
cognate B
antigen I
bound O
to O
the O
surface O
of O
an O
antigen O
- O
presenting O
cell O
. O

Here O
we O
show O
that O
forced O
expression O
of O
the O
lung B
Kruppel I
- I
like I
transcription I
factor I
( O
LKLF B
) O
in O
Jurkat O
T O
cells O
is O
sufficient O
to O
program O
a O
quiescent O
phenotype O
characterized O
by O
decreased O
proliferation O
, O
reduced O
cell O
size O
and O
protein O
synthesis O
and O
decreased O
surface O
expression O
of O
activation O
markers O
. O

LKLF B
appeared O
to O
function O
, O
at O
least O
in O
part O
, O
by O
decreasing O
expression O
of O
the O
proto O
- O
oncogene O
encoding O
c O
- O
Myc O
. O

Forced O
expression O
of O
LKLF B
was O
associated O
with O
markedly O
decreased O
c O
- O
Myc O
expression O
. O

In O
addition O
, O
many O
effects O
of O
LKLF B
expression O
were O
mimicked O
by O
expression O
of O
the O
dominant B
- I
negative I
MadMyc I
protein I
and O
rescued O
by O
overexpression O
of O
c O
- O
Myc O
. O

Thus O
, O
LKLF B
is O
both O
necessary O
and O
sufficient O
to O
program O
quiescence O
in O
T O
cells O
and O
functions O
, O
in O
part O
, O
by O
negatively O
regulating O
a O
c O
- O
Myc O
- O
- O
dependent O
pathway O
. O

HTLV B
- I
1 I
p12 I
( I
I I
) I
protein I
enhances O
STAT5 O
activation O
and O
decreases O
the O
interleukin O
- O
2 O
requirement O
for O
proliferation O
of O
primary O
human O
peripheral O
blood O
mononuclear O
cells O
. O

The O
p12 B
( I
I I
) I
protein I
, O
encoded O
by O
the O
pX B
open I
reading I
frame I
I I
of O
the O
human O
T O
- O
lymphotropic O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
, O
is O
a O
hydrophobic B
protein I
that O
localizes O
to O
the O
endoplasmic O
reticulum O
and O
the O
Golgi O
. O

Although O
p12 B
( I
I I
) I
contains O
4 O
minimal O
proline O
- O
rich O
, O
src B
homology I
3 I
- I
binding I
motifs I
( O
PXXP B
) O
, O
a O
characteristic O
commonly O
found O
in O
proteins O
involved O
in O
signaling O
pathways O
, O
it O
has O
not O
been O
known O
whether O
p12 B
( I
I I
) I
has O
a O
role O
in O
modulating O
intracellular O
signaling O
pathways O
. O

This O
study O
demonstrated O
that O
p12 B
( I
I I
) I
binds O
to O
the O
cytoplasmic O
domain O
of O
the O
interleukin B
- I
2 I
receptor I
( I
IL I
- I
2R I
) I
beta I
chain I
that O
is O
involved O
in O
the O
recruitment O
of O
the O
Jak1 B
and I
Jak3 I
kinases I
. O

As O
a O
result O
of O
this O
interaction O
, O
p12 B
( I
I I
) I
increases O
signal B
transducers I
and I
activators I
of I
transcription I
5 I
( O
STAT5 O
) O
DNA O
binding O
and O
transcriptional O
activity O
and O
this O
effect O
depends O
on O
the O
presence O
of O
both O
IL B
- I
2R I
beta I
and I
gamma I
( I
c I
) I
chains I
and O
Jak3 O
. O

Transduction O
of O
primary O
human O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
) O
with O
a O
human B
immunodeficiency I
virus I
type I
1 I
- I
based I
retroviral I
vector I
expressing O
p12 B
( I
I I
) I
also O
resulted O
in O
increased O
STAT5 O
phosphorylation O
and O
DNA O
binding O
. O

However O
, O
p12 B
( I
I I
) I
could O
increase O
proliferation O
of O
human O
PBMCs O
only O
after O
stimulation O
of O
T O
- O
cell O
receptors O
by O
treatment O
of O
cells O
with O
low O
concentrations O
of O
alphaCD3 B
and I
alphaCD28 I
antibodies I
. O

Together O
, O
these O
data O
indicate O
that O
p12 B
( I
I I
) I
may O
confer O
a O
proliferative O
advantage O
on O
HTLV O
- O
1 O
- O
infected O
cells O
in O
the O
presence O
of O
suboptimal O
antigen O
stimulation O
and O
that O
this O
event O
may O
account O
for O
the O
clonal O
proliferation O
of O
infected O
T O
cells O
in O
vivo O
. O

Single O
dose O
intranasal O
administration O
of O
retinal B
autoantigen I
generates O
a O
rapid O
accumulation O
and O
cell O
activation O
in O
draining O
lymph O
node O
and O
spleen O
: O
implications O
for O
tolerance O
therapy O
. O

BACKGROUND O
/ O
AIMS O
: O
A O
single O
intranasal O
delivery O
of O
retinal B
autoantigen I
suppresses O
effectively O
experimental O
autoimmune O
uveoretinitis O
( O
EAU O
) O
. O

METHODS O
: O
Flow O
cytometry O
, O
cell O
proliferation O
assays O
, O
and O
microscopy O
were O
used O
to O
track O
antigen B
following O
a O
single O
, O
intranasal O
dose O
of O
Alexa B
- I
488 I
labelled I
retinal I
antigen I
. O

RESULTS O
: O
A O
rapid O
accumulation O
of O
antigen B
within O
both O
superficial O
cervical O
lymph O
nodes O
( O
SCLN O
) O
and O
spleen O
was O
observed O
after O
30 O
minutes O
. O

Significant O
proliferative O
responses O
to O
IRBP O
were O
elicited O
by O
48 O
hours O
indicating O
that O
systemic O
priming O
of O
naive O
T O
cells O
to O
retinal B
antigen I
had O
occurred O
. O

CONCLUSIONS O
: O
The O
results O
provide O
novel O
evidence O
that O
following O
a O
single O
intranasal O
application O
rapid O
transfer O
of O
antigen B
occurs O
. O

Regulation O
of O
interleukin B
( I
IL I
) I
- I
18 I
receptor I
alpha I
chain I
expression O
on O
CD4 O
( O
+ O
) O
T O
cells O
during O
T O
helper O
( O
Th O
) O
1 O
/ O
Th2 O
differentiation O
. O

Interleukin B
( I
IL I
) I
- I
18 I
has O
been O
well O
characterized O
as O
a O
costimulatory B
factor I
for O
the O
induction O
of O
IL B
- I
12 I
- I
mediated I
interferon I
( I
IFN I
) I
- I
gamma I
production O
by O
T O
helper O
( O
Th O
) O
1 O
cells O
, O
but O
also O
can O
induce O
IL O
- O
4 O
production O
and O
thus O
facilitate O
the O
differentiation O
of O
Th2 O
cells O
. O

To O
determine O
the O
mechanisms O
by O
which O
IL O
- O
18 O
might O
regulate O
these O
diametrically O
distinct O
immune O
responses O
, O
we O
have O
analyzed O
the O
role O
of O
cytokines O
in O
the O
regulation O
of O
IL B
- I
18 I
receptor I
alpha I
chain I
( O
IL B
- I
18Ralpha I
) O
expression O
. O

The O
majority O
of O
peripheral O
CD4 O
( O
+ O
) O
T O
cells O
constitutively O
expressed O
the O
IL B
- I
18Ralpha I
. O

Upon O
antigen O
stimulation O
in O
the O
presence O
of O
IL O
- O
12 O
, O
marked O
enhancement O
of O
IL B
- I
18Ralpha I
expression O
was O
observed O
. O

IL O
- O
12 O
- O
mediated O
upregulation O
of O
IL B
- I
18Ralpha I
required O
IFN O
- O
gamma O
. O

Activated O
CD4 O
( O
+ O
) O
T O
cells O
that O
expressed O
low O
levels O
of O
IL B
- I
18Ralpha I
could O
produce O
IFN O
- O
gamma O
when O
stimulated O
with O
the O
combination O
of O
IL O
- O
12 O
and O
IL O
- O
18 O
, O
while O
CD4 O
( O
+ O
) O
cells O
which O
expressed O
high O
levels O
of O
IL B
- I
18Ralpha I
could O
respond O
to O
IL O
- O
18 O
alone O
. O

In O
contrast O
, O
T O
cell O
stimulation O
in O
the O
presence O
of O
IL O
- O
4 O
resulted O
in O
a O
downregulation O
of O
IL B
- I
18Ralpha I
expression O
. O

Both O
IL O
- O
4 O
( O
- O
/ O
) O
- O
and O
signal O
transducer O
and O
activator O
of O
transcription O
( O
Stat O
) O
6 O
( O
- O
/ O
) O
- O
T O
cells O
expressed O
higher O
levels O
of O
IL B
- I
18Ralpha I
after O
TCR O
stimulation O
. O

Thus O
, O
positive O
/ O
negative O
regulation O
of O
the O
IL B
- I
18Ralpha I
by O
the O
major O
inductive O
cytokines O
( O
IL O
- O
12 O
and O
IL O
- O
4 O
) O
determines O
the O
capacity O
of O
IL O
- O
18 O
to O
polarize O
an O
immune O
response O
. O

Glucocorticoid B
- I
regulated I
transcription I
factors I
. O

Inhibition O
of O
pro B
- I
inflammatory I
transcription I
factors I
such O
as O
activator O
protein O
( O
AP O
) O
- O
1 O
, O
signal O
transducers O
and O
activators O
of O
transcription O
( O
STATs O
) O
, O
nuclear O
factor O
of O
activated O
T O
cells O
( O
NFAT O
) O
and O
nuclear O
factor O
( O
NF O
) O
- O
kappa O
B O
is O
thought O
to O
be O
a O
major O
action O
of O
glucocorticoids O
. O

Acetylation O
of O
histones B
allows O
unwinding O
of O
the O
local B
DNA I
structure I
and O
enables O
RNA O
polymerase O
II O
to O
enhance O
gene O
transcription O
. O

Histone O
acetylation O
is O
regulated O
by O
a O
balance O
between O
the O
activity O
of O
histone O
acetyltransferases O
( O
HATs B
) O
and O
histone O
deacetylases O
( O
HDACs B
) O
. O

GR O
acts O
as O
a O
direct O
inhibitor O
of O
NF O
- O
kappa O
B O
- O
induced O
HAT O
activity O
and O
also O
by O
recruiting O
HDAC2 B
to O
the O
NF B
- I
kappa I
B I
/ I
HAT I
complex I
. O

A O
sub O
- O
group O
of O
patients O
with O
glucocorticoid O
- O
insensitive O
asthma O
have O
an O
inability O
to O
induce O
histone O
acetylation O
in O
response O
to O
dexamethasone O
suggesting O
reduced O
expression O
of O
a O
GR B
- I
specific I
HAT I
. O

Identification O
of O
the O
precise O
mechanism O
by O
which O
activated B
GR I
recruits O
HDAC2 B
may O
reveal O
new O
targets O
for O
the O
development O
of O
drugs O
that O
may O
dissociate O
the O
antiinflammatory O
actions O
of O
glucocorticoids O
from O
their O
side O
effects O
that O
are O
largely O
due O
to O
gene O
induction O
. O

Biomechanical O
strain O
induces O
class O
a O
scavenger B
receptor I
expression O
in O
human O
monocyte O
/ O
macrophages O
and O
THP O
- O
1 O
cells O
: O
a O
potential O
mechanism O
of O
increased O
atherosclerosis O
in O
hypertension O
. O

We O
tested O
the O
hypothesis O
that O
biomechanical O
strain O
can O
induce O
expression O
of O
the O
class B
A I
scavenger I
receptor I
( O
SRA B
) O
, O
an O
important O
lipoprotein B
receptor I
in O
atherogenesis O
. O

METHODS O
AND O
RESULTS O
: O
Human O
monocyte O
/ O
macrophages O
or O
THP O
- O
1 O
cells O
were O
cultured O
in O
a O
device O
that O
imposes O
uniform O
biaxial O
cyclic O
1 O
- O
Hz O
strains O
of O
0 O
% O
, O
1 O
% O
, O
2 O
% O
, O
or O
3 O
% O
, O
and O
SRA B
expression O
was O
analyzed O
. O

Mechanical O
strains O
induced O
SRA B
mRNA I
( O
3 O
. O
5 O
+ O
/ O
- O
0 O
. O
6 O
- O
fold O
at O
3 O
% O
strain O
for O
48 O
hours O
, O
P O
< O
0 O
. O
01 O
) O
and O
SRA B
protein I
in O
THP O
- O
1 O
cells O
in O
an O
amplitude O
- O
dependent O
manner O
. O

This O
induction O
was O
accompanied O
by O
augmented O
expression O
of O
the O
class B
B I
scavenger I
receptor I
CD36 I
( O
2 O
. O
8 O
+ O
/ O
- O
0 O
. O
3 O
- O
fold O
, O
P O
< O
0 O
. O
001 O
) O
but O
not O
by O
increased O
peroxisome O
proliferator O
- O
activated O
receptor O
- O
gamma O
expression O
. O

Immunohistochemistry O
revealed O
that O
among O
macrophages O
in O
atherosclerotic O
lesions O
of O
the O
aorta O
, O
the O
proportion O
of O
macrophages O
with O
SRA B
expression O
was O
highest O
in O
hypertensive O
animals O
on O
a O
high O
- O
cholesterol O
diet O
( O
43 O
. O
9 O
+ O
/ O
- O
0 O
. O
7 O
% O
, O
versus O
12 O
. O
0 O
+ O
/ O
- O
2 O
. O
0 O
% O
for O
normotensive O
animals O
on O
a O
high O
- O
cholesterol O
diet O
and O
4 O
. O
7 O
+ O
/ O
- O
4 O
. O
7 O
% O
for O
animals O
on O
standard O
chow O
; O
P O
< O
0 O
. O
001 O
) O
. O

CONCLUSIONS O
: O
Biomechanical O
strain O
induces O
SRA B
expression O
by O
monocyte O
/ O
macrophages O
, O
suggesting O
a O
novel O
mechanism O
for O
promotion O
of O
atherosclerosis O
in O
hypertensive O
patients O
. O

RESULTS O
: O
Glucose O
induced O
MCP B
- I
1 I
mRNA I
expression O
in O
a O
time O
- O
and O
dose O
- O
dependent O
manner O
. O

MCP B
- I
1 I
protein I
in O
cell O
culture O
supernant O
was O
also O
increased O
. O

High O
- O
glucose O
- O
conditioned O
supernatant O
possessed O
an O
increased O
chemotactic O
activity O
for O
monocytes O
, O
which O
was O
neutralized O
by O
anti B
- I
MCP I
- I
1 I
antibody I
. O

Curcumin O
, O
an O
inhibitor O
of O
AP O
- O
1 O
, O
dose O
- O
dependently O
suppressed O
the O
induction O
of O
MCP B
- I
1 I
mRNA I
by O
high O
glucose O
. O

Tyrosine O
kinase O
inhibitors O
such O
as O
genistein O
( O
12 O
. O
5 O
to O
50 O
micromol O
/ O
L O
) O
and O
herbimycin O
A O
( O
0 O
. O
1 O
to O
1 O
micromol O
/ O
L O
) O
inhibited O
the O
high O
- O
glucose O
- O
induced O
MCP B
- I
1 I
mRNA I
expression O
in O
a O
dose O
- O
dependent O
manner O
, O
and O
also O
suppressed O
the O
high O
- O
glucose O
- O
induced O
AP O
- O
1 O
binding O
activity O
. O

Whereas O
B O
cell O
Ag O
receptor O
( O
BCR O
) O
cross O
- O
linking O
alone O
stimulated O
increased O
expression O
of O
CD86 O
, O
up O
- O
regulation O
of O
CD80 O
required O
dual O
stimulation O
with O
anti O
- O
IgM O
and O
anti B
- I
CD54 I
. O

In O
the O
process O
of O
neoplastic O
transformation O
, O
the O
EBV B
- I
encoded I
latent I
membrane I
protein I
1 I
( I
LMP1 I
) I
oncogene I
represents O
the O
major O
driving O
force O
. O

LMP1 O
acts O
like O
a O
constitutively O
activated O
receptor O
of O
the O
tumor B
necrosis I
factor I
receptor I
family I
and O
allows O
the O
amplification O
or O
bypassing O
of O
physiological O
regulatory O
signals O
through O
direct O
and O
indirect O
interactions O
with O
proteins O
of O
the O
tumor B
necrosis I
factor I
receptor I
- I
associated I
factor I
( I
TRAF I
) I
family I
. O

Cytotoxic O
T O
lymphocytes O
directed O
against O
well O
- O
characterized O
epitopes O
of O
EBV B
latency I
genes I
represent O
an O
already O
successful O
and O
promising O
therapeutic O
approach O
to O
EBV O
- O
associated O
lymphomas O
, O
in O
particular O
PTLDs O

The O
ability O
of O
interferon B
( I
IFN I
) I
- I
alpha I
to O
induce O
autoimmunity O
and O
exacerbate O
Th1 O
diseases O
is O
well O
known O
. O

This O
is O
associated O
with O
enhanced O
phosphorylation O
of O
STAT1 O
, O
STAT3 O
, O
and O
Fyn B
, I
a I
Src I
homology I
tyrosine I
kinase I
, O
which O
interacts O
with O
both O
TCR O
and O
IFN O
- O
alpha O
signal O
components O
. O

Activation O
of O
the O
p21 B
( I
CIP1 I
/ I
WAF1 I
) I
promoter I
by O
bone B
morphogenetic I
protein I
- I
2 I
in O
mouse O
B O
lineage O
cells O
. O

BMPs B
exert O
a O
negative O
growth O
effect O
on O
various O
types O
of O
cells O
. O

We O
have O
previously O
reported O
that O
BMP B
- I
2 I
inhibited O
the O
growth O
of O
HS O
- O
72 O
mouse O
hybridoma O
cells O
by O
inducing O
p21 O
( O
CIP1 O
/ O
WAF1 O
) O
expression O
. O

In O
the O
present O
study O
, O
we O
demonstrated O
that O
BMP B
- I
2 I
activated O
the O
mouse O
p21 B
( I
CIP1 I
/ I
WAF1 I
) I
promoter I
in O
HS O
- O
72 O
cells O
, O
and O
that O
a O
29 B
- I
base I
pair I
( I
b I
) I
region I
of O
the O
promoter O
( O
- O
1928 O
/ O
- O
1900 O
relative O
to O
the O
TATA O
box O
) O
, O
conserved O
between O
mice O
and O
humans O
, O
was O
responsive O
to O
BMP B
- I
2 I
as O
well O
as O
expression O
of O
Smad1 B
, O
Smad4 B
, O
and O
constitutively O
active O
mutants O
of O
BMP B
type I
I I
receptors I
. O

Furthermore O
, O
an O
oligonucleotide O
containing O
the O
29 B
- I
b I
region I
was O
found O
to O
be O
associated O
with O
Smad4 B
and O
phosphorylated B
Smad1 I
in O
the O
nuclear O
extract O
of O
BMP B
- I
2 I
- O
stimulated O
HS O
- O
72 O
cells O
. O

These O
results O
suggested O
that O
BMP B
- I
2 I
might O
activate O
p21 O
( O
CIP1 O
/ O
WAF1 O
) O
transcription O
by O
inducing O
a O
binding O
of O
Smad4 B
and O
Smad1 B
to O
the O
29 B
- I
b I
region I
in O
HS O
- O
72 O
cells O
. O

Therefore O
CD8 B
alpha I
expression O
DCs O
does O
not O
indicate O
a O
lymphoid O
origin O
and O
differences O
among O
CD8 O
alpha O
+ O
and O
CD8 O
alpha O
- O
DCs O
might O
rather O
reflect O
maturation O
status O
than O
ontogeny O
. O

Macrophage O
stimulation O
with O
Murabutide O
, O
an O
HIV O
- O
suppressive O
muramyl O
peptide O
derivative O
, O
selectively O
activates O
extracellular B
signal I
- I
regulated I
kinases I
1 I
and I
2 I
, O
C O
/ O
EBPbeta O
and O
STAT1 O
: O
role O
of O
CD14 O
and O
Toll B
- I
like I
receptors I
2 I
and I
4 I
. O

We O
also O
examined O
whether O
signaling O
by O
muramyl O
peptides O
involves O
the O
use O
of O
cell O
surface O
receptors O
, O
including O
CD14 O
and O
Toll O
- O
like O
receptor O
2 O
( O
TLR2 O
) O
or O
TLR4 O
that O
are O
known O
to O
be O
signal B
- I
transducing I
receptors I
for O
other O
bacterial O
cell O
wall O
components O
. O

We O
demonstrate O
that O
, O
unlike O
LPS O
, O
the O
safe O
immunomodulator O
MB O
selectively O
activates O
extracellular B
signal I
- I
regulated I
kinases I
( I
Erk I
) I
1 I
/ I
2 I
, O
in O
the O
absence O
of O
detectable O
Jun O
N O
- O
terminal O
kinase O
( O
JNK O
) O
or O
p38 B
mitogen I
- I
activated I
kinase I
activation O
. O

Surprisingly O
, O
neither O
MB O
nor O
MDP O
were O
able O
to O
transduce O
signals O
via O
CD14 O
and O
TLR2 B
or I
4 I
. O

These O
findings O
present O
major O
differences O
in O
the O
early O
cell O
activation O
process O
between O
LPS O
and O
muramyl O
peptides O
, O
and O
strongly O
argue O
for O
the O
implication O
of O
co B
- I
receptors I
other O
than O
TLR2 O
and O
TLR4 O
in O
mediating O
the O
signaling O
events O
induced O
by O
defined O
subunits O
of O
bacterial O
peptidoglycans O
. O

Nuclear B
peroxisome I
proliferator I
- I
activated I
receptors I
alpha I
and I
gamma I
have O
opposing O
effects O
on O
monocyte O
chemotaxis O
in O
endometriosis O
. O

The O
peroxisome B
proliferator I
- I
activated I
receptors I
( I
PPARs I
) I
alpha I
and I
gamma I
are O
nuclear O
receptors O
that O
play O
important O
roles O
in O
inflammatory O
diseases O
like O
ulcerative O
colitis O
and O
arthritis O
. O

We O
identified O
PPAR B
- I
alpha I
and I
- I
gamma I
messenger O
RNA O
by O
RT O
- O
PCR O
and O
protein O
by O
immunoblotting O
of O
lysates O
of O
peritoneal O
macrophages O
and O
monocytic O
U937 O
cells O
. O

Using O
immunocytochemistry O
, O
we O
localized O
PPAR B
- I
alpha I
and I
- I
gamma I
within O
the O
nuclei O
of O
both O
cell O
types O
. O

Peritoneal O
fluid O
from O
patients O
with O
endometriosis O
activated O
U937 O
cells O
transiently O
transfected O
with O
a O
PPAR B
- I
alpha I
/ I
GAL4 I
luciferase I
reporter I
. O

By O
contrast O
, O
peritoneal O
fluid O
did O
not O
cause O
significant O
activation O
of O
PPAR B
- I
gamma I
/ I
GAL4 I
constructs I
. O

The O
U937 O
cells O
transiently O
transfected O
with O
a O
PPAR B
response I
element I
luciferase I
reporter I
showed O
disease O
stage O
- O
dependent O
up O
- O
regulation O
when O
treated O
with O
peritoneal O
fluid O
from O
patients O
with O
endometriosis O
. O

We O
conclude O
that O
peritoneal O
fluid O
of O
endometriosis O
patients O
contains O
activators O
of O
PPAR B
- I
alpha I
that O
stimulate O
macrophage O
chemotaxis O
. O

Inhibitors O
of O
PPAR B
- I
alpha I
or O
activators O
of O
PPAR B
- I
gamma I
could O
be O
developed O
for O
the O
treatment O
of O
inflammation O
associated O
with O
endometriosis O
. O

Analysis O
of O
PBMCs O
on O
days O
1 O
, O
3 O
, O
5 O
, O
and O
10 O
after O
trauma O
revealed O
that O
expression O
of O
both O
p65p50 B
heterodimers I
and O
p50p50 B
homodimers I
was O
significantly O
reduced O
compared O
with O
that O
in O
controls O
. O

Although O
no O
direct O
correlation O
was O
found O
between O
levels O
of O
interleukin O
- O
10 O
or O
transforming O
growth O
factor O
- O
beta O
and O
NF O
- O
kappa O
B O
, O
these O
immunosuppressive B
cytokines I
were O
significantly O
elevated O
in O
trauma O
patients O
by O
10 O
days O
after O
admission O
. O

Down O
- O
regulation O
of O
IL B
- I
12 I
p40 I
gene I
in O
Plasmodium O
berghei O
- O
infected O
mice O
. O

We O
analyzed O
the O
mechanism O
that O
causes O
suppression O
of O
IL B
- I
12 I
p40 I
gene I
induction O
during O
Plasmodium O
berghei O
infection O
. O

Although O
IL O
- O
12 O
together O
with O
IFN O
- O
gamma O
plays O
an O
important O
role O
in O
protection O
against O
pathogenic O
infection O
, O
the O
IL B
- I
12 I
p70 I
protein I
production O
of O
infected O
macrophages O
is O
lower O
than O
that O
by O
the O
uninfected O
macrophages O
. O

We O
showed O
in O
the O
present O
study O
that O
the O
induction O
of O
IL B
- I
12 I
p40 I
gene I
but O
not O
IL B
- I
12 I
p35 I
gene I
in O
macrophages O
of O
P O
. O
berghei O
- O
infected O
mice O
was O
profoundly O
inhibited O
. O

The O
induction O
of O
IFN B
- I
regulatory I
factor I
- I
1 I
gene I
was O
comparable O
in O
transcription O
level O
in O
uninfected O
and O
infected O
cells O
, O
while O
the O
unidentified O
complex O
formation O
of O
IFN O
- O
regulatory O
factor O
- O
1 O
was O
observed O
in O
infected O
cells O
. O

Therefore O
, O
the O
inhibition O
of O
the O
IL B
- I
12 I
p40 I
gene I
induction O
appeared O
to O
be O
regulated O
at O
transcriptional O
regulation O
level O
of O
the O
gene O
. O

The O
Friend B
of I
GATA I
proteins I
U O
- O
shaped O
, O
FOG B
- I
1 I
, O
and O
FOG B
- I
2 I
function O
as O
negative O
regulators O
of O
blood O
, O
heart O
, O
and O
eye O
development O
in O
Drosophila O
. O

Friend B
of I
GATA I
( I
FOG I
) I
proteins I
regulate O
GATA O
factor O
- O
activated O
gene O
transcription O
. O

During O
vertebrate O
hematopoiesis O
, O
FOG B
and I
GATA I
proteins I
cooperate O
to O
promote O
erythrocyte O
and O
megakaryocyte O
differentiation O
. O

The O
Drosophila B
FOG I
homologue I
U I
- I
shaped I
( O
Ush B
) O
is O
expressed O
similarly O
in O
the O
blood O
cell O
anlage O
during O
embryogenesis O
. O

In O
this O
report O
, O
we O
show O
that O
Ush B
is O
expressed O
in O
hemocyte O
precursors O
and O
plasmatocytes O
throughout O
embryogenesis O
and O
larval O
development O
, O
and O
the O
GATA B
factor I
Serpent I
is O
essential O
for O
Ush B
embryonic O
expression O
. O

Furthermore O
, O
loss O
of O
ush O
function O
results O
in O
an O
overproduction O
of O
crystal O
cells O
, O
whereas O
forced O
expression O
of O
Ush B
reduces O
this O
cell O
population O
. O

Murine B
FOG I
- I
1 I
and I
FOG I
- I
2 I
also O
can O
repress O
crystal O
cell O
production O
, O
but O
a O
mutant O
version O
of O
FOG B
- I
2 I
lacking O
a O
conserved O
motif O
that O
binds O
the O
corepressor B
C I
- I
terminal I
binding I
protein I
fails O
to O
affect O
the O
cell O
lineage O
. O

The O
GATA B
factor I
Pannier I
( O
Pnr B
) O
is O
required O
for O
eye O
and O
heart O
development O
in O
Drosophila O
. O

When O
Ush B
, O
FOG B
- I
1 I
, O
FOG B
- I
2 I
, O
or O
mutant B
FOG I
- I
2 I
is O
coexpressed O
with O
Pnr B
during O
these O
developmental O
processes O
, O
severe O
eye O
and O
heart O
phenotypes O
result O
, O
consistent O
with O
a O
conserved O
negative O
regulation O
of O
Pnr B
function O
. O

These O
results O
indicate O
that O
the O
fly O
and O
mouse O
FOG B
proteins I
function O
similarly O
in O
three O
distinct O
cellular O
contexts O
in O
Drosophila O
, O
but O
may O
use O
different O
mechanisms O
to O
regulate O
genetic O
events O
in O
blood O
vs O
. O
cardial O
or O
eye O
cell O
lineages O

The O
RING B
finger I
protein I
Siah B
- I
1 I
regulates O
the O
level O
of O
the O
transcriptional O
coactivator O
OBF O
- O
1 O
. O

The O
transcriptional O
coactivator O
OBF O
- O
1 O
, O
which O
interacts O
with O
Oct O
- O
1 O
and O
Oct O
- O
2 O
and O
the O
octamer B
site I
DNA I
, O
has O
been O
shown O
to O
be O
critical O
for O
development O
of O
a O
normal O
immune O
response O
and O
the O
formation O
of O
germinal O
centers O
in O
secondary O
lymphoid O
organs O
. O

Here O
we O
have O
identified O
the O
RING B
finger I
protein I
Siah B
- I
1 I
as O
a O
protein O
interacting O
specifically O
with O
OBF O
- O
1 O
. O

This O
interaction O
is O
mediated O
by O
the O
C B
- I
terminal I
part O
of O
Siah B
- I
1 I
and O
by O
residues O
in O
the O
N O
- O
terminus O
of O
OBF O
- O
1 O
, O
partly O
distinct O
from O
the O
residues O
required O
for O
formation O
of O
a O
complex O
with O
the O
Oct B
POU I
domains I
and O
the O
DNA O
. O

Interaction O
between O
Siah B
- I
1 I
and O
OBF O
- O
1 O
leads O
to O
downregulation O
of O
OBF O
- O
1 O
protein O
level O
but O
not O
mRNA O
, O
and O
to O
a O
corresponding O
reduction O
in O
octamer O
site O
- O
dependent O
transcription O
activation O
. O

Inhibition O
of O
the O
ubiquitin O
- O
proteasome O
pathway O
in O
B O
cells O
leads O
to O
elevated O
levels O
of O
OBF B
- I
1 I
protein I
. O

Furthermore O
, O
in O
immunized O
mice O
, O
OBF B
- I
1 I
protein I
amounts O
are O
dramatically O
increased O
in O
primary O
activated O
B O
cells O
, O
without O
concomitant O
increase O
in O
OBF B
- I
1 I
mRNA I
. O

These O
data O
suggest O
that O
Siah B
- I
1 I
is O
part O
of O
a O
novel O
regulatory O
loop O
controlling O
the O
level O
of O
OBF B
- I
1 I
protein I
in O
B O
cells O
. O

The O
association O
of O
trans B
- I
acting I
T I
cell I
factors I
( O
TCFs B
) O
or O
lymphoid B
enhancer I
factor I
1 I
( O
LEF O
- O
1 O
) O
with O
their O
coactivator O
beta O
- O
catenin O
mediates O
transient O
transcriptional O
responses O
to O
extracellular O
Wnt O
signals O
. O

We O
show O
here O
that O
T O
cell O
maturation O
depends O
on O
the O
presence O
of O
the O
beta B
- I
catenin I
- I
- I
binding I
domain I
in O
TCF O
- O
1 O
. O

Accelerated O
spontaneous O
thymocyte O
death O
in O
the O
absence O
of O
TCF O
- O
1 O
correlates O
with O
aberrantly O
low O
expression O
of O
the O
anti B
- I
apoptotic I
protein I
Bcl O
- O
x O
( O
L O
) O
. O

Increasing O
anti O
- O
apoptotic O
effectors O
in O
thymocytes O
by O
the O
use O
of O
a O
Bcl B
- I
2 I
transgene I
rescued O
TCF O
- O
1 O
- O
deficient O
DP O
thymocytes O
from O
apoptosis O
. O

Thus O
, O
TCF O
- O
1 O
, O
upon O
association O
with O
beta O
- O
catenin O
, O
transiently O
ensures O
the O
survival O
of O
immature O
T O
cells O
, O
which O
enables O
them O
to O
generate O
and O
edit O
T B
cell I
receptor I
( I
TCR I
) I
alpha I
chains I
and O
attempt O
TCR O
- O
mediated O
positive O
selection O
. O

TRAIL B
/ I
Apo2L I
ligand I
selectively O
induces O
apoptosis O
and O
overcomes O
drug O
resistance O
in O
multiple O
myeloma O
: O
therapeutic O
applications O
. O

Preclinical O
in O
vitro O
and O
in O
vivo O
evaluations O
were O
performed O
to O
assess O
the O
potential O
therapeutic O
applications O
of O
human O
recombinant O
tumor B
necrosis I
factor I
( I
TNF I
) I
- I
related I
apoptosis I
- I
inducing I
ligand I
/ I
Apo2 I
ligand I
( O
TRAIL B
/ I
Apo2L I
) O
in O
MM O
. O

TRAIL B
/ I
Apo2L I
potently O
induced O
apoptosis O
of O
MM O
cells O
from O
patients O
and O
the O
majority O
of O
MM O
cell O
lines O
, O
including O
cells O
sensitive O
or O
resistant O
to O
dexamethasone O
( O
Dex O
) O
, O
doxorubicin O
( O
Dox O
) O
, O
melphalan O
, O
and O
mitoxantrone O
. O

TRAIL B
/ I
Apo2L I
also O
overcame O
the O
survival O
effect O
of O
interleukin O
6 O
on O
MM O
cells O
and O
did O
not O
affect O
the O
survival O
of O
peripheral O
blood O
and O
bone O
marrow O
mononuclear O
cells O
and O
purified O
B O
cells O
from O
healthy O
donors O
. O

The O
status O
of O
the O
TRAIL B
receptors I
( O
assessed O
by O
immunoblotting O
and O
flow O
cytometry O
) O
could O
not O
predict O
TRAIL O
sensitivity O
of O
MM O
cells O
. O

The O
anti O
- O
MM O
activity O
of O
TRAIL B
/ I
Apo2L I
was O
confirmed O
in O
nu O
/ O
xid O
/ O
bg O
mice O
xenografted O
with O
human O
MM O
cells O
; O
TRAIL O
( O
500 O
microg O
intraperitoneally O
daily O
for O
14 O
days O
) O
was O
well O
tolerated O
and O
significantly O
suppressed O
the O
growth O
of O
plasmacytomas O
. O

Dox O
up O
- O
regulated O
the O
expression O
of O
the O
TRAIL B
receptor I
death B
receptor I
5 I
( O
DR5 B
) O
and O
synergistically O
enhanced O
the O
effect O
of O
TRAIL O
not O
only O
against O
MM O
cells O
sensitive O
to O
, O
but O
also O
against O
those O
resistant O
to O
, O
Dex O
- O
or O
Dox O
- O
induced O
apoptosis O
. O

Nuclear O
factor O
( O
NF O
) O
- O
kappaB O
inhibitors O
, O
such O
as O
SN50 O
( O
a O
cell O
- O
permeable O
inhibitor O
of O
the O
nuclear O
translocation O
and O
transcriptional O
activity O
of O
NF O
- O
kappaB O
) O
or O
the O
proteasome O
inhibitor O
PS O
- O
341 O
, O
enhanced O
the O
proapoptotic O
activity O
of O
TRAIL B
/ I
Apo2L I
against O
TRAIL O
- O
sensitive O
MM O
cells O
, O
whereas O
SN50 O
reversed O
the O
TRAIL O
resistance O
of O
ARH O
- O
77 O
and O
IM O
- O
9 O
MM O
cells O
. O

These O
preclinical O
studies O
suggest O
that O
TRAIL B
/ I
Apo2L I
can O
overcome O
conventional O
drug O
resistance O
and O
provide O
the O
basis O
for O
clinical O
trials O
of O
TRAIL O
- O
based O
treatment O
regimens O
to O
improve O
outcome O
in O
patients O
with O
MM O
. O

CD28 O
costimulation O
is O
required O
not O
only O
to O
induce O
IL O
- O
12 O
receptor O
but O
also O
to O
render O
janus B
kinases I
/ I
STAT4 I
responsive O
to O
IL O
- O
12 O
stimulation O
in O
TCR O
- O
triggered O
T O
cells O
. O

Nevertheless O
, O
there O
was O
a O
substantial O
difference O
in O
IL O
- O
12 O
responsiveness O
between O
these O
two O
groups O
of O
T O
cells O
: O
compared O
to O
anti O
- O
CD28 O
- O
costimulated O
T O
cells O
, O
T O
cells O
that O
were O
not O
costimulated O
with O
anti O
- O
CD28 O
exhibited O
decreased O
levels O
of O
Janus O
kinases O
( O
JAK O
) O
JAK2 B
/ I
TYK2 I
and O
STAT4 O
phosphorylation O
and O
IFN O
- O
y O
production O
following O
IL O
- O
12 O
stimulation O
. O

These O
resutls O
indicate O
that O
CD28 O
costimulation O
not O
only O
contributes O
to O
up O
- O
regulating O
IL O
- O
12R O
expression O
but O
is O
also O
required O
to O
render O
JAKs B
/ I
STAT4 I
responsive O
to O
IL O
- O
12 O
stimulation O
. O

Constitutively O
activated O
Akt B
- I
1 I
is O
vital O
for O
the O
survival O
of O
human O
monocyte O
- O
differentiated O
macrophages O
. O

Role O
of O
Mcl B
- I
1 I
, O
independent O
of O
nuclear O
factor O
( O
NF O
) O
- O
kappaB O
, O
Bad O
, O
or O
caspase O
activation O
. O

Recent O
data O
from O
mice O
deficient O
for O
phosphatase O
and O
tensin B
homologue I
deleted O
from O
chromosome O
10 O
or O
src B
homology I
2 I
domain I
- I
containing I
5 I
' I
inositol I
phosphatase I
, O
phosphatases O
that O
negatively O
regulate O
the O
phosphatidylinositol O
3 O
- O
kinase O
( O
PI3K O
) O
pathway O
, O
revealed O
an O
increased O
number O
of O
macrophages O
in O
these O
animals O
, O
suggesting O
an O
essential O
role O
for O
the O
PI3K O
pathway O
for O
macro O
- O
phage O
survival O
. O

Here O
, O
we O
focused O
on O
the O
role O
of O
the O
PI3K B
- I
regulated I
serine I
/ I
threonine I
kinase I
Akt B
- I
1 I
in O
modulating O
macrophage O
survival O
. O

Akt B
- I
1 I
was O
constitutively O
activated O
in O
human O
macrophages O
and O
addition O
of O
the O
PI3K O
inhibitor O
, O
LY294002 O
, O
suppressed O
the O
activation O
of O
Akt B
- I
1 I
and O
induced O
cell O
death O
. O

Furthermore O
, O
suppression O
of O
Akt B
- I
1 I
by O
inhibition O
of O
PI3K O
or O
a O
dominant B
negative I
( I
DN I
) I
Akt I
- I
1 I
resulted O
in O
loss O
of O
mitochondrial O
transmembrane O
potential O
, O
activation O
of O
caspases B
- I
9 I
and I
- I
3 I
, O
and O
DNA O
fragmentation O
. O

The O
effects O
of O
PI3K O
inhibition O
were O
reversed O
by O
the O
ectopic O
expression O
of O
constitutively O
activated O
Akt B
- I
1 I
or O
Bcl O
- O
x O
( O
L O
) O
. O

Inhibition O
of O
PI3K O
/ O
Akt O
- O
1 O
pathway O
either O
by O
LY294002 O
or O
DN B
Akt I
- I
1 I
had O
no O
effect O
on O
the O
constitutive O
or O
inducible O
activation O
of O
nuclear O
factor O
( O
NF O
) O
- O
kappaB O
in O
human O
macrophages O
. O

However O
, O
after O
inhibition O
of O
the O
PI3K O
/ O
Akt B
- I
1 I
pathway O
, O
a O
marked O
decrease O
in O
the O
expression O
of O
the O
antiapoptotic O
molecule O
Mcl B
- I
1 I
, O
but O
not O
other O
Bcl O
- O
2 O
family O
members O
was O
observed O
, O
and O
Mcl B
- I
1 I
rescued O
macrophages O
from O
LY294002 O
- O
induced O
cell O
death O
. O

Further O
, O
inhibition O
of O
Mcl B
- I
1 I
by O
antisense O
oligonucleotides O
, O
also O
resulted O
in O
macrophage O
apoptosis O
. O

Thus O
, O
our O
findings O
demonstrate O
that O
the O
constitutive O
activation O
of O
Akt B
- I
1 I
regulates O
macrophage O
survival O
through O
Mcl B
- I
1 I
, O
which O
is O
independent O
of O
caspases O
, O
NF O
- O
kappaB O
, O
or O
Bad O
. O

Recent O
evidence O
suggests O
that O
overexpression O
of O
the O
glucocorticoid B
receptor I
splice I
variant I
GRbeta O
in O
inflammatory O
cells O
might O
contribute O
to O
steroid O
insensitivity O
in O
diseases O
such O
as O
asthma O
. O

NPs O
that O
were O
` O
` O
FP O
- O
insensitive O
' O
' O
in O
terms O
of O
suppression O
of O
eosinophil O
numbers O
( O
major B
basic I
protein I
- O
positive O
) O
had O
a O
significantly O
greater O
percentage O
of O
GRbeta O
- O
positive O
inflammatory O
cells O
, O
a O
higher O
ratio O
of O
GRbeta O
- O
positive O
/ O
GRalpha O
- O
positive O
cells O
, O
and O
increased O
numbers O
of O
GRbeta O
- O
positive O
eosinophils O
and O
macrophages O
in O
comparison O
with O
those O
that O
were O
` O
` O
FP O
- O
sensitive O
. O
' O
' O

Transcriptional O
regulation O
of O
galectin B
- I
10 I
( O
eosinophil B
Charcot I
- I
Leyden I
crystal I
protein I
) O
: O
a O
GC O
box O
( O
- O
44 O
to O
- O
50 O
) O
controls O
butyric O
acid O
induction O
of O
gene O
expression O
. O

Galectin B
- I
10 I
( O
gal B
- I
10 I
, O
also O
known O
as O
Charcot B
- I
Leyden I
crystal I
protein I
) O
is O
a O
member O
of O
the O
galectin B
family I
of O
beta B
- I
galactoside I
binding I
proteins I
that O
is O
expressed O
uniquely O
in O
eosinophilic O
and O
basophilic O
leukocytes O
. O

To O
gain O
a O
better O
understanding O
of O
galectin O
gene O
expression O
, O
we O
present O
an O
analysis O
of O
the O
transcriptional O
regulation O
of O
the O
gene O
encoding O
gal B
- I
10 I
. O

Analysis O
of O
the O
minimal O
promoter O
revealed O
nine O
consensus O
- O
binding O
sites O
for O
transcription O
factors O
, O
including O
several O
that O
are O
also O
found O
in O
the O
minimal B
promoters I
of O
galectins B
- I
1 I
, I
- I
2 I
, I
and I
- I
3 I
. O

The O
decrease O
in O
gal O
- O
10 O
promoter O
activity O
after O
disruption O
of O
either O
the O
GC O
box O
( O
- O
44 O
to O
- O
50 O
) O
or O
the O
Oct B
site I
( O
- O
255 O
to O
- O
261 O
) O
suggests O
that O
these O
sites O
, O
along O
with O
the O
previously O
characterized O
GATA B
and I
EoTF I
sites I
, O
are O
necessary O
for O
full O
promoter O
activity O
. O

By O
supershift O
analysis O
, O
we O
demonstrate O
binding O
of O
the O
transcription O
factors O
Sp1 O
and O
Oct1 O
to O
the O
consensus B
GC I
box I
and O
the O
Oct B
site I
, O
respectively O
. O

Similar O
to O
gal B
- I
1 I
, O
gal O
- O
10 O
expression O
is O
induced O
by O
butyric O
acid O
, O
an O
effect O
that O
is O
lost O
upon O
ablation O
of O
the O
GC O
box O
. O

Additionally O
, O
we O
demonstrate O
AML3 O
binding O
to O
the O
consensus B
AML I
site I
and O
YY1 B
binding I
to O
the O
Inr B
sequence I
, O
both O
elements O
functioning O
as O
silencers O
in O
the O
gal B
- I
10 I
promoter I
. O

Adipophilin B
is O
a O
sensitive O
marker O
for O
lipid O
loading O
in O
human O
blood O
monocytes O
. O

Adipophilin B
, O
a O
marker O
of O
lipid O
accumulation O
initially O
described O
in O
adipocytes O
, O
was O
recently O
shown O
to O
be O
induced O
in O
macrophage O
foam O
cells O
. O

We O
found O
that O
even O
freshly O
isolated O
blood O
monocytes O
express O
adipophilin B
and O
that O
the O
amount O
of O
adipophilin B
protein I
is O
variable O
in O
monocytes O
from O
different O
healthy O
individuals O
. O

However O
, O
the O
physiological O
expression O
of O
adipophilin B
does O
not O
correlate O
with O
the O
levels O
of O
free O
fatty O
acids O
, O
cholesterylesters O
or O
free O
cholesterol O
. O

Enzymatically B
modified I
low I
- I
density I
lipoprotein I
( O
E B
- I
LDL I
) O
induces O
rapid O
foam O
cell O
formation O
in O
monocytes O
and O
upregulates O
adipophilin B
mRNA O
and O
protein O
within O
2 O
h O
of O
incubation O
. O

This O
rapid O
induction O
of O
adipophilin B
is O
accompanied O
by O
a O
significant O
increase O
of O
free O
fatty O
acids O
in O
monocytes O
incubated O
with O
E B
- I
LDL I
. O

Adipophilin B
facilitates O
the O
uptake O
of O
free O
fatty O
acids O
, O
and O
here O
we O
demonstrate O
that O
free O
fatty O
acids O
increase O
is O
related O
to O
the O
early O
upregulation O
of O
adipophilin O
expression O
in O
blood O
monocytes O
. O

Fatty O
acids O
are O
ligands O
for O
peroxisome O
proliferator O
- O
activated O
receptor O
- O
gamma O
( O
PPARgamma O
) O
, O
and O
the O
upregulation O
of O
adipophilin B
mRNA I
by O
PPARgamma O
agonists O
like O
15d O
- O
PGJ O
( O
2 O
) O
and O
ciglitazone O
indicates O
that O
PPARgamma O
may O
mediate O
the O
induction O
of O
adipophilin O
expression O
in O
human O
blood O
monocytes O
. O

In O
melanoma O
cell O
lines O
, O
two O
different O
patterns O
of O
MHC O
class O
II O
expression O
have O
been O
described O
, O
either O
an O
IFN O
gamma O
- O
inducible O
expression O
of O
HLA O
- O
DR O
and O
HLA O
- O
DP O
, O
with O
a O
faint O
or O
null O
expression O
of O
HLA O
- O
DQ O
, O
resembling O
that O
described O
for O
melanocytes O
, O
or O
a O
constitutive O
expression O
, O
i O
. O
e O
. O
, O
IFN O
- O
gamma O
independent O
, O
of O
all O
three O
HLA B
- I
D I
isotypes I
. O

In O
agreement O
with O
the O
evidence O
of O
a O
coordinate O
transcription O
of O
the O
HLA B
- I
D I
genes I
in O
these O
cell O
lines O
, O
we O
have O
shown O
the O
constitutive O
expression O
of O
CIITA B
( I
class I
II I
transactivator I
) I
transcripts I
, O
CIITA O
being O
known O
as O
the O
master O
switch O
of O
MHC O
class O
II O
expression O
. O

Unexpectedly O
, O
these O
transcripts O
initiate O
from O
promoter B
III I
of O
the O
CIITA O
gene O
, O
a O
promoter O
that O
is O
mainly O
used O
constitutively O
in O
B O
lymphocytes O
. O

This O
expression O
was O
further O
shown O
to O
occur O
through O
factor O
( O
s O
) O
acting O
on O
the O
enhancer O
located O
upstream O
of O
CIITA B
promoter I
III I
, O
which O
was O
previously O
described O
in O
epithelioid O
cells O
as O
an O
IFN O
- O
gamma O
- O
response O
sequence O
. O

Constitutive O
transcription O
of O
CIITA O
from O
promoter B
III I
having O
been O
observed O
in O
unrelated O
melanoma O
cell O
lines O
, O
we O
propose O
the O
hypothesis O
that O
this O
phenomenon O
might O
not O
be O
a O
random O
event O
, O
but O
could O
be O
linked O
to O
the O
neoplasic O
state O
of O
the O
melanoma O
cells O

Calcineurin O
, O
a O
Ca B
( I
2 I
+ I
) I
/ I
calmodulin I
- I
dependent I
Ser I
/ I
Thr I
phosphatase I
( I
protein I
phosphatase I
2B I
) I
, O
plays O
a O
critical O
role O
in O
IL O
- O
2 O
production O
during O
T O
cell O
activation O
. O

We O
report O
here O
that O
the O
60 B
- I
kDa I
catalytic I
subunit I
of O
calcineurin B
A I
( O
Cn B
A I
) O
was O
partially O
cleaved O
to O
a O
45 O
- O
kDa O
form O
in O
phytohemagglutinin O
A O
( O
PHA O
) O
or O
phorbol O
ester O
+ O
ionomycin O
( O
P O
+ O
I O
) O
- O
activated O
Jurkat O
cells O
. O

In O
parallel O
, O
proteolytic O
activation O
of O
upstream O
caspases O
( O
caspase O
- O
8 O
and O
- O
9 O
) O
as O
well O
as O
effector B
caspase I
- I
3 I
was O
also O
observed O
. O

Cn B
A I
cleavage O
was O
caspase O
mediated O
, O
since O
it O
was O
inhibitable O
by O
pan O
- O
caspase O
inhibitor O
Cbz O
- O
Asp O
- O
CH O
( O
2 O
) O
OC O
( O
O O
) O
- O
2 O
, O
6 O
- O
dichlorobenzene O
( O
Z O
- O
D O
- O
DCB O
) O
. O

Cn B
A I
cleavage O
was O
also O
observed O
when O
purified O
calcineurin O
was O
digested O
in O
vitro O
with O
caspase O
- O
3 O
. O

Truncated B
Cn I
A I
was O
associated O
with O
enhanced O
phosphatase O
activity O
and O
reduced O
calmodulin O
sensitivity O
. O

Taken O
together O
, O
our O
results O
suggest O
that O
caspase O
- O
mediated O
cleavage O
of O
Cn B
A I
contributes O
to O
IL O
- O
2 O
production O
during O
T O
cell O
activation O
. O

The O
cells O
were O
matured O
by O
addition O
of O
tumor B
necrosis I
factor I
( I
TNF I
) I
- I
a I
, O
IL O
- O
1 O
beta O
, O
and O
prostaglandin O
E2 O
in O
the O
presence O
of O
sulfasalazine O
or O
its O
metabolites O
- O
- O
aminosalicylate O
and O
sulfapyridine O
, O
or O
their O
combinations O
. O

In O
distinction O
to O
drug O
- O
free O
maturing O
dendritic O
cells O
, O
2 O
. O
5 O
micromol O
/ O
L O
sulfasalazine O
upregulated O
the O
levels O
of O
CD14 O
and O
CD68 O
and O
downregulated O
the O
levels O
of O
CD40 O
, O
CD80 O
, O
and O
CD83 B
( O
for O
all O
CD O
markers O
, O
p O
< O
0 O
. O
03 O
for O
difference O
between O
measurements O
in O
the O
absence O
and O
the O
presence O
of O
sulfasalazine O
) O
. O

The O
nonobese O
patient O
with O
diabetes O
( O
NOD O
) O
mouse O
is O
a O
spontaneous O
model O
of O
type O
1 O
diabetes O
with O
a O
strong O
genetic O
component O
that O
maps O
to O
the O
major B
histocompatibility I
complex I
( I
MHC I
) I
region I
of O
the O
genome B
. O

A O
specific O
proteasome O
defect O
has O
been O
identified O
in O
NOD O
mouse O
in O
select O
lymphocytic O
and O
monocytic O
lineages O
that O
results O
from O
down O
- O
regulation O
of O
expression O
of O
the O
proteasome B
subunit I
LMP2 I
, O
which O
is O
encoded O
by O
a O
gene O
in O
the O
MHC B
genomic I
region I
. O

Down O
- O
regulation O
of O
TDT O
transcription O
in O
CD4 O
( O
+ O
) O
CD8 O
( O
+ O
) O
thymocytes O
by O
Ikaros O
proteins O
in O
direct O
competition O
with O
an O
Ets B
activator I
. O

Ikaros O
is O
a O
unique O
regulator O
of O
lymphopoiesis O
that O
associates O
with O
pericentromeric B
heterochromatin I
and O
has O
been O
implicated O
in O
heritable O
gene O
inactivation O
. O

Binding O
and O
competition O
experiments O
demonstrate O
that O
Ikaros B
dimers I
compete O
with O
an O
Ets B
activator I
for O
occupancy O
of O
the O
lymphocyte B
- I
specific I
TdT I
promoter I
. O

Mutations O
that O
selectively O
disrupt O
Ikaros O
binding O
to O
an O
integrated B
TdT I
promoter I
had O
no O
effect O
on O
promoter O
function O
in O
a O
CD4 O
( O
+ O
) O
CD8 O
( O
+ O
) O
thymocyte O
line O
. O

Current O
models O
propose O
that O
the O
functions O
of O
Ikaros O
should O
be O
disrupted O
by O
a O
small O
isoform B
that O
retains O
the O
dimerization O
domain O
and O
lacks O
the O
DNA O
- O
binding O
domain O
. O

Surprisingly O
, O
in O
the O
CD4 O
( O
+ O
) O
CD8 O
( O
+ O
) O
thymocyte O
line O
, O
overexpression O
of O
a O
small B
Ikaros I
isoform I
had O
no O
effect O
on O
differentiation O
or O
on O
the O
pericentromeric O
targeting O
and O
DNA O
- O
binding O
properties O
of O
Ikaros O
. O

Rather O
, O
the O
small O
isoform B
assembled O
into O
multimeric B
complexes I
with O
DNA B
- I
bound I
Ikaros I
at O
the O
pericentromeric O
foci O
. O

The O
capacity O
for O
in O
vivo O
multimer O
formation O
suggests O
that O
interactions O
between O
Ikaros B
dimers I
bound O
to O
the O
TdT B
promoter I
and O
those O
bound O
to O
pericentromeric B
repeat I
sequences I
may O
contribute O
to O
the O
pericentromeric O
repositioning O
of O
the O
inactive B
gene I
. O

Therapeutic O
use O
of O
type B
I I
IFN I
( O
IFN O
- O
alpha O
/ O
beta O
) O
has O
become O
common O
. O

It O
is O
thus O
notable O
that O
the O
pleiotropic O
effects O
of O
type B
I I
IFN I
on O
CMI O
remain O
poorly O
understood O
. O

We O
characterized O
the O
effects O
of O
type B
I I
IFN I
on O
the O
production O
of O
IL O
- O
12 O
, O
the O
central B
immunoregulatory I
cytokine I
of O
the O
CD4 B
( I
+ I
) I
T I
cell I
arm I
of O
CMI O
. O

We O
show O
that O
type B
I I
IFN I
are O
potent O
inhibitors O
of O
IL O
- O
12 O
production O
by O
human O
monocytes O
/ O
macrophages O
. O

The O
underlying O
mechanism O
involves O
transcriptional O
inhibition O
of O
the O
IL B
- I
12p40 I
gene I
, O
marked O
by O
down O
- O
regulation O
of O
PU O
. O
1 O
binding O
activity O
at O
the O
upstream B
Ets I
site I
of O
the O
IL B
- I
12p40 I
promoter I
. O

Type B
I I
IFN I
have O
previously O
been O
shown O
to O
be O
able O
to O
substitute O
for O
IL O
- O
12 O
in O
driving O
IFN O
- O
gamma O
production O
from O
T O
and O
NK O
cells O
. O

Nuclear O
factor O
- O
kappaB O
suppressive O
and O
inhibitor B
- I
kappaB I
stimulatory O
effects O
of O
troglitazone O
in O
obese O
patients O
with O
type O
2 O
diabetes O
: O
evidence O
of O
an O
antiinflammatory O
action O
? O

To O
test O
these O
properties O
in O
humans O
, O
we O
investigated O
the O
effect O
of O
troglitazone O
on O
the O
proinflammatory B
transcription I
factor I
nuclear I
factor I
- I
kappaB I
and O
its O
inhibitory B
protein I
IkappaB I
in O
mononuclear O
cells O
( O
MNC O
) O
and O
plasma B
soluble I
intracellular I
adhesion I
molecule I
- I
1 I
, O
monocyte O
chemoattractant O
protein O
- O
1 O
, O
plasminogen B
activator I
inhibitor I
- I
1 I
, O
and O
C O
- O
reactive O
protein O
. O

Plasma B
monocyte I
chemoattractant I
protein I
- I
1 I
and O
soluble B
intracellular I
adhesion I
molecule I
- I
1 I
concentrations O
did O
not O
decrease O
significantly O
after O
troglitazone O
treatment O
, O
although O
there O
was O
a O
trend O
toward O
inhibition O
. O

Reactive O
oxygen O
species O
generation O
by O
polymorphonuclear O
cells O
and O
MNC O
, O
p47 B
( I
phox I
) I
subunit I
protein I
quantities O
, O
plasminogen B
activator I
inhibitor I
- I
1 I
, O
and O
C O
- O
reactive O
protein O
levels O
decreased O
significantly O
after O
troglitazone O
intake O
. O

OX40 O
stimulation O
by O
gp34 B
/ I
OX40 I
ligand I
enhances O
productive O
human O
immunodeficiency O
virus O
type O
1 O
infection O
. O

OX40 B
is O
a O
member O
of O
the O
tumor O
necrosis O
factor O
( O
TNF O
) O
receptor O
superfamily O
and O
known O
to O
be O
an O
important O
costimulatory B
molecule I
expressed O
on O
activated O
T O
cells O
. O

To O
investigate O
the O
role O
of O
costimulation O
of O
OX40 B
in O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
infection O
by O
its O
natural O
ligand O
, O
gp34 B
, O
the O
OX40 O
- O
transfected O
ACH O
- O
2 O
cell O
line O
, O
ACH O
- O
2 O
/ O
OX40 O
, O
chronically O
infected O
with O
HIV O
- O
1 O
, O
was O
cocultured O
with O
paraformaldehyde O
( O
PFA O
) O
- O
fixed O
gp34 O
- O
transfected O
mouse O
cell O
line O
, O
SV O
- O
T2 O
/ O
gp34 O
. O

This O
was O
followed O
by O
apparent O
apoptosis O
, O
and O
both O
processes O
were O
specifically O
inhibited O
by O
the O
gp34 B
- O
specific O
neutralizing B
monoclonal I
antibody I
5A8 I
. O

Endogenous O
TNF O
alpha O
( O
TNF O
- O
alpha O
) O
and O
TNF B
- I
beta I
production O
were O
not O
involved O
in O
the O
enhanced O
HIV O
- O
1 O
production O
. O

Furthermore O
, O
enhanced O
HIV O
- O
1 O
transcription O
in O
gp34 B
- O
stimulated O
ACH O
- O
2 O
/ O
OX40 O
cells O
was O
dependent O
on O
the O
kappa O
B O
site O
of O
the O
HIV O
- O
1 O
long O
terminal O
repeat O
, O
and O
the O
OX40 O
- O
gp34 O
interaction O
activated O
NF O
- O
kappa O
B O
consisting O
of O
p50 B
and I
p65 I
subunits I
. O

The O
enhancement O
was O
again O
significantly O
inhibited O
by O
5A8 B
. O

The O
present O
study O
first O
shows O
that O
OX40 O
- O
gp34 O
interaction O
stimulates O
HIV O
- O
1 O
expression O
and O
suggests O
that O
OX40 O
triggering O
by O
gp34 B
may O
play O
an O
important O
role O
in O
enhancing O
HIV O
- O
1 O
production O
in O
both O
acutely O
and O
latently O
infected O
CD4 O
( O
+ O
) O
T O
cells O
in O
vivo O
. O

Peroxizome B
proliferator I
- I
activated I
receptor I
- I
gamma I
( O
PPARgamma O
) O
is O
a O
member O
of O
the O
nuclear O
receptor O
family O
of O
transcription O
factors O
that O
regulate O
adipocyte O
differentiation O
. O

Recent O
studies O
indicate O
that O
liganded B
PPARgamma I
not O
only O
promotes O
differentiation O
but O
also O
inhibits O
the O
activation O
of O
macrophages O
. O

Osteopontin B
, O
a O
component O
of O
extracellular O
matrix O
, O
is O
synthesized O
by O
macrophages O
in O
atherosclerotic O
plaques O
. O

Transient O
transfection O
assays O
of O
the O
human B
osteopontin I
promoter I
/ I
luciferase I
construct I
which O
contains O
a O
5 O
' O
- O
flanking O
region O
between O
- O
1500 O
and O
+ O
87 O
relative O
to O
the O
transcription O
start O
site O
demonstrate O
that O
either O
treatment O
with O
troglitazone O
or O
cotransfection O
of O
PPARgamma B
expression I
vector I
inhibits O
osteopontin O
promoter O
activity O
. O

Transcription O
factor O
NF O
- O
kappa O
B O
regulates O
Ig B
lambda I
light O
chain O
gene O
rearrangement O
. O

The O
tissue O
- O
and O
stage O
- O
specific O
assembly O
of O
Ig B
and I
TCR I
genes I
is O
mediated O
by O
a O
common O
V B
( I
D I
) I
J I
recombinase I
complex I
in O
precursor O
lymphocytes O
. O

Directed O
alterations O
in O
the O
accessibility O
of O
V B
, I
D I
, I
and I
J I
gene I
segments I
target O
the O
recombinase B
to O
specific O
Ag B
receptor I
loci I
. O

Accessibility O
within O
a O
given O
locus B
is O
regulated O
by O
the O
functional O
interaction O
of O
transcription O
factors O
with O
cognate O
enhancer O
elements O
and O
correlates O
with O
the O
transcriptional O
activity O
of O
unrearranged O
gene B
segments I
. O

As O
demonstrated O
in O
our O
prior O
studies O
, O
rearrangement O
of O
the O
Igkappa B
locus I
is O
regulated O
by O
the O
inducible O
transcription O
factor O
NF O
- O
kappaB O
. O

In O
contrast O
to O
the O
Igkappa B
locus I
, O
known O
transcriptional B
control I
elements I
in O
the O
Iglambda B
locus I
lack O
functional O
NF O
- O
kappaB O
binding O
sites O
. O

Consistent O
with O
this O
observation O
, O
the O
expression O
of O
assembled O
Iglambda B
genes I
in O
mature O
B O
cells O
has O
been O
shown O
to O
be O
NF O
- O
kappaB O
independent O
. O

Nonetheless O
, O
we O
now O
show O
that O
specific O
repression O
of O
NF O
- O
kappaB O
inhibits O
germline O
transcription O
and O
recombination O
of O
Iglambda B
gene I
segments I
in O
precursor O
B O
cells O
. O

Molecular O
analyses O
indicate O
that O
the O
block O
in O
NF O
- O
kappaB O
impairs O
Iglambda O
rearrangement O
at O
the O
level O
of O
recombinase B
accessibility O
. O

In O
contrast O
, O
the O
activities O
of O
known O
Iglambda B
promoter I
and O
enhancer O
elements O
are O
unaffected O
in O
the O
same O
cellular O
background O
. O

These O
findings O
expand O
the O
range O
of O
NF O
- O
kappaB O
action O
in O
precursor O
B O
cells O
beyond O
Igkappa O
to O
include O
the O
control O
of O
recombinational O
accessibility O
at O
both O
L B
chain I
loci I
. O

Moreover O
, O
our O
results O
strongly O
suggest O
the O
existence O
of O
a O
novel O
Iglambda B
regulatory I
element I
that O
is O
either O
directly O
or O
indirectly O
activated O
by O
NF O
- O
kappaB O
during O
the O
early O
stages O
of O
B O
cell O
development O
. O

Transcription O
factor O
STAT5A O
is O
a O
substrate O
of O
Bruton B
' I
s I
tyrosine I
kinase I
in O
B O
cells O
. O

Here O
we O
show O
that O
STAT5A O
can O
serve O
as O
a O
functional O
substrate O
of O
Bruton B
' I
s I
tyrosine I
kinase I
( O
BTK O
) O
. O

Purified B
recombinant I
BTK I
was O
capable O
of O
directly O
binding O
purified B
recombinant I
STAT5A I
with O
high O
affinity O
( O
K O
( O
d O
) O
= O
44 O
nm O
) O
, O
as O
determined O
by O
surface O
plasmon O
resonance O
using O
a O
BIAcore O
biosensor O
system O
. O

BTK O
was O
also O
capable O
of O
tyrosine O
- O
phosphorylating O
ectopically O
expressed O
recombinant B
STAT5A I
on O
Tyr O
( O
694 O
) O
both O
in O
vitro O
and O
in O
vivo O
in O
a O
Janus O
kinase O
3 O
- O
independent O
fashion O
. O

BTK O
phosphorylated O
the O
Y665F B
, I
Y668F I
, I
and I
Y682F I
, I
Y683F I
mutants I
but O
not O
the O
Y694F B
mutant I
of O
STAT5A O
. O

STAT5A O
mutations O
in O
the O
Src B
homology I
2 I
( I
SH2 I
) I
and I
SH3 I
domains I
did O
not O
alter O
the O
BTK O
- O
mediated O
tyrosine O
phosphorylation O
. O

Recombinant B
BTK I
proteins I
with O
mutant O
pleckstrin O
homology O
, O
SH2 B
, I
or I
SH3 I
domains I
were O
capable O
of O
phosphorylating O
STAT5A O
, O
whereas O
recombinant B
BTK I
proteins I
with O
SH1 O
/ O
kinase O
domain O
mutations O
were O
not O
. O

In O
pull O
- O
down O
experiments O
, O
only O
full B
- I
length I
BTK I
and O
its O
SH1 B
/ I
kinase I
domain I
( O
but O
not O
the O
pleckstrin O
homology O
, O
SH2 B
, I
or I
SH3 I
domains I
) O
were O
capable O
of O
binding O
STAT5A O
. O

Ectopically O
expressed O
BTK B
kinase I
domain I
was O
capable O
of O
tyrosine O
- O
phosphorylating O
STAT5A O
both O
in O
vitro O
and O
in O
vivo O
. O

BTK O
- O
mediated O
tyrosine O
phosphorylation O
of O
ectopically O
expressed O
wild O
type O
( O
but O
not O
Tyr B
( I
694 I
) I
mutant I
) O
STAT5A O
enhanced O
its O
DNA O
binding O
activity O
. O

In O
BTK O
- O
competent O
chicken O
B O
cells O
, O
anti O
- O
IgM O
- O
stimulated O
tyrosine O
phosphorylation O
of O
STAT5 B
protein I
was O
prevented O
by O
pretreatment O
with O
the O
BTK O
inhibitor O
LFM O
- O
A13 O
but O
not O
by O
pretreatment O
with O
the O
JAK3 O
inhibitor O
HI O
- O
P131 O
. O

B O
cell O
antigen O
receptor O
ligation O
resulted O
in O
enhanced O
tyrosine O
phosphorylation O
of O
STAT5 O
in O
BTK O
- O
deficient O
chicken O
B O
cells O
reconstituted O
with O
wild B
type I
human I
BTK I
but O
not O
in O
BTK O
- O
deficient O
chicken O
B O
cells O
reconstituted O
with O
kinase B
- I
inactive I
mutant I
BTK I
. O

Role O
of O
T B
- I
bet I
in O
commitment O
of O
TH1 O
cells O
before O
IL O
- O
12 O
- O
dependent O
selection O
. O

We O
show O
that O
T B
- I
bet I
, O
without O
apparent O
assistance O
from O
interleukin B
12 I
( I
IL I
- I
12 I
) I
/ O
STAT4 O
, O
specifies O
TH1 O
effector O
fate O
by O
targeting O
chromatin O
remodeling O
to O
individual O
interferon B
- I
gamma I
( I
IFN I
- I
gamma I
) I
alleles I
and O
by O
inducing O
IL B
- I
12 I
receptor I
beta2 I
expression O
. O

Subsequently O
, O
it O
appears O
that O
IL O
- O
12 O
/ O
STAT4 O
serves O
two O
essential O
functions O
in O
the O
development O
of O
TH1 O
cells O
: O
as O
growth B
signal I
, O
inducing O
survival O
and O
cell O
division O
; O
and O
as O
trans O
- O
activator O
, O
prolonging O
IFN O
- O
gamma O
synthesis O
through O
a O
genetic O
interaction O
with O
the O
coactivator O
, O
CREB O
- O
binding O
protein O
. O

In O
response O
to O
IL O
- O
4 O
, O
the O
IL O
- O
4R O
activates O
a O
set O
of O
phosphotyrosine B
binding I
domain I
- I
containing I
proteins I
, O
including O
insulin B
receptor I
substrate I
1 I
/ I
2 I
, O
Shc O
, O
and O
IL B
- I
4R I
interacting I
protein I
, O
as O
well O
as O
Stat6 O
. O

To O
determine O
the O
roles O
of O
the O
phosphotyrosine B
binding I
adaptors I
in O
Th2 O
differentiation O
, O
we O
prepared O
a O
retrovirus O
containing O
a O
mutant O
of O
the O
human B
( I
h I
) I
IL I
- I
4R I
alpha I
- I
chain I
, O
Y497F B
, O
which O
is O
unable O
to O
recruit O
these O
adaptors O
. O

The O
mutant B
hIL I
- I
4Ralpha I
, O
as O
well O
as O
the O
wild B
- I
type I
( I
WT I
) I
hIL I
- I
4Ralpha I
, O
was O
introduced O
into O
naive O
CD4 O
T O
cells O
. O

Upon O
hIL O
- O
4 O
stimulation O
, O
Y497F B
worked O
as O
well O
as O
the O
WT B
hIL I
- I
4Ralpha I
in O
driving O
Th2 O
differentiation O
, O
as O
measured O
by O
Gata3 O
up O
- O
regulation O
and O
IL O
- O
4 O
production O
. O

Furthermore O
, O
IL O
- O
4 O
- O
driven O
cell O
expansion O
was O
also O
normal O
in O
the O
cells O
infected O
with O
Y497F B
, O
although O
cells O
infected O
with O
Y497F B
were O
not O
capable O
of O
phosphorylating O
insulin O
receptor O
substrate O
2 O
. O

These O
results O
suggest O
that O
the O
signal O
pathway O
mediated O
by O
Y497 B
is O
dispensable O
for O
both O
IL O
- O
4 O
- O
driven O
Th2 O
differentiation O
and O
cell O
expansion O
. O

Both O
WT B
and I
Y497F I
hIL I
- I
4Ralpha I
lose O
the O
ability O
to O
drive O
Th2 O
differentiation O
and O
cell O
expansion O
in O
Stat6 O
- O
knockout O
CD4 O
T O
cells O
. O

Thus O
, O
activated B
Stat6 I
is O
necessary O
and O
sufficient O
to O
mediate O
both O
IL O
- O
4 O
- O
driven O
Th2 O
differentiation O
and O
cell O
expansion O
in O
CD4 O
T O
cells O
. O

The O
effect O
of O
HIV B
- I
1 I
regulatory I
proteins I
on O
cellular O
genes O
: O
derepression O
of O
the O
IL O
- O
2 O
promoter O
by O
Tat O
. O

Tat O
derepresses O
and O
activates O
the O
distal B
AP I
- I
1 I
site I
( O
position B
- I
185 I
to I
- I
177 I
) O
in O
the O
IL O
- O
2 O
promoter O
. O

In O
nonstimulated O
T O
cells O
a O
repressor O
complex O
containing O
NF O
- O
IL6 O
, O
JunB O
, O
c O
- O
Fos O
and O
Fra O
- O
1 O
is O
formed O
on O
the O
AP B
- I
1 I
( I
IL I
- I
2 I
/ I
d I
) I
site I
and O
represses O
IL O
- O
2 O
promoter O
activity O
. O

After O
T O
cell O
activation O
, O
a O
heterodimeric B
activator I
containing O
p65 O
and O
c O
- O
Jun O
binds O
to O
the O
AP B
- I
1 I
( I
IL I
- I
2 I
/ I
d I
) I
site I
. O

HIV O
Tat O
enhances O
activation O
of O
NF O
- O
kappaB O
and O
consequently O
, O
activates O
the O
AP B
- I
1 I
( I
IL I
- I
2 I
/ I
d I
) I
site I
. O

TPO O
- O
induced O
proliferation O
also O
was O
reduced O
by O
a O
specific O
inhibitor O
of O
the O
mitogen O
- O
activated O
protein O
kinase O
( O
MAPK O
) O
pathway O
( O
PD098059 O
) O
, O
which O
inhibits O
activation O
of O
the O
MAPK B
extracellular I
signal I
- I
regulated I
kinases I
( O
ERK O
) O
ERK1 O
and O
ERK2 O
, O
and O
AG490 O
, O
an O
inhibitor O
of O
Janus B
kinase I
- I
2 I
, O
which O
completely O
blocked O
TPO O
- O
induced O
proliferation O
. O

CONCLUSION O
: O
Taken O
together O
, O
these O
data O
suggest O
that O
TGF O
- O
beta1 O
modulates O
TPO O
- O
mediated O
effects O
on O
megakaryocytic O
proliferation O
by O
interfering O
with O
TPO O
- O
induced O
signal O
transduction O
, O
particularly O
by O
reducing O
the O
activities O
of O
MAPK B
ERK1 I
/ I
ERK2 I
and I
STAT5 I
. O

Invariant B
chain I
induces O
B O
cell O
maturation O
by O
activating O
a O
TAF B
( I
II I
) I
105 I
- I
NF I
- I
kappaB I
- O
dependent O
transcription O
program O
. O

Recently O
, O
invariant B
chain I
( O
Ii O
) O
, O
a O
major B
histocompatibility I
complex I
class I
II I
chaperone I
, O
as O
well O
as O
the O
transcription O
factors O
c O
- O
Rel O
and O
p65 O
/ O
RelA O
, O
were O
found O
to O
play O
a O
role O
in O
the O
final O
antigen O
- O
independent O
differentiation O
stage O
of O
B O
cells O
in O
the O
spleen O
. O

Our O
studies O
indicate O
that O
Ii O
- O
induced O
B O
cell O
maturation O
involves O
activation O
of O
transcription O
mediated O
by O
the O
NF B
- I
kappaB I
p65 I
/ I
RelA I
homodimer I
and O
requires O
the O
B B
cell I
- I
enriched I
coactivator I
TBP B
- I
associated I
factor I
( I
II I
) I
105 I
. O

Inhibition O
of O
the O
transcription O
factors O
AP O
- O
1 O
and O
NF O
- O
kappaB O
in O
CD4 O
T O
cells O
by O
peroxisome B
proliferator I
- I
activated I
receptor I
gamma I
ligands I
. O

The O
peroxisome O
proliferator O
- O
activated O
receptor O
gamma O
( O
PPARgamma O
) O
, O
a O
member O
of O
the O
nuclear B
hormone I
receptor I
superfamily I
, O
is O
essential O
for O
adipocyte O
differentiation O
and O
glucose O
homeostasis O
. O

PPARgamma B
ligands I
also O
strongly O
inhibited O
SEA O
- O
induced O
Vbeta3 O
T O
cell O
activation O
in O
vivo O
. O

These O
results O
, O
together O
with O
previous O
findings O
of O
the O
inhibitory O
effect O
of O
PPARgamma B
ligands I
on O
activated O
macrophages O
, O
provide O
clear O
evidence O
for O
PPARgamma O
as O
a O
negative B
regulator I
of O
the O
inflammatory O
activation O
of O
both O
macrophage O
and O
T O
cells O
. O

A O
prominent O
role O
for O
activator O
protein O
- O
1 O
in O
the O
transcription O
of O
the O
human B
2B4 I
( I
CD244 I
) I
gene I
in O
NK O
cells O
. O

The O
cell B
surface I
glycoprotein I
2B4 I
( O
CD244 B
) O
of O
the O
Ig O
superfamily O
is O
involved O
in O
the O
regulation O
of O
NK O
and O
T O
lymphocyte O
functions O
. O

We O
have O
recently O
identified O
CD48 O
as O
the O
high B
affinity I
counterreceptor I
for O
2B4 B
in O
both O
mice O
and O
humans O
. O

The O
cytoplasmic O
domain O
of O
2B4 B
associates O
with O
src B
homology I
2 I
domain I
- I
containing I
protein I
or O
signaling B
lymphocyte I
activation I
molecule I
- I
associated I
protein I
, O
whose O
mutation O
is O
the O
underlying O
genetic O
defect O
in O
the O
X O
- O
linked O
lymphoproliferative O
syndrome O
. O

In O
this O
study O
, O
we O
report O
the O
molecular O
cloning O
and O
characterization O
of O
the O
human B
2B4 I
( I
h2B4 I
) I
promoter I
. O

Through O
primer O
extension O
analysis O
, O
we O
found O
that O
the O
transcription O
of O
the O
h2B4 B
gene I
initiates O
at O
multiple O
start O
sites O
. O

We O
isolated O
h2B4 B
genomic I
clones I
and O
PCR O
amplified O
the O
5 O
' O
untranslated O
region O
containing O
the O
promoter O
elements O
. O

EMSAs O
with O
Abs O
specific O
for O
various O
protein O
factors O
of O
the O
AP O
- O
1 O
family O
revealed O
that O
multiple O
members O
of O
the O
Jun B
family I
are O
involved O
in O
the O
regulation O
of O
the O
h2B4 B
gene I
. O

These O
results O
demonstrate O
a O
significant O
role O
for O
AP O
- O
1 O
in O
the O
transcriptional O
regulation O
of O
the O
h2B4 B
gene I
. O

Functional O
correction O
of O
FA O
- O
C O
cells O
with O
FANCC B
suppresses O
the O
expression O
of O
interferon B
gamma I
- I
inducible I
genes I
. O

Because O
hematopoietic O
cells O
derived O
from O
Fanconi O
anemia O
( O
FA O
) O
patients O
of O
the O
C O
- O
complementation O
group O
( O
FA O
- O
C O
) O
are O
hypersensitive O
to O
the O
inhibitory O
effects O
of O
interferon O
gamma O
( O
IFNgamma O
) O
, O
the O
products O
of O
certain O
IFNgamma B
- I
inducible I
genes I
known O
to O
influence O
hematopoietic O
cell O
survival O
were O
quantified O
. O

High O
constitutive O
expression O
of O
the O
IFNgamma B
- I
inducible I
genes I
, O
IFN B
- I
stimulated I
gene I
factor I
3 I
gamma I
subunit I
( O
ISGF3gamma B
) O
, O
IFN O
regulatory O
factor O
- O
1 O
( O
IRF O
- O
1 O
) O
, O
and O
the O
cyclin B
- I
dependent I
kinase I
inhibitor I
p21 I
( O
WAF1 O
) O
was O
found O
in O
FANCC B
mutant O
B O
lymphoblasts O
, O
low O
- O
density O
bone O
marrow O
cells O
, O
and O
murine O
embryonic O
fibroblasts O
. O

Paradoxically O
, O
these O
cells O
do O
not O
activate B
signal I
transducer I
and I
activator I
of I
transcription I
( I
STAT I
) I
1 I
properly O
. O

In O
an O
attempt O
to O
clarify O
mechanisms O
by O
which O
FA O
- O
C O
cells O
overexpress O
IFNgamma B
- I
inducible I
genes I
in O
the O
face O
of O
defective O
STAT1 O
phosphorylation O
, O
it O
was O
reasoned O
that O
decreased O
levels O
of O
activated B
STAT1 I
might O
result O
in O
reduced O
expression O
of O
a O
hematopoietic B
IFNgamma I
- I
responsive I
protein I
that O
normally O
modulates O
expression O
of O
other O
IFNgamma B
- I
responsive I
genes I
. O

Levels O
of O
the O
IFNgamma O
- O
inducible O
factor O
IFN B
consensus I
sequence I
binding I
protein I
( O
ICSBP O
) O
, O
a O
negative B
trans I
- I
acting I
regulator I
of O
some O
IFNgamma B
- I
inducible I
genes I
, O
were O
quantified O
. O

However O
, O
enforced O
expression O
of O
ICSBP O
failed O
to O
down O
- O
regulate O
IRF O
- O
1 O
, O
ISGF3gamma B
, O
and O
p21 B
( I
WAF1 I
) I
. O

Thus O
, O
the O
FANCC B
protein I
functions O
to O
modulate O
expression O
of O
a O
family O
of O
genes O
that O
in O
normal O
cells O
are O
inducible O
only O
by O
specific O
environmental O
cues O
for O
apoptosis O
or O
mitogenic O
inhibition O
, O
but O
it O
does O
so O
independently O
of O
the O
classic O
IFN O
- O
STAT1 O
pathway O
and O
is O
not O
the O
direct O
result O
of O
reduced O
ICSBP O
expression O
. O

These O
committed O
lymphoid O
cells O
must O
then O
undergo O
V O
( O
D O
) O
J O
recombination O
at O
the O
immunoglobulin O
gene O
or O
T B
cell I
receptor I
gene I
locus I
resulting O
in O
clonal O
production O
of O
functional O
B O
or O
T O
lymphocytes O
, O
respectively O
. O

Lymphocyte O
commitment O
and O
differentiation O
are O
accompanied O
by O
programmed O
gene O
expression O
or O
repression O
events O
which O
are O
driven O
by O
lineage B
and I
stage I
specific I
transcription I
factors I
. O

Here O
, O
we O
only O
discuss O
some O
of O
the O
genetic O
approaches O
our O
laboratory O
( O
except O
where O
it O
is O
noted O
) O
has O
undertaken O
to O
investigate O
the O
molecular O
pathways O
mediated O
by O
E2A B
transcription I
factors I
in O
lymphocyte O
development O

Inhibition O
of O
AP O
- O
1 O
by O
the O
glucocorticoid O
- O
inducible O
protein B
GILZ I
. O

One O
of O
the O
most O
prominent O
glucocorticoid O
- O
induced O
genes O
is O
glucocorticoid B
- I
induced I
leucine I
zipper I
( O
GILZ B
) O
, O
which O
has O
been O
reported O
to O
inhibit O
activation O
- O
induced O
up O
- O
regulation O
of O
Fas B
ligand I
( I
FasL I
) I
mRNA I
. O

Indeed O
, O
transient O
expression O
of O
GILZ B
in O
Jurkat O
T O
cells O
blocked O
induction O
of O
a O
reporter O
construct O
driven O
by O
the O
FasL O
promoter O
. O

This O
could O
be O
accounted O
for O
by O
GILZ B
- O
mediated O
inhibition O
of O
Egr O
- O
2 O
and O
Egr O
- O
3 O
, O
NFAT B
/ I
AP I
- I
1 I
- O
inducible O
transcription O
factors O
that O
bind O
a O
regulatory O
element O
in O
the O
FasL O
promoter O
and O
up O
- O
regulate O
FasL O
expression O
. O

GILZ B
also O
potently O
inhibited O
AP B
- I
1 I
- I
driven I
and I
IL I
- I
2 I
promoter I
- I
driven I
reporter I
constructs I
, O
and O
recombinant O
GILZ B
specifically O
interacted O
with O
c O
- O
Fos O
and O
c O
- O
Jun O
in O
vitro O
and O
inhibited O
the O
binding O
of O
active B
AP I
- I
1 I
to O
its O
target O
DNA O
. O

Whereas O
homodimerization O
of O
GILZ B
required O
the O
presence O
of O
its O
leucine O
zipper O
, O
the O
interaction O
with O
c O
- O
Fos O
and O
c O
- O
Jun O
occurred O
through O
the O
N O
- O
terminal O
60 B
- I
amino I
acid I
region I
of O
GILZ B
. O

Thus O
, O
GILZ B
represents O
a O
glucocorticoid O
- O
induced O
gene O
product O
that O
can O
inhibit O
a O
variety O
of O
activation O
- O
induced O
events O
, O
at O
least O
in O
part O
by O
direct O
interference O
with O
AP O
- O
1 O
, O
and O
is O
therefore O
a O
candidate O
for O
a O
mediator O
of O
glucocorticoid O
- O
induced O
immunosuppression O
. O

Vaccination O
with O
a O
peptide O
representing O
a O
CTL O
epitope O
from O
the O
human O
papillomavirus O
( O
HPV O
) O
16 O
E7 B
protein I
induces O
a O
specific O
CTL O
response O
that O
prevents O
the O
outgrowth O
of O
HPV16 O
E7 O
- O
expressing O
tumors O
. O

The O
HPV16 O
E7 O
peptide O
kinetics O
correlated O
with O
the O
kinetics O
of O
HPV16 B
E7 I
- O
specific O
CTL O
induction O
. O

In O
contrast O
, O
Ad5 O
E1A O
peptide O
injection O
resulted O
in O
physical O
deletion O
of O
preexisting O
Ad5 B
E1A I
- O
specific O
CTLs B
within O
24 O
h O
after O
injection O
. O

These O
data O
suggest O
that O
ubiquitous O
expression O
of O
the O
tolerizing O
Ad5 O
E1A O
peptide O
within O
a O
short O
period O
of O
time O
causes O
activation O
- O
induced O
cell O
death O
of O
Ad5 B
E1A I
- O
specific O
CTLs B
. O

Smad3 B
and O
Smad4 B
mediate O
transforming O
growth O
factor O
- O
beta1 O
- O
induced O
IgA O
expression O
in O
murine O
B O
lymphocytes O
. O

Transforming O
growth O
factor O
( O
TGF O
) O
- O
beta1 O
is O
well O
established O
as O
a O
critical O
IgA B
isotype I
switching I
factor I
and O
Smad B
molecules I
have O
been O
reported O
to O
act O
as O
transducers B
and O
transcriptional O
factors O
in O
the O
expression O
of O
TGF O
- O
beta1 O
- O
targeted O
genes O
. O

We O
examined O
the O
involvement O
of O
Smad B
proteins I
in O
TGF O
- O
beta1 O
- O
induced O
IgA O
expression O
. O

First O
, O
we O
found O
that O
TGF O
- O
beta1 O
significantly O
increases O
endogenous B
germ I
- I
line I
( I
GL I
) I
alpha I
transcripts I
by O
LPS O
- O
stimulated O
CH12 O
. O
LX O
. O
4933 O
( O
mu O
( O
+ O
) O
) O
B O
lymphoma O
cells O
. O

To O
investigate O
its O
signaling O
mechanisms O
, O
the O
lymphoma O
cell O
line O
was O
transfected O
with O
pFL3 B
that O
contains O
the O
TGF B
- I
beta I
- I
responsive I
element I
of O
the O
GLalpha B
promoter I
, O
and O
stimulated O
with O
TGF O
- O
beta1 O
. O

Similar O
to O
endogenous B
GLalpha I
transcripts I
, O
TGF O
- O
beta1 O
induces O
GLalpha B
promoter I
activity O
and O
overexpression O
of O
Smad3 B
markedly O
enhances O
the O
promoter O
activity O
. O

This O
activity O
is O
further O
augmented O
by O
cotransfected B
Smad4 I
. O

On O
the O
other O
hand O
, O
Smad7 O
substantially O
abrogates O
the O
synergistic O
effect O
of O
Smad3 B
/ I
4 I
on O
GLalpha B
promoter I
activity O
. O

In O
addition O
, O
overexpression O
of O
Smad3 B
/ I
4 I
enhances O
TGF O
- O
beta1 O
- O
induced O
endogenous B
GLalpha I
transcripts I
in O
normal O
spleen O
B O
cell O
s O
. O

Finally O
, O
in O
the O
presence O
of O
TGF O
- O
beta1 O
, O
overexpression O
of O
Smad3 B
/ I
4 I
selectively O
increases O
both O
surface O
IgA O
expression O
and O
IgA O
production O
. O

The O
results O
from O
the O
present O
study O
indicate O
that O
Smad3 B
, O
Smad4 B
, O
and O
Smad7 O
, O
at O
least O
in O
part O
, O
serve O
as O
mediators O
linking O
TGF O
- O
beta1 O
to O
transcriptional O
regulation O
of O
IgA B
switching I
related I
gene I
and O
regulation O
of O
IgA O
class O
switching O
. O

The O
translesion B
DNA I
polymerase I
zeta I
plays O
a O
major O
role O
in O
Ig O
and O
bcl O
- O
6 O
somatic O
hypermutation O
. O

Ig O
somatic O
mutations O
would O
be O
introduced O
by O
a O
polymerase B
( O
pol O
) O
while O
repairing O
DNA O
outside O
main O
DNA O
replication O
. O

We O
show O
that O
human O
B O
cells O
constitutively O
express O
the O
translesion B
pol I
zeta I
, O
which O
effectively O
extends O
DNA O
past O
mismatched O
bases O
( O
mispair O
extender O
) O
, O
and O
pol B
eta I
, O
which O
bypasses O
DNA O
lesions O
in O
an O
error O
- O
free O
fashion O
. O

Upon O
B B
cell I
receptor I
( O
BCR O
) O
engagement O
and O
coculture O
with O
activated O
CD4 O
+ O
T O
cells O
, O
these O
lymphocytes O
upregulated O
pol B
zeta I
, O
downregulated O
pol B
eta I
, O
and O
mutated O
the O
Ig B
and I
bcl I
- I
6 I
genes I
. O

Inhibition O
of O
the O
pol B
zeta I
REV3 B
catalytic I
subunit I
by O
specific O
phosphorothioate O
- O
modified O
oligonucleotides O
impaired O
Ig O
and O
bcl O
- O
6 O
hypermutation O
and O
UV O
damage O
- O
induced O
DNA O
mutagenesis O
, O
without O
affecting O
cell O
cycle O
or O
viability O
. O

Thus O
, O
pol B
zeta I
plays O
a O
critical O
role O
in O
Ig O
and O
bcl O
- O
6 O
hypermutation O
, O
perhaps O
facilitated O
by O
the O
downregulation O
of O
pol B
eta I
. O

Molecular O
mechanism O
of O
cell O
cycle O
progression O
induced O
by O
the O
oncogene B
product I
Tax I
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
. O

The O
trans B
- I
activator I
protein I
Tax I
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
( O
HTLV O
- O
I O
) O
plays O
an O
important O
role O
in O
the O
development O
of O
adult O
T O
- O
cell O
leukemia O
through O
, O
at O
least O
in O
part O
, O
its O
ability O
to O
stimulate O
cell O
growth O
. O

Introduction O
of O
Tax O
into O
resting O
Kit O
225 O
cells O
induced O
activation O
of O
the O
G1 O
/ O
S O
transition O
regulation O
cascade O
consisting O
of O
activation O
of O
cyclin B
dependent I
kinase I
2 I
( O
CDK2 O
) O
and O
CDK4 O
, O
phosphorylation O
of O
the O
Rb B
family I
proteins I
and O
an O
increase O
in O
free O
E2F O
. O

The O
kinase O
activation O
was O
found O
to O
result O
from O
Tax O
- O
induced O
expression O
of O
genes O
for O
cell B
cycle I
regulatory I
molecules I
including O
cyclin O
D2 O
, O
cyclin O
E O
, O
E2F1 O
, O
CDK2 O
, O
CDK4 O
and O
CDK6 B
, O
and O
Tax O
- O
induced O
reduction O
of O
CDK B
inhibitors I
p19 I
( O
INK4d B
) O
and O
p27 O
( O
Kip1 O
) O
. O

These O
results O
indicate O
the O
important O
role O
of O
Tax O
- O
mediated O
trans O
- O
activation O
of O
the O
genes O
for O
cell B
cycle I
regulatory I
molecules I
in O
Tax O
- O
induced O
cell O
cycle O
progression O
. O

Cot B
kinase I
induces O
cyclooxygenase O
- O
2 O
expression O
in O
T O
cells O
through O
activation O
of O
the O
nuclear O
factor O
of O
activated O
T O
cells O
. O

Here O
we O
report O
that O
Cot B
kinase I
, O
a O
mitogen B
- I
activated I
protein I
kinase I
kinase I
kinase I
involved O
in O
T O
cell O
activation O
, O
up O
- O
regulates O
COX O
- O
2 O
gene O
expression O
in O
Jurkat O
T O
cells O
. O

Induction O
of O
COX O
- O
2 O
promoter O
activity O
by O
Cot B
kinase I
occurred O
mainly O
through O
activation O
of O
the O
nuclear O
factor O
of O
activated O
T O
cells O
( O
NFAT O
) O
. O

Mutation O
of O
the O
distal B
( I
- I
105 I
/ I
- I
97 I
) I
and O
proximal B
( I
- I
76 I
/ I
- I
61 I
) I
NFAT B
response I
elements I
in O
the O
COX B
- I
2 I
promoter I
abolished O
the O
activation O
induced O
by O
Cot B
kinase I
. O

Even O
more O
, O
coexpression O
of O
a O
dominant O
negative O
version O
of O
NFAT O
inhibited O
Cot B
kinase I
- O
mediated O
COX B
- I
2 I
promoter I
activation O
, O
whereas O
cotransfection O
of O
a O
constitutively O
active O
version O
of O
the O
calcium B
- I
dependent I
phosphatase I
calcineurin I
synergizes O
with O
Cot B
kinase I
in O
the O
up O
- O
regulation O
of O
COX B
- I
2 I
promoter I
- O
driven O
transcription O
. O

Strikingly O
, O
Cot B
kinase I
increased O
transactivation O
mediated O
by O
a O
GAL4 B
- I
NFAT I
fusion I
protein I
containing O
the O
N O
- O
terminal O
transactivation O
domain O
of O
NFATp O
. O

In O
contrast O
to O
phorbol O
ester O
plus O
calcium O
ionophore O
A23187 O
, O
Cot B
kinase I
increases O
both O
COX B
- I
2 I
promoter I
activity O
and O
NFAT O
- O
mediated O
transactivation O
in O
a O
cyclosporin O
A O
- O
independent O
manner O
. O

These O
data O
indicate O
that O
Cot B
kinase I
up O
- O
regulates O
COX B
- I
2 I
promoter I
- O
driven O
transcription O
through O
the O
NFAT B
response I
elements I
, O
being O
the O
Cot B
kinase I
- O
induced O
NFAT O
- O
dependent O
transactivation O
presumably O
implicated O
in O
this O
up O
- O
regulation O
. O

Positive O
and O
negative O
roles O
of O
the O
trans B
- I
acting I
T I
cell I
factor I
- I
1 I
for O
the O
acquisition O
of O
distinct O
Ly B
- I
49 I
MHC I
class I
I I
receptors I
by O
NK O
cells O
. O

Members O
of O
the O
Ly B
- I
49 I
gene I
family I
code O
for O
class B
I I
MHC I
- I
specific I
receptors I
that O
regulate O
NK O
cell O
function O
. O

Due O
to O
a O
combinatorial O
distribution O
of O
Ly B
- I
49 I
receptors I
, O
NK O
cells O
display O
considerable O
clonal O
heterogeneity O
. O

The O
acquisition O
of O
one O
Ly B
- I
49 I
receptor I
, O
Ly B
- I
49A I
is O
strictly O
dependent O
on O
the O
transcriptional B
trans I
- I
acting I
factor I
T B
cell I
- I
specific I
factor I
- I
1 I
( O
TCF O
- O
1 O
) O
. O

Indeed O
, O
TCF O
- O
1 O
binds O
to O
two O
sites O
in O
the O
Ly B
- I
49a I
promoter I
and O
regulates O
its O
activity O
, O
suggesting O
that O
the O
Ly B
- I
49a I
gene I
is O
a O
direct O
TCF O
- O
1 O
target O
. O

TCF O
- O
1 O
deficiency O
resulted O
in O
the O
altered O
usage O
of O
additional O
Ly B
- I
49 I
receptors I
. O

We O
show O
in O
this O
study O
, O
using O
TCF B
- I
1 I
beta I
( I
2 I
) I
- I
microglobulin I
double O
- O
deficient O
mice O
, O
that O
these O
repertoire O
alterations O
are O
not O
due O
to O
Ly O
- O
49 O
/ O
MHC O
class O
I O
interactions O
. O

Our O
findings O
rather O
suggest O
a O
TCF O
- O
1 O
- O
dependent O
, O
cell O
autonomous O
effect O
on O
the O
acquisition O
of O
multiple O
Ly B
- I
49 I
receptors I
. O

Besides O
reduced O
receptor O
usage O
( O
Ly B
- I
49A I
and I
D I
) O
, O
we O
also O
observed O
no O
effect O
( O
Ly B
- I
49C I
) O
and O
significantly O
expanded O
( O
Ly B
- I
49G I
and I
I I
) O
receptor O
usage O
in O
the O
absence O
of O
TCF O
- O
1 O
. O

These O
effects O
did O
not O
in O
all O
cases O
correlate O
with O
the O
presence O
of O
TCF B
binding I
sites I
in O
the O
respective O
proximal O
promoter O
. O

Consistent O
with O
the O
observed O
differential O
, O
positive O
or O
negative O
role O
of O
TCF O
- O
1 O
for O
Ly B
- I
49 I
receptor I
acquisition O
, O
reporter O
gene O
assays O
revealed O
the O
presence O
of O
an O
inducing O
as O
well O
as O
a O
repressing O
TCF B
site I
in O
certain O
proximal O
Ly B
- I
49 I
promoters I
. O

These O
findings O
reveal O
an O
important O
role O
of O
TCF O
- O
1 O
for O
the O
formation O
of O
the O
NK B
cell I
receptor I
repertoire O
. O

Ligation O
of O
CD11b O
and O
CD11c B
beta I
( I
2 I
) I
integrins O
by O
antibodies O
or O
soluble B
CD23 I
induces O
macrophage O
inflammatory O
protein O
1alpha O
( O
MIP O
- O
1alpha O
) O
and O
MIP B
- I
1beta I
production O
in O
primary O
human O
monocytes O
through O
a O
pathway O
dependent O
on O
nuclear O
factor O
- O
kappaB O
. O

We O
found O
that O
ligation O
of O
CD11b O
or O
CD11c O
but O
not O
CD11a B
alpha I
chains I
of O
beta B
( I
2 I
) I
integrins I
by O
antibodies O
or O
soluble B
CD23 I
( I
sCD23 I
) I
fusion I
proteins I
rapidly O
induced O
transcription O
and O
secretion O
of O
interleukin O
8 O
, O
macrophage B
inflammatory I
protein I
( I
MIP I
) I
1alpha I
, O
and O
MIP B
- I
1beta I
. O

Because O
the O
promoters O
of O
these O
chemokine B
genes I
contain O
kappaB B
binding I
sites I
, O
we O
assessed O
the O
possible O
role O
of O
nuclear O
factor O
- O
kappaB O
( O
NF O
- O
kappaB O
) O
in O
controlling O
induction O
of O
the O
genes O
through O
beta O
( O
2 O
) O
integrin O
engagement O
. O

Electrophoretic O
mobility O
shift O
assays O
showed O
that O
sCD23 B
or O
antibodies O
to O
CD11b O
or O
to O
CD11c O
up O
- O
regulated O
DNA O
- O
binding O
activity O
of O
NF O
- O
kappaB O
. O

Activation O
of O
NF O
- O
kappaB O
was O
accompanied O
by O
degradation O
of O
its O
cytosolic B
inhibitor I
IkappaB I
- I
alpha I
. O

Blockade O
of O
depletion O
of O
IkappaB O
- O
alpha O
by O
proteasome O
inhibitors O
( O
proteasome O
inhibitor O
I O
or O
acetyl O
- O
leucinyl O
- O
leucinyl O
- O
norleucinal O
) O
led O
to O
concomitant O
inhibition O
of O
NF O
- O
kappaB O
DNA O
- O
binding O
activity O
and O
expression O
of O
MIP B
- I
1alpha I
and I
MIP I
- I
1beta I
messenger I
RNA I
induced O
by O
beta O
( O
2 O
) O
integrin O
ligation O
. O

These O
results O
suggest O
that O
triggering O
of O
CD11b O
or O
CD11c B
beta I
( I
2 I
) I
integrin O
on O
primary O
human O
monocytes O
provides O
activation O
signals O
leading O
to O
nuclear O
translocation O
of O
NF O
- O
kappaB O
and O
subsequent O
secretion O
of O
MIP O
- O
1alpha O
and O
MIP B
- I
1beta I
that O
may O
have O
an O
important O
role O
in O
recruitment O
of O
other O
inflammatory O
cells O
during O
initiation O
of O
an O
inflammatory O
response O

Synergistic O
transcriptional O
activation O
of O
human B
Acyl I
- I
coenzyme I
A I
: I
cholesterol I
acyltransterase I
- I
1 I
gene I
by O
interferon O
- O
gamma O
and O
all O
- O
trans O
- O
retinoic O
acid O
THP O
- O
1 O
cells O
. O

Acyl B
- I
coenzyme I
A I
: I
cholesterol I
acyltransferase I
( O
ACAT B
) O
is O
an O
intracellular B
enzyme I
involved O
in O
cellular O
cholesterol O
homeostasis O
and O
in O
atherosclerotic O
foam O
cell O
formation O
. O

Human B
ACAT I
- I
1 I
gene I
contains O
two O
promoters O
( O
P1 O
and O
P7 B
) O
, O
each O
located O
in O
a O
different O
chromosome B
( I
1 I
and I
7 I
) I
( O
Li O
, O
B O
. O
L O
. O
, O
Li O
, O
X O
. O
L O
. O
, O
Duan O
, O
Z O
. O
J O
. O
, O
Lee O
, O
O O
. O
, O
Lin O
, O
S O
. O
, O
Ma O
, O
Z O
. O
M O
. O
, O
Chang O
, O
C O
. O
C O
. O
, O
Yang O
, O
X O
. O
Y O
. O
, O
Park O
, O
J O
. O
P O
. O
, O
Mohandas O
, O
T O
. O
K O
. O
, O
Noll O
, O
W O
. O
, O
Chan O
, O
L O
. O
, O
and O
Chang O
, O
T O
. O
Y O
. O
( O
1999 O
) O
J O
. O
Biol O
Chem O
. O

Interferon O
- O
gamma O
( O
IFN O
- O
gamma O
) O
, O
a O
cytokine O
that O
exerts O
many O
pro O
- O
atherosclerotic O
effects O
in O
vivo O
, O
causes O
up O
- O
regulation O
of O
ACAT B
- I
1 I
mRNA I
in O
human O
blood O
monocyte O
- O
derived O
macrophages O
and O
macrophage O
- O
like O
cells O
but O
not O
in O
other O
cell O
types O
. O

To O
examine O
the O
molecular O
nature O
of O
this O
observation O
, O
we O
identified O
within O
the O
ACAT B
- I
1 I
P1 I
promoter I
a O
159 B
- I
base I
pair I
core I
region I
. O

This O
region O
contains O
4 O
Sp1 B
elements I
and O
an O
IFN O
- O
gamma O
activated O
sequence O
( O
GAS O
) O
that O
overlaps O
with O
the O
second O
Sp1 O
element O
. O

In O
the O
monocytic O
cell O
line O
THP O
- O
1 O
cell O
, O
the O
combination O
of O
IFN O
- O
gamma O
and O
all O
- O
trans O
- O
retinoic O
acid O
( O
a O
known O
differentiation O
agent O
) O
enhances O
the O
ACAT B
- I
1 I
P1 I
promoter I
but O
not O
the O
P7 B
promoter I
. O

Additional O
experiments O
showed O
that O
all O
- O
trans O
- O
retinoic O
acid O
causes O
large O
induction O
of O
the O
transcription O
factor O
STAT1 O
, O
while O
IFN O
- O
gamma O
causes O
activation O
of O
STAT1 O
such O
that O
it O
binds O
to O
the O
GAS B
/ I
Sp1 I
site I
in O
the O
ACAT B
- I
1 I
P1 I
promoter I
. O

Our O
work O
provides O
a O
molecular O
mechanism O
to O
account O
for O
the O
effect O
of O
IFN O
- O
gamma O
in O
causing O
transcriptional O
activation O
of O
ACAT B
- I
1 I
in O
macrophage O
- O
like O
cells O
. O

This O
approach O
has O
the O
potential O
advantage O
of O
suppressing O
the O
expression O
of O
various O
proinflammatory B
Th2 I
cytokines I
simultaneously O
rather O
than O
suppressing O
the O
activity O
of O
a O
single O
cytokine O
. O

METHODS O
AND O
RESULTS O
: O
BALB O
/ O
c O
mice O
, O
making O
a O
CD4 O
+ O
Th2 O
( O
IL O
- O
4 O
+ O
) O
cell O
response O
, O
express O
both O
MHC O
class O
II O
antigens O
( O
IA B
( I
d I
) I
, O
IE B
( I
d I
) I
) O
and O
are O
atherosclerosis O
- O
resistant O
. O

C57Bl O
/ O
6 O
mice O
produce O
a O
CD4 O
+ O
Th1 O
( O
interferon O
[ O
IFN O
] O
gamma O
+ O
) O
response O
, O
express O
IA B
( I
b I
) I
but O
no O
IE O
, O
and O
are O
atherosclerosis O
- O
prone O
. O

Decreasing O
Th1 O
cells O
by O
antibodies O
( O
alpha B
- I
CD4 I
) O
or O
cytokines O
( O
IL O
- O
4 O
) O
also O
caused O
> O
/ O
= O
80 O
% O
reductions O
in O
lesion O
size O
. O

CONCLUSIONS O
: O
In O
mildly O
hypercholesterolemic O
C57Bl O
/ O
6 O
mice O
, O
presence O
of O
IA B
( I
b I
) I
and O
absence O
of O
IE O
regulated O
CD4 O
+ O
T O
helper O
- O
cell O
phenotype O
; O
fatty O
lesions O
were O
proportional O
to O
IFNgamma O
+ O
Th1 O
cells O
in O
both O
C57Bl O
/ O
6 O
and O
BALB O
/ O
c O
strains O
. O

Requirement O
for O
p38 O
and O
p44 B
/ I
p42 I
mitogen O
- O
activated O
protein O
kinases O
in O
RAGE B
- O
mediated O
nuclear O
factor O
- O
kappaB O
transcriptional O
activation O
and O
cytokine O
secretion O
. O

Advanced O
glycation O
end O
product O
( O
AGE O
) O
activation O
of O
the O
signal B
- I
transducing I
receptor I
for I
AGE I
( O
RAGE B
) O
has O
been O
linked O
to O
a O
proinflammatory O
phenotypic O
change O
within O
cells O
. O

The O
NF O
- O
kappaB O
response O
was O
blocked O
with O
a O
synthetic O
peptide O
corresponding O
to O
the O
putative B
ligand I
- I
binding I
domain I
of O
RAGE B
, O
with O
anti O
- O
RAGE B
antiserum O
, O
and O
by O
coexpression O
of O
truncated B
receptors I
lacking O
the O
intracellular O
domain O
. O

Signal O
transduction O
from O
RAGE B
to O
NF O
- O
kappaB O
involved O
the O
generation O
of O
reactive O
oxygen O
species O
, O
since O
reporter O
gene O
expression O
was O
blocked O
with O
the O
antioxidant O
N O
- O
acetyl O
- O
L O
- O
cysteine O
. O

CML B
- I
modified I
albumin I
produced O
rapid O
transient O
activation O
of O
tyrosine O
phosphorylation O
, O
extracellular B
signal I
- I
regulated I
kinase I
1 I
and I
2 I
, O
and O
p38 O
mitogen O
- O
activated O
protein O
kinase O
( O
MAPK O
) O
, O
but O
not O
c B
- I
Jun I
NH I
( I
2 I
) I
- I
terminal I
kinase I
. O

RAGE B
- O
mediated O
NF O
- O
kappaB O
activation O
was O
suppressed O
by O
the O
selective O
p38 O
MAPK O
inhibitor O
SB203580 O
and O
by O
coexpression O
of O
a O
kinase O
- O
dead O
p38 O
dominant O
- O
negative O
mutant O
. O

Activation O
of O
NF O
- O
kappaB O
by O
CML B
- I
modified I
albumin I
increased O
secretion O
of O
proinflammatory O
cytokines O
( O
tumor O
necrosis O
factor O
- O
alpha O
, O
interleukin O
- O
1beta O
, O
and O
monocyte O
chemoattractant O
protein O
- O
1 O
) O
severalfold O
, O
and O
inhibition O
of O
p38 O
MAPK O
blocked O
these O
increases O
. O

These O
results O
indicate O
that O
p38 O
MAPK O
activation O
mediates O
RAGE B
- O
induced O
NF O
- O
kappaB O
- O
dependent O
secretion O
of O
proinflammatory O
cytokines O
and O
suggest O
that O
accelerated O
inflammation O
may O
be O
a O
consequence O
of O
cellular O
activation O
induced O
by O
this O
receptor O
. O

The O
NF B
- I
kappaB I
/ I
Rel I
transcription I
factors I
play O
an O
important O
role O
in O
the O
expression O
of O
genes O
involved O
in O
B O
cell O
development O
, O
differentiation O
and O
function O
. O

T O
cell O
responses O
to O
Ags O
involve O
recognition O
of O
selected O
peptide B
epitopes I
contained O
within O
the O
antigenic B
protein I
. O

In O
this O
report O
, O
we O
describe O
a O
new O
approach O
for O
direct O
identification O
of O
CD4 O
+ O
T O
cell O
epitopes O
of O
complex O
Ags O
that O
uses O
human B
class I
II I
tetramers I
to O
identify O
reactive O
cells O
. O

With O
a O
panel O
of O
60 O
overlapping O
peptides O
covering O
the O
entire O
sequence O
of O
the O
VP16 B
protein I
, O
a O
major O
Ag O
for O
HSV O
- O
2 O
, O
we O
generated O
a O
panel O
of O
class B
II I
MHC I
tetramers I
loaded O
with O
peptide O
pools O
that O
were O
used O
to O
stain O
peripheral O
lymphocytes O
of O
an O
HSV O
- O
2 O
infected O
individual O
. O

With O
this O
approach O
, O
we O
identified O
four O
new O
DRA1 O
* O
0101 O
/ O
DRB1 O
* O
0401 O
- O
and O
two O
DRA1 O
* O
0101 O
/ O
DRB1 O
* O
0404 O
- O
restricted O
, O
VP16 B
- I
specific I
epitopes I
. O

By O
using O
tetramers B
to O
sort O
individual O
cells O
, O
we O
easily O
obtained O
a O
large O
number O
of O
clones O
specific O
to O
these O
epitopes O
. O

Although O
DRA1 O
* O
0101 O
/ O
DRB1 O
* O
0401 O
and O
DRA1 O
* O
0101 O
/ O
DRB1 O
* O
0404 O
are O
structurally O
very O
similar O
, O
nonoverlapping O
VP16 B
epitopes I
were O
identified O
, O
illustrating O
high O
selectivity O
of O
individual O
allele O
polymorphisms O
within O
common O
MHC O
variants O
. O

Here O
we O
report O
upregulation O
of O
NF O
- O
kappaB O
and O
inflammatory B
molecules I
, O
and O
their O
correlation O
with O
local O
pancreatic O
injury O
, O
in O
a O
model O
of O
severe O
pancreatitis O
. O

NF O
- O
kappaB O
and O
activator O
protein O
- O
1 O
( O
AP O
- O
1 O
) O
activation O
were O
assessed O
by O
gel O
shift O
assay O
, O
and O
mRNA O
expression O
of O
interleukin O
- O
6 O
, O
tumor O
necrosis O
factor O
- O
alpha O
, O
KC O
, O
monocyte O
chemoattractant O
protein O
- O
1 O
, O
and O
inducible B
nitric I
oxide I
synthase I
was O
assessed O
by O
semiquantitative O
RT O
- O
PCR O
. O

Morphological O
damage O
and O
trypsin O
activation O
were O
much O
greater O
in O
the O
pancreatic O
head O
than O
tail O
, O
in O
parallel O
with O
a O
stronger O
activation O
of O
NF B
- I
kappaB I
and I
cytokine I
mRNA I
. O

CD45 B
tyrosine I
phosphatase I
controls O
common O
gamma B
- I
chain I
cytokine I
- O
mediated O
STAT O
and O
extracellular O
signal O
- O
related O
kinase O
phosphorylation O
in O
activated O
human O
lymphoblasts O
: O
inhibition O
of O
proliferation O
without O
induction O
of O
apoptosis O
. O

To O
this O
end O
, O
we O
generated O
lymphoblasts O
which O
proliferate O
in O
response O
to O
common O
gamma B
- I
chain I
cytokines I
, O
but O
readily O
undergo O
apoptosis O
after O
cytokine O
withdrawal O
. O

In O
experiments O
with O
the O
CD45R0 B
mAb I
UCHL I
- I
1 I
, O
but O
not O
control B
CD45 I
mAbs I
, O
we O
found O
significant O
inhibition O
of O
proliferation O
. O

Interestingly O
, O
the O
pan B
- I
CD45 I
mAb I
GAP8 I
. I
3 I
, O
which O
is O
most O
effective O
in O
inhibition O
of O
OKT O
- O
3 O
- O
mediated O
proliferation O
in O
quiescent O
lymphocytes O
, O
was O
ineffective O
in O
lymphoblasts O
. O

Addition O
of O
CD3 B
mAb I
OKT I
- I
3 I
had O
no O
influence O
on O
IL O
- O
2 O
- O
mediated O
proliferation O
( O
with O
or O
without O
UCHL B
- I
1 I
) O
. O

In O
contrast O
, O
after O
addition O
of O
OKT B
- I
3 I
to O
IL O
- O
4 O
- O
and O
IL O
- O
7 O
- O
stimulated O
proliferation O
assays O
, O
UCHL B
- I
1 I
signals O
could O
not O
significantly O
alter O
cellular O
proliferation O
. O

In O
Western O
blots O
using O
mAbs O
detecting O
phosphorylated B
STAT I
- I
3 I
, I
STAT I
- I
5 I
, I
STAT I
- I
6 I
, O
or O
extracellular B
signal I
- I
related I
kinase I
1 I
/ I
2 I
, O
we O
found O
that O
CD45R0 O
signaling O
could O
effectively O
diminish O
phosphorylation O
of O
these O
intracellular O
signaling O
components O
. O

Costimulation O
with O
OKT B
- I
3 I
and O
IL O
- O
2 O
optimally O
induced O
secretion O
of O
IFN O
- O
gamma O
, O
TNF O
- O
alpha O
, O
and O
IL O
- O
5 O
, O
which O
was O
not O
decreased O
by O
CD45 O
signals O
. O

Furthermore O
, O
we O
show O
the O
existence O
of O
CD45 B
epitopes I
( O
GAP8 B
. I
3 I
) O
, O
which O
are O
active O
and O
critical O
for O
signaling O
in O
quiescent O
lymphocytes O
, O
but O
are O
nonfunctional O
in O
activated O
human O
lymphoblasts O
. O

The O
Pax5 O
gene O
encoding O
the O
transcription B
factor I
BSAP I
is O
required O
for O
progression O
of O
B O
- O
lymphopoiesis O
beyond O
the O
pro O
- O
B O
cell O
stage O
. O

Pax5 O
appears O
to O
mediate O
B O
- O
lineage O
commitment O
by O
repressing O
the O
transcription O
of O
non B
- I
B I
- I
lymphoid I
genes I
and O
by O
simultaneously O
activating O
the O
expression O
of O
B B
- I
lineage I
- I
specific I
genes I
. O

Pax5 O
thus O
functions O
both O
as O
a O
transcriptional O
repressor O
and O
activator O
, O
depending O
on O
its O
interactions O
with O
corepressors B
of O
the O
Groucho B
protein I
family I
or O
with O
positive O
regulators O
such O
as O
the O
TATA O
- O
binding O
protein O
. O

The O
four O
calcium O
- O
regulated O
transcription O
factors O
of O
the O
NFAT O
family O
act O
synergistically O
with O
AP B
- I
1 I
( I
Fos I
/ I
Jun I
) I
proteins I
on O
composite O
DNA O
elements O
which O
contain O
adjacent O
NFAT B
and I
AP I
- I
1 I
binding I
sites I
, O
where O
they O
form O
highly O
stable O
ternary O
complexes O
to O
regulate O
the O
expression O
of O
diverse O
inducible O
genes O
. O

Concomitant O
induction O
of O
NFAT O
and O
AP O
- O
1 O
requires O
concerted O
activation O
of O
two O
different O
signaling O
pathways O
: O
calcium O
/ O
calcineurin O
, O
which O
promotes O
NFAT O
dephosphorylation O
, O
nuclear O
translocation O
and O
activation O
; O
and O
protein B
kinase I
C I
( I
PKC I
) I
/ I
Ras I
, O
which O
promotes O
the O
synthesis O
, O
phosphorylation O
and O
activation O
of O
members O
of O
the O
Fos B
and I
Jun I
families I
of O
transcription O
factors O
. O

A O
fifth O
member O
of O
the O
NFAT O
family O
, O
NFAT5 B
, O
controls O
the O
cellular O
response O
to O
osmotic O
stress O
, O
by O
a O
mechanism O
that O
requires O
dimer O
formation O
and O
is O
independent O
of O
calcineurin O
or O
of O
interaction O
with O
AP O
- O
1 O
. O

Two O
coxsackievirus O
B3 O
( O
CVB3 O
) O
variants O
( O
H3 O
and O
H310A1 O
) O
differ O
by O
a O
single O
amino O
acid O
mutation O
in O
the O
VP2 B
capsid I
protein I
. O

Depletion O
of O
Vgamma1 O
( O
+ O
) O
cells O
using O
monoclonal B
anti I
- I
Vgamma1 I
antibody I
enhanced O
myocarditis O
and O
CD4 O
( O
+ O
) O
- O
, O
IFN O
- O
gamma O
( O
+ O
) O
- O
cell O
responses O
in O
both O
H3 O
- O
and O
H310A1 O
- O
infected O
mice O
yet O
decreased O
the O
CD4 O
( O
+ O
) O
- O
, O
IL O
- O
4 O
( O
+ O
) O
- O
cell O
response O
. O

Plasmin B
- O
induced O
expression O
of O
cytokines O
and O
tissue O
factor O
in O
human O
monocytes O
involves O
AP O
- O
1 O
and O
IKKbeta O
- O
mediated O
NF O
- O
kappaB O
activation O
. O

It O
was O
previously O
shown O
that O
plasmin B
activates O
human O
peripheral O
monocytes O
in O
terms O
of O
lipid O
mediator O
release O
and O
chemotactic O
migration O
. O

Here O
it O
is O
demonstrated O
that O
plasmin B
induces O
proinflammatory O
cytokine O
release O
and O
tissue O
factor O
( O
TF O
) O
expression O
by O
monocytes O
. O

Plasmin B
0 O
. O
043 O
to O
1 O
. O
43 O
CTA O
U O
/ O
mL O
, O
but O
not O
active B
site I
- I
blocked I
plasmin I
, O
triggered O
concentration O
- O
dependent O
expression O
of O
mRNA O
for O
interleukin O
- O
1alpha O
( O
IL O
- O
1alpha O
) O
, O
IL O
- O
1beta O
, O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
, O
and O
TF O
with O
maximum O
responses O
after O
4 O
hours O
. O

Plasmin B
- O
mediated O
mRNA O
expression O
was O
inhibited O
in O
a O
concentration O
- O
dependent O
manner O
by O
the O
lysine O
analogue O
trans O
- O
4 O
- O
( O
aminomethyl O
) O
cyclohexane O
- O
1 O
- O
carboxylic O
acid O
( O
t O
- O
AMCA O
) O
. O

Electrophoretic O
mobility O
shift O
assays O
indicated O
plasmin B
- O
induced O
activation O
of O
NF O
- O
kappaB O
; O
DNA O
- O
binding O
complexes O
were O
composed O
of O
p50 O
, O
p65 O
, O
and O
c O
- O
Rel O
, O
as O
shown O
by O
supershift O
experiments O
. O

At O
variance O
with O
endotoxic O
lipopolysaccharide O
, O
plasmin B
elicited O
the O
rapid O
degradation O
of O
another O
cytoplasmic B
NF I
- I
kappaB I
inhibitor I
, I
p105 I
. O

Proteolysis O
of O
NF O
- O
kappaB O
inhibitors O
was O
apparently O
due O
to O
transient O
activation O
of O
IkappaB B
kinase I
( I
IKK I
) I
beta I
that O
reached O
maximum O
activity O
at O
1 O
hour O
after O
plasmin B
stimulation O
. O

In O
addition O
, O
AP O
- O
1 O
binding O
was O
increased O
in O
plasmin B
- O
treated O
monocytes O
, O
with O
most O
complexes O
composed O
of O
JunD O
, O
c O
- O
Fos O
, O
and O
FosB O
. O

These O
findings O
further O
substantiate O
the O
role O
of O
plasmin B
as O
a O
proinflammatory O
activator O
of O
human O
monocytes O
and O
reveal O
an O
important O
new O
link O
between O
the O
plasminogen O
- O
plasmin O
system O
and O
inflammation O
. O

While O
it O
has O
been O
shown O
that O
progenitor O
cells O
of O
P O
. O
vera O
patients O
are O
hypersensitive O
to O
several O
growth O
factors O
including O
erythropoietin O
, O
insulin B
- I
like I
growth I
factor I
- I
1 I
, O
thrombopoietin O
, O
interleukin O
- O
3 O
, O
and O
granulocyte B
/ I
monocyte I
colony I
- I
stimulating I
factor I
, O
the O
molecular O
pathogenesis O
of O
this O
disease O
remains O
unknown O
. O

METHODS O
: O
Peripheral O
granulocytes O
from O
patients O
with O
P O
. O
vera O
and O
from O
healthy O
volunteers O
were O
assayed O
for O
STAT1 B
, I
3 I
, I
and I
5 I
DNA O
binding O
by O
electrophoretic O
mobility O
shift O
assay O
. O

Constitutively B
active I
STAT3 I
may O
contribute O
to O
the O
growth O
factor O
hypersensitivity O
of O
P O
. O
vera O
cells O
. O

Identification O
of O
phosphorylation O
sites O
for O
Bruton B
' I
s I
tyrosine I
kinase I
within O
the O
transcriptional B
regulator I
BAP I
/ I
TFII I
- I
I I
. O

Bruton B
' I
s I
tyrosine I
kinase I
( O
Btk O
) O
, O
a O
member O
of O
the O
Tec B
family I
of I
cytosolic I
kinases I
, O
is O
essential O
for O
B O
cell O
development O
and O
function O
. O

BAP B
/ I
TFII I
- I
I I
, O
a O
protein O
implicated O
in O
transcriptional O
regulation O
, O
is O
associated O
with O
Btk O
in O
B O
cells O
and O
is O
transiently O
phosphorylated O
on O
tyrosine O
following O
B O
cell O
receptor O
engagement O
. O

BAP B
/ I
TFII I
- I
I I
is O
a O
substrate O
for O
Btk O
in O
vitro O
and O
is O
hyperphosphorylated O
on O
tyrosine O
upon O
coexpression O
with O
Btk O
in O
mammalian O
cells O
. O

In O
an O
effort O
to O
understand O
the O
physiologic O
consequences O
of O
BAP B
/ I
TFII I
- I
I I
tyrosine O
phosphorylation O
following O
B O
cell O
receptor O
stimulation O
, O
site O
- O
directed O
mutagenesis O
and O
phosphopeptide O
mapping O
were O
used O
to O
locate O
the O
predominant O
sites O
of O
BAP B
/ I
TFII I
- I
I I
phosphorylation O
by O
Btk O
in O
vitro O
. O

These O
residues O
, O
Tyr248 O
, O
Tyr357 O
, O
and O
Tyr462 O
, O
were O
also O
found O
to O
be O
the O
major O
sites O
for O
Btk O
- O
dependent O
phosphorylation O
of O
BAP B
/ I
TFII I
- I
I I
in O
vivo O
. O

Residues O
Tyr357 O
and O
Tyr462 O
are O
contained O
within O
the O
loop O
regions O
of O
adjacent O
helix B
- I
loop I
- I
helix I
- I
like I
repeats I
within O
BAP B
/ I
TFII I
- I
I I
. O

Mutation O
of O
either O
Tyr248 O
, O
Tyr357 O
, O
or O
Tyr462 O
to O
phenylalanine O
reduced O
transcription O
from O
a O
c O
- O
fos O
promoter O
relative O
to O
wild B
- I
type I
BAP I
/ I
TFII I
- I
I I
in O
transfected O
COS O
- O
7 O
cells O
, O
consistent O
with O
the O
interpretation O
that O
phosphorylation O
at O
these O
sites O
contributes O
to O
transcriptional O
activation O
. O

Phosphorylation O
of O
BAP B
/ I
TFII I
- I
I I
by O
Btk O
may O
link O
engagement O
of O
receptors O
such O
as O
surface O
immunoglobulin O
to O
modulation O
of O
gene O
expression O
. O

Expression O
of O
interferon B
consensus I
sequence I
binding I
protein I
induces O
potent O
immunity O
against O
BCR O
/ O
ABL O
- O
induced O
leukemia O
. O

Mice O
deficient O
in O
the O
interferon B
consensus I
sequence I
binding I
protein I
( O
ICSBP O
) O
develop O
a O
disease O
resembling O
chronic O
myeloid O
leukemia O
( O
CML O
) O
, O
which O
in O
humans O
is O
caused O
by O
the O
BCR B
/ I
ABL I
oncoprotein I
. O

A O
transcriptional O
block O
in O
the O
IL O
- O
2 O
promoter O
at O
the O
- B
150 I
AP I
- I
1 I
site I
in O
effector O
CD8 O
+ O
T O
cells O
. O

CD28 O
+ O
CD8 O
( O
+ O
) O
T O
cells O
unable O
to O
transcribe O
the O
IL O
- O
2 O
gene O
in O
response O
to O
antigenic O
stimulation O
had O
a O
block O
in O
transactivation O
of O
the O
- B
150 I
CD28 I
response I
element I
( I
CD28RE I
) I
/ I
AP I
- I
1 I
site I
of O
the O
IL O
- O
2 O
promoter O
, O
but O
did O
transactivate O
the O
composite O
NFAT B
/ I
AP I
- I
1 I
and I
OCT I
/ I
AP I
- I
1 I
sites I
, O
and O
a O
consensus B
AP I
- I
1 I
motif I
. O

Mutation O
of O
the O
nonconsensus B
- I
150 I
AP I
- I
1 I
site I
to O
a O
consensus O
AP O
- O
1 O
site O
, O
or O
insertion O
of O
a O
CD28RE B
/ I
AP I
- I
1 I
consensus I
site I
upstream O
of O
the O
native O
- B
150 I
CD28RE I
/ I
AP I
- I
1 I
site I
restored O
transactivation O
of O
the O
altered O
promoter O
. O

These O
results O
suggest O
that O
the O
defect O
at O
the O
- B
150 I
site I
may O
reflect O
the O
absence O
or O
inactivity O
of O
a O
required O
factor O
rather O
than O
repression O
of O
the O
IL O
- O
2 O
promoter O
. O

Stem O
cell O
factor O
and O
interleukin O
- O
3 O
induce O
stepwise O
generation O
of O
erythroid O
precursor O
cells O
from O
a O
basic O
fibroblast B
growth I
factor I
- O
dependent O
hematopoietic O
stem O
cell O
line O
, O
A O
- O
6 O
. O

Those O
cells O
were O
positive O
for O
stem B
cell I
markers I
, O
c O
- O
kit O
and O
CD34 O
, O
and O
a O
myeloid B
cell I
marker I
, I
F4 I
/ I
80 I
. O

Some O
cell O
fractions O
were O
also O
positive O
for O
Mac B
- I
1 I
, I
a I
macrophage I
marker I
or O
Gr B
- I
1 I
, I
a I
granulocytic I
maker I
, O
but O
negative O
for O
an O
erythroid B
marker I
TER119 I
. O

They O
also O
showed O
the O
expression O
of O
mRNA O
for O
the O
myeloid B
- I
specific I
PU I
. I
1 I
but O
did O
not O
that O
for O
the O
erythroid O
- O
specific O
GATA O
- O
1 O
. O

Among O
various O
cytokines O
, O
interleukin O
- O
3 O
( O
IL O
- O
3 O
) O
induced O
erythroid O
precursor O
cells O
that O
expressed O
the O
erythroid O
- O
specific O
GATA O
- O
1 O
and O
beta B
- I
major I
globin I
. O

Distinct O
BMI B
- I
1 I
and O
EZH2 B
expression O
patterns O
in O
thymocytes O
and O
mature O
T O
cells O
suggest O
a O
role O
for O
Polycomb B
genes I
in O
human O
T O
cell O
differentiation O
. O

BMI B
- I
1 I
and O
EZH2 B
Polycomb B
- I
group I
( I
PcG I
) I
proteins I
belong O
to O
two O
distinct O
protein O
complexes O
involved O
in O
the O
regulation O
of O
hematopoiesis O
. O

Using O
unique O
PcG O
- O
specific O
antisera O
and O
triple O
immunofluorescence O
, O
we O
found O
that O
mature O
resting O
peripheral O
T O
cells O
expressed O
BMI B
- I
1 I
, O
whereas O
dividing O
blasts O
were O
EZH2 O
( O
+ O
) O
. O

By O
contrast O
, O
subcapsular O
immature O
double O
- O
negative O
( O
DN O
) O
( O
CD4 O
( O
- O
) O
/ O
CD8 O
( O
- O
) O
) O
T O
cells O
in O
the O
thymus O
coexpressed O
BMI B
- I
1 I
and O
EZH2 B
or O
were O
BMI O
- O
1 O
single O
positive O
. O

Their O
descendants O
, O
double O
- O
positive O
( O
DP O
; O
CD4 O
( O
+ O
) O
/ O
CD8 O
( O
+ O
) O
) O
cortical O
thymocytes O
, O
expressed O
EZH2 B
without O
BMI B
- I
1 I
. O

Maturation O
of O
DP O
cortical O
thymocytes O
to O
single O
- O
positive O
( O
CD4 O
( O
+ O
) O
/ O
CD8 O
( O
- O
) O
or O
CD8 O
( O
+ O
) O
/ O
CD4 O
( O
- O
) O
) O
medullar O
thymocytes O
correlated O
with O
decreased O
detectability O
of O
EZH2 B
and O
continued O
relative O
absence O
of O
BMI B
- I
1 I
. O

Our O
data O
show O
that O
BMI B
- I
1 I
and O
EZH2 B
expression O
in O
mature O
peripheral O
T O
cells O
is O
mutually O
exclusive O
and O
linked O
to O
proliferation O
status O
, O
and O
that O
this O
pattern O
is O
not O
yet O
established O
in O
thymocytes O
of O
the O
cortex O
and O
medulla O
. O

T O
cell O
stage O
- O
specific O
PcG O
expression O
profiles O
suggest O
that O
PcG B
genes I
contribute O
to O
regulation O
of O
T O
cell O
differentiation O
. O

Epstein O
- O
Barr O
Virus O
and O
its O
glycoprotein B
- I
350 I
upregulate O
IL O
- O
6 O
in O
human O
B O
- O
lymphocytes O
via O
CD21 O
, O
involving O
activation O
of O
NF O
- O
kappaB O
and O
different O
signaling O
pathways O
. O

EBV O
utilizes O
CD21 B
/ I
CR2 I
as O
its O
receptor O
on O
B O
cells O
to O
initiate O
the O
infection O
process O
. O

EBV O
binds O
to O
CR2 B
through O
its O
major B
envelope I
glycoprotein I
- I
350 I
( O
gp350 B
) O
and O
is O
also O
a O
remarkable O
immunomodulating O
agent O
. O

We O
now O
show O
that O
while O
both O
purified O
recombinant B
gp350 I
( O
rgp350 B
) O
and O
EBV O
upregulate O
IL O
- O
6 O
mRNA O
synthesis O
in O
B O
cells O
, O
EBV O
- O
induced O
IL O
- O
6 O
gene O
activation O
occurs O
for O
a O
significantly O
longer O
period O
of O
time O
( O
i O
. O
e O
. O
12 O
hours O
for O
EBV O
as O
compared O
to O
6 O
hours O
for O
rgp350 B
) O
. O

Moreover O
, O
the O
half O
- O
life O
of O
EBV O
- O
induced O
IL O
- O
6 O
mRNA O
was O
also O
significantly O
longer O
( O
10 O
hours O
) O
than O
that O
of O
mRNA O
induced O
by O
rgp350 B
( O
about O
6 O
hours O
) O
. O

Both O
EBV O
and O
gp350 B
enhance O
the O
binding O
of O
the O
NF O
- O
kappaB O
transcription O
factor O
, O
as O
determined O
by O
band O
- O
shift O
and O
augment O
NF O
- O
kappaB O
- O
mediated O
activation O
of O
a O
CAT B
reporter I
plasmid I
. O

Furthermore O
, O
we O
demonstrate O
that O
while O
the O
activation O
of O
IL O
- O
6 O
gene O
expression O
by O
gp350 B
is O
mediated O
primarily O
by O
the O
protein O
kinase O
C O
pathway O
, O
EBV O
can O
mediate O
its O
effects O
through O
multiple O
signaling O
pathways O
. O

To O
our O
knowledge O
this O
is O
the O
first O
report O
showing O
that O
the O
binding O
of O
a O
herpesvirus B
envelope I
glycoprotein I
to O
CR2 B
on O
human O
B O
cells O
results O
in O
the O
activation O
of O
the O
NF O
- O
kappaB O
transcription O
factor O
leading O
to O
the O
upregulation O
of O
IL O
- O
6 O
gene O
expression O
in O
these O
lymphocytes O
. O

In O
the O
present O
study O
, O
sequence O
analysis O
was O
conducted O
on O
lacI B
DNA I
and O
hprt B
cDNA I
from O
the O
mutants O
, O
to O
determine O
the O
mutational O
specificity O
of O
N O
- O
OH O
- O
AAF O
in O
the O
rat O
. O

Also O
, O
multiplex O
PCR O
analysis O
of O
genomic O
DNA O
from O
the O
hprt O
mutants O
indicated O
that O
12 O
% O
of O
mutants O
from O
treated O
rats O
had O
major O
deletions O
in O
the O
hprt B
gene I
; O
no O
corresponding O
incidence O
of O
large O
deletions O
was O
evident O
among O
lacI O
mutations O
. O

The O
differences O
between O
N O
- O
OH O
- O
AAF O
mutation O
in O
the O
endogenous O
gene O
and O
transgene B
can O
be O
partially O
explained O
by O
the O
structures O
of O
the O
two O
genes O
. O

Caspase O
- O
dependent O
cleavage O
of O
the O
hematopoietic B
specific I
adaptor I
protein I
Gads I
alters O
signalling O
from O
the O
T O
cell O
receptor O
. O

Gads B
is O
a O
SH2 B
and I
SH3 I
domain I
- O
containing O
, O
hematopoietic B
- I
specific I
adaptor I
protein I
that O
functions O
in O
signalling O
from O
the O
T O
cell O
receptor O
. O

Gads B
acts O
by O
linking O
SLP O
- O
76 O
, O
bound O
by O
the O
carboxy B
- I
terminal I
Gads I
SH3 I
domain I
, O
to O
tyrosine B
phosphorylated I
LAT I
which O
contains O
binding O
sites O
for O
the O
Gads B
SH2 I
domain I
. O

Gads B
is O
distinguished O
from O
Grb2 O
and O
the O
closely O
related O
Grap B
protein I
by O
the O
presence O
of O
a O
120 B
amino I
acid I
unique I
region I
between O
the O
SH2 O
domain O
and O
the O
carboxy B
terminal I
SH3 I
domain I
. O

Here O
we O
demonstrate O
that O
the O
unique O
region O
of O
Gads B
contains O
a O
capase B
cleavage I
site I
. O

Induction O
of O
apoptosis O
in O
lymphocytes O
results O
in O
detectable O
Gads B
cleavage O
by O
60 O
min O
. O

Gads B
cleavage O
is O
blocked O
in O
vivo O
by O
treating O
cells O
with O
a O
caspase O
3 O
inhibitor O
. O

A O
putative B
caspase I
3 I
cleavage I
site I
was O
identified O
within O
the O
unique O
region O
and O
mutation O
of O
this O
site O
prevented O
Gads B
cleavage O
in O
vitro O
, O
and O
in O
vivo O
. O

The O
Gads B
cleavage O
products O
retained O
the O
predicted O
binding O
specificity O
for O
SLP O
- O
76 O
and O
LAT O
. O

Expression O
of O
the O
Gads B
cleavage O
products O
in O
Jurkat O
T O
cells O
inhibited O
NFAT O
activation O
following O
TCR O
cross O
linking O
. O

These O
findings O
indicate O
that O
cleavage O
of O
Gads B
in O
vivo O
could O
function O
to O
alter O
signalling O
downstream O
of O
the O
T O
cell O
receptor O
by O
disrupting O
cross O
talk O
between O
SLP O
- O
76 O
and O
LAT O
. O

Recruitment O
of O
p300 O
by O
cAMP B
- I
responsive I
element I
- I
binding I
protein I
- I
Rel I
cross O
- O
talk O
at O
the O
composite B
CD28 I
response I
element I
( O
CD28RE O
) O
- O
TRE B
element I
of O
the O
IL O
- O
2 O
promoter O
is O
essential O
for O
promoter O
inducibility O
during O
T O
- O
cell O
activation O
, O
and O
CD28RE B
- I
TRE I
is O
the O
exclusive O
target O
of O
the O
human O
T O
- O
cell O
lymphotropic O
virus O
type O
I O
oncoprotein B
Tax I
. O

The O
intrinsic O
histone O
acetyltransferase O
activity O
of O
p300 O
is O
dispensable O
for O
activation O
of O
the O
IL O
- O
2 O
promoter O
, O
and O
the O
N B
- I
terminal I
743 I
residues I
contain O
the O
minimal O
structural O
requirements O
for O
synergistic O
transactivation O
of O
the O
CD28RE B
- I
TRE I
, O
the O
IL O
- O
2 O
promoter O
, O
and O
endogenous O
IL O
- O
2 O
gene O
expression O
. O

These O
findings O
provide O
evidence O
that O
p300 O
assembles O
at O
the O
IL O
- O
2 O
promoter O
to O
form O
an O
enhanceosome O
- O
like O
signal O
transduction O
target O
that O
is O
centrally O
integrated O
at O
the O
CD28RE B
- I
TRE I
element I
of O
the O
IL O
- O
2 O
promoter O
through O
specific O
protein O
module O
- O
targeted O
associations O
in O
activated O
T O
- O
cells O
. O

METHODS O
: O
Cord O
blood O
mononuclear O
cells O
were O
Th1 O
- O
or O
Th2 O
- O
polarized O
by O
culture O
in O
IL O
- O
12 O
- O
or O
IL O
- O
4 O
- O
employing O
established O
methods O
; O
PBMC O
from O
house O
dust O
mite O
( O
HDM O
) O
- O
sensitive O
atopics O
and O
controls O
were O
stimulated O
overnight O
with O
HDM O
; O
cytokine O
production O
was O
measured O
by O
ELISA O
and O
GATA B
- I
3 I
mRNA I
expression O
by O
PCR O
. O

The O
heat O
shock O
response O
reduces O
myelin B
oligodendrocyte I
glycoprotein I
- O
induced O
experimental O
autoimmune O
encephalomyelitis O
in O
mice O
. O

EAE O
was O
actively O
induced O
in O
C57BL O
/ O
6 O
mice O
using O
an O
encephalitogenic O
myelin B
oligodendrocyte I
glycoprotein I
( O
MOG B
( I
35 I
- I
55 I
) I
) O
peptide O
. O

T O
- O
cell O
activation O
, O
assessed O
by O
the O
production O
of O
interferon O
gamma O
( O
IFNgamma O
) O
in O
response O
to O
MOG B
( I
35 I
- I
55 I
) I
, O
was O
also O
decreased O
by O
the O
HSR O
. O

The O
HSR O
reduced O
inflammatory O
gene O
expression O
in O
the O
brain O
that O
normally O
occurs O
during O
EAE O
, O
including O
the O
early O
increase O
in O
RANTES O
( O
regulated B
on I
activation I
of I
normal I
T I
- I
cell I
expressed I
and I
secreted I
) O
expression O
, O
and O
the O
later O
expression O
of O
the O
inducible O
form O
of O
nitric O
oxide O
synthase O
. O

Core B
- I
binding I
factor I
beta I
( O
CBFbeta B
) O
, O
but O
not O
CBFbeta B
- I
smooth I
muscle I
myosin I
heavy I
chain I
, O
rescues O
definitive O
hematopoiesis O
in O
CBFbeta B
- O
deficient O
embryonic O
stem O
cells O
. O

Core B
- I
binding I
factor I
beta I
( O
CBFbeta B
) O
is O
the O
non B
- I
DNA I
- I
binding I
subunit I
of O
the O
heterodimeric B
CBFs I
. O

Genes B
encoding I
CBFbeta I
( O
CBFB B
) O
, O
and O
one O
of O
the O
DNA B
- I
binding I
CBFalpha I
subunits I
, I
Runx1 I
( O
also O
known O
as O
CBFalpha2 B
, O
AML1 O
, O
and O
PEBP2alphaB B
) O
, O
are O
required O
for O
normal O
hematopoiesis O
and O
are O
also O
frequent O
targets O
of O
chromosomal O
translocations O
in O
acute O
leukemias O
in O
humans O
. O

Homozygous O
disruption O
of O
either O
the O
Runx1 B
or I
Cbfb I
gene I
in O
mice O
results O
in O
embryonic O
lethality O
at O
midgestation O
due O
to O
hemorrhaging O
in O
the O
central O
nervous O
system O
, O
and O
severely O
impairs O
fetal O
liver O
hematopoiesis O
. O

Definitive O
hematopoiesis O
is O
restored O
by O
ectopic O
expression O
of O
full B
- I
length I
Cbfb I
transgenes I
, O
as O
well O
as O
by O
a O
transgene O
encoding O
only O
the O
heterodimerization B
domain I
of O
CBFbeta B
. O

In O
contrast O
, O
the O
CBFbeta B
- O
smooth B
muscle I
myosin I
heavy I
chain I
( I
SMMHC I
) I
fusion I
protein I
generated O
by O
the O
inv B
( I
16 I
) I
associated O
with O
acute O
myeloid O
leukemias O
( O
M4Eo O
) O
can O
not O
rescue O
definitive O
hematopoiesis O
by O
Cbfb O
- O
deficient O
ES O
cells O
. O

Sequences O
responsible O
for O
the O
inability O
of O
CBFbeta B
- O
SMMHC O
to O
rescue O
definitive O
hematopoiesis O
reside O
in O
the O
SMMHC B
portion I
of O
the O
fusion O
protein O
. O

Results O
also O
show O
that O
the O
CBFbeta B
- I
SMMHC I
fusion I
protein I
transdominantly O
inhibits O
definitive O
hematopoiesis O
, O
but O
not O
to O
the O
same O
extent O
as O
homozygous O
loss O
of O
Runx1 B
or O
Cbfb B
. O

CBFbeta B
- I
SMMHC I
preferentially O
inhibits O
the O
differentiation O
of O
myeloid O
lineage O
cells O
, O
while O
increasing O
the O
number O
of O
blastlike O
cells O
in O
culture O
. O

The O
implication O
of O
EBV O
in O
the O
skin O
lesions O
was O
determined O
by O
the O
presence O
of O
EBV O
- O
DNA O
, O
EBV B
- I
encoded I
nuclear I
RNA I
( O
EBER B
) O
and O
a O
clonality O
of O
EBV B
- I
DNA I
fragments I
containing O
the O
terminal B
repeats I
. O

Transcripts O
of O
EBV B
- I
encoded I
genes I
were O
screened O
by O
reverse O
transcription O
- O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
, O
and O
confirmed O
by O
Southern O
blot O
hybridization O
. O

The O
expression O
of O
EBV B
- I
related I
antigens I
was O
examined O
by O
immunostaining O
using O
paraffin O
- O
embedded O
tissue O
sections O
and O
cell O
pellets O
of O
EBV O
- O
positive O
cell O
lines O
. O

Our O
study O
demonstrated O
that O
all O
samples O
from O
the O
patients O
contained O
EBV O
nuclear O
antigen O
( O
EBNA O
) O
- O
1 O
mRNA O
which O
was O
transcribed O
using O
the O
Q B
promoter I
, O
whereas O
both O
the O
Q B
promoter I
and O
another O
upstream B
promoter I
( O
Cp B
/ I
Wp I
) O
were O
used O
in O
EBV O
- O
positive O
cell O
lines O
, O
B95 O
. O
8 O
, O
Raji O
and O
Jiyoye O
. O

Latent B
membrane I
protein I
- I
1 I
( I
LMP I
- I
1 I
) I
mRNA I
was O
detected O
in O
seven O
of O
eight O
patients O
and O
all O
cell O
lines O
, O
whereas O
EBNA B
- I
2 I
transcripts I
were O
found O
only O
in O
the O
cell O
lines O
. O

Immunostaining O
showed O
no O
LMP B
- I
1 I
, I
EBNA I
- I
2 I
or I
ZEBRA I
antigens I
in O
the O
paraffin O
- O
embedded O
tissue O
sections O
, O
although O
they O
were O
positive O
in O
the O
cell O
line O
cells O
. O

Latent B
BHRF1 I
transcripts I
encoding O
bcl B
- I
2 I
homologue I
and O
BCRF1 B
transcripts I
encoding O
viral B
interleukin I
( I
vIL I
) I
- I
10 I
were O
detected O
in O
one O
and O
two O
of O
eight O
patients O
, O
respectively O
. O

Our O
results O
indicate O
that O
the O
restricted O
expression O
of O
the O
latency B
- I
associated I
EBV I
genes I
and O
the O
production O
of O
vIL B
- I
10 I
and I
bcl I
- I
2 I
homologue I
may O
favour O
tumour O
growth O
, O
evading O
the O
host O
immune O
surveillance O
. O

Oxidized B
low I
density I
lipoprotein I
( O
oxLDL O
) O
is O
inflammatory O
and O
signals O
through O
PPARs O
. O

[ O
( O
3 O
) O
H O
] O
azPC O
bound O
recombinant B
PPARgamma I
with O
an O
affinity O
( O
K O
( O
d O
) O
( O
( O
app O
) O
) O
approximately O
40 O
nm O
) O
that O
was O
equivalent O
to O
rosiglitazone O
( O
BRL49653 O
) O
, O
and O
competition O
with O
rosiglitazone O
showed O
that O
binding O
occurred O
in O
the O
ligand B
- I
binding I
pocket I
. O

The O
scavenger B
receptor I
CD36 I
is O
encoded O
by O
a O
PPRE B
- I
responsive I
gene I
, O
and O
azPC O
enhanced O
expression O
of O
CD36 O
in O
primary O
human O
monocytes O
. O

We O
found O
that O
anti B
- I
CD36 I
inhibited O
azPC O
uptake O
, O
and O
it O
inhibited O
PPRE O
reporter O
induction O
. O

Results O
with O
a O
small O
molecule O
phospholipid B
flippase I
mimetic I
suggest O
azPC O
acts O
intracellularly O
and O
that O
cellular O
azPC O
accumulation O
was O
efficient O
. O

Regulation O
of O
the O
human B
MAT2B I
gene I
encoding O
the O
regulatory B
beta I
subunit I
of O
methionine B
adenosyltransferase I
, O
MAT B
II I
. O

Methionine B
adenosyltransferase I
( O
MAT B
) O
catalyzes O
the O
biosynthesis O
of O
S B
- I
adenosylmethionine I
( O
AdoMet B
) O
, O
a O
key O
molecule O
in O
transmethylation O
reactions O
and O
polyamine O
biosynthesis O
. O

The O
MAT B
II I
isozyme I
consists O
of O
a O
catalytic B
alpha2 I
and I
a I
regulatory I
beta I
subunit I
. O

Down O
- O
regulation O
of O
the O
MAT B
II I
beta I
subunit I
expression O
causes O
a O
6 O
- O
10 O
- O
fold O
increase O
in O
intracellular O
AdoMet B
levels O
. O

To O
understand O
the O
mechanism O
by O
which O
the O
beta O
subunit O
expression O
is O
regulated O
, O
we O
cloned O
the O
MAT2B B
gene I
, O
determined O
its O
organization O
, O
characterized O
its O
5 O
' O
- O
flanking O
sequences O
, O
and O
elucidated O
the O
in O
vitro O
and O
in O
vivo O
regulation O
of O
its O
promoter O
. O

Transcription O
of O
the O
MAT2B B
gene I
initiates O
at O
position O
- O
203 O
relative O
to O
the O
translation O
start O
site O
. O

Promoter B
deletion I
analysis I
defined O
a O
minimal O
promoter O
between O
positions B
+ I
52 I
and I
+ I
93 I
base O
pairs O
, O
a O
GC B
- I
rich I
region I
. O

Inclusion O
of O
the O
sequences O
between O
- O
4 O
and O
+ O
52 O
enhanced O
promoter O
activity O
; O
this O
was O
primarily O
because O
of O
an O
Sp1 B
recognition I
site I
at O
+ O
9 O
/ O
+ O
15 O
. O

Supershift O
assays O
showed O
no O
effect O
of O
the O
anti B
- I
Sp1 I
antibody I
on O
complex O
formation O
, O
whereas O
the O
anti B
- I
Sp3 I
antibody I
had O
a O
strong O
effect O
on O
protein O
. O
DNA O
complex O
formation O
, O
suggesting O
that O
Sp3 O
is O
one O
of O
the O
main O
factors O
binding O
to O
this O
Sp1 O
site O
. O

Chromatin O
immunoprecipitation O
assays O
supported O
the O
involvement O
of O
both O
Sp1 O
and O
Sp3 O
in O
complexes O
formed O
on O
the O
MAT2B B
promoter I
. O

The O
data O
show O
that O
the O
5 B
' I
- I
untranslated I
sequences I
play O
an O
important O
role O
in O
regulating O
the O
MAT2B B
gene I
and O
identifies O
the O
Sp1 O
site O
at O
+ O
9 O
as O
a O
potential O
target O
for O
modulating O
MAT2B O
expression O
, O
a O
process O
that O
can O
have O
a O
major O
effect O
on O
intracellular O
AdoMet B
levels O
. O

Influenza O
A O
virus O
infection O
results O
in O
the O
production O
of O
chemotactic O
( O
RANTES O
, O
MIP O
- O
1 O
alpha O
, O
MCP O
- O
1 O
, O
MCP B
- I
3 I
, O
and O
IP O
- O
10 O
) O
, O
pro O
- O
inflammatory O
( O
IL O
- O
1 O
beta O
, O
IL O
- O
6 O
, O
IL O
- O
18 O
, O
and O
TNF O
- O
alpha O
) O
, O
and O
antiviral B
( I
IFN I
- I
alpha I
/ I
beta I
) I
cytokines I
. O

Cytokine O
gene O
expression O
is O
associated O
with O
the O
activation O
of O
NF O
- O
kappa O
B O
, O
AP O
- O
1 O
, O
STAT O
and O
IRF B
signal I
transducing I
molecules I
in O
influenza O
A O
virus O
- O
infected O
cells O
. O

In O
addition O
of O
upregulating O
cytokine O
gene O
expression O
, O
influenza O
A O
virus O
infection O
activates O
caspase B
- I
1 I
enzyme I
, O
which O
is O
involved O
in O
the O
proteolytic O
processing O
of O
proIL O
- O
1 O
beta O
and O
proIL B
- I
18 I
into O
their O
biologically O
active O
forms O
. O

Influenza O
A O
virus O
- O
induced O
IFN O
- O
alpha O
/ O
beta O
is O
essential O
in O
host O
' O
s O
antiviral O
defence O
by O
activating O
the O
expression O
of O
antiviral B
Mx I
, O
PKR B
and I
oligoadenylate I
synthetase I
genes I
. O

Mutant O
frequencies O
were O
measured O
in O
the O
spleen B
lymphocyte I
hprt I
gene I
, O
and O
lacI O
mutant O
frequencies O
were O
determined O
in O
the O
liver O
and O
spleen O
lymphocytes O
. O

Expression O
of O
Mad1 B
in O
T O
cells O
leads O
to O
reduced O
thymic O
cellularity O
and O
impaired O
mitogen O
- O
induced O
proliferation O
. O

To O
investigate O
Mad1 B
function O
in O
vivo O
, O
transgenic O
mice O
were O
generated O
that O
express O
a O
Mad1 B
transgene I
in O
T O
lineage O
cells O
under O
the O
control O
of O
the O
proximal B
lck I
promoter I
. O

Furthermore O
, O
thymocytes O
and O
splenic O
T O
cells O
from O
lck O
- O
Mad1 O
transgenic O
mice O
display O
a O
profound O
proliferative O
defect O
in O
response O
to O
activation O
with O
either O
PMA O
/ O
Ionomycin O
or O
immobilized B
anti I
- I
CD3 I
/ I
CD28 I
antibody I
. O

The O
growth O
inhibition O
caused O
by O
Mad1 B
is O
overcome O
by O
expression O
of O
active B
c I
- I
Myc I
. O

Differential O
requirement O
for O
the O
transcription B
factor I
PU I
. I
1 I
in O
the O
generation O
of O
natural O
killer O
cells O
versus O
B O
and O
T O
cells O
. O

PU O
. O
1 O
is O
a O
member O
of O
the O
Ets B
family I
of I
transcription I
factors I
required O
for O
the O
development O
of O
various O
lymphoid O
and O
myeloid O
cell O
lineages O
, O
but O
its O
role O
in O
natural O
killer O
( O
NK O
) O
cell O
development O
is O
not O
known O
. O

Moreover O
, O
PU O
. O
1 O
( O
- O
/ O
- O
) O
NK O
cells O
displayed O
reduced O
expression O
of O
the O
receptors O
for O
stem O
cell O
factor O
and O
interleukin B
( I
IL I
) I
- I
7 I
, O
suggesting O
a O
nonredundant O
role O
for O
PU O
. O
1 O
in O
regulating O
the O
expression O
of O
these O
cytokine B
receptor I
genes I
during O
NK O
cell O
development O
. O

PU O
. O
1 O
( O
- O
/ O
- O
) O
NK O
cells O
also O
showed O
defective O
expression O
of O
inhibitory O
and O
activating O
members O
of O
the O
Ly49 B
family I
and O
failed O
to O
proliferate O
in O
response O
to O
IL O
- O
2 O
and O
IL O
- O
12 O
. O

We O
also O
found O
that O
NAC O
, O
PDTC O
, O
and O
SB203580 O
suppressed O
the O
activities O
of O
DEPs O
and O
their O
benzene O
extracts O
, O
suggesting O
the O
roles O
of O
oxidants O
- O
mediated O
NF O
- O
kappa O
B O
activation O
and O
p38MAPK B
pathways O
. O

The O
nuclear B
receptor I
PPAR I
gamma I
is O
expressed O
by O
mouse O
T O
lymphocytes O
and O
PPAR O
gamma O
agonists O
induce O
apoptosis O
. O

Peroxisome B
proliferator I
- I
activated I
receptor I
( I
PPAR I
) I
- I
gamma I
is O
a O
nuclear B
hormone I
receptor I
that O
serves O
as O
a O
trans O
factor O
to O
regulate O
lipid O
metabolism O
. O

Intense O
interest O
is O
focused O
on O
PPAR B
- I
gamma I
and O
its O
ligands O
owing O
to O
its O
putative O
role O
in O
adipocyte O
differentiation O
. O

Little O
is O
known O
, O
however O
, O
about O
the O
functions O
of O
PPAR B
- I
gamma I
in O
the O
immune O
system O
, O
especially O
in O
T O
lymphocytes O
. O

We O
demonstrate O
that O
both O
naive O
and O
activated O
ovalbumin O
- O
specific O
T O
cells O
from O
DO11 O
. O
10 O
- O
transgenic O
mice O
express O
PPAR B
- I
gamma I
mRNA O
and O
protein O
. O

In O
order O
to O
determine O
the O
function O
of O
PPAR B
- I
gamma I
, O
T O
cells O
were O
stimulated O
with O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
and O
ionomycin O
or O
antigen O
and O
antigen O
- O
presenting O
cells O
. O

The O
decrease O
in O
cell O
viability O
was O
due O
to O
apoptosis O
of O
the O
T O
lymphocytes O
, O
and O
occurred O
only O
when O
cells O
were O
treated O
with O
PPAR B
- I
gamma I
, O
and O
not O
PPAR O
- O
alpha O
agonists O
, O
revealing O
specificity O
of O
this O
response O
for O
PPAR B
- I
gamma I
. O

Expression O
of O
SART3 B
antigen I
and O
induction O
of O
CTLs O
by O
SART3 O
- O
derived O
peptides O
in O
breast O
cancer O
patients O
. O

We O
recently O
reported O
the O
SART3 B
tumour I
- I
rejection I
antigen I
as O
possessing O
tumour O
epitopes O
capable O
of O
inducing O
HLA O
- O
class O
I O
- O
restricted O
cytotoxic O
T O
lymphocytes O
( O
CTLs O
) O
. O

This O
study O
investigated O
expression O
of O
the O
SART3 B
antigen I
in O
breast O
cancer O
to O
explore O
an O
appropriate O
molecule O
for O
use O
in O
specific O
immunotherapy O
of O
breast O
cancer O
patients O
. O

The O
SART3 B
antigen I
was O
detected O
in O
all O
of O
the O
breast O
cancer O
cell O
lines O
tested O
, O
30 O
of O
40 O
( O
75 O
% O
) O
breast O
cancer O
tissue O
samples O
, O
and O
0 O
of O
3 O
non O
- O
tumourous O
breast O
tissue O
samples O
. O

SART3 O
derived O
peptides O
at O
positions B
109 I
- I
118 I
and I
315 I
- I
323 I
induced O
HLA O
- O
A24 O
restricted O
CTLs O
that O
reacted O
to O
breast O
cancer O
cells O
from O
the O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
) O
of O
breast O
cancer O
patients O
. O

Therefore O
, O
the O
SART3 B
antigen I
and O
its O
peptides O
could O
be O
an O
appropriate O
molecule O
for O
use O
in O
specific O
immunotherapy O
of O
the O
majority O
of O
HLA O
- O
A24 O
- O
positive O
breast O
cancer O
patients O

Autostimulation O
of O
the O
Epstein O
- O
Barr O
virus O
BRLF1 B
promoter I
is O
mediated O
through O
consensus O
Sp1 B
and I
Sp3 I
binding I
sites I
. O

Consistent O
with O
this O
biologic O
function O
, O
the O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
Rta B
protein I
powerfully O
stimulates O
the O
promoter O
of O
its O
own O
gene O
, O
Rp B
, O
in O
EBV O
- O
positive O
B O
cells O
in O
transient O
- O
transfection O
reporter O
- O
based O
assays O
. O

We O
analyzed O
the O
activity O
of O
RpCAT B
in O
response O
to O
Rta O
by O
deletional O
and O
site O
- O
directed O
mutagenesis O
. O

Two O
cognate B
Sp1 I
binding I
sites I
located O
at O
- O
279 O
and O
- O
45 O
relative O
to O
the O
transcriptional O
start O
site O
proved O
crucial O
for O
Rta O
- O
mediated O
activation O
. O

Previously O
described O
binding O
sites O
for O
the O
cellular O
transcription B
factor I
Zif268 I
and O
the O
viral B
transactivator I
ZEBRA I
were O
found O
to O
be O
dispensable O
for O
activation O
of O
RpCAT B
by O
Rta O
. O

Gel O
shift O
analysis O
, O
using O
extracts O
of O
B O
cells O
in O
latency O
or O
induced O
into O
the O
lytic O
cycle O
, O
identified O
Sp1 O
and O
Sp3 O
as O
the O
predominant O
cellular O
proteins O
bound O
to O
Rp B
near O
- O
45 O
. O

During O
the O
lytic O
cycle O
, O
ZEBRA O
bound O
Rp B
near O
the O
Sp1 B
/ I
Sp3 I
site I
. O

The O
binding O
of O
Sp1 O
and O
Sp3 O
to O
Rp B
correlated O
with O
the O
reporter O
activities O
in O
the O
mutagenesis O
study O
, O
establishing O
a O
direct O
link O
between O
transcriptional O
activation O
of O
Rp B
by O
Rta O
and O
DNA O
binding O
by O
Sp1 O
and O
/ O
or O
Sp3 O
. O

The O
relative O
abundance O
or O
functional O
state O
of O
the O
cellular O
Sp1 O
and O
Sp3 O
transcription O
factors O
may O
be O
altered O
in O
response O
to O
stimuli O
that O
induce O
the O
BRLF1 B
promoter I
and O
thereby O
contribute O
to O
the O
activation O
of O
the O
viral O
lytic O
cycle O
. O

Gene O
transfer O
of O
antisense O
hypoxia B
inducible I
factor I
- I
1 I
alpha I
enhances O
the O
therapeutic O
efficacy O
of O
cancer O
immunotherapy O
. O

Hypoxia B
inducible I
factor I
- I
1 I
( O
HIF B
- I
1 I
) O
is O
a O
constitutively O
expressed O
basic O
helix B
- I
loop I
- I
helix I
transcription I
factor I
, O
formed O
by O
the O
assembly O
of O
HIF B
- I
1alpha I
and O
HIF B
- I
1beta I
( O
Arnt O
) O
, O
that O
is O
stablized O
in O
response O
to O
hypoxia O
, O
and O
rapidly O
degraded O
under O
normoxic O
conditions O
. O

Here O
, O
we O
demonstrate O
that O
engineered O
down O
- O
regulation O
of O
HIF B
- I
1alpha I
by O
intratumoral O
gene O
transfer O
of O
an O
antisense B
HIF I
- I
1alpha I
plasmid I
leads O
to O
the O
down O
- O
regulation O
of O
VEGF B
, O
and O
decreased O
tumor O
microvessel O
density O
. O

In O
summary O
, O
whilst O
intensive O
investigations O
are O
in O
progress O
to O
target O
the O
many O
HIF B
- I
1 I
effectors O
, O
the O
results O
herein O
indicate O
that O
blocking O
hypoxia O
- O
inducible O
pathways O
and O
enhancing O
NK O
- O
mediated O
antitumor O
immunity O
by O
targeting O
HIF B
- I
1 I
itself O
may O
be O
advantageous O
, O
especially O
when O
combined O
with O
cancer O
immunotherapy O
. O

Runx2 B
: O
a O
novel O
oncogenic O
effector O
revealed O
by O
in O
vivo O
complementation O
and O
retroviral O
tagging O
. O

The O
Runx2 B
( O
Cbfa1 B
, O
Pebp2alphaA B
, O
Aml3 B
) O
gene O
was O
previously O
identified O
as O
a O
frequent O
target O
for O
transcriptional O
activation O
by O
proviral O
insertion O
in O
T O
- O
cell O
lymphomas O
of O
CD2 O
- O
MYC O
transgenic O
mice O
. O

We O
have O
recently O
shown O
that O
over O
- O
expression O
of O
the O
full O
- O
length O
, O
most O
highly O
expressed O
Runx2 B
isoform O
in O
the O
thymus O
perturbs O
T O
- O
cell O
development O
, O
leads O
to O
development O
of O
spontaneous O
lymphomas O
at O
low O
frequency O
and O
is O
strongly O
synergistic O
with O
Myc O
. O

To O
gain O
further O
insight O
into O
the O
relationship O
of O
Runx2 B
to O
other O
lymphomagenic O
pathways O
, O
we O
tested O
the O
effect O
of O
combining O
the O
CD2 B
- I
Runx2 I
transgene I
either O
with O
a O
Pim1 B
transgene I
( O
E B
( I
mu I
) I
- I
Pim1 I
) O
or O
with O
the O
p53 O
null O
genotype O
, O
as O
each O
of O
these O
displays O
independent O
synergy O
with O
Myc O
. O

However O
, O
Runx2 B
appeared O
to O
have O
a O
dominant O
effect O
on O
the O
tumour O
phenotype O
in O
each O
case O
, O
with O
most O
tumours O
conforming O
to O
the O
CD3 O
( O
+ O
) O
, O
CD8 O
( O
+ O
) O
, O
CD4 O
( O
+ O
/ O
- O
) O
phenotype O
seen O
in O
CD2 O
- O
Runx2 O
mice O
. O

Analysis O
of O
known O
Moloney B
MLV I
target I
genes I
in O
these O
lymphomas O
showed O
a O
high O
frequency O
of O
rearrangement O
at O
c O
- O
Myc O
or O
N O
- O
Myc O
( O
82 O
% O
) O
, O
and O
a O
significant O
number O
at O
Pim1 B
or O
Pim2 B
( O
23 O
% O
) O
, O
and O
at O
Pal1 B
/ I
Gfi1 I
( O
18 O
% O
) O
. O

These O
results O
indicate O
that O
Runx2 B
makes O
a O
distinct O
contribution O
to O
T O
- O
cell O
lymphoma O
development O
which O
does O
not O
coincide O
with O
any O
of O
the O
oncogene O
complementation O
groups O
previously O
identified O
by O
retroviral O
tagging O
. O

Subsequently O
, O
DCs O
act O
as O
APCs O
involved O
in O
the O
uptake O
, O
processing O
, O
and O
presentation O
of O
apoptotic B
tumor I
Ags I
to O
cross O
- O
prime O
CD8 O
( O
+ O
) O
CTL O
cells O
. O

However O
, O
this O
lytic O
activity O
was O
significantly O
increased O
after O
blockade O
of O
p58 B
with O
specific O
monoclonal O
antibodies O
. O

Interestingly O
, O
we O
demonstrated O
that O
stimulation O
by O
tumor O
cells O
was O
required O
to O
trigger O
the O
inhibitory O
effect O
of O
p58 B
on O
the O
lytic O
activity O
of O
antigen O
- O
specific O
CTLs O
and O
that O
stimulation O
of O
the O
inhibitory O
function O
of O
p58 B
by O
tumor O
cells O
correlated O
with O
an O
inhibition O
of O
nuclear O
factor O
- O
kappaB O
activation O
in O
p58 O
+ O
tumor O
- O
specific O
CTLS O
. O

However O
, O
no O
T B
- I
cell I
receptor I
gene I
rearrangement O
was O
identified O
in O
cultured O
progeny O
. O

Id O
- O
3 O
, O
a O
basic B
helix I
loop I
helix I
factor I
with O
dominant O
negative O
function O
for O
T O
- O
cell O
differentiation O
transcription O
factors O
, O
also O
was O
upregulated O
and O
may O
explain O
unsuccessful O
T O
- O
cell O
maturation O
. O

The O
TCF B
- I
1 I
isoform I
found O
in O
CD56 O
( O
+ O
bright O
) O
cells O
, O
which O
express O
lectin O
but O
not O
immunoglobulin B
class I
I I
recognizing O
inhibitory B
receptors I
, O
was O
identical O
to O
that O
induced O
in O
NK O
cell O
differentiation O
culture O
and O
was O
distinctly O
different O
from O
isoforms O
in O
T O
cells O
. O

These O
results O
suggest O
that O
TCF O
- O
1 O
does O
not O
target O
human B
killer I
immunoglobulin I
receptor I
genes I
, O
TCF O
- O
1 O
is O
uniquely O
expressed O
in O
circulating O
CD56 O
( O
+ O
bright O
) O
NK O
cells O
, O
and O
specific O
TCF B
- I
1 I
isoforms I
may O
play O
an O
important O
role O
in O
regulating O
NK O
differentiation O
from O
a O
common O
NK O
/ O
T O
- O
cell O
progenitor O
. O

Transcriptional O
activation O
by O
a O
matrix B
associating I
region I
- I
binding I
protein I
. O

contextual O
requirements O
for O
the O
function O
of O
bright B
. O

Bright B
( O
B B
cell I
regulator I
of I
IgH I
transcription I
) O
is O
a O
B O
cell O
- O
specific O
, O
matrix B
associating I
region I
- I
binding I
protein I
that O
transactivates O
gene O
expression O
from O
the O
IgH B
intronic I
enhancer I
( O
E B
mu I
) O
. O

We O
show O
here O
that O
Bright B
has O
multiple O
contextual O
requirements O
to O
function O
as O
a O
transcriptional O
activator O
. O

Bright B
can O
not O
transactivate O
via O
out O
of O
context O
, O
concatenated B
binding I
sites I
. O

Two O
of O
the O
three O
previously O
identified O
binding O
sites O
in O
E B
mu I
are O
required O
for O
full O
Bright B
transactivation O
. O

The O
Bright B
DNA I
binding I
domain I
defined O
a O
new O
family O
, O
which O
includes O
SWI1 B
, O
a O
component O
of O
the O
SWI B
. I
SNF I
complex I
shown O
to O
have O
high O
mobility O
group O
- O
like O
DNA O
binding O
characteristics O
. O

Similar O
to O
one O
group O
of O
high B
mobility I
group I
box I
proteins I
, O
Bright B
distorts O
E B
mu I
binding I
site I
- O
containing O
DNA O
on O
binding O
, O
supporting O
the O
concept O
that O
it O
mediates O
E B
mu I
remodeling O
. O

Transfection O
studies O
further O
implicate O
Bright B
in O
facilitating O
spatially O
separated O
promoter O
- O
enhancer O
interactions O
in O
both O
transient O
and O
stable O
assays O
. O

Finally O
, O
we O
show O
that O
overexpression O
of O
Bright B
leads O
to O
enhanced O
DNase O
I O
sensitivity O
of O
the O
endogenous O
E B
mu I
matrix O
associating O
regions O
. O

These O
data O
further O
suggest O
that O
Bright B
may O
contribute O
to O
increased O
gene O
expression O
by O
remodeling O
the O
immunoglobulin B
locus I
during O
B O
cell O
development O
. O

BCL O
- O
6 O
is O
essential O
for O
germinal O
center O
formation O
and O
thus O
for O
affinity O
maturation O
of O
immunoglobulin B
( I
Ig I
) I
genes I
by O
somatic O
mutations O
. O

Translocations O
of O
the O
BCL O
- O
6 O
gene O
to O
heterologous O
promoters O
and O
mutations O
of O
its O
5 B
' I
- I
noncoding I
regulatory I
region I
were O
reported O
to O
be O
potential O
mechanisms O
for O
deregulating O
BCL O
- O
6 O
expression O
and O
for O
playing O
a O
role O
in O
the O
genesis O
of O
non O
- O
Hodgkin O
lymphoma O
. O

To O
determine O
the O
presence O
and O
potential O
role O
of O
BCL O
- O
6 O
mutations O
in O
cHD O
, O
the O
5 B
' I
- I
noncoding I
BCL I
- I
6 I
proportion O
of O
single O
Hodgkin O
and O
Reed O
- O
Sternberg O
( O
HRS O
) O
cells O
from O
6 O
cases O
of O
cHD O
and O
6 O
cases O
of O
HD O
- O
derived O
cell O
lines O
was O
analyzed O
. O

Gadd45gamma B
is O
dispensable O
for O
normal O
mouse O
development O
and O
T O
- O
cell O
proliferation O
. O

Gadd45gamma B
, O
a O
family O
member O
of O
the O
growth B
arrest I
and I
DNA I
damage I
- I
inducible I
gene I
family I
45 I
( O
Gadd45 B
) O
, O
is O
strongly O
induced O
by O
interleukin O
- O
2 O
( O
IL O
- O
2 O
) O
in O
peripheral O
T O
cells O
. O

While O
in O
most O
tissues O
all O
Gadd45 B
family I
members I
are O
expressed O
, O
Gadd45gamma B
is O
the O
only O
member O
that O
is O
induced O
by O
IL O
- O
2 O
. O

Here O
we O
show O
that O
the O
IL O
- O
2 O
- O
induced O
expression O
of O
Gadd45gamma B
is O
dependent O
on O
a O
signaling O
pathway O
mediated O
by O
the O
tyrosine B
kinase I
Jak3 I
and O
the O
transcription O
factors O
Stat5a O
and O
Stat5b O
( O
signal O
transducer O
and O
activator O
of O
transcription O
) O
. O

Previous O
studies O
with O
ectopically O
overexpressed O
Gadd45gamma B
in O
various O
cell O
lines O
implicated O
its O
function O
in O
negative O
growth O
control O
. O

To O
analyze O
the O
physiological O
role O
of O
Gadd45gamma B
we O
used O
homologous O
recombination O
to O
generate O
mice O
lacking O
Gadd45gamma B
. O

Gadd45gamma B
- O
deficient O
mice O
develop O
normally O
, O
are O
indistinguishable O
from O
their O
littermates O
, O
and O
are O
fertile O
. O

Furthermore O
, O
hematopoiesis O
in O
mice O
lacking O
Gadd45gamma B
is O
not O
impaired O
and O
Gadd45gamma B
- O
deficient O
T O
lymphocytes O
show O
normal O
responses O
to O
IL O
- O
2 O
. O

These O
data O
demonstrate O
that O
Gadd45gamma B
is O
not O
essential O
for O
normal O
mouse O
development O
and O
hematopoiesis O
, O
possibly O
due O
to O
functional O
redundancy O
among O
the O
Gadd45 B
family I
members I
. O

Gadd45gamma B
is O
also O
dispensable O
for O
IL O
- O
2 O
- O
induced O
T O
- O
cell O
proliferation O
. O

Decreased O
expression O
of O
c B
- I
myc I
family I
genes I
in O
thymuses O
from O
myasthenia O
gravis O
patients O
. O

We O
studied O
the O
expression O
of O
apoptosis O
- O
associated O
genes O
, O
bcl O
- O
xL O
, O
bad O
, O
caspase O
- O
3 O
, O
and O
c B
- I
myc I
family I
genes I
in O
myasthenia O
gravis O
( O
MG O
) O
thymuses O
. O

We O
observed O
that O
the O
mRNA O
levels O
of O
myc B
family I
genes I
, O
c O
- O
myc O
and O
max O
, O
were O
markedly O
reduced O
in O
MG O
thymuses O
. O

The O
levels O
of O
molecules O
whose O
expressions O
are O
associated O
with O
myc O
, O
such O
as O
STAM B
, O
prothymosin B
- I
alpha I
, O
and O
NFkappaB O

The O
staining O
was O
considered O
to O
be O
highly O
specific O
because O
it O
could O
be O
completely O
blocked O
by O
preabsorption O
with O
recombinant B
IFN I
- I
gamma I
. O

The O
basic B
helix I
- I
loop I
- I
helix I
( I
bHLH I
) I
proteins I
E12 O
and O
E47 O
and O
an O
inhibitor B
HLH I
protein I
, O
Id3 O
, O
play O
key O
roles O
in O
thymocyte O
differentiation O
. O

Whereas O
expression O
of O
E2A O
mRNA O
and O
protein O
are O
unaltered O
, O
Id3 B
transcripts I
are O
rapidly O
induced O
upon O
signaling O
from O
the O
TCR O
. O

Investigation O
of O
retinoid B
receptor I
expression O
, O
known O
to O
mediate O
intracellular O
RA O
signaling O
, O
revealed O
presence O
of O
RAR B
alpha I
, I
RAR I
gamma I
, I
RXR I
beta I
, I
and I
RXR I
gamma I
transcripts I
in O
all O
cell O
lines O
studied O
, O
and O
HMC O
- O
1 O
cells O
were O
the O
only O
line O
lacking O
RXR O
alpha O
. O

Regulation O
of O
activator O
protein O
- O
1 O
and O
NF O
- O
kappa O
B O
in O
CD8 O
+ O
T O
cells O
exposed O
to O
peripheral B
self I
- I
antigens I
. O

The O
transcriptional O
events O
that O
control O
T O
cell O
tolerance O
to O
peripheral B
self I
Ags I
are O
still O
unknown O
. O

In O
this O
study O
, O
we O
analyzed O
the O
regulation O
of O
AP O
- O
1 O
- O
and O
NF O
- O
kappa O
B O
- O
mediated O
transcription O
during O
in O
vivo O
induction O
of O
tolerance O
to O
a O
self B
Ag I
expressed O
exclusively O
on O
hepatocytes O
. O

Naive O
CD8 O
( O
+ O
) O
Desire O
( O
Des O
) O
( O
+ O
) O
T O
cells O
isolated O
from O
the O
Des O
TCR O
- O
transgenic O
mice O
that O
are O
specific O
for O
the O
H B
- I
2K I
( I
b I
) I
class I
I I
Ag I
were O
transferred O
into O
Alb O
- O
K O
( O
b O
) O
- O
transgenic O
mice O
that O
express O
the O
H B
- I
2K I
( I
b I
) I
Ag I
on O
hepatocytes O
only O
. O

Indeed O
, O
in O
vivo O
primed O
T O
cells O
predominantly O
express O
p50 B
/ I
p50 I
and I
p65 I
/ I
p50 I
dimers I
, O
whereas O
these O
p50 B
- I
containing I
complexes I
are O
barely O
detectable O
in O
tolerant O
T O
cells O
that O
express O
p65 B
- I
and I
c I
- I
Rel I
- I
containing I
complexes I
. O

However O
, O
the O
differentiation O
induced O
by O
the O
ER O
- O
35795 O
was O
not O
antagonized O
at O
all O
by O
the O
RAR O
antagonist O
, O
but O
was O
inhibited O
by O
an O
RXR B
homodimer I
antagonist O
( O
LGD100754 O
, O
( O
2E O
, O
4E O
, O
6Z O
) O
- O
7 O
- O
( O
3 O
- O
n O
- O
propoxy O
- O
5 O
, O
6 O
, O
7 O
, O
8 O
- O
tetrahydro O
- O
5 O
, O
5 O
, O
8 O
, O
8 O
- O
tetramethylnaphthale O
- O
2 O
- O
yl O
) O
- O
3 O
- O
methylocta O
- O
2 O
, O
4 O
, O
6 O
- O
trienoic O
acid O
) O

Its O
agonistic O
action O
on O
RXR B
/ I
RAR I
heterodimer I
, O
on O
the O
other O
hand O
, O
was O
neutralized O
by O
the O
RAR O
antagonist O
. O

During O
HL60 O
cell O
differentiation O
, O
atRA O
induced O
RARbeta B
mRNA I
, O
while O
the O
RXR O
had O
no O
effect O
. O

Targeting O
Src B
homology I
2 I
domain I
- I
containing I
tyrosine I
phosphatase I
( O
SHP O
- O
1 O
) O
into O
lipid O
rafts O
inhibits O
CD3 O
- O
induced O
T O
cell O
activation O
. O

To O
study O
the O
mechanism O
by O
which O
protein O
tyrosine O
phosphatases O
( O
PTPs B
) O
regulate O
CD3 O
- O
induced O
tyrosine O
phosphorylation O
, O
we O
investigated O
the O
distribution O
of O
PTPs B
in O
subdomains O
of O
plasma O
membrane O
. O

We O
report O
here O
that O
the O
bulk O
PTP B
activity O
associated O
with O
T O
cell O
membrane O
is O
present O
outside O
the O
lipid O
rafts O
, O
as O
determined O
by O
sucrose O
density O
gradient O
sedimentation O
. O

In O
Jurkat O
T O
cells O
, O
approximately O
5 O
- O
- O
10 O
% O
of O
Src B
homology I
2 I
domain I
- I
containing I
tyrosine I
phosphatase I
( O
SHP O
- O
1 O
) O
is O
constitutively O
associated O
with O
plasma O
membrane O
, O
and O
nearly O
50 O
% O
of O
SHP B
- I
2 I
is O
translocated O
to O
plasma O
membrane O
after O
vanadate O
treatment O
. O

Similar O
to O
transmembrane B
PTP I
, O
CD45 O
, O
the O
membrane O
- O
associated O
populations O
of O
SHP O
- O
1 O
and O
SHP B
- I
2 I
are O
essentially O
excluded O
from O
lipid O
rafts O
, O
where O
other O
signaling O
molecules O
such O
as O
Lck B
, I
linker I
for I
activation I
of I
T I
cells I
, O
and O
CD3 B
zeta I
are O
enriched O
. O

We O
further O
demonstrated O
that O
CD3 O
- O
induced O
tyrosine O
phosphorylation O
of O
these O
substrates O
is O
largely O
restricted O
to O
lipid O
rafts O
, O
unless O
PTPs B
are O
inhibited O
. O

It O
suggests O
that O
a O
restricted O
partition O
of O
PTPs B
among O
membrane O
subdomains O
may O
regulate O
protein O
tyrosine O
phosphorylation O
in O
T O
cell O
membrane O
. O

To O
test O
this O
hypothesis O
, O
we O
targeted O
SHP O
- O
1 O
into O
lipid O
rafts O
by O
using O
the O
N B
- I
terminal I
region I
of I
Lck I
( O
residues B
1 I
- I
- I
14 I
) O
. O

The O
results O
indicate O
that O
the O
expression O
of O
Lck B
/ I
SHP I
- I
1 I
chimera I
inside O
lipid O
rafts O
profoundly O
inhibits O
CD3 O
- O
induced O
tyrosine O
phosphorylation O
of O
CD3 B
zeta I
/ I
epsilon I
, O
IL O
- O
2 O
generation O
, O
and O
nuclear O
mobilization O
of O
NF O
- O
AT O
. O

Collectively O
, O
these O
results O
suggest O
that O
the O
exclusion O
of O
PTPs B
from O
lipid O
rafts O
may O
be O
a O
mechanism O
that O
potentiates O
TCR O
/ O
CD3 O
activation O

Further O
, O
retroviral O
tagging O
of O
naive O
progenitors O
with O
the O
Th2 B
- I
specific I
transcription I
factor I
GATA I
- I
3 I
provided O
direct O
evidence O
for O
instructive O
differentiation O
, O
and O
no O
evidence O
for O
the O
selective O
outgrowth O
of O
cells O
committed O
to O
either O
the O
Th1 O
or O
Th2 O
fate O
. O

In O
vitro O
- O
activated O
human O
lupus O
T O
cells O
express O
normal O
estrogen B
receptor I
proteins I
which O
bind O
to O
the O
estrogen O
response O
element O
. O

We O
have O
shown O
that O
estrogen O
receptor O
( O
ERalpha B
, O
ERbeta O
) O
transcripts O
are O
expressed O
in O
SLE O
and O
normal O
T O
cells O
. O

In O
this O
study O
, O
T O
cell O
nuclear O
extracts O
from O
female O
lupus O
patients O
and O
normal O
donors O
were O
tested O
for O
biologically O
active O
ER B
proteins I
capable O
of O
binding O
to O
the O
human B
estrogen I
response I
element I
( O
hERE B
) O
by O
electrophoretic O
mobility O
shift O
assays O
. O

When O
peripheral O
blood O
T O
cells O
were O
stimulated O
with O
17beta O
- O
estradiol O
( O
E2 O
) O
, O
PMA O
and O
ionomycin O
, O
two O
major O
retarded O
bands O
in O
T O
cell O
nuclear O
extracts O
exhibited O
a O
migration O
pattern O
similar O
to O
slow O
migrating O
protein B
- I
ERE I
complexes I
in O
human O
breast O
cancer O
cell O
extracts O
. O

The O
formation O
of O
the O
complexes O
was O
inhibited O
by O
competition O
with O
the O
hERE O
cold O
oligonucleotide O
and O
partially O
with O
anti B
- I
ERalpha I
antibodies I
. O

There O
was O
no O
notable O
difference O
in O
the O
migration O
pattern O
of O
ERE B
- I
binding I
proteins I
between O
the O
SLE O
and O
normal O
T O
cell O
extracts O
. O

Together O
, O
these O
results O
suggest O
that O
activated O
human O
T O
cells O
, O
whether O
lupus O
- O
derived O
or O
normal O
- O
derived O
, O
contain O
biologically O
active O
ERalpha B
proteins I
. O

UTI O
decreased O
the O
TNFalpha O
production O
of O
LPS O
- O
stimulated O
monocytes O
, O
but O
did O
not O
inhibit O
the O
TNFalpha B
mRNA I
expression O
. O

The O
secretion O
of O
MCP B
- I
1 I
protein I
was O
significantly O
increased O
( O
195 O
% O
as O
compared O
to O
the O
control O
) O
in O
cells O
treated O
with O
pathological O
concentrations O
of O
homocysteine O
. O

Such O
effect O
was O
accompanied O
by O
an O
increased O
expression O
of O
MCP B
- I
1 I
mRNA I
( O
176 O
% O
as O
compared O
to O
the O
control O
) O
in O
endothelial O
cells O
which O
resulted O
in O
enhanced O
monocyte O
chemotaxis O
. O

The O
p38 O
MAP O
kinase O
as O
well O
as O
other O
members O
of O
the O
p38 O
MAP O
kinase O
pathway O
, O
including O
MKK3 O
, O
MKK6 B
, O
ATF O
- O
2 O
and O
Elk O
- O
1 O
, O
were O
activated O
in O
homocysteine O
- O
treated O
cells O
. O

Terminal O
effectors O
of O
B O
cell O
Fas O
- O
resistance O
include O
the O
known O
anti B
- I
apoptotic I
gene I
products I
, O
Bcl O
- O
xL O
and O
FLIP B
, O
and O
a O
novel O
anti B
- I
apoptotic I
gene I
that O
encodes O
FAIM B
( O
Fas B
Apoptosis I
Inhibitory I
Molecule I
) O
. O

faim B
was O
identified O
by O
differential O
display O
and O
exists O
in O
two O
alternatively O
spliced O
forms O
; O
faim B
- I
S I
is O
broadly O
expressed O
, O
but O
faim O
- O
L O
expression O
is O
tissue O
- O
specific O
. O

The O
FAIM B
sequence I
is O
highly O
evolu O
- O
tionarily O
conserved O
, O
suggesting O
an O
important O
role O
for O
this O
molecule O
throughout O
phylogeny O
. O

Stromal B
cell I
- I
derived I
factor I
1 I
alpha I
- O
induced O
chemotaxis O
in O
T O
cells O
is O
mediated O
by O
nitric O
oxide O
signaling O
pathways O
. O

Stromal B
cell I
- I
derived I
factor I
1 I
alpha I
( O
SDF1 B
alpha I
) O
and O
its O
cognate O
chemokine B
receptor I
CXCR4 I
act O
as O
potent O
chemoattractants O
and O
regulate O
trafficking O
and O
homing O
of O
hematopoietic O
progenitor O
cells O
and O
lymphocytes O
. O

However O
, O
the O
molecular O
mechanisms O
regulating O
SDF1 B
alpha I
- O
driven O
cell O
migration O
are O
not O
well O
defined O
. O

In O
this O
study O
, O
we O
have O
explored O
the O
roles O
of O
the O
second O
messenger O
NO O
and O
the O
transcription O
factor O
NF O
- O
kappa O
B O
in O
SDF1 B
alpha I
- O
induced O
T O
cell O
migration O
. O

SDF1 B
alpha I
treatment O
of O
Jurkat O
T O
cells O
increased O
the O
activity O
of O
NO O
synthase O
, O
which O
catalyzes O
the O
generation O
of O
NO O
. O

We O
observed O
that O
pretreatment O
of O
Jurkat O
cells O
or O
activated O
PBLs O
with O
several O
NO O
donors O
significantly O
enhanced O
the O
SDF1 B
alpha I
- O
induced O
migration O
, O
whereas O
various O
inhibitors O
of O
NO O
synthase O
markedly O
abrogated O
the O
chemotactic O
response O
in O
a O
concentration O
- O
dependent O
manner O
. O

Furthermore O
, O
we O
observed O
that O
inhibitors O
of O
the O
transcription O
factor O
NF O
- O
kappa O
B O
, O
which O
is O
linked O
to O
NO O
signaling O
pathways O
, O
also O
significantly O
blocked O
the O
SDF1 B
alpha I
- O
induced O
chemotactic O
response O
. O

However O
, O
these O
compounds O
did O
not O
have O
a O
significant O
effect O
on O
SDF1 B
alpha I
- O
induced O
mitogen O
- O
activated O
protein O
kinase O
activity O
. O

In O
addition O
, O
the O
MAP O
/ O
Erk O
kinase O
kinase O
inhibitor O
PD98059 O
did O
not O
abrogate O
SDF1 B
alpha I
- O
induced O
chemotaxis O
. O

AKT B
, O
which O
has O
been O
shown O
to O
mediate O
NO O
production O
, O
was O
also O
phosphorylated O
upon O
SDF1 B
alpha I
stimulation O
. O

These O
studies O
suggest O
that O
NO O
- O
related O
signaling O
pathways O
may O
mediate O
SDF1 B
alpha I
- O
induced O
chemotaxis O
, O
but O
not O
mitogen O
- O
activated O
protein O
kinase O
activation O
. O

Deletion O
of O
autoreactive O
thymocytes O
at O
the O
DP O
stage O
is O
the O
basis O
for O
tolerance O
to O
thymus B
- I
expressed I
self I
antigens I
. O

Using O
triple O
transgenic O
mice O
expressing O
a O
TCR B
transgene I
, O
dominant B
negative I
ras I
/ I
Mek I
proteins I
and O
a O
reporter O
gene O
construct O
with O
AP B
- I
1 I
or I
NF I
- I
kappa I
B I
binding I
sites I
, O
we O
showed O
a O
complete O
lack O
of O
transcriptional O
activity O
of O
NF O
- O
kappa O
B O
but O
not O
AP O
- O
1 O
in O
DP O
thymocytes O
, O
whereas O
both O
were O
transcriptionally O
active O
in O
mature O
T O
cells O
after O
antigenic O
stimulation O
. O

Lack O
of O
NF O
- O
kappa O
B O
induction O
correlated O
with O
increased O
death O
in O
response O
to O
antigen B
. O

In O
contrast O
, O
we O
found O
a O
complete O
lack O
of O
constitutive O
expression O
of O
the O
epsilon B
isoform I
of I
Protein I
Kinase I
C I
( O
PKC O
) O
in O
DP O
thymocytes O
, O
although O
it O
was O
present O
in O
mature O
thymocytes O
and O
peripheral O
T O
cells O
. O

Although O
cytokine O
receptors O
are O
known O
to O
signal O
through O
STAT B
family I
transcription I
factors I
, O
the O
mechanisms O
by O
which O
other O
cell O
- O
surface O
molecules O
, O
such O
as O
CD2 O
, O
transduce O
signals O
is O
unclear O
. O

MATERIALS O
AND O
METHODS O
: O
T O
cells O
were O
treated O
with O
anti O
- O
CD2 O
antibodies O
or O
cells O
bearing O
the O
natural O
CD2 B
ligand I
CD58 I
, O
after O
which O
signaling O
through O
STAT O
transcription O
factors O
was O
assessed O
. O

Transcription O
of O
key O
target O
genes O
such O
as O
IRF1 B
and O
c O
- O
fos O
proceeds O
with O
delayed O
kinetics O
following O
CD2 O
stimulation O
, O
suggesting O
that O
this O
unique O
pattern O
of O
STAT O
activation O
may O
lead O
to O
a O
distinct O
cellular O
response O
following O
CD2 O
ligation O
. O

NFATc1 B
and O
NFATc2 B
together O
control O
both O
T O
and O
B O
cell O
activation O
and O
differentiation O
. O

NFAT B
transcription I
factors I
play O
critical O
roles O
in O
gene O
transcription O
during O
immune O
responses O
. O

To O
investigate O
further O
the O
two O
most O
prominent O
NFAT B
family I
members I
, O
NFATc1 B
and O
NFATc2 B
, O
we O
generated O
mice O
bearing O
lymphoid O
systems O
devoid O
of O
both O
. O

Doubly O
deficient O
T O
cells O
displayed O
cell O
surface O
markers O
of O
activation O
yet O
were O
significantly O
deficient O
in O
the O
development O
of O
multiple O
effector O
functions O
, O
including O
Th B
cytokine I
production O
, O
surface B
effector I
molecule I
expression O
, O
and O
cytolytic O
activity O
. O

Nevertheless O
, O
doubly O
deficient O
B O
cells O
were O
hyperactivated O
, O
as O
evidenced O
by O
extremely O
elevated O
serum O
IgG1 B
and O
IgE O
, O
as O
well O
as O
plasma O
cell O
expansion O
and O
infiltration O
of O
end O
organs O
. O

Thus O
, O
in O
T O
cells O
, O
NFATc1 B
and O
NFATc2 B
are O
dispensable O
for O
inflammatory O
reactivity O
but O
are O
required O
for O
effector O
differentiation O
, O
while O
in O
B O
cells O
, O
NFATs B
regulate O
both O
normal O
homeostasis O
and O
differentiation O
. O

Epstein O
- O
barr O
virus O
immediate B
- I
early I
protein I
BZLF1 I
is O
SUMO O
- O
1 O
modified O
and O
disrupts O
promyelocytic O
leukemia O
bodies O
. O

Although O
the O
immediate B
- I
early I
proteins I
of O
both O
herpes O
simplex O
virus O
( O
HSV O
) O
and O
cytomegalovirus O
( O
CMV O
) O
are O
known O
to O
modify O
promyelocytic O
leukemia O
( O
PML O
) O
( O
ND10 O
) O
bodies O
in O
the O
nucleus O
of O
the O
host O
cell O
, O
it O
has O
been O
unclear O
whether O
lytic O
infection O
with O
gamma O
herpesviruses O
induces O
a O
similar O
effect O
. O

The O
PML B
protein I
is O
induced O
by O
interferon O
, O
involved O
in O
major O
histocompatibility O
complex O
class O
I O
presentation O
, O
and O
necessary O
for O
certain O
types O
of O
apoptosis O
. O

To O
examine O
whether O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
lytic O
replication O
interferes O
with O
PML O
bodies O
, O
we O
expressed O
the O
EBV B
immediate I
- I
early I
genes I
BZLF1 B
( I
Z I
) I
and O
BRLF1 B
( I
R I
) I
in O
EBV O
- O
positive O
cell O
lines O
and O
examined O
PML O
localization O
. O

As O
was O
previously O
reported O
for O
the O
HSV B
- I
1 I
ICP0 I
and I
CMV I
IE1 I
proteins I
, O
Z O
reduces O
the O
amount O
of O
SUMO B
- I
1 I
- I
modified I
PML I
. O

We O
also O
found O
that O
Z O
itself O
is O
SUMO O
- O
1 O
modified O
( O
through O
amino O
acid O
12 O
) O
and O
that O
Z O
competes O
with O
PML O
for O
limiting O
amounts O
of O
SUMO B
- I
1 I
. O

Suppression O
of O
nuclear O
factor O
- O
kappaB O
and O
stimulation O
of O
inhibitor B
kappaB I
by O
troglitazone O
: O
evidence O
for O
an O
anti O
- O
inflammatory O
effect O
and O
a O
potential O
antiatherosclerotic O
effect O
in O
the O
obese O
. O

We O
measured O
intranuclear B
NFkappaB I
, O
total O
cellular B
NFkappaB I
, O
inhibitor B
kappaB I
( I
IkappaB I
) I
alpha I
, O
reactive O
oxygen O
species O
( O
ROS O
) O
generation O
, O
and O
p47 B
( I
phox I
) I
subunit I
( O
a O
key O
component O
protein O
of O
nicotinamide B
adenine I
dinucleotide I
phosphate I
oxidase I
) O
in O
MNC O
. O

Plasma B
tumor I
necrosis I
factor I
( I
TNF I
) I
- I
alpha I
, O
soluble B
intercellular I
adhesion I
molecule I
- I
1 I
( O
sICAM B
- I
1 I
) O
, O
monocyte O
chemoattractant O
protein O
- O
1 O
( O
MCP O
- O
1 O
) O
, O
plasminogen B
activator I
inhibitor I
type I
1 I
( O
PAI O
- O
1 O
) O
, O
C B
- I
reactive I
protein I
( I
CRP I
) I
, O
and O
interleukin O
( O
IL O
) O
- O
10 O
( O
antiinflammatory B
cytokine I
) O
concentrations O
were O
also O
measured O
as O
mediators O
of O
inflammatory O
activity O
that O
are O
regulated O
by O
the O
proinflammatory B
transcription I
factor I
NFkappaB I
. O

MNC O
were O
separated O
; O
and O
the O
levels O
of O
intranuclear B
NFkappaB I
, O
total O
cellular B
NFkappaB I
, O
IkappaBalpha O
, O
and O
p47 B
( I
phox I
) I
subunit I
and O
ROS O
generation O
were O
determined O
. O

Plasma O
was O
used O
to O
measure O
insulin O
glucose O
, O
TNFalpha O
, O
sICAM B
, O
MCP O
- O
1 O
, O
PAI O
- O
1 O
, O
CRP B
, O
and O
IL O
- O
10 O
. O

There O
was O
a O
fall O
in O
intranuclear B
NFkappaB I
, O
total O
cellular B
NFkappaB I
, O
and O
p47 B
( I
phox I
) I
subunit I
, O
with O
an O
increase O
in O
cellular O
IkappaBalpha O
at O
week O
2 O
, O
which O
persisted O
until O
week O
4 O
. O

Plasma O
TNF O
- O
alpha O
, O
sICAM B
- I
1 I
, O
MCP O
- O
1 O
, O
and O
PAI O
- O
1 O
concentrations O
fell O
significantly O
at O
week O
4 O
. O

Plasma O
IL O
- O
10 O
concentration O
increased O
significantly O
, O
whereas O
plasma B
CRP I
concentrations O
decreased O
. O

Requirement O
for O
p56 B
LCK I
and I
ZAP I
- I
70 I
protein I
tyrosine I
kinases I
. O

Phosphorylation O
of O
the O
N O
- O
terminal O
domain O
of O
I B
kappa I
B I
inhibitory I
subunits I
induces O
activation O
of O
the O
transcription O
factor O
NF O
- O
kappa O
B O
. O

Specific O
missense O
mutations O
in O
NEMO B
result O
in O
hyper O
- O
IgM O
syndrome O
with O
hypohydrotic O
ectodermal O
dysplasia O
. O

The O
gene O
that O
encodes O
nuclear B
factor I
kappaB I
( I
NF I
- I
kappaB I
) I
essential I
modulator I
( O
or O
NEMO B
, O
also O
known O
as O
IKKgamma B
) O
is O
required O
for O
activation O
of O
the O
transcription O
factor O
NF O
- O
kappaB O
. O

We O
describe O
mutations O
in O
the O
putative B
zinc I
- I
finger I
domain I
of O
NEMO B
that O
result O
in O
an O
X O
- O
linked O
primary O
immunodeficiency O
characterized O
by O
hyper O
- O
IgM O
syndrome O
and O
hypohydrotic O
ectodermal O
dysplasia O
( O
XHM O
- O
ED O
) O
. O

These O
mutations O
prevent O
CD40 O
ligand O
( O
CD40L O
) O
- O
mediated O
degradation O
of O
inhibitor O
of O
NF B
- I
kappaB I
alpha I
( O
IkappaB O
- O
alpha O
) O
and O
account O
for O
the O
following O
observations O
: O
B O
cells O
from O
XHM O
- O
ED O
patients O
are O
unable O
to O
undergo O
immunoglobulin O
class O
- O
switch O
recombination O
and O
antigen O
- O
presenting O
cells O
( O
APCs O
) O
are O
unable O
to O
synthesize O
the O
NF B
- I
kappaB I
- I
regulated I
cytokines I
interleukin O
12 O
( O
IL O
- O
12 O
) O
or O
tumor O
necrosis O
factor O
alpha O
( O
TNF O
- O
alpha O
) O
when O
stimulated O
with O

Nevertheless O
, O
innate O
immunity O
is O
preserved O
in O
XHM O
- O
ED O
patients O
because O
APCs O
retain O
the O
capacity O
to O
respond O
to O
stimulation O
by O
lipopolysaccharide O
or O
Staphylococcus B
aureus I
Cowan I
' I
s I
antigen I
( O
SAC B
) O
. O

Overall O
, O
the O
phenotype O
observed O
in O
XHM O
- O
ED O
patients O
shows O
that O
the O
putative B
zinc I
- I
finger I
domain I
of O
NEMO B
has O
a O
regulatory O
function O
and O
demonstrates O
the O
definite O
requirement O
of O
CD40 O
- O
mediated O
NF O
- O
kappaB O
activation O
for O
B O
cell O
immunoglobulin O
class O
- O
switching O
. O

APL O
diagnostic O
t O
( O
15 O
; O
17 O
) O
chromosomal O
translocation O
and O
expresses O
the O
PML B
- I
RAR I
alpha I
fusion I
protein I
. O

ATRA O
and O
its O
metabolites O
could O
induce O
NB4 O
cells O
differentiation O
with O
similar O
activity O
, O
as O
evaluated O
by O
cell O
morphology O
, O
by O
the O
nitroblue O
tetrazolium O
reduction O
test O
( O
82 O
- O
88 O
% O
at O
120 O
h O
) O
or O
by O
the O
expression O
of O
the O
maturation B
specific I
cell I
surface I
marker I
CD11c I
. O

The O
ATRA O
metabolites O
were O
found O
to O
exert O
their O
differentiation O
effects O
via O
the O
RAR B
alpha I
nuclear I
receptors I
, O
because O
the O
RAR O
alpha O
- O
specific O
antagonist O
BMS614 O
blocked O
metabolite O
- O
induced O
CD11c O
expression O
in O
NB4 O
cells O
. O

Expression O
of O
oestrogen B
and I
progesterone I
receptors I
by O
mast O
cells O
alone O
, O
but O
not O
lymphocytes O
, O
macrophages O
or O
other O
immune O
cells O
in O
human O
upper O
airways O
. O

RESULTS O
: O
Consistent O
with O
the O
known O
features O
of O
nasal O
polyps O
, O
CD4 O
+ O
( O
T O
helper O
/ O
inducer O
) O
, O
CD8 O
+ O
( O
cytotoxic O
/ O
suppressor O
) O
, O
CD68 O
+ O
( O
macrophages O
) O
, O
mast O
cells O
, O
eosinophils O
and O
neutrophils O
were O
all O
clearly O
detected O
by O
their O
relevant O
monoclonal O
antibodies O
or O
appropriate O
histochemical O
staining O
, O
but O
only O
mast O
cells O
tested O
positive O
for O
ER O
/ O
PR O
labelling O
with O
their O
polyclonal B
and I
monoclonal I
antibodies I
. O

tyrosine O
phosphatase O
( O
PTPase B
) O
and O
/ O
or O
protein O
kinase O
C O
( O
PKC O
) O
. O

The O
results O
demonstrate O
that O
both O
A O
/ O
R O
and O
redox O
imbalance O
led O
to O
I O
kappa O
B O
alpha O
degradation O
within O
30 O
min O
and O
the O
concomitant O
appearance O
of O
p65 O
in O
the O
nucleus O
, O
consistent O
with O
rapid O
cytosolic O
activation O
of O
NF O
kappa O
B O
and O
subsequent O
nuclear O
translocation O
of O
the O
activated B
p65 I
subunit I
. O

Apoptosis O
induced O
by O
DMA O
- O
2 O
, O
4 O
- O
D O
was O
dose O
and O
time O
dependent O
, O
independent O
of O
Fas O
, O
TNF O
receptor O
1 O
or O
the O
aromatic B
hydrocarbon I
receptor I
, O
and O
involved O
disruption O
of O
the O
mitochondrial O
transmembrane O
potential O
and O
activation O
of O
caspase B
- I
9 I
. O

While O
an O
inhibitor O
of O
caspase B
- I
9 I
, O
as O
well O
as O
caspase B
- I
9 I
and O
caspase O
- O
3 O
inhibitors O
in O
combination O
, O
strongly O
blocked O
DMA O
- O
2 O
, O
4 O
- O
D O
- O
induced O
apoptosis O
, O
an O
inhibitor O
of O
caspase O
- O
3 O
had O
a O
moderate O
inhibitory O
effect O
. O

Unlike O
Fas O
- O
mediated O
apoptosis O
, O
the O
initiator B
caspase I
, O
caspase B
- I
8 I
, O
was O
not O
involved O
in O
DMA O
- O
2 O
, O
4 O
- O
D O
- O
induced O
apoptosis O
. O

Inhibition O
of O
Th1 O
differentiation O
by O
IL O
- O
6 O
is O
mediated O
by O
SOCS1 B
. O

IL O
- O
6 O
upregulates O
suppressor B
of I
cytokine I
signaling I
1 I
( O
SOCS1 B
) O
expression O
in O
activated O
CD4 O
+ O
T O
cells O
, O
thereby O
interfering O
with O
signal B
transducer I
and I
activator I
of I
transcription I
1 I
( O
STAT1 O
) O
phosphorylation O
induced O
by O
interferon O
gamma O
( O
IFNgamma O
) O
. O

Inhibition O
of O
IFNgamma O
receptor O
- O
mediated O
signals O
by O
IL O
- O
6 O
prevents O
autoregulation O
of O
IFNgamma B
gene I
expression O
by O
IFNgamma O
during O
CD4 O
+ O
T O
cell O
activation O
, O
thereby O
preventing O
Th1 O
differentiation O
. O

Interaction O
between O
CCAAT O
/ O
enhancer O
binding O
protein O
and O
cyclic B
AMP I
response I
element I
binding I
protein I
1 I
regulates O
human O
immunodeficiency O
virus O
type O
1 O
transcription O
in O
cells O
of O
the O
monocyte O
/ O
macrophage O
lineage O
. O

Recent O
observations O
have O
shown O
two O
CCAAT B
/ I
enhancer I
binding I
protein I
( I
C I
/ I
EBP I
) I
binding I
sites I
to O
be O
critically O
important O
for O
efficient O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
replication O
within O
cells O
of O
the O
monocyte O
/ O
macrophage O
lineage O
, O
a O
cell O
type O
likely O
involved O
in O
transport O
of O
the O
virus O
to O
the O
brain O
. O

Additionally O
, O
sequence O
variation O
at O
C B
/ I
EBP I
site I
I I
, O
which O
lies O
immediately O
upstream O
of O
the O
distal B
nuclear I
factor I
kappa I
B I
site I
and O
immediately O
downstream O
of O
a O
binding O
site O
for O
activating B
transcription I
factor I
( O
ATF O
) O
/ O
cyclic O
AMP O
response O
element O
binding O
protein O
( O
CREB O
) O
, O
has O
been O
shown O
to O
affect O
HIV O
- O
1 O
long O
terminal O
repeat O
( O
LTR O
) O
activity O
. O

Given O
that O
C O
/ O
EBP O
proteins O
have O
been O
shown O
to O
interact O
with O
many O
other O
transcription O
factors O
including O
members O
of O
the O
ATF B
/ I
CREB I
family I
, O
we O
proceeded O
to O
determine O
whether O
an O
adjacent O
ATF B
/ I
CREB I
binding I
site I
could O
affect O
C B
/ I
EBP I
protein I
binding O
to O
C B
/ I
EBP I
site I
I I
. O

Electrophoretic O
mobility O
shift O
analyses O
indicated O
that O
selected O
ATF B
/ I
CREB I
site I
variants I
assisted O
in O
the O
recruitment O
of O
C O
/ O
EBP O
proteins O
to O
an O
adjacent O
, O
naturally O
occurring O
, O
low O
- O
affinity O
C O
/ O
EBP O
site O
. O

First O
, O
low O
amounts O
of O
CREB O
- O
1 O
and O
C O
/ O
EBP O
appear O
to O
heterodimerize O
and O
bind O
to O
a O
site O
consisting O
of O
a O
half O
site O
from O
both O
the O
ATF B
/ I
CREB I
and I
C I
/ I
EBP I
binding I
sites I
. O

In O
addition O
, O
CREB B
- I
1 I
homodimers I
bind O
to O
the O
ATF B
/ I
CREB I
site I
and O
recruit O
C B
/ I
EBP I
dimers I
to O
their O
cognate O
weak B
binding I
sites I
. O

This O
interaction O
is O
reciprocal O
, O
since O
C B
/ I
EBP I
dimer I
binding O
to O
a O
strong O
C O
/ O
EBP O
site O
leads O
to O
enhanced O
CREB O
- O
1 O
recruitment O
to O
ATF B
/ I
CREB I
sites I
that O
are O
weakly O
bound O
by O
CREB O
. O

Sequence O
variation O
at O
both O
C B
/ I
EBP I
and I
ATF I
/ I
CREB I
sites I
affects O
the O
molecular O
interactions O
involved O
in O
mediating O
both O
of O
these O
mechanisms O
. O

Most O
importantly O
, O
sequence O
variation O
at O
the O
ATF B
/ I
CREB I
binding I
site I
affected O
basal O
LTR O
activity O
as O
well O
as O
LTR O
function O
following O
interleukin O
- O
6 O
stimulation O
, O
a O
treatment O
that O
leads O
to O
increases O
in O
C O
/ O
EBP O
activation O
. O

Thus O
, O
HIV O
- O
1 O
LTR O
ATF B
/ I
CREB I
binding I
site I
sequence O
variation O
may O
modulate O
cellular O
signaling O
at O
the O
viral O
promoter O
through O
the O
C O
/ O
EBP O
pathway O

The O
inhibitory O
effect O
of O
ASA O
on O
IL O
- O
4 O
transcription O
was O
not O
mediated O
by O
decreased O
nuclear O
expression O
of O
the O
known O
salicylate B
target I
nuclear I
factor I
( I
NF I
) I
- I
kappaB I
and O
was O
accompanied O
by O
reduced O
binding O
of O
an O
inducible O
factor O
to O
an O
IL B
- I
4 I
promoter I
region I
upstream O
of O
, O
but O
not O
overlapping O
, O
the O
NF B
of I
activated I
T I
cells I
- I
and I
NF I
- I
kappaB I
- I
binding I
P1 I
element I
. O

OBJECTIVE O
: O
To O
examine O
the O
molecular O
and O
cellular O
mechanisms O
in O
a O
model O
of O
acute O
inflammatory O
monarticular O
arthritis O
induced O
by O
methylated B
bovine I
serum I
albumin I
( O
mBSA B
) O
and O
interleukin O
- O
1 O
( O
IL O
- O
1 O
) O
. O

METHODS O
: O
Mice O
were O
injected O
intraarticularly O
with O
mBSA B
on O
day O
0 O
and O
subcutaneously O
with O
recombinant B
human I
IL I
- I
1beta I
on O
days O
0 O
- O
2 O
. O

RESULTS O
: O
C57BL O
/ O
6 O
( O
B6 O
) O
, O
129 O
/ O
Sv O
, O
and O
( O
B6 O
x O
129 O
/ O
Sv O
) O
F1 O
hybrid O
mice O
, O
all O
H O
- O
2b O
strains O
, O
were O
susceptible O
to O
mBSA B
/ O
IL O
- O
1 O
- O
induced O
arthritis O
, O
whereas O
C3H O
/ O
HeJ O
( O
H O
- O
2k O
) O
mice O
were O
not O
. O

B6 O
mice O
lacking O
T O
and O
B O
cells O
( O
RAG1 O
- O
/ O
- O
) O
or O
major O
histocompatibility O
complex O
( O
MHC O
) O
class O
II O
antigens O
( O
MHCII O
- O
/ O
- O
) O
, O
and O
B6 O
mice O
treated O
with O
a O
CD4 B
+ I
T I
cell I
- I
depleting I
monoclonal I
antibody I
, O
were O
resistant O
to O
disease O
. O

In O
B6 O
mice O
, O
flow O
cytometry O
demonstrated O
an O
IL O
- O
1 O
- O
dependent O
leukocyte O
infiltration O
into O
the O
synovial O
compartment O
and O
RNase O
protection O
assays O
revealed O
induction O
of O
messenger O
RNA O
( O
mRNA O
) O
for O
the O
chemokines O
monocyte O
chemoattractant O
protein O
1 O
, O
macrophage B
inhibitory I
protein I
2 I
( O
MIP O
- O
2 O
) O
, O
RANTES O
, O
MIP O
- O
1alpha O
, O
and O
MIP B
- I
1beta I
, O
in O
vivo O
and O
in O
vitro O
. O

CONCLUSION O
: O
Arthritis O
induced O
by O
mBSA B
/ O
IL O
- O
1 O
is O
strain O
specific O
and O
dependent O
on O
CD4 O
+ O
T O
lymphocytes O
and O
at O
least O
partially O
on O
RelB O
, O
but O
not O
on O
B O
lymphocytes O
or O
antibody O
. O

Positive O
and O
negative O
regulation O
of O
granulopoiesis O
by O
endogenous B
RARalpha I
. O

Acute O
promyelocytic O
leukemia O
( O
APL O
) O
is O
always O
associated O
with O
chromosomal O
translocations O
that O
disrupt O
the O
retinoic B
acid I
receptor I
alpha I
( I
RARalpha I
) I
gene I
. O

Whether O
these O
translocations O
relate O
to O
a O
role O
for O
endogenous B
RARalpha I
in O
normal O
granulopoiesis O
remains O
uncertain O
because O
most O
studies O
addressing O
this O
question O
have O
used O
non O
- O
physiological O
overexpression O
systems O
. O

Granulocyte O
differentiation O
in O
cells O
derived O
from O
RARalpha O
- O
deficient O
( O
RARalpha O
( O
- O
/ O
- O
) O
) O
mice O
was O
studied O
and O
evaluated O
in O
the O
context O
of O
agonist B
- I
bound I
and I
ligand I
- I
free I
RARalpha I
. O

Conversely O
, O
RARalpha O
acts O
to O
limit O
differentiation O
in O
the O
absence O
of O
ligand B
because O
granulocyte O
precursors O
from O
RARalpha O
( O
- O
/ O
- O
) O
mice O
differentiate O
earlier O
in O
culture O
. O

Thus O
, O
the O
block O
in O
granulopoiesis O
exerted O
by O
RARalpha O
fusion O
proteins O
expressed O
in O
APL O
cells O
may O
correspond O
to O
an O
amplification O
of O
a O
normal O
function O
of O
unliganded B
RARalpha I
. O

Expression O
and O
function O
of O
a O
stem B
cell I
promoter I
for O
the O
murine B
CBFalpha2 I
gene I
: O
distinct O
roles O
and O
regulation O
in O
natural O
killer O
and O
T O
cell O
development O
. O

The O
Runt B
family I
transcription I
factor I
CBFalpha2 B
( O
AML1 O
, O
PEBP2alphaB B
, O
or O
Runx1 B
) O
is O
required O
by O
hematopoietic O
stem O
cells O
and O
expressed O
at O
high O
levels O
in O
T O
- O
lineage O
cells O
. O

In O
human O
T O
cells O
CBFalpha2 B
is O
usually O
transcribed O
from O
a O
different B
promoter I
( O
distal O
promoter O
) O
than O
in O
myeloid O
cells O
( O
proximal O
promoter O
) O
, O
but O
the O
developmental O
and O
functional O
significance O
of O
this O
promoter O
switch O
has O
not O
been O
known O
. O

Here O
, O
we O
report O
that O
both O
coding B
and I
noncoding I
sequences I
of O
the O
distal B
5 I
' I
end I
are O
highly O
conserved O
between O
the O
human B
and I
the I
murine I
genes I
, O
and O
the O
distal O
promoter O
is O
responsible O
for O
the O
overwhelming O
majority O
of O
CBFalpha2 O
expression O
in O
murine O
hematopoietic O
stem O
cells O
as O
well O
as O
in O
T O
cells O
. O

The O
distal B
N I
- I
terminal I
isoform I
binds O
to O
functionally O
important O
regulatory B
sites I
from O
known O
target O
genes O
with O
two O
- O
to O
threefold O
higher O
affinity O
than O
the O
proximal B
N I
- I
terminal I
isoform I
. O

Neither O
full B
- I
length I
isoform I
alters O
growth O
of O
a O
myeloid O
cell O
line O
under O
nondifferentiating O
conditions O
, O
but O
the O
proximal B
isoform I
selectively O
delays O
mitotic O
arrest O
of O
the O
cell O
line O
under O
differentiating O
conditions O
, O
resulting O
in O
the O
generation O
of O
greater O
numbers O
of O
neutrophils O
. O

Importantly O
, O
we O
demonstrate O
that O
one O
mechanism O
by O
which O
PI3 O
- O
K O
mediates O
the O
proliferation O
of O
infected O
B O
lymphocytes O
is O
through O
the O
induction O
of O
a O
granulocyte B
- I
monocyte I
colony I
- I
stimulating I
factor I
( O
GM O
- O
CSF O
) O
- O
dependent O
autocrine O
loop O
. O

The O
mechanism O
responsible O
for O
the O
delayed O
nuclear O
accumulation O
of O
phosphorylated B
STAT3 I
was O
examined O
in O
detail O
, O
focusing O
on O
the O
role O
of O
B B
cell I
- I
derived I
lymphokines I
. O

sIg O
- O
induced O
STAT3 O
activation O
was O
completely O
inhibited O
by O
combining O
IL B
- I
6 I
- I
and I
IL I
- I
10 I
- I
specific I
neutralizing I
antibodies I
, O
or O
by O
adding O
individual O
neutralizing O
antibodies O
to O
B O
cells O
obtained O
from O
lymphokine O
- O
deficient O
animals O
. O

This O
work O
indicates O
that O
a O
lymphokine O
pathway O
is O
responsible O
for O
STAT3 O
activation O
that O
occurs O
late O
after O
B O
cell O
stimulation O
, O
and O
points O
out O
differences O
in O
B O
cell O
activation O
that O
result O
from O
stimulation O
through O
the O
antigen O
receptor O
and O
through O
pharmacological O
mimicry O
of O
signaling B
mediators I
. O

Transcription B
factor I
AP I
- I
4 I
is O
a O
ligand B
for O
immunoglobulin B
- I
kappa I
promoter I
E I
- I
box I
elements I
. O

Immunoglobulin B
( I
Ig I
) I
- I
kappa I
promoters I
from O
humans O
and O
mice O
share O
conserved B
sequences I
. O

The O
octamer O
element O
is O
common O
to O
all O
Ig B
promoters I
and O
pivotal O
for O
their O
function O
. O

However O
, O
other O
conserved O
sequence O
motifs O
, O
that O
differ O
between O
Ig B
variable I
gene I
families I
, O
are O
required O
for O
normal O
promoter O
function O
. O

One O
example O
is O
an O
E O
- O
box O
of O
the O
E47 B
/ I
E12 I
type I
( I
5 I
' I
- I
CAGCTG I
- I
3 I
' I
) I
, O
which O
is O
found O
in O
all O
promoters O
of O
the O
human B
and I
murine I
Ig I
- I
kappa I
gene I
subgroups I
/ I
families I
, O
with O
the O
exception O
of O
subgroups O
II O
and O
VI O
and O
their O
related O
murine B
families I
. O

In O
the O
present O
study O
we O
show O
that O
the O
ubiquitously O
expressed O
transcription B
factor I
AP I
- I
4 I
, O
and O
not O
E47 O
, O
interacts O
specifically O
with O
the O
kappa B
promoter I
E I
- I
boxes I
when O
tested O
in O
electrophoretic O
mobility O
- O
shift O
assays O
using O
nuclear O
extracts O
derived O
from O
human O
and O
murine O
B O
- O
cell O
lines O
. O

Furthermore O
, O
AP B
- I
4 I
, O
unlike O
E47 O
, O
did O
not O
act O
as O
a O
transactivator O
, O
which O
is O
in O
agreement O
with O
previous O
studies O
on O
intact O
kappa B
promoters I
, O
showing O
that O
transcription O
is O
absent O
when O
the O
octamer O
element O
has O
been O
mutated O
. O

Based O
on O
these O
data O
, O
and O
the O
conservation O
of O
the O
5 B
' I
- I
CAGCTG I
- I
3 I
' I
motif I
among O
human B
and I
murine I
kappa I
promoters I
, O
we O
propose O
that O
AP B
- I
4 I
is O
the O
major B
ligand I
for O
Ig B
- I
kappa I
promoter I
E I
- I
boxes I
. O

Translocation O
of O
antigenic O
peptides O
into O
the O
cytosol O
of O
antigen O
presenting O
cells O
facilitates O
proteosomal O
processing O
and O
loading O
into O
Class B
I I
molecules I
for O
MHC O
presentation O
on O
the O
cell O
surface O
. O

The O
DNA O
binding O
domain O
of O
the O
Drosophila B
transcription I
factor I
( O
Antennapedia B
) O
, O
a O
60 B
amino I
acid I
protein I
, O
is O
rapidly O
taken O
up O
by O
cells O
and O
has O
been O
fused O
to O
selected O
antigens O
to O
enhance O
their O
immunogenicity O
. O

The O
culture O
supernatants O
contained O
increased O
levels O
of O
prostaglandin B
E I
( I
2 I
) I
( I
PGE I
( I
2 I
) I
) I
( O
shown O
to O
favor O
TH2 O
cell O
development O
) O
and O
also O
inhibited O
EBV O
- O
CTL O
effector O
cell O
development O
. O

In O
this O
study O
, O
we O
obtained O
PBL O
from O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
IgG B
antibody I
positive O
kidney O
transplant O
recipients O
( O
R O
) O
and O
their O
living O
- O
related O
donors O
( O
LRD O
) O
one O
year O
after O
renal O
transplantation O
. O

The O
addition O
of O
BMC O
to O
the O
EBV O
- O
CTL O
generation O
cultures O
increased O
the O
intracellular O
expression O
in O
CD3 O
+ O
cells O
of O
IL B
- I
4 I
, I
- I
5 I
, I
- I
6 I
, I
- I
10 I
, I
and I
- I
13 I
. O

These O
CD3 O
+ O
cells O
also O
expressed O
increased O
levels O
of O
the O
TH2 B
associated I
receptor I
CCR3 I
. O

Protein O
Kinase O
A O
( O
PKA O
) O
, O
a O
cAMP B
kinase I
that O
is O
involved O
in O
the O
upregulation O
of O
TH2 O
cytokine O
activity O
, O
was O
increased O
in O
EBV O
- O
CTL O
cultures O
by O
the O
presence O
of O
BMC O
. O

Moreover O
, O
TH2 O
cells O
induced O
by O
culturing O
with O
autologous O
BMC O
directly O
inhibit O
EBV O
- O
CTL O
generation O
, O
and O
TH2 O
associated O
PKA O
, O
CCR3 B
, O
and O
STAT O
- O
6 O
phosphorylation O
are O
enhanced O
by O
BMC O
. O

Pax B
- I
5a I
/ I
B I
cell I
- I
specific I
activator I
protein I
and O
an O
alternatively B
spliced I
isoform I
, I
Pax I
- I
5d I
, O
may O
have O
opposing O
functions O
in O
transcriptional O
regulation O
due O
to O
the O
lack O
of O
a O
transactivation O
domain O
in O
Pax O
- O
5d O
. O

To O
study O
B O
cell O
- O
specific O
changes O
that O
occur O
during O
the O
aging O
process O
, O
we O
investigated O
expression O
patterns O
of O
Pax B
- I
5a I
and I
5d I
in O
mature O
B O
cells O
of O
young O
and O
aged O
mice O
. O

RNase O
protection O
assays O
showed O
a O
similar O
transcriptional O
pattern O
for O
both O
age O
groups O
that O
indicates O
that O
aging O
has O
no O
affect O
on O
transcription O
initiation O
or O
alternative O
splicing O
for O
either O
isoform B
. O

In O
contrast O
, O
a O
significant O
reduction O
in O
the O
DNA O
binding O
activity O
of O
Pax O
- O
5a O
but O
not O
Pax O
- O
5d O
protein O
was O
observed O
in O
aged O
B O
cells O
in O
vitro O
, O
while O
Western O
blot O
analyses O
showed O
that O
similar O
levels O
of O
Pax B
- I
5a I
and I
5d I
proteins O
were O
present O
in O
both O
age O
groups O
. O

The O
observed O
decrease O
in O
Pax O
- O
5a O
binding O
activity O
correlated O
with O
changes O
in O
expression O
of O
two O
Pax B
- I
5 I
target I
genes I
in O
aged O
B O
cells O
. O

Expression O
of O
the O
Ig B
J I
chain I
and O
the O
secreted O
form O
of O
Ig B
mu I
, O
which O
are O
both O
known O
to O
be O
suppressed O
by O
Pax O
- O
5a O
in O
mature O
B O
cells O
, O
were O
increased O
in O
B O
cells O
of O
aged O
mice O
. O

Together O
, O
our O
studies O
suggest O
that O
changes O
associated O
with O
the O
aging O
phenotype O
cause O
posttranslational O
modification O
( O
s O
) O
of O
Pax O
- O
5a O
but O
not O
Pax O
- O
5d O
, O
which O
may O
lead O
to O
an O
abnormal O
B O
cell O
phenotype O
in O
aged O
mice O
, O
associated O
with O
elevated O
levels O
of O
J B
chain I
, O
and O
secretion O
of O
IgM O

NF B
- I
kappa I
B I
/ I
Rel I
participation O
in O
the O
lymphokine O
- O
dependent O
proliferation O
of O
T O
lymphoid O
cells O
. O

We O
show O
in O
this O
study O
that O
inhibition O
of O
NF O
- O
kappaB O
through O
the O
expression O
of O
an O
IkappaBalpha O
( O
inhibitory O
protein O
that O
dissociates O
from O
NF O
- O
kappaB O
) O
mutant O
refractory O
to O
signal O
- O
induced O
degradation O
( O
IkappaBalpha B
( I
DeltaN I
) I
) O
interfered O
with O
the O
acquisition O
of O
competence O
to O
proliferate O
in O
response O
to O
IL O
- O
4 O
as O
well O
as O
IL O
- O
2 O
. O

Thymocytes O
and O
T O
cells O
from O
IkappaBalpha B
( I
DeltaN I
) I
transgenic O
mice O
expressed O
normal O
levels O
of O
IL B
- I
2R I
subunits I
. O

These O
results O
indicate O
that O
the O
NF O
- O
kappaB O
/ O
Rel O
/ O
IkappaBalpha O
system O
can O
regulate O
cytokine O
receptor O
capacitation O
through O
effects O
on O
the O
induction O
of O
downstream O
signaling O
by O
the O
Stat B
transcription I
factor I
family I
. O

BMS O
- O
189453 O
is O
a O
synthetic O
retinoid O
that O
acts O
as O
an O
antagonist O
at O
retinoic B
acid I
receptors I
alpha I
, I
beta I
, I
and I
gamma I
. O

In O
Sprague O
Dawley O
rats O
at O
daily O
oral O
doses O
of O
15 O
, O
60 O
, O
or O
240 O
mg O
/ O
kg O
for O
1 O
month O
, O
BMS O
- O
189453 O
produced O
increases O
in O
leukocyte O
counts O
, O
alkaline O
phosphatase O
and O
alanine B
aminotransferase I
levels O
, O
and O
marked O
testicular O
degeneration O
and O
atrophy O
at O
all O
doses O
. O

Sequential O
involvement O
of O
NFAT O
and O
Egr B
transcription O
factors O
in O
FasL O
regulation O
. O

The O
transcription O
factors O
Egr2 O
and O
Egr3 B
are O
potent O
activators O
of O
FasL O
expression O
. O

Here O
we O
find O
that O
Egr2 O
and O
Egr3 B
are O
NFAT O
target O
genes O
. O

Activation O
of O
FasL O
occurs O
via O
the O
NFAT O
- O
dependent O
induction O
of O
Egr3 B
, O
as O
demonstrated O
by O
the O
ability O
of O
exogenously O
provided O
NFATp O
to O
restore O
Egr B
- O
dependent O
FasL O
promoter O
activity O
in O
DKO O
lymph O
node O
cells O
. O

Further O
, O
Egr3 B
expression O
is O
enriched O
in O
Th1 O
cells O
, O
suggesting O
a O
molecular O
basis O
for O
the O
known O
preferential O
expression O
of O
FasL O
in O
the O
Th1 O
versus O
Th2 O
subset O
. O

Genomic O
effects O
are O
mediated O
by O
cytosolic B
receptors I
that O
alter O
expression O
of O
specific O
genes O
. O

Specific O
nongenomic O
effects O
occur O
within O
a O
few O
minutes O
and O
are O
mediated O
by O
steroid B
- I
selective I
membrane I
receptors I
. O

We O
also O
measured O
the O
effect O
of O
high O
glucose O
on O
the O
expression O
of O
intercellular O
adhesion O
molecule O
- O
1 O
and O
vascular B
adhesion I
molecule I
- I
1 I
by O
flow O
cytometry O
and O
semiquantitative O
RT O
- O
PCR O
in O
mesangial O
cells O
and O
the O
adhesion O
of O
leukocytes O
to O
mesangial O
cells O
. O

Neither O
vascular B
adhesion I
molecule I
- I
1 I
protein O
nor O
mRNA O
expression O
was O
, O
however O
, O
affected O
by O
high O
glucose O
and O
high O
mannitol O
. O

Functional O
blocking O
of O
intercellular O
adhesion O
molecule O
- O
1 O
on O
mesangial O
cells O
with O
rat B
intercellular I
adhesion I
molecule I
- I
1 I
monoclonal I
antibody I
, O
calphostin O
C O
, O
staurosporine O
, O
or O
N O
- O
tosyl O
- O
L O
- O
phenylalanine O
chloromethyl O
ketone O
significantly O
inhibited O
high O
glucose O
- O
or O
high O
mannitol O
- O
induced O
increase O
in O
leukocyte O
adhesion O
( O
p O
< O
< O
0 O
. O
05 O
) O
. O

To O
address O
this O
issue O
, O
we O
studied O
a O
child O
with O
SCN O
who O
was O
totally O
unresponsive O
to O
G O
- O
CSF O
and O
had O
a O
novel O
point O
mutation O
in O
the O
extracellular O
domain O
of O
the O
G O
- O
CSF O
receptor O
( O
GCSF B
- I
R I
) O
. O

The O
in O
vitro O
effect O
of O
G O
- O
CSF O
and O
corticosteroids O
on O
granulopoiesis O
was O
evaluated O
in O
clonogenic O
assays O
of O
marrow O
mononuclear O
cells O
, O
by O
proliferation O
studies O
of O
the O
murine O
myeloid O
cell O
line O
32D O
expressing O
the O
patient O
' O
s O
mutated B
G I
- I
CSFR I
, O
and O
by O
measuring O
STAT5 O
activation O
in O
nuclear O
extracts O
from O
stimulated O
cells O
. O

In O
contrast O
, O
inclusion O
of O
both O
G O
- O
CSF O
and O
hydrocortisone O
in O
the O
cytokine B
` I
` I
cocktail I
' I
' I
markedly O
increased O
the O
neutrophil O
numbers O
. O

Proliferation O
of O
32D O
cells O
expressing O
the O
mutated B
receptor I
and O
STAT5 O
activation O
were O
improved O
by O
a O
combination O
of O
G O
- O
CSF O
and O
dexamethasone O
. O

When O
small O
daily O
doses O
of O
oral O
prednisone O
were O
then O
administered O
to O
the O
patient O
with O
conventional O
doses O
of O
subcutaneous B
G I
- I
CSF I
, O
the O
patient O
responded O
with O
increased O
neutrophil O
numbers O
and O
with O
a O
complete O
reversal O
of O
the O
infectious O
problems O
. O

Interestingly O
, O
the O
retinoid O
also O
inhibited O
in O
FCS O
- O
stimulated O
cells O
the O
protein O
expression O
of O
two O
mesangial B
adhesion I
molecules I
, O
fibronectin O
and O
osteopontin B
, O
but O
it O
did O
not O
modify O
the O
protein O
expression O
of O
intercellular O
adhesion O
molecule O
- O
1 O
and O
vascular B
adhesion I
molecule I
- I
1 I
. O

All O
major O
RARs B
and I
RXRs I
isotypes I
were O
expressed O
in O
CHMC O
regardless O
of O
the O
presence O
or O
absence O
of O
9 O
- O
cRA O
. O

Transcripts O
to O
RAR O
- O
alpha O
, O
RAR O
- O
beta O
and O
RXR O
- O
alpha O
increased O
after O
incubation O
with O
9 O
- O
cRA O
whereas O
RXR B
- I
gamma I
was O
inhibited O
, O
suggesting O
a O
major O
role O
for O
RARs O
and O
RXRs O
in O
9 O
- O
cRA O
- O
anti O
- O
inflammatory O
effects O
. O

Expression O
of O
mammalian B
defensin I
genes I
. O

In O
epithelial O
cells O
, O
defensin B
genes I
are O
found O
as O
both O
constitutively O
expressed O
and O
inducible O
. O

In O
vivo O
, O
up O
- O
regulation O
of O
several O
defensin B
genes I
occurs O
in O
both O
infectious O
and O
inflammatory O
states O
. O

Gene O
regulation O
occurs O
via O
signal O
transduction O
pathways O
common O
to O
other O
innate O
immune O
responses O
, O
utilizing O
transcription O
factors O
such O
as O
nuclear O
factor O
( O
NF O
) O
- O
kappaB O
and O
NF B
interleukin I
- I
6 I
. O

CD3 O
/ O
CD28 O
- O
promoted O
CREB O
- O
CBP O
interaction O
was O
dependent O
on O
p38 O
mitogen O
- O
activated O
protein O
kinase O
( O
MAPK O
) O
and O
calcium B
/ I
calmodulin I
- I
dependent I
protein I
kinase I
( I
CaMK I
) I
IV I
in O
addition O
to O
the O
previously O
identified O
extracellular O
signal O
- O
regulated O
kinase O
pathway O
. O

Extracellular B
signal I
- I
regulated I
kinase I
, I
CaMKIV I
, O
and O
p38 O
MAPK O
were O
also O
the O
kinases O
involved O
in O
CREB O
Ser O
( O
133 O
) O
phosphorylation O
induced O
by O
CD3 O
/ O
CD28 O
. O

The O
murine O
IL O
- O
2 O
promoter O
contains O
distal B
regulatory I
elements I
responsive O
to O
the O
Ah O
receptor O
, O
a O
member O
of O
the O
evolutionarily O
conserved O
bHLH B
- I
PAS I
transcription I
factor I
family I
. O

We O
had O
previously O
shown O
that O
activation O
of O
the O
arylhydrocarbon B
receptor I
( O
AHR O
) O
, O
a O
member O
of O
the O
bHLH B
- I
PAS I
family I
of I
transcription I
factors I
, O
leads O
to O
increased O
mRNA O
expression O
of O
IL O
- O
2 O
in O
murine O
fetal O
thymocytes O
. O

Binding O
motifs O
for O
the O
liganded B
AHR I
can O
be O
identified O
in O
the O
distal B
region I
- I
1300 I
to I
- I
800 I
of O
the O
mouse B
IL I
- I
2 I
promoter I
. O

We O
show O
here O
that O
these O
DNA B
motifs I
, O
the O
so O
- O
called O
dioxin B
response I
elements I
, O
after O
binding O
to O
the O
liganded B
AHR I
are O
sufficient O
to O
transactivate O
luciferase O
expression O
in O
a O
reporter O
gene O
system O
. O

Thus O
, O
the O
IL O
- O
2 O
promoter O
region O
contains O
novel O
distal B
regulatory I
elements I
that O
can O
be O
addressed O
by O
the O
AHR O
to O
induce O
IL O
- O
2 O
and O
can O
cooperate O
with O
the O
proximal O
promoter O

Visualization O
of O
Syk B
- I
antigen I
receptor I
interactions O
using O
green B
fluorescent I
protein I
: O
differential O
roles O
for O
Syk O
and O
Lyn O
in O
the O
regulation O
of O
receptor O
capping O
and O
internalization O
. O

The O
cross O
- O
linking O
of O
the O
B O
cell O
Ag O
receptor O
( O
BCR O
) O
is O
coupled O
to O
the O
stimulation O
of O
multiple O
intracellular O
signal O
transduction O
cascades O
via O
receptor O
- O
associated O
, O
protein O
tyrosine O
kinases O
of O
both O
the O
Src B
and I
Syk I
families I
. O

To O
monitor O
changes O
in O
the O
subcellular O
distribution O
of O
Syk O
in O
B O
cells O
responding O
to O
BCR O
cross O
- O
linking O
, O
we O
expressed O
in O
Syk O
- O
deficient O
DT40 O
B O
cells O
a O
fusion O
protein O
consisting O
of O
Syk O
coupled O
to O
green B
fluorescent I
protein I
. O

Treatment O
of O
these O
cells O
with O
anti B
- I
IgM I
Abs I
leads O
to O
the O
recruitment O
of O
the O
kinase O
from O
cytoplasmic O
and O
nuclear O
compartments O
to O
the O
site O
of O
the O
cross B
- I
linked I
receptor I
at O
the O
plasma O
membrane O
. O

The O
Syk B
- I
receptor I
complexes I
aggregate O
into O
membrane O
patches O
that O
redistribute O
to O
form O
a O
cap O
at O
one O
pole O
of O
the O
cell O
. O

Syk O
is O
not O
demonstrably O
associated O
with O
the O
internalized B
receptor I
. O

Catalytically O
active O
Syk O
promotes O
and O
stabilizes O
the O
formation O
of O
tightly B
capped I
BCR I
complexes I
at O
the O
plasma O
membrane O
. O

Lyn O
is O
not O
required O
for O
the O
recruitment O
of O
Syk O
to O
the O
cross B
- I
linked I
receptor I
, O
but O
is O
required O
for O
the O
internalization O
of O
the O
clustered O
BCR B
complexes I
. O

In O
the O
absence O
of O
Lyn O
, O
receptor B
- I
Syk I
complexes I
at O
the O
plasma O
membrane O
are O
long O
lived O
, O
and O
the O
receptor O
- O
mediated O
activation O
of O
the O
NF O
- O
AT O
transcription O
factor O
is O
enhanced O
. O

Renal O
interstitial O
fibrosis O
is O
reduced O
in O
angiotensin B
II I
type I
1a I
receptor I
- O
deficient O
mice O
. O

This O
study O
established O
a O
UUO O
model O
in O
angiotensin B
type I
1a I
receptor I
( O
AT1a B
) O
deficient O
( O
mutant O
) O
mice O
to O
elucidate O
the O
role O
of O
angiotensin B
II I
through O
AT1a B
on O
the O
fibrosis O
of O
the O
obstructed O
kidney O
( O
OBK O
) O
. O

The O
relative O
volume O
of O
the O
tubulointerstitium O
was O
measured O
by O
an O
image O
analyzer O
; O
deposition O
of O
collagen B
types I
III I
and I
IV I
and O
monocyte O
/ O
macrophage O
infiltration O
were O
histologically O
examined O
using O
specific O
antibodies O
. O

UUO O
in O
wild O
mice O
resulted O
in O
a O
marked O
expansion O
of O
relative O
volume O
of O
the O
tubulointerstitium O
, O
together O
with O
increased O
deposition O
of O
collagen B
types I
III I
and I
IV I
and O
number O
of O
infiltrated O
monocytes O
/ O
macrophages O
in O
the O
interstitium O
, O
relative O
to O
sham O
- O
operated O
mice O
. O

The O
results O
provide O
direct O
evidence O
that O
angiotensin B
II I
acting O
via O
the O
AT1a B
plays O
a O
pivotal O
role O
in O
the O
development O
of O
tubulointerstitial O
fibrosis O
in O
UUO O
. O

HLA B
- I
DQ I
tetramers I
identify O
epitope O
- O
specific O
T O
cells O
in O
peripheral O
blood O
of O
herpes O
simplex O
virus O
type O
2 O
- O
infected O
individuals O
: O
direct O
detection O
of O
immunodominant O
antigen O
- O
responsive O
cells O
. O

MHC B
tetramers I
, O
which O
constitute O
a O
labeled B
MHC I
- I
peptide I
ligand I
suitable O
for O
binding O
to O
the O
Ag B
- I
specific I
receptor I
on O
T O
cells O
, O
provide O
a O
novel O
approach O
for O
the O
detection O
and O
characterization O
of O
such O
rare O
cells O
. O

Peptides O
representing O
potential O
epitope B
regions I
of O
the O
VP16 B
protein I
from O
HSV O
- O
2 O
were O
loaded O
onto O
recombinant B
DQ0602 I
molecules I
to O
generate O
a O
panel O
of O
Ag B
- I
specific I
DQ0602 I
tetramers I
. O

VP16 B
Ag I
- O
specific O
DQ O
- O
restricted O
T O
cells O
were O
identified O
and O
expanded O
from O
the O
peripheral O
blood O
of O
HSV O
- O
2 O
- O
infected O
individuals O
, O
representing O
two O
predominant O
epitope O
specificities O
. O

Although O
the O
VP16 O
369 O
- O
380 O
peptide O
has O
a O
lower O
binding O
affinity O
for O
DQ0602 B
molecules I
than O
the O
VP16 O
33 O
- O
52 O
peptide O
, O
T O
cells O
that O
recognized O
the O
VP16 O
369 O
- O
380 O
peptide O
occurred O
at O
a O
much O
higher O
frequency O
than O
those O
that O
were O
specific O
for O
the O
VP16 O
33 O
- O
52 O
peptide O
. O

In O
contrast O
to O
the O
tumor O
cells O
( O
L O
& O
H O
cells O
) O
of O
lymphocyte O
predominant O
Hodgkin O
disease O
( O
LPHD O
) O
, O
Hodgkin O
and O
Reed O
- O
Sternberg O
( O
HRS O
) O
cells O
of O
classical O
Hodgkin O
disease O
( O
cHD O
) O
are O
unable O
to O
transcribe O
immunoglobulin O
, O
despite O
the O
presence O
of O
rearranged B
immunoglobulin I
genes I
. O

As O
immunoglobulin O
transcription O
is O
mainly O
regulated O
by O
the O
B B
- I
cell I
transcription I
factors I
Oct2 O
and O
BOB O
. O
1 O
/ O
OBF O
. O
1 O
, O
we O
analyzed O
35 O
cases O
of O
LPHD O
, O
32 O
cases O
of O
cHD O
, O
and O
2 O
Hodgkin O
disease O
cell O
lines O
for O
the O
expression O
of O
these O
transcription O
factors O
and O
also O
in O
parallel O
for O
immunoglobulin O
expression O
. O

Furthermore O
, O
the O
reintroduction O
of O
BOB O
. O
1 O
/ O
OBF O
. O
1 O
and O
Oct2 O
into O
cultured O
HRS O
cells O
restored O
the O
activity O
of O
cotransduced O
immunoglobulin B
promoter I
constructs I
. O

Our O
findings O
dismiss O
the O
concept O
that O
the O
different O
immunoglobulin O
expression O
in O
cHD O
and O
LPHD O
is O
due O
to O
disrupting O
mutations O
of O
immunoglobulin B
V I
genes I
in O
cHD O
but O
is O
most O
likely O
due O
to O
a O
down O
- O
regulation O
of O
Oct2 O
and O
/ O
or O
BOB O
. O
1 O
/ O
OBF O
. O
1 O
. O

The O
NF B
- I
kappa I
B I
family I
of I
transcription I
factors I
is O
an O
important O
regulator O
of O
genes O
expressed O
during O
inflammatory O
responses O
, O
immunoglobulin O
( O
Ig O
) O
class O
switching O
, O
cellular O
differentiation O
, O
and O
apoptosis O
. O

We O
investigated O
the O
expression O
of O
active B
NF I
- I
kappa I
B I
p65 I
( I
Rel I
A I
) I
in O
cases O
of O
mycosis O
fungoides O
( O
MF O
) O
and O
the O
effect O
of O
chemical O
inhibitors O
of O
NF O
- O
kappa O
B O
on O
apoptosis O
in O
cutaneous O
T O
cell O
lymphoma O
( O
CTCL O
) O
cell O
lines O
. O

Paraffin O
- O
embedded O
tissues O
from O
23 O
cutaneous O
lesions O
and O
a O
single O
lymph O
node O
biopsy O
from O
patients O
diagnosed O
with O
MF O
were O
evaluated O
for O
p65 O
( O
Rel O
A O
) O
expression O
by O
using O
a O
monoclonal B
mouse I
antibody I
that O
detects O
the O
activated O
form O
of O
p65 O
( O
Rel O
A O
) O
. O

Neoplastic O
T O
lymphocytes O
from O
22 O
of O
24 O
cases O
of O
MF O
showed O
strong O
nuclear O
and O
cytoplasmic O
expression O
of O
active B
p65 I
( I
Rel I
A I
) I
. O

These O
data O
show O
that O
the O
active O
form O
of O
NF B
- I
kappa I
B I
p65 I
( I
Rel I
A I
) I
is O
commonly O
expressed O
in O
neoplastic O
T O
lymphocytes O
in O
patients O
with O
MF O
. O

Tax O
activates O
the O
expression O
of O
viral O
and O
cellular O
genes O
through O
two O
different O
enhancers O
: O
a O
cAMP B
- I
responsive I
( I
CRE I
) I
- I
like I
element I
and O
a O
kappaB O
element O
. O

Tax703 B
preferentially O
activated O
the O
kappaB O
element O
but O
not O
the O
CRE O
- O
like O
one O
, O
whereas O
TaxM22 B
showed O
the O
reverse O
. O

In O
addition O
, O
Tax703 B
and O
Tax O
, O
but O
not O
TaxM22 B
, O
converted O
cell O
growth O
of O
a O
mouse O
T O
- O
cell O
line O
from O
being O
interleukin O
( O
IL O
) O
- O
2 O
- O
dependent O
to O
being O
IL O
- O
2 O
- O
independent O
. O

Unlike O
the O
wild B
- I
type I
Tax I
, O
Tax703 B
and O
TaxM22 B
only O
weakly O
activated O
the O
AP O
- O
1 O
site O
in O
the O
T O
- O
cell O
line O
. O

Thus O
, O
Tax O
seems O
to O
activate O
the O
AP O
- O
1 O
site O
via O
mechanisms O
distinct O
from O
those O
of O
kappaB B
or I
CRE I
- I
like I
elements I
, O
and O
the O
activation O
of O
the O
AP O
- O
1 O
site O
is O
dispensable O
for O
IL O
- O
2 O
- O
independent O
growth O
of O
CTLL O
- O
2 O
. O

Electrophoretic O
mobility O
shift O
assays O
showed O
that O
Tax O
induced O
strong O
binding O
activity O
to O
an O
AP O
- O
1 O
site O
in O
CTLL O
- O
2 O
, O
whereas O
Tax703 B
did O
not O
, O
indicating O
that O
the O
induction O
of O
binding O
activity O
to O
the O
AP O
- O
1 O
site O
is O
essential O
for O
the O
transcriptional O
activation O
by O
Tax O
. O

The O
binding B
complex I
induced O
by O
Tax O
in O
CTLL O
- O
2 O
contained O
JunD O
and O
Fra B
- I
2 I
. O

Activation O
of O
transcription O
through O
the O
AP O
- O
1 O
site O
in O
Jurkat O
cells O
by O
JunD O
and O
/ O
or O
Fra B
- I
2 I
was O
weak O
. O

Thus O
, O
the O
induction O
of O
AP B
- I
1 I
mRNA I
by O
Tax O
may O
not O
be O
sufficient O
for O
a O
complete O
activation O
of O
AP O
- O
1 O
site O
by O
Tax O
. O

Our O
results O
suggest O
that O
Tax O
activates O
the O
transcription O
of O
cellular O
genes O
with O
AP O
- O
1 O
sites O
by O
inducing O
the O
DNA O
- O
binding O
activity O
of O
AP O
- O
1 O
proteins O
in O
T O
cells O
, O
a O
mechanism O
distinct O
from O
those O
of O
CRE B
- I
like I
and I
kappaB I
elements I
. O

We O
therefore O
designed O
HIV B
- I
1 I
genomes I
that O
replicate O
exclusively O
upon O
addition O
of O
the O
nontoxic O
effector O
doxycycline O
( O
dox O
) O
. O

Nuclear O
extracts O
prepared O
from O
the O
Mono O
Mac O
6 O
cells O
and O
RA O
synovial O
tissue O
were O
analyzed O
by O
electrophoretic O
mobility O
shift O
analysis O
( O
EMSA O
) O
for O
NF B
- I
kappaB I
DNA I
binding I
proteins I
. O

RESULTS O
: O
Induction O
of O
NF O
- O
kappaB O
DNA O
binding O
by O
the O
p65 B
( I
RelA I
) I
/ I
p50 I
heterodimer I
was O
observed O
in O
response O
to O
incubation O
of O
Mono O
Mac O
6 O
cells O
with O
SF O
( O
20 O
% O
in O
culture O
medium O
) O
from O
5 O
of O
8 O
subjects O
with O
RA O
, O
4 O
of O
5 O
with O
OA O
, O
and O
none O
of O
3 O
with O
undifferentiated O
seronegative O
oligoarthritis O
. O

Incubation O
of O
SF O
with O
neutralizing O
antibodies O
against O
tumor B
necrosis I
factor I
- I
alpha I
( I
TNF I
- I
alpha I
) I
, O
but O
not O
antibodies O
against O
interleukin O
6 O
( O
IL O
- O
6 O
) O
, O
significantly O
reduced O
the O
induction O
of O
p65 O
/ O
p50 O
binding O
activity O
in O
SF O
from O
subjects O
with O
RA O
and O
OA O
. O

The O
induction O
of O
this O
complex O
by O
SF O
was O
not O
affected O
by O
neutralization O
of O
TNF O
- O
alpha O
or O
IL O
- O
6 O
in O
SF O
, O
and O
the O
complex O
was O
not O
inducible O
by O
TNF O
- O
alpha O
, O
IL O
- O
1beta O
, O
TNF O
- O
alpha O
/ O
IL O
- O
1beta O
, O
IL O
- O
6 O
, O
platelet B
derived I
growth I
factor I
, O
lipopolysaccharide O
, O
or O
tetradecanoyl O
phorbol O
acetate O
. O

The O
slowly O
migrating B
complex I
could O
not O
be O
supershifted O
with O
antibodies O
against O
NF O
- O
kappaB O
, O
Jun O
, O
or O
the O
transcriptional O
coactivators O
p300 O
or O
CBP O
. O

CONCLUSION O
: O
Biological O
activity O
of O
TNF O
- O
alpha O
in O
SF O
from O
RA O
and O
OA O
subjects O
is O
capable O
of O
inducing O
p65 B
/ I
p50 I
NF I
- I
kappaB I
DNA O
binding O
activity O
in O
macrophages O
. O

Peroxisome B
proliferator I
activator I
receptor I
- I
gamma I
agonists O
and O
15 O
- O
deoxy O
- O
Delta O
( O
12 O
, O
14 O
) O
( O
12 O
, O
14 O
) O
- O
PGJ O
( O
2 O
) O
induce O
apoptosis O
in O
normal O
and O
malignant O
B O
- O
lineage O
cells O
. O

The O
research O
described O
herein O
evaluates O
the O
expression O
and O
functional O
significance O
of O
peroxisome B
proliferator I
activator I
receptor I
- I
gamma I
( I
PPAR I
- I
gamma I
) I
on O
B O
- O
lineage O
cells O
. O

Normal O
mouse O
B O
cells O
and O
a O
variety O
of O
B O
lymphoma O
cells O
reflective O
of O
stages O
of O
B O
cell O
differentiation O
( O
e O
. O
g O
. O
, O
70Z O
/ O
3 O
, O
CH31 O
, O
WEHI O
- O
231 O
, O
CH12 O
, O
and O
J558 O
) O
express O
PPAR B
- I
gamma I
mRNA I
and O
, O
by O
Western O
blot O
analysis O
, O
the O
67 B
- I
kDa I
PPAR I
- I
gamma I
protein I
. O

Only O
PPAR O
- O
gamma O
agonists O
( O
thiazolidinediones O
) O
, O
and O
not O
PPAR O
- O
alpha O
agonists O
, O
mimicked O
the O
effect O
of O
15d O
- O
PGJ O
( O
2 O
) O
on O
B O
- O
lineage O
cells O
, O
indicating O
that O
the O
mechanism O
by O
which O
15d O
- O
PGJ O
( O
2 O
) O
negatively O
affects O
B O
- O
lineage O
cells O
involves O
in O
part O
PPAR B
- I
gamma I
. O

We O
found O
that O
leukemic O
LGL O
from O
19 O
patients O
displayed O
high O
levels O
of O
activated B
STAT3 I
. O

However O
, O
we O
found O
that O
the O
Bcl B
- I
2 I
- I
family I
protein I
Mcl I
- I
1 I
was O
significantly O
reduced O
by O
AG O
- O
490 O
treatment O
. O

Activated B
STAT3 I
was O
shown O
to O
bind O
an O
SIE B
- I
related I
element I
in O
the O
murine B
mcl I
- I
1 I
promoter I
. O

Using O
a O
luciferase O
reporter O
assay O
, O
we O
demonstrated O
that O
v O
- O
src O
overexpression O
in O
NIH3T3 O
induced O
STAT3 O
- O
dependent O
transcriptional O
activity O
from O
the O
mcl B
- I
1 I
promoter I
and O
increased O
endogenous O
Mcl O
- O
1 O
protein O
levels O
. O

Decreased O
immediate O
inflammatory B
gene I
induction O
in O
activating B
transcription I
factor I
- I
2 I
mutant O
mice O
. O

Transcription B
factor I
activating I
transcription I
factor I
( I
ATF I
) I
- I
2 I
is O
activated O
by O
inflammatory O
signals O
transduced O
by O
the O
JNK O
and O
p38 O
MAP O
kinase O
pathways O
. O

To O
better O
define O
the O
role O
of O
ATF O
- O
2 O
in O
inflammation O
, O
adult O
mice O
expressing O
small O
amounts O
of O
a O
mutant B
ATF I
- I
2 I
protein I
were O
challenged O
with O
lipopolysaccharide O
( O
LPS O
) O
, O
anti O
- O
CD3 O
antibody O
or O
virus O
. O

ATF O
- O
2 O
mutant O
thymocytes O
treated O
with O
anti O
- O
CD3 O
antibody O
in O
vitro O
demonstrated O
reduced O
induction O
of O
c O
- O
Jun O
, O
JunB O
, O
JunD O
and O
Fra B
- I
2 I
. O

LIGHT B
, O
a O
TNF B
- I
like I
molecule I
, O
costimulates O
T O
cell O
proliferation O
and O
is O
required O
for O
dendritic O
cell O
- O
mediated O
allogeneic O
T O
cell O
response O
. O

LIGHT B
is O
a O
recently O
identified O
member O
of O
the O
TNF B
superfamily I
and O
its O
receptors O
, O
herpesvirus B
entry I
mediator I
and O
lymphotoxin B
beta I
receptor I
, O
are O
found O
in O
T O
cells O
and O
stromal O
cells O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
LIGHT B
is O
selectively O
expressed O
on O
immature O
dendritic O
cells O
( O
DCs O
) O
generated O
from O
human O
PBMCs O
. O

In O
contrast O
, O
LIGHT B
is O
not O
detectable O
in O
DCs O
either O
freshly O
isolated O
from O
PBMCs O
or O
rendered O
mature O
in O
vitro O
by O
LPS O
treatment O
. O

Blockade O
of O
LIGHT B
by O
its O
soluble B
receptors I
, O
lymphotoxin B
beta I
receptor I
- I
Ig I
or O
HVEM B
- I
Ig I
, O
inhibits O
the O
induction O
of O
DC O
- O
mediated O
primary O
allogeneic O
T O
cell O
response O
. O

Furthermore O
, O
engagement O
of O
LIGHT B
costimulates O
human O
T O
cell O
proliferation O
, O
amplifies O
the O
NF O
- O
kappaB O
signaling O
pathway O
, O
and O
preferentially O
induces O
the O
production O
of O
IFN O
- O
gamma O
, O
but O
not O
IL O
- O
4 O
, O
in O
the O
presence O
of O
an O
antigenic O
signal O
. O

Our O
results O
suggest O
that O
LIGHT B
is O
a O
costimulatory B
molecule I
involved O
in O
DC O
- O
mediated O
cellular O
immune O
responses O
. O

Suppression O
of O
HIV O
type O
1 O
replication O
by O
a O
dominant B
- I
negative I
Ets I
- I
1 I
mutant I
. O

Activity O
of O
the O
distal B
region I
of O
the O
human O
immunodeficiency O
virus O
( O
HIV O
- O
1 O
) O
long O
terminal O
repeat O
( O
LTR O
) O
, O
which O
contains O
binding O
sites O
for O
the O
Ets B
- I
1 I
and I
USF I
- I
1 I
proteins I
, O
is O
integral O
for O
HIV O
- O
1 O
replication O
. O

The O
Ets B
- I
1 I
and I
USF I
- I
1 I
proteins I
play O
a O
critical O
role O
in O
the O
activity O
of O
the O
HIV B
- I
1 I
LTR I
distal I
enhancer I
region I
, O
as O
indicated O
by O
the O
potent O
dominant O
negative O
effect O
of O
a O
mutant B
Ets I
- I
1 I
lacking I
trans I
- I
activation I
domains I
on O
the O
transcriptional O
activity O
of O
the O
LTR O
. O

To O
determine O
the O
biological O
relevance O
of O
the O
Ets B
- I
1 I
and I
USF I
- I
1 I
proteins I
in O
HIV O
- O
1 O
replication O
, O
we O
examined O
the O
effect O
of O
expression O
of O
the O
dominant O
- O
negative O
mutant O
of O
Ets O
- O
1 O
( O
dnEts B
- I
1 I
) O
on O
HIV O
- O
1 O
infection O
of O
T O
cells O
. O

We O
demonstrated O
that O
expression O
of O
dnEts B
markedly O
suppressed O
HIV O
- O
1 O
infection O
of O
a O
T O
cell O
line O
. O

This O
finding O
indicates O
that O
formation O
of O
a O
transcriptionaly B
active I
USF I
- I
1 I
/ I
Ets I
- I
1 I
complex I
is O
important O
in O
the O
productive O
infection O
of O
cells O
by O
HIV O
- O
1 O
, O
and O
suggests O
that O
inhibition O
of O
the O
interaction O
between O
USF B
- I
1 I
and O
Ets O
- O
1 O
with O
the O
HIV O
- O
1 O
LTR O
may O
provide O
a O
new O
target O
for O
anti O
- O
HIV O
- O
1 O
gene O
therapy O
. O

Human O
eosinophils O
constitutively O
express O
nuclear B
factor I
of I
activated I
T I
cells I
p I
and I
c I
. O

The O
expression O
of O
almost O
all O
of O
the O
cytokines O
produced O
by O
eosinophils O
, O
including O
the O
proallergic B
cytokine I
IL I
- I
4 I
, O
is O
now O
known O
to O
be O
regulated O
at O
the O
level O
of O
transcription O
by O
members O
of O
the O
nuclear O
factor O
of O
activated O
T O
cells O
( O
NFAT O
) O
family O
of O
transcription O
factors O
. O

NFAT O
expression O
was O
determined O
by O
using O
immunoprecipitation O
and O
Western O
blot O
analysis O
, O
DNA O
- O
binding O
assays O
, O
and O
RT O
- O
PCR O
analysis O
of O
eosinophil B
mRNA I
. O

RESULTS O
: O
Both O
peripheral O
blood O
and O
bronchoalveolar O
lavage O
fluid O
eosinophils O
expressed O
NFATp B
and I
NFATc I
protein I
. O

A O
brief O
incubation O
with O
the O
T B
( I
H I
) I
2 I
cytokines I
IL O
- O
4 O
and O
IL O
- O
5 O
was O
sufficient O
to O
induce O
the O
nuclear O
translocation O
of O
NFATc O
. O

Eosinophil O
nuclear O
extracts O
contain O
multiple O
factors O
that O
can O
specifically O
recognize O
the O
IL B
- I
4 I
promoter I
P1 I
NFAT I
site I
in O
DNA O
- O
binding O
assays O
, O
including O
NFATp O
. O

BLyS B
BINDS O
TO O
B O
CELLS O
WITH O
HIGH O
AFFINITY O
AND O
INDUCES O
ACTIVATION O
OF O
THE O
TRANSCRIPTION O
FACTORS O
NF O
- O
kappaB O
AND O
ELF O
- O
1 O
. O

B B
lymphocyte I
stimulator I
( O
BLyS B
) O
is O
a O
novel O
member O
of O
the O
TNF B
family I
of I
proteins I
expressed O
by O
myeloid O
cells O
as O
membrane O
- O
bound O
and O
soluble O
forms O
. O

BLyS B
was O
shown O
to O
act O
specifically O
on O
B O
cells O
, O
inducing O
proliferation O
and O
immunoglobulin O
production O
both O
in O
vitro O
and O
in O
vivo O
. O

The O
present O
study O
was O
undertaken O
to O
characterize O
binding O
of O
radiolabeled B
BLyS I
to O
its O
cognate O
receptor O
on O
human O
B O
lymphocytes O
and O
examine O
intracellular O
events O
initiated O
by O
BLyS B
binding O
. O

Similar O
to O
other O
TNF B
family I
members I
, O
BLyS B
is O
present O
in O
solution O
as O
a O
homotrimer B
as O
determined O
by O
gel O
filtration O
chromatography O
and O
light O
scattering O
analysis O
. O

BLyS B
binding O
to O
B O
cells O
is O
specific O
as O
other O
TNF B
family I
members I
tested O
did O
not O
compete O
for O
( O
125 O
) O
I O
- O
BLyS B
binding O
. O

Analysis O
of O
equilibrium O
binding O
of O
( B
125 I
) I
I I
- I
labeled I
BLyS I
to O
purified O
human O
tonsillar O
B O
cells O
demonstrated O
saturable O
binding O
. O

In O
addition O
we O
report O
that O
BLyS B
binding O
to O
B O
cells O
results O
in O
the O
activation O
of O
NF O
- O
kappaB O
and O
the O
Ets B
family I
transcription I
factor I
, O
ELF O
- O
1 O
, O
and O
in O
the O
induction O
of O
mRNA O
for O
Polo B
- I
like I
kinase I
( O
PLK B
) O
. O

The O
Nef B
protein I
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
has O
been O
shown O
to O
enhance O
the O
infectivity O
of O
virus O
particles O
, O
downmodulate O
cell O
surface O
proteins O
, O
and O
associate O
with O
many O
intracellular O
proteins O
that O
are O
thought O
to O
facilitate O
HIV O
infection O
. O

One O
of O
the O
challenges O
in O
defining O
the O
molecular O
events O
regulated O
by O
Nef O
has O
been O
obtaining O
good O
expression O
of O
Nef B
protein I
in O
T O
cells O
. O

We O
have O
designed O
a O
Nef B
protein I
that O
is O
readily O
expressed O
in O
T O
- O
cell O
lines O
and O
whose O
function O
is O
inducibly O
activated O
. O

It O
is O
composed O
of O
a O
fusion O
between O
full B
- I
length I
Nef I
and O
the O
estrogen B
receptor I
hormone I
- I
binding I
domain I
( O
Nef B
- I
ER I
) O
. O

The O
Nef B
- I
ER I
is O
kept O
in O
an O
inactive O
state O
due O
to O
steric O
hindrance O
, O
and O
addition O
of O
the O
membrane O
- O
permeable O
drug O
4 O
- O
hydroxytamoxifen O
( O
4 O
- O
HT O
) O
, O
which O
binds O
to O
the O
ER B
domain I
, O
leads O
to O
inducible O
activation O
of O
Nef B
- I
ER I
within O
cells O
. O

We O
demonstrate O
that O
Nef B
- I
ER I
inducibly O
associates O
with O
the O
62 B
- I
kDa I
Ser I
/ I
Thr I
kinase I
and O
is O
localized O
to O
specific O
membrane O
microdomains O
( O
lipid O
rafts O
) O
only O
after O
activation O
. O

Using O
this O
inducible O
Nef O
, O
we O
also O
compared O
the O
specific O
requirements O
for O
CD4 O
and O
HLA B
- I
A2 I
downmodulation O
in O
a O
SupT1 O
T O
- O
cell O
line O
. O

Half O
- O
maximal O
downmodulation O
of O
cell O
surface O
CD4 O
required O
very O
little O
active O
Nef B
- I
ER I
and O
occurred O
as O
early O
as O
4 O
h O
after O
addition O
of O
4 O
- O
HT O
. O

In O
contrast O
, O
50 O
% O
downmodulation O
of O
HLA B
- I
A2 I
by O
Nef O
required O
16 O
to O
24 O
h O
and O
about O
50 O
- O
to O
100 O
- O
fold O
- O
greater O
concentrations O
of O
4 O
- O
HT O
. O

These O
data O
suggest O
that O
HLA B
- I
A2 I
downmodulation O
may O
require O
certain O
threshold O
levels O
of O
active O
Nef O
. O

The O
differential O
timing O
of O
CD4 O
and O
HLA B
- I
A2 I
downmodulation O
may O
have O
implications O
for O
HIV O
pathogenesis O
and O
immune O
evasion O
. O

Using O
a O
rat O
model O
of O
acute O
lung O
inflammation O
induced O
by O
intratracheal O
instillation O
of O
sodium O
metavanadate O
( O
NaVO3 O
) O
at O
the O
dose O
of O
200 O
microg O
V O
/ O
kg O
, O
we O
investigated O
the O
relationship O
between O
the O
cytologic O
characterization O
of O
pulmonary O
inflammation O
and O
the O
expression O
of O
chemokine B
mRNA I
. O

By O
Northern O
analysis O
, O
macrophage B
inflammatory I
protein I
( I
MIP I
) I
- I
2 I
mRNA I
in O
BAL O
cells O
increased O
markedly O
1 O
h O
after O
NaVO3 O
instillation O
and O
reduced O
a O
little O
bit O
at O
4 O
h O
, O
whereas O
MIP B
- I
1alpha I
mRNA I
in O
BAL O
cells O
was O
expressed O
relatively O
high O
1 O
h O
after O
NaVO3 O
instillation O
, O
although O
a O
basal O
expression O
was O
detected O
in O
control O
group O
, O
and O
returned O
rapidly O
nearly O
to O
control O
level O
at O
4 O
h O
. O

The O
facts O
that O
PMN O
influx O
was O
preceded O
by O
increased O
MIP O
- O
2 O
mRNA O
expression O
, O
suggesting O
that O
MIP O
- O
2 O
is O
involved O
in O
the O
development O
of O
NaVO3 O
- O
induced O
pulmonary O
inflammation O
, O
whereas O
increased O
MIP B
- I
1alpha I
mRNA I
expression O
was O
followed O
by O
decreased O
AMs O
in O
BAL O
cells O
, O
suggesting O
AMs O
might O
be O
activated O
by O
MIP O
- O
1alpha O
, O
adherent O
to O
the O
lining O
surface O
of O
the O
airways O
and O
then O
resistant O
to O
be O
washed O
out O
. O

To O
delineate O
the O
mechanisms O
of O
transcriptional O
activation O
, O
we O
recently O
cloned O
the O
5 O
' O
- O
flanking O
region O
of O
the O
MIP B
- I
2 I
gene I
. O

The O
promotor B
region I
contains O
consensus O
binding O
sites O
for O
transcription O
factor O
nuclear O
factor O
kappaB O
( O
NF O
- O
kappaB O
) O
and O
activator O
protein O
- O
1 O
( O
AP O
- O
1 O
) O
. O

Using O
electrophoretic O
mobility O
shift O
assay O
, O
increased O
nuclear O
NF O
- O
kappaB O
, O
not O
AP O
- O
1 O
, O
binding O
activity O
was O
detected O
1 O
h O
after O
NaVO3 O
instillation O
, O
which O
correlated O
with O
the O
induction O
of O
MIP B
- I
2 I
mRNA I
. O

p65 O
( O
Rel O
A O
) O
and O
p50 B
protein I
appears O
to O
be O
involved O
in O
MIP O
- O
2 O
NF O
- O
kappaB O
binding O
. O

In O
addition O
, O
elevated O
MIP B
- I
2 I
mRNA I
levels O
are O
accompanied O
by O
increased O
NF O
- O
kappaB O
binding O
activity O
in O
BAL O
cells O
, O
suggesting O
possible O
MIP O
- O
2 O
transcriptional O
regulation O
through O
NF O
- O
kappaB O
. O

In O
this O
study O
we O
analysed O
the O
induction O
of O
factors O
involved O
in O
cytokine O
signal O
transduction O
, O
such O
as O
STAT B
1 I
proteins I
and O
IRF B
- I
1 I
mRNA I
, O
in O
normal O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
exposed O
to O
HIV O
- O
infected O
cells O
, O
and O
the O
induction O
of O
apoptosis O
. O

Western O
blot O
analyses O
and O
reverse O
transcriptase O
- O
polymerase O
chain O
reaction O
results O
indicate O
that O
both O
cells O
infected O
with O
a O
X4 O
strain O
and O
cells O
infected O
with O
a O
R5 O
strain O
are O
able O
to O
increase O
intracellular O
levels O
of O
STAT B
1alpha I
and I
beta I
proteins O
as O
well O
as O
IRF B
- I
1 I
mRNA I
. O

HIV O
- O
1 O
- O
infected O
cells O
dose O
- O
dependently O
induced O
apoptotic O
commitment O
in O
normal O
PBMC O
, O
as O
revealed O
by O
DNA O
fragmentation O
analysis O
, O
but O
this O
was O
not O
accompanied O
by O
an O
increase O
of O
caspase O
- O
3 O
activity O
, O
even O
if O
a O
slight O
up O
- O
regulation O
of O
IL B
- I
1beta I
- I
converting I
enzyme I
mRNA I
was O
detected O
. O

The O
physical O
association O
of O
protein B
kinase I
C I
theta I
with O
a O
lipid O
raft O
- O
associated O
inhibitor O
of O
kappa B
B I
factor I
kinase I
( I
IKK I
) I
complex I
plays O
a O
role O
in O
the O
activation O
of O
the O
NF O
- O
kappa O
B O
cascade O
by O
TCR O
and O
CD28 O
. O

We O
investigated O
the O
role O
of O
protein B
kinase I
C I
theta I
( O
PKCtheta B
) O
in O
the O
activation O
of O
the O
NF O
- O
kappaB O
cascade O
in O
primary O
human O
CD4 O
( O
+ O
) O
lymphocytes O
. O

Among O
six O
or O
so O
PKC O
isoforms O
expressed O
in O
T O
cells O
, O
only O
PKCtheta B
participates O
in O
the O
assembly O
of O
the O
supramolecular O
activation O
clusters O
at O
the O
contact O
site O
of O
the O
TCR O
with O
Ag O
. O

Signaling O
via O
both O
the O
TCR O
and O
CD28 O
is O
required O
for O
optimal O
activation O
of O
the O
multisubunit B
IkappaB I
kinase I
( I
IKK I
) I
complex I
in O
primary O
human O
T O
lymphocytes O
; O
this O
activation O
could O
be O
inhibited O
by O
a O
Ca O
( O
2 O
+ O
) O
- O
independent O
PKC O
isoform O
inhibitor O
, O
rottlerin O
. O

Moreover O
, O
endogenous O
PKCtheta B
physically O
associates O
with O
activated O
IKK B
complexes I
in O
CD3 O
/ O
CD28 O
- O
costimulated O
primary O
CD4 O
( O
+ O
) O
T O
cells O
. O

The O
same O
set O
of O
stimuli O
also O
induced O
relocation O
of O
endogenous O
PKCtheta B
and O
IKKs B
to O
a O
GM1 O
ganglioside O
- O
enriched O
, O
detergent O
- O
insoluble O
membrane O
compartment O
in O
primary O
T O
cells O
. O

IKKs B
recruited O
to O
these O
lipid O
rafts O
were O
capable O
of O
phosphorylating O
a O
recombinant O
IkappaBalpha O
sustrate O
. O

Confocal O
microscopy O
further O
demonstrated O
that O
exogenously O
expressed O
PKCtheta B
and O
IKKss B
colocalize O
in O
the O
membrane O
of O
CD3 O
/ O
CD28 O
- O
costimulated O
Jurkat O
T O
cells O
. O

Constitutively O
active O
but O
not O
kinase B
- I
inactive I
PKCtheta I
activated O
IKKbeta O
in O
Jurkat O
T O
cells O
. O

Expression O
of O
dominant B
- I
active I
PKCtheta I
also O
had O
stimulatory O
effects O
on O
the O
CD28 O
response O
element O
of O
the O
IL O
- O
2 O
promoter O
. O

Taken O
together O
, O
these O
data O
show O
that O
the O
activation O
of O
PKCtheta B
by O
the O
TCR O
and O
CD28 O
plays O
an O
important O
role O
in O
the O
assembly O
and O
activation O
of O
IKK B
complexes I
in O
the O
T O
cell O
membrane O

Bone O
resorption O
is O
regulated O
by O
the O
immune O
system O
, O
where O
T O
- O
cell O
expression O
of O
RANKL O
( O
receptor B
activator I
of I
nuclear I
factor I
( I
NF I
) I
- I
kappaB I
ligand I
) O
, O
a O
member O
of O
the O
tumour B
- I
necrosis I
factor I
family I
that O
is O
essential O
for O
osteoclastogenesis O
, O
may O
contribute O
to O
pathological O
conditions O
, O
such O
as O
autoimmune O
arthritis O
. O

IFN O
- O
gamma O
induces O
rapid O
degradation O
of O
the O
RANK B
adapter I
protein I
, O
TRAF6 O
( O
tumour B
necrosis I
factor I
receptor I
- I
associated I
factor I
6 I
) O
, O
which O
results O
in O
strong O
inhibition O
of O
the O
RANKL O
- O
induced O
activation O
of O
the O
transcription O
factor O
NF O
- O
kappaB O
and O
JNK O
. O

Our O
study O
shows O
that O
there O
is O
cross O
- O
talk O
between O
the O
tumour O
necrosis O
factor O
and O
IFN B
families I
of O
cytokines O
, O
through O
which O
IFN O
- O
gamma O
provides O
a O
negative O
link O
between O
T O
- O
cell O
activation O
and O
bone O
resorption O
. O

Stromal B
- I
derived I
factor I
1 I
and O
thrombopoietin O
regulate O
distinct O
aspects O
of O
human O
megakaryopoiesis O
. O

The O
role O
of O
the O
chemokine O
binding O
stromal B
- I
derived I
factor I
1 I
( O
SDF B
- I
1 I
) O
in O
normal O
human O
megakaryopoiesis O
at O
the O
cellular O
and O
molecular O
levels O
and O
its O
comparison O
with O
that O
of O
thrombopoietin O
( O
TPO O
) O
have O
not O
been O
determined O
. O

In O
this O
study O
it O
was O
found O
that O
SDF B
- I
1 I
, O
unlike O
TPO O
, O
does O
not O
stimulate O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cell O
proliferation O
or O
differentiation O
or O
have O
an O
antiapoptotic O
effect O
. O

However O
, O
it O
does O
induce O
chemotaxis O
, O
trans O
- O
Matrigel O
migration O
, O
and O
secretion O
of O
matrix O
metalloproteinase B
9 I
( O
MMP O
- O
9 O
) O
and O
vascular B
endothelial I
growth I
factor I
( O
VEGF B
) O
by O
these O
cells O
, O
and O
both O
SDF B
- I
1 I
and O
TPO O
increase O
the O
adhesion O
of O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cells O
to O
fibrinogen O
and O
vitronectin B
. O

Investigating O
the O
intracellular O
signaling O
pathways O
induced O
by O
SDF B
- I
1 I
and O
TPO O
revealed O
some O
overlapping O
patterns O
of O
protein O
phosphorylation O
/ O
activation O
( O
mitogen B
- I
activated I
protein I
kinase I
[ I
MAPK I
] I
p42 I
/ I
44 I
, O
MAPK O
p38 O
, O
and O
AKT B
[ I
protein I
kinase I
B I
] I
) O
and O
some O
that O
were O
distinct O
for O
TPO O
( O
eg O
, O
JAK O
- O
STAT O
) O
and O
for O
SDF B
- I
1 I
( O
eg O
, O
NF O
- O
kappa O
B O
) O
. O

It O
was O
also O
found O
that O
though O
inhibition O
of O
phosphatidyl O
- O
inositol O
3 O
- O
kinase O
( O
PI B
- I
3K I
) O
by O
LY294002 O
in O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cells O
induced O
apoptosis O
and O
inhibited O
chemotaxis O
adhesion O
and O
the O
secretion O
of O
MMP O
- O
9 O
and O
VEGF B
, O
the O
inhibition O
of O
MAPK B
p42 I
/ I
44 I
( O
by O
the O
MEK O
inhibitor O
U0126 O
) O
had O
no O
effect O
on O
the O
survival O
, O
proliferation O
, O
and O
migration O
of O
these O
cells O
. O

Accordingly O
, O
PI B
- I
3K I
is O
involved O
in O
TPO O
- O
mediated O
inhibition O
of O
apoptosis O
, O
TPO O
- O
and O
SDF O
- O
1 O
- O
regulated O
adhesion O
to O
fibrinogen O
and O
vitronectin B
, O
and O
SDF B
- I
1 I
- O
mediated O
migration O
. O

This O
study O
expands O
the O
understanding O
of O
the O
role O
of O
SDF B
- I
1 I
and O
TPO O
in O
normal O
human O
megakaryopoiesis O
and O
indicates O
the O
molecular O
basis O
of O
the O
observed O
differences O
in O
cellular O
responses O
. O

Adhesion O
of O
immature O
and O
mature O
T O
cells O
induces O
in O
human O
thymic O
epithelial O
cells O
( O
TEC O
) O
activation O
of O
IL B
- I
6 I
gene I
trascription I
factors I
( O
NF O
- O
kappaB O
and O
NF O
- O
IL6 O
) O
and O
IL O
- O
6 O
gene O
expression O
: O
role O
of O
alpha3beta1 B
and I
alpha6beta4 I
integrins I
. O

We O
demonstrated O
that O
thymocytes O
adhere O
to O
TEC O
involving O
beta1 B
and I
beta4 I
integrins I
and O
induce O
the O
clustering O
of O
alpha3beta1 B
and I
alpha6beta4 I
heterodimers I
at O
the O
TEC O
surface O
. O

In O
addition O
thymocyte O
adhesion O
was O
followed O
by O
activation O
of O
NF O
- O
kappaB O
and O
NF O
- O
IL6 O
gene B
transcription I
factors I
and O
enhanced O
IL O
- O
6 O
production O
. O

The O
two O
latter O
phenomena O
were O
reproduced O
by O
the O
cross O
- O
linking O
of O
the O
alpha3 B
, O
alpha6 B
, O
beta1 B
and I
beta4 I
integrins I
, O
thus O
implying O
that O
the O
alpha3beta1 B
and I
alpha6beta4 I
heterodimers I
can O
signal O
during O
thymocyte O
adhesion O
. O

We O
found O
that O
adhesion O
of O
unstimulated O
T O
cell O
i O
) O
involved O
beta1 O
, O
but O
not O
beta4 O
integrin O
functions O
at O
the O
surface O
ii O
) O
induced O
the O
clustering O
of O
alpha3beta1 B
, O
but O
not O
alpha2beta1 B
heterodimers I
at O
the O
TEC O
surface O
and O
iii O
) O
up O
- O
regulated O
the O
nuclear O
binding O
activity O
of O
NF O
- O
kappaB O
transcription O
factor O
and O
the O
IL O
- O
6 O
secretion O
. O

We O
propose O
that O
alpha3beta1 B
and I
alpha6beta4 I
heterodimers I
are O
induced O
to O
cluster O
at O
the O
TEC O
surface O
recognizing O
yet O
unknown O
cellular B
ligands I
differentially O
expressed O
during O
T O
cell O
development O
. O

Identification O
and O
characterization O
of O
SKAT B
- I
2 I
, O
a O
novel O
Th2 B
- I
specific I
zinc I
finger I
gene I
. O

We O
have O
identified O
a O
novel O
Kruppel B
- I
type I
zinc I
finger I
( I
ZF I
) I
gene I
, O
SKAT B
- I
2 I
, O
which O
is O
selectively O
expressed O
by O
murine O
Th2 O
cells O
. O

The O
protein O
encoded O
by O
this O
gene O
has O
14 O
C2H2 O
- O
type O
ZF O
tandemly O
arrayed O
at O
its O
C O
terminus O
and O
N O
- O
terminal O
SCAN B
box I
and O
KRAB B
domains I
. O

SKAT B
- I
2 I
is O
tissue O
restricted O
in O
expression O
at O
the O
RNA O
level O
, O
detectable O
only O
in O
brain O
and O
at O
low O
levels O
in O
kidney O
and O
spleen O
and O
few O
hematopoietic O
cell O
lines O
. O

By O
in O
situ O
hybridization O
, O
SKAT B
- I
2 I
expression O
was O
found O
to O
peak O
in O
antigen O
- O
stimulated O
CD4 O
( O
+ O
) O
T O
cells O
after O
2 O
- O
3 O
days O
of O
culture O
under O
Th2 O
but O
not O
Th1 O
biasing O
conditions O
. O

In O
transient O
transfection O
experiments O
in O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
/ O
ionomycin O
- O
stimulated O
EL4 O
cells O
, O
SKAT B
- I
2 I
was O
found O
to O
up O
- O
regulate O
the O
activity O
of O
the O
IL B
- I
4 I
but I
not I
the I
IL I
- I
5 I
promoter I
, O
contrasting O
with O
the O
ability O
of O
GATA O
- O
3 O
to O
activate O
both O
promoters O
. O

This O
result O
was O
confirmed O
using O
clones O
of O
EL4 O
cells O
stably O
expressing O
an O
inducible O
form O
of O
SKAT B
- I
2 I
, O
thus O
SKAT B
- I
2 I
is O
a O
novel O
Th2 B
- I
specific I
gene I
that O
may O
play O
a O
role O
in O
selective O
regulation O
of O
cytokine O
genes O
in O
T O
cells O
. O

hsp70 B
interacting I
protein I
Hip I
does O
not O
affect O
glucocorticoid O
receptor O
folding O
by O
the O
hsp90 O
- O
based O
chaperone O
machinery O
except O
to O
oppose O
the O
effect O
of O
BAG B
- I
1 I
. O

Reticulocyte O
lysate O
contains O
a O
chaperone O
system O
that O
assembles O
glucocorticoid B
receptor I
( I
GR I
) I
. I
hsp90 I
heterocomplexes I
. O

Using O
purified B
proteins I
, O
we O
have O
prepared O
a O
five O
- O
protein O
heterocomplex O
assembly O
system O
consisting O
of O
two O
proteins O
essential O
for O
heterocomplex O
assembly O
- O
hsp90 O
and O
hsp70 O
- O
and O
three O
proteins O
that O
act O
as O
co O
- O
chaperones O
to O
enhance O
assembly O
- O
Hop B
, O
hsp40 B
, O
p23 O
[ O
Morishima O
, O
Y O
. O
, O
Kanelakis O
, O
K O
. O
C O
. O
, O
Silverstein O
, O
A O
. O
M O
. O
, O
Dittmar O
, O
K O
. O
D O
. O
, O
Estrada O
, O
L O
. O
, O
and O
Pratt O
, O
W O
. O
B O
. O
( O
2000 O
) O
J O
. O
Biol O
. O
Chem O
. O
275 O
, O
6894 O
- O

The O
hsp70 B
co I
- I
chaperone I
Hip I
has O
been O
recovered O
in O
receptor B
. I
hsp90 I
heterocomplexes I
at O
an O
intermediate O
stage O
of O
assembly O
in O
reticulocyte O
lysate O
, O
and O
Hip B
is O
also O
thought O
to O
be O
an O
intrinsic O
component O
of O
the O
assembly O
machinery O
. O

Here O
we O
show O
that O
immunodepletion O
of O
Hip B
from O
reticulocyte O
lysate O
or O
addition O
of O
high O
levels O
of O
Hip B
to O
the O
purified O
five O
- O
protein O
system O
does O
not O
affect O
GR O
. O
hsp90 O
heterocomplex O
assembly O
or O
the O
activation O
of O
steroid O
binding O
activity O
that O
occurs O
with O
assembly O
. O

Despite O
the O
fact O
that O
Hip B
does O
not O
affect O
assembly O
, O
it O
is O
recovered O
in O
GR B
. I
hsp90 I
heterocomplexes I
assembled O
by O
both O
systems O
. O

In O
the O
five O
- O
protein O
system O
, O
Hip B
prevents O
inhibition O
of O
assembly O
by O
the O
hsp70 B
co I
- I
chaperone I
BAG I
- I
1 I
, O
and O
cotransfection O
of O
Hip B
with O
BAG B
- I
1 I
opposes O
BAG B
- I
1 I
reduction O
of O
steroid O
binding O
activity O
in O
COS O
cells O
. O

We O
conclude O
that O
Hip B
is O
not O
a O
component O
of O
the O
assembly O
machinery O
but O
that O
it O
could O
play O
a O
regulatory O
role O
in O
opposition O
to O
BAG B
- I
1 I
. O

Therefore O
, O
deletion O
of O
the O
STAT6 B
gene I
facilitates O
development O
of O
potent O
anti O
- O
tumor O
immunity O
via O
a O
CD4 O
( O
+ O
) O
- O
independent O
pathway O
. O

Activation O
of O
oncogenic B
transcription I
factor I
AP I
- I
1 I
in O
T O
cells O
infected O
with O
human O
T O
cell O
leukemia O
virus O
type O
1 O
. O

A O
transient O
transfection O
study O
showed O
that O
Tax O
can O
activate O
transcription O
through O
the O
AP O
- O
1 O
- O
binding O
site O
in O
a O
human O
T O
cell O
line O
, O
whereas O
any O
combination O
of O
AP O
- O
1 O
proteins O
did O
so O
much O
less O
than O
Tax O
, O
indicating O
that O
the O
activation O
of O
the O
AP O
- O
1 O
site O
by O
Tax O
may O
require O
a O
mechanism O
other O
than O
the O
induction O
of O
AP B
- I
1 I
mRNA I
. O

However O
, O
the O
HTLV B
- I
1 I
genes I
, O
including O
tax O
, O
are O
not O
significantly O
expressed O
in O
fresh O
leukemia O
cells O
from O
ATL O
patients O
. O

In O
contrast O
, O
3 O
, O
3 O
' O
, O
4 O
, O
4 O
' O
, O
5 O
- O
PeCB O
, O
a O
congener O
of O
coplanar O
structure O
, O
as O
well O
as O
2 O
, O
3 O
, O
7 O
, O
8 O
- O
TCDD O
did O
not O
induce O
apoptosis O
in O
these O
human O
monocytic O
cells O
, O
although O
they O
potently O
induced O
CYP B
1A1 I
in O
human O
hepatoma O
Hep O
G2 O
cells O
. O

Taken O
together O
, O
the O
data O
indicate O
that O
2 O
, O
2 O
' O
, O
4 O
, O
6 O
, O
6 O
' O
- O
PeCB O
induces O
apoptosis O
in O
human O
monocytic O
cells O
through O
a O
mechanism O
that O
is O
independent O
of O
the O
arylhydrocarbon B
receptor I
. O

The O
conditionally O
active O
Raf B
proteins I
were O
regulated O
by O
beta O
- O
estradiol O
as O
cDNAs O
containing O
the O
Raf B
catalytic I
, O
but O
lacking O
negative B
- I
regulatory I
domains I
, O
were O
ligated O
to O
the O
hormone O
binding O
domain O
of O
the O
estrogen O
receptor O
( O
deltaRaf B
: I
ER I
) O
. O

Continuous O
deltaRaf B
expression O
prevented O
apoptosis O
in O
the O
absence O
of O
exogenous O
cytokines O
and O
altered O
the O
morphology O
of O
the O
FD O
/ O
deltaRaf O
: O
ER O
cells O
as O
they O
grew O
in O
large O
aggregated O
masses O
( O
> O
100 O
cells O
) O
whereas O
the O
parental O
cytokine O
- O
dependent O
FDC O
- O
P1 O
cells O
grew O
in O
smaller O
grape O
- O
like O
clusters O
( O
< O
10 O
cells O
) O
. O

FD O
/ O
deltaRaf O
- O
1 O
: O
ER O
cells O
growing O
in O
response O
to O
Raf O
activation O
displayed O
decreased O
levels O
of O
the O
Mac B
- I
2 I
and I
Mac I
- I
3 I
molecules I
on O
their O
cell O
surface O
. O

Expression O
of O
activated O
Raf B
oncoproteins I
also O
abrogated O
cytokine O
dependency O
and O
prevented O
apoptosis O
of O
TF O
- O
1 O
cells O
. O

Moreover O
, O
the O
differentiation O
status O
of O
these O
Raf O
- O
responsive O
cells O
was O
more O
immature O
upon O
Raf O
activation O
as O
culture O
with O
the O
differentiation O
- O
inducing O
agent O
phorbol O
12 O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
and O
beta O
- O
estradiol O
resulted O
in O
decreased O
levels O
of O
the O
CD11b B
and I
CD18 I
integrin I
molecules I
on O
the O
cell O
surface O
. O

In O
contrast O
when O
the O
Raf O
- O
responsive O
cells O
were O
induced O
to O
differentiate O
with O
PMA O
and O
GM O
- O
CSF O
, O
in O
the O
absence O
of O
deltaRaf B
: I
ER I
activation O
, O
increased O
levels O
of O
the O
CD11b B
and I
CD18 I
molecules I
were O
detected O
. O

Elevation O
of O
intracellular O
cAMP O
in O
T O
cells O
, O
induced O
by O
agents O
such O
as O
IL O
- O
1alpha O
or O
PGs B
, O
inhibits O
T O
cell O
activation O
. O

Characterization O
of O
IL O
- O
4 O
and O
IL O
- O
13 O
signals O
dependent O
on O
the O
human B
IL I
- I
13 I
receptor I
alpha I
chain I
1 I
: O
redundancy O
of O
requirement O
of O
tyrosine O
residue O
for O
STAT3 O
activation O
. O

IL O
- O
4 O
and O
IL O
- O
13 O
are O
pleiotropic B
cytokines I
whose O
biological O
activities O
overlap O
with O
each O
other O
. O

IL B
- I
13 I
receptor I
alpha I
chain I
1 I
( O
IL B
- I
13R I
alpha I
1 I
) O
is O
necessary O
for O
binding O
to O
IL O
- O
13 O
, O
and O
the O
heterodimer O
composed O
of O
IL B
- I
13R I
alpha I
1 I
and O
IL O
- O
4R O
alpha O
chain O
transduces O
IL O
- O
13 O
and O
IL O
- O
4 O
signals O
; O
however O
, O
the O
functional O
mapping O
of O
the O
intracellular O
domain O
of O
IL B
- I
13R I
alpha I
1 I
is O
not O
fully O
understood O
. O

In O
this O
study O
, O
we O
constructed O
wild O
and O
mutated O
types O
of O
human B
IL I
- I
13R I
alpha I
1 I
, O
and O
analyzed O
IL O
- O
4 O
and O
IL O
- O
13 O
signals O
using O
an O
IL B
- I
13R I
alpha I
1 I
- O
transfected O
human O
B O
cell O
line O
. O

Expression O
of O
IL B
- I
13R I
alpha I
1 I
evoked O
STAT3 O
activation O
by O
IL O
- O
4 O
and O
IL O
- O
13 O
, O
and O
in O
stimulated O
human O
B O
cells O
, O
on O
which O
IL B
- I
13R I
alpha I
1 I
was O
highly O
expressed O
, O
IL O
- O
4 O
and O
IL O
- O
13 O
induced O
STAT3 O
activation O
. O

Furthermore O
, O
we O
found O
that O
the O
Box1 B
region I
and O
the O
C B
- I
terminal I
tail I
of O
IL B
- I
13R I
alpha I
1 I
were O
critical O
for O
binding O
to O
Tyk2 O
, O
and O
activation O
of O
Jak1 O
, O
Tyk2 O
, O
the O
insulin B
receptor I
substrate I
- I
1 I
and O
STAT6 O
respectively O
. O

These O
results O
suggest O
that O
STAT3 O
activation O
is O
involved O
with O
IL O
- O
4 O
and O
IL O
- O
13 O
signals O
in O
human O
B O
cells O
along O
with O
the O
activation O
of O
STAT6 O
, O
and O
that O
there O
is O
a O
unique O
sequence O
in O
IL B
- I
13R I
alpha I
1 I
to O
activate O
STAT3 O
. O

Janus B
tyrosine I
kinase I
( I
Jak I
) I
3 I
and O
transcription O
factors O
Stat5a O
and O
Stat5b O
are O
essential O
for O
the O
proliferation O
of O
normal O
T O
cells O
and O
are O
constitutively O
hyperactivated O
in O
both O
HTLV O
- O
1 O
- O
transformed O
human O
T O
cell O
lines O
and O
lymphocytes O
isolated O
from O
HTLV O
- O
1 O
- O
infected O
patients O
; O
therefore O
, O
a O
critical O
role O
for O
the O
Jak3 O
- O
Stat5 O
pathway O
in O
the O
progression O
of O
this O
disease O
has O
been O
postulated O
. O

We O
recently O
reported O
that O
tyrphostin O
AG O
- O
490 O
selectively O
blocked O
IL O
- O
2 O
activation O
of O
Jak3 B
/ I
Stat5 I
and O
growth O
of O
murine O
T O
cell O
lines O
. O

Disruption O
of O
constitutive O
Jak3 O
/ O
Stat5 O
activation O
by O
AG O
- O
490 O
was O
demonstrated O
by O
inhibition O
of O
1 O
) O
tyrosine O
phosphorylation O
of O
Jak3 O
, O
Stat5a O
( O
Tyr O
( O
694 O
) O
) O
, O
and O
Stat5b O
( O
Tyr O
( O
699 O
) O
) O
; O
2 O
) O
serine O
phosphorylation O
of O
Stat5a O
( O
Ser O
( O
726 O
) O
) O
as O
determined O
by O
a O
novel O
phosphospecific B
Ab I
; O
and O
3 O
) O
Stat5a O
/ O
b O
DNA O
binding O
to O
the O
Stat5 O
- O
responsive O
beta O

In O
contrast O
, O
AG O
- O
490 O
had O
no O
effect O
on O
DNA O
binding O
by O
p50 B
/ I
p65 I
components I
of O
NF O
- O
kappaB O
, O
a O
transcription O
factor O
activated O
by O
the O
HTLV B
- I
1 I
- I
encoded I
phosphoprotein I
, I
Tax I
. O

The O
Epstein B
- I
Barr I
virus I
promoter I
initiating O
B O
- O
cell O
transformation O
is O
activated O
by O
RFX B
proteins I
and O
the O
B B
- I
cell I
- I
specific I
activator I
protein I
BSAP I
/ I
Pax5 I
. O

Epstein O
- O
Barr O
virus O
( O
EBV O
) O
- O
induced O
B O
- O
cell O
growth O
transformation O
, O
a O
central O
feature O
of O
the O
virus O
' O
strategy O
for O
colonizing O
the O
human O
B O
- O
cell O
system O
, O
requires O
full O
virus O
latent O
gene O
expression O
and O
is O
initiated O
by O
transcription O
from O
the O
viral B
promoter I
Wp I
. O

Bandshift O
studies O
indicate O
that O
this O
region O
contains O
three O
factor O
binding O
sites O
, O
termed O
sites B
B I
, I
C I
, I
and I
D I
, O
in O
addition O
to O
a O
previously O
characterized O
CREB B
site I
. O

Here O
we O
show O
that O
site O
C O
binds O
members O
of O
the O
ubiquitously O
expressed O
RFX B
family I
of I
proteins I
, O
notably O
RFX1 O
, O
RFX3 B
, O
and O
the O
associated O
factor O
MIBP1 O
, O
whereas O
sites B
B I
and I
D I
both O
bind O
the O
B B
- I
cell I
- I
specific I
activator I
protein I
BSAP I
/ I
Pax5 I
. O

In O
reporter O
assays O
with O
mutant B
Wp I
constructs I
, O
the O
loss O
of O
factor O
binding O
to O
any O
one O
of O
these O
sites O
severely O
impaired O
promoter O
activity O
in O
B O
cells O
, O
while O
the O
wild O
- O
type O
promoter O
could O
be O
activated O
in O
non O
- O
B O
cells O
by O
ectopic O
BSAP O
expression O
. O

Activation O
of O
the O
Lck B
tyrosine I
protein I
kinase I
by O
the O
Herpesvirus O
saimiri O
tip B
protein I
involves O
two O
binding O
interactions O
. O

The O
Tip B
protein I
of O
Herpesvirus O
saimiri O
strain O
484C O
binds O
to O
and O
activates O
the O
Lck B
tyrosine I
protein I
kinase I
. O

Two O
sequences O
in O
the O
Tip B
protein I
were O
previously O
shown O
to O
be O
involved O
in O
binding O
to O
Lck O
. O

A O
proline O
- O
rich O
region O
, O
residues O
132 O
- O
141 O
, O
binds O
to O
the O
SH3 B
domain I
of O
the O
Lck B
protein I
. O

We O
show O
here O
that O
the O
other O
Lck B
- I
binding I
domain I
, O
residues O
104 O
- O
113 O
, O
binds O
to O
the O
carboxyl B
- I
terminal I
half I
of O
Lck O
and O
that O
this O
binding O
does O
not O
require O
the O
Lck B
SH3 I
domain I
. O

Mutated O
Tip O
containing O
only O
one O
functional O
Lck B
- I
binding I
domain I
can O
bind O
stably O
to O
Lck O
, O
although O
not O
as O
strongly O
as O
wild B
- I
type I
Tip I
. O

Interaction O
of O
Tip O
with O
Lck O
through O
either O
Lck B
- I
binding I
domain I
increases O
the O
activity O
of O
Lck O
in O
vivo O
. O

Mutant O
forms O
of O
Tip O
lacking O
one O
or O
the O
other O
of O
the O
two O
Lck B
- I
binding I
domains I
retained O
the O
ability O
to O
stimulate O
Stat3 O
- O
dependent O
transcription O
. O

Tip O
lacking O
the O
proline O
- O
rich O
Lck B
- I
binding I
domain I
exhibited O
almost O
wild O
- O
type O
activity O
in O
this O
assay O
. O

In O
contrast O
, O
ablation O
of O
either O
Lck B
- I
binding I
domain I
abolished O
the O
ability O
of O
Tip O
to O
stimulate O
NF O
- O
AT O
- O
dependent O
transcription O
. O

Full O
biological O
activity O
of O
Tip O
, O
therefore O
, O
appears O
to O
require O
both O
Lck B
- I
binding I
domains I
. O

We O
have O
previously O
reported O
that O
the O
activation O
of O
resting O
human O
immature O
peripheral O
blood O
T O
( O
PBT O
) O
lymphocytes O
is O
associated O
with O
the O
loss O
of O
retinoid B
X I
receptor I
alpha I
( O
RXRalpha B
) O
expression O
. O

In O
the O
present O
study O
, O
we O
have O
demonstrated O
that O
, O
unlike O
resting O
cells O
, O
activation O
of O
cycling O
human O
mature O
PBT O
lymphocytes O
, O
and O
T O
lymphocyte O
leukemia O
cell O
lines O
is O
accompanied O
by O
the O
accumulation O
of O
RXRalpha B
mRNA O
and O
protein O
. O

Interestingly O
, O
cyclosporin O
A O
further O
augmented O
RXRalpha B
expression O
, O
indicating O
the O
involvement O
of O
calcineurin O
pathways O
in O
the O
process O
. O

Transfection O
analysis O
in O
Jurkat O
cells O
, O
using O
RXRE O
- O
dependent O
reporter O
assays O
, O
showed O
that O
RXRalpha B
accumulated O
during O
T O
cell O
activation O
was O
transcriptionally O
inactive O
. O

The O
expression O
of O
constitutively O
active O
MAP O
/ O
ERK O
kinase O
kinase O
1 O
( O
MEKK1 O
) O
inhibited O
RXRE O
- O
dependent O
transcription O
, O
whereas O
dominant B
negative I
MEKK1 I
increased O
the O
transcription O
, O
indicating O
the O
involvement O
of O
JNK O
signaling O
pathways O
in O
the O
process O
. O

In O
contrast O
, O
expression O
of O
constitutively B
active I
MEK1 I
, O
which O
activates O
ERK O
pathway O
, O
enhanced O
RXRE O
- O
dependent O
activation O
. O

These O
data O
demonstrate O
a O
dual O
regulatory O
control O
of O
RXRalpha B
expression O
during O
the O
activation O
of O
resting O
and O
cycling O
T O
lymphocytes O
and O
indicate O
a O
dynamic O
balance O
between O
JNK O
and O
ERK O
pathways O
in O
modulating O
RXRE O
- O
mediated O
transactivation O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
role O
of O
the O
proteasome O
for O
ligand O
- O
dependent O
endocytosis O
and O
degradation O
of O
the O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
- I
interleukin I
- I
2 I
receptor I
( I
IL I
- I
2R I
) I
complex I
. O

Proteasome O
inhibitors O
impaired O
internalization O
of O
IL B
- I
2 I
. I
IL I
- I
2R I
and O
prevented O
the O
lysosomal O
degradation O
of O
this O
cytokine O
. O

Based O
on O
time O
- O
course O
studies O
, O
proteasome O
activity O
is O
primarily O
required O
after O
initial O
endocytosis O
of O
the O
IL B
- I
2 I
. I
IL I
- I
2R I
. O

Proteasome O
function O
was O
also O
necessary O
for O
the O
lysosomal O
degradation O
of O
IL O
- O
2 O
internalized O
by O
IL O
- O
2R O
that O
were O
comprised O
of O
cytoplasmic B
tailless I
beta B
- I
or I
gamma I
c I
- I
subunits I
, O
suggesting O
that O
the O
target O
protein O
for O
the O
proteasome O
is O
independent O
of O
either O
the O
cytoplasmic O
tail O
of O
the O
IL O
- O
2R O
beta B
- I
or I
gamma I
c I
- I
subunits I
and O
their O
associated O
signaling O
components O
. O

Therefore O
, O
a O
functional O
proteasome O
is O
required O
for O
optimal O
endocytosis O
of O
the O
IL B
- I
2R I
/ I
ligand I
complex I
and O
is O
essential O
for O
the O
subsequent O
lysosomal O
degradation O
of O
IL O
- O
2 O
, O
possibly O
by O
regulating O
trafficking O
to O
the O
lysosome O
. O

Functional O
characterization O
of O
the O
two O
alternative O
promoters O
of O
human B
p45 I
NF I
- I
E2 I
gene I
. O

OBJECTIVE O
: O
The O
transcription O
factor O
NF O
- O
E2 O
, O
a O
heterodimeric B
protein I
complex I
composed O
of O
p45 O
and O
small O
Maf B
family I
proteins I
, O
is O
considered O
crucial O
for O
the O
proper O
differentiation O
of O
erythrocytes O
and O
megakaryocytes O
in O
vivo O
. O

We O
report O
the O
results O
of O
studies O
aimed O
at O
understanding O
the O
regulatory O
mechanisms O
controlling O
p45 B
gene I
expression O
in O
erythroid O
cells O
. O

MATERIALS O
AND O
METHODS O
: O
Human B
p45 I
mRNAs I
have O
two O
alternative O
isoforms O
, O
aNF B
- I
E2 I
and O
fNF B
- I
E2 I
, O
and O
these O
isoforms O
are O
transcribed O
from O
the O
alternative B
promoters I
. O

For O
functional O
characterization O
of O
both O
promoters O
, O
plasmids O
in O
which O
reporter O
genes O
were O
placed O
under O
the O
control O
of O
a O
series O
of O
truncated O
or O
mutated O
promoter B
fragments I
were O
transfected O
to O
human O
hematopoietic O
cell O
lines O
. O

fNF B
- I
E2 I
mRNA I
was O
found O
to O
be O
more O
abundant O
in O
erythroid O
cells O
than O
megakaryocytic O
cells O
at O
day O
7 O
of O
culture O
. O

Although O
both O
isomers O
were O
expressed O
in O
human O
erythroid O
- O
megakaryocytic O
cell O
lines O
, O
megakaryocytic O
maturation O
with O
loss O
of O
erythroid O
phenotype O
induced O
by O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
resulted O
in O
exclusive O
downregulation O
of O
fNF B
- I
E2 I
, O
suggesting O
that O
fNF O
- O
E2 O
promoter O
is O
more O
erythroid O
specific O
. O

Functional O
analysis O
of O
fNF O
- O
E2 O
promoter O
showed O
that O
the O
promoter O
is O
active O
only O
in O
erythroid O
- O
megakaryocytic O
cells O
and O
that O
the O
double B
GATA I
sit I
e O
in O
the O
proximal O
region O
is O
necessary O
for O
its O
efficient O
activity O
. O

CONCLUSION O
: O
These O
results O
suggest O
that O
GATA B
proteins I
, O
which O
govern O
the O
differentiation O
of O
erythroid O
lineage O
cells O
, O
are O
required O
for O
full O
promoter O
activity O
of O
the O
p45 B
gene I
. O

Transcriptional O
activation O
of O
heme B
oxygenase I
- I
1 I
and O
its O
functional O
significance O
in O
acetaminophen O
- O
induced O
hepatitis O
and O
hepatocellular O
injury O
in O
the O
rat O
. O

BACKGROUND O
/ O
AIM O
: O
Glutathione O
depletion O
contributes O
to O
acetaminophen O
hepatotoxicity O
and O
is O
known O
to O
induce O
the O
oxidative O
stress O
reactant O
heme B
oxygenase I
- I
1 I
. O

The O
aim O
of O
this O
study O
was O
to O
assess O
cell O
- O
type O
specific O
expression O
of O
heme B
oxygenase I
- I
1 I
and O
its O
impact O
on O
liver O
injury O
and O
microcirculatory O
disturbances O
in O
a O
model O
of O
acetaminophen O
- O
induced O
hepatitis O
. O

METHODS O
: O
Gene O
expression O
of O
heme B
oxygenase I
- I
1 I
was O
studied O
by O
Northern O
- O
and O
Western O
analysis O
as O
well O
as O
immunohistochemistry O
. O

The O
time O
course O
of O
heme B
oxygenase I
- I
1 I
and I
- I
2 I
, O
cytokine B
- I
induced I
neutrophil I
chemoattractant I
- I
1 I
, O
and O
intercellular O
adhesion O
molecule O
- O
1 O
was O
studied O
by O
Northern O
analysis O
. O

RESULTS O
: O
Acetaminophen O
caused O
a O
moderate O
sinusoidal O
perfusion O
failure O
( O
- O
15 O
% O
) O
and O
infiltration O
of O
neutrophils O
along O
with O
activation O
of O
nuclear O
factor O
- O
kappaB O
and O
intercellular O
adhesion O
molecule O
- O
1 O
and O
cytokine B
- I
induced I
neutrophil I
chemoattractant I
- I
1 I
mRNAs O
. O

Induction O
of O
heme B
oxygenase I
- I
1 I
mRNA O
and O
protein O
( O
approximately O
30 O
- O
fold O
) O
in O
hepatocytes O
and O
non O
- O
parenchymal O
cells O
paralleled O
the O
inflammatory O
response O
. O

CONCLUSIONS O
: O
The O
inflammatory O
response O
associated O
with O
acetaminophen O
hepatotoxicity O
is O
modulated O
by O
the O
parallel O
induction O
of O
the O
heme B
oxygenase I
- I
1 I
gene I
. O

However O
, O
heme B
oxygenase I
- I
1 I
has O
no O
permissive O
effect O
on O
sinusoidal O
perfusion O
and O
does O
not O
affect O
liver O
injury O
in O
this O
model O
. O

RESULTS O
: O
All O
cell O
lines O
tested O
expressed O
TNF B
- I
alpha I
receptors I
I I
and I
II I
and O
responded O
to O
TNF O
- O
alpha O
by O
upregulation O
of O
intercellular O
adhesion O
molecule O
- O
1 O
. O

Anti B
- I
GM I
- I
CSF I
antibodies I
inhibited O
the O
TNF O
- O
alpha O
- O
induced O
growth O
, O
suggesting O
the O
presence O
of O
an O
autocrine O
loop O
for O
cell O
proliferation O
mediated O
by O
GM O
- O
CSF O
. O

One O
mechanism O
by O
which O
glucocorticoids O
could O
exert O
their O
anti O
- O
inflammatory O
action O
is O
via O
rapidly O
saturable O
, O
stereo B
- I
specific I
cytoplasmic I
protein I
receptors I
. O

Synovium O
, O
obtained O
from O
knee O
joints O
of O
rheumatoid O
patients O
undergoing O
surgery O
, O
was O
incubated O
with O
clostridiopeptidase B
A I
and O
trypsin B
- I
EDTA I
to O
obtain O
cell O
suspensions O
. O

We O
concluded O
from O
this O
, O
that O
one O
or O
more O
of O
the O
cell O
types O
present O
in O
synovial O
tissue O
contain O
a O
specific B
steroid I
receptor I
, O
but O
that O
this O
is O
lacking O
in O
synovial O
fluid O
polymorphonuclear O
leucocytes O
. O

Glucorticoid B
receptors I
were O
studied O
in O
various O
populations O
of O
normal O
human O
peripheral O
blood O
lymphocytes O
and O
leukemic O
lymphoblasts O
. O

Functional O
and O
physical O
interaction O
of O
protein B
- I
tyrosine I
kinases I
Fyn I
and I
Csk I
in O
the O
T O
- O
cell O
signaling O
system O
. O

The O
Src B
- I
like I
protein I
- I
tyrosine I
kinase I
Fyn O
is O
associated O
with O
T O
- O
cell O
antigen O
receptor O
. O

Transient O
expression O
of O
actively O
mutated O
Fyn O
, O
having O
Phe O
- O
528 O
instead O
of O
Tyr O
- O
528 O
or O
Thr O
- O
338 O
instead O
of O
Ile O
- O
338 O
, O
in O
Jurkat O
T O
- O
cells O
stimulated B
the I
serum I
response I
element I
( O
SRE O
) O
, O
12 B
- I
O I
- I
tetradecanoyl I
- I
phorbol I
- I
13 I
- I
acetate I
response I
element I
, O
cyclic O
AMP O
response O
element O
, O
and O
c O
- O
fos O
promoter O
. O

The O
stimulation O
of O
SRE O
was O
particularly O
prominent O
not O
only O
with O
active O
Fyn O
but O
also O
with O
normal B
( I
wild I
- I
type I
) I
Fyn I
. O

SRE O
was O
also O
stimulated O
by O
both O
normal B
and I
active I
Lck I
. O

Furthermore O
, O
normal B
and I
active I
Fyn I
stimulated O
transcription O
from O
the O
IL O
- O
2 O
gene O
promoter O
when O
transfected O
cells O
were O
stimulated O
by O
concanavalin B
A I
plus O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
. O

Interestingly O
, O
a O
mutant B
Fyn I
, O
which O
has O
deletions O
within O
the O
SH2 B
region I
and O
so O
is O
able O
to O
transform O
chicken O
embryo O
fibroblasts O
, O
did O
not O
stimulate O
either O
the O
c B
- I
fos I
or I
IL I
- I
2 I
promoter I
, O
suggesting O
the O
importance O
of O
this O
region O
in O
T O
- O
cell O
signaling O
. O

Csk B
, O
which O
phosphorylates O
tyrosine O
residues O
in O
the O
negative O
regulatory O
sites O
of O
Src O
family O
kinases O
, O
down O
- O
regulated O
Fyn O
- O
and O
Lck O
- O
mediated O
stimulation O
of O
the O
serum O
response O
element O
and O
Fyn O
- O
mediated O
enhancement O
of O
IL O
- O
2 O
promoter O
activity O
. O

These O
data O
suggest O
that O
Fyn O
and O
Lck O
, O
whose O
activities O
are O
regulated O
by O
Csk B
, O
are O
involved O
in O
different O
phases O
of O
T O
- O
cell O
activation O
. O

A O
novel O
NF O
- O
kappa O
B O
complex O
containing O
p65 B
homodimers I
: O
implications O
for O
transcriptional O
control O
at O
the O
level O
of O
subunit O
dimerization O
. O

The O
predominant O
inducible O
form O
of O
the O
NF O
- O
kappa O
B O
transcription O
factor O
is O
a O
heteromeric B
complex I
containing O
two O
Rel B
- I
related I
DNA I
- I
binding I
subunits I
, O
termed B
p65 I
and O
p50 O
. O

Prior O
transfection O
studies O
have O
shown O
that O
when O
these O
p65 B
and I
p50 I
subunits I
are O
expressed O
independently O
as O
stable B
homodimers I
, O
p65 O
stimulates O
kappa O
B O
- O
directed O
transcription O
, O
whereas O
p50 O
functions O
as O
a O
kappa O
B O
- O
specific O
repressor O
. O

While O
authentic O
p50 O
homodimers O
( O
previously O
termed O
KBF1 O
) O
have O
been O
detected O
in O
nuclear O
extracts O
from O
nontransfected O
cells O
, O
experimental O
evidence O
supporting O
the O
existence O
of O
p65 B
homodimers I
in O
vivo O
was O
lacking O
. O

We O
now O
provide O
direct O
biochemical O
evidence O
for O
the O
presence O
of O
an O
endogenous O
pool O
of O
inducible O
p65 B
homodimers I
in O
intact O
human O
T O
cells O
. O

As O
with O
the O
prototypical O
NF O
- O
kappa O
B O
p50 O
- O
p65 O
heterodimer O
, O
this O
novel O
p65 B
homodimeric I
form I
of O
NF O
- O
kappa O
B O
is O
functionally O
sequestered O
in O
the O
cytoplasm O
but O
rapidly O
appears O
in O
the O
nuclear O
compartment O
following O
cellular O
stimulation O
. O

Site O
- O
directed O
mutagenesis O
studies O
indicate O
that O
the O
homodimerization O
function O
of O
p65 O
is O
dependent O
upon O
the O
presence O
of O
cysteine O
216 O
and O
a O
conserved O
recognition O
motif O
for O
protein O
kinase O
A O
( O
RRPS B
; O
amino O
acids O
273 O
to O
276 O
) O
, O
both O
of O
which O
reside O
within O
a O
91 O
- O
amino O
- O
acid O
segment O
of O
the O
Rel O
homology O
domain O
that O
mediates O
self O
- O
association O
. O

Taken O
together O
with O
prior O
in O
vivo O
transcription O
studies O
, O
these O
results O
suggest O
that O
the O
biological O
activities O
of O
p65 B
and I
p50 I
homodimers I
are O
independently O
regulated O
, O
thereby O
providing O
an O
integrated O
and O
flexible O
control O
mechanism O
for O
the O
rapid O
activation O
and O
repression O
of O
NF O
- O
kappa O
B O
/ O
Rel O
- O
directed O
gene O
expression O
. O

This O
method O
utilises O
an O
immunomagnetic O
separation O
technique O
for O
B O
cell O
purification O
and O
a O
polymerase O
chain O
reaction O
( O
PCR O
) O
based O
assay O
for O
the O
determination O
of O
methylation O
status O
at O
the O
androgen B
receptor I
( I
AR I
) I
gene I
locus I
to O
assess O
whether O
X O
inactivation O
is O
random O
or O
non O
- O
random O
at O
this O
locus O
. O

Effects O
of O
IL O
- O
4 O
and O
Fc B
gamma I
receptor I
II I
engagement O
on O
Egr O
- O
1 O
expression O
during O
stimulation O
of O
B O
lymphocytes O
by O
membrane O
immunoglobulin O
crosslinking O
. O

We O
compared O
the O
expression O
of O
Egr O
- O
1 O
during O
B O
cell O
stimulation O
with O
Fab B
' I
2 I
and O
IgG B
anti I
- I
immunoglobulin I
( O
anti O
- O
Ig O
) O
, O
since O
it O
is O
known O
that O
Fab B
' I
2 I
anti I
- I
Ig I
is O
mitogenic O
while O
IgG B
anti I
- I
Ig I
is O
not O
, O
owing O
to O
a O
dominant O
inhibitory O
effect O
of O
crosslinking O
the O
B O
cell O
Fc O
gamma O
RII O
to O
membrane B
Ig I
. O

While O
mitogenic O
doses O
of O
Fab B
' I
2 I
anti I
- I
Ig I
induce O
large O
and O
rapid O
increases O
in O
Egr O
- O
1 O
expression O
, O
IgG B
anti I
- I
Ig I
results O
in O
smaller O
increases O
in O
Egr O
- O
1 O
mRNA O
, O
comparable O
to O
that O
seen O
with O
submitogenic O
concentrations O
of O
Fab B
' I
2 I
anti I
- I
Ig I
. O

However O
, O
the O
correlation O
between O
Egr O
- O
1 O
expression O
and O
B O
cell O
proliferation O
breaks O
down O
when O
IL O
- O
4 O
is O
added O
as O
a O
co O
- O
mitogen O
to O
induce O
B O
cell O
proliferation O
with O
IgG B
anti I
- I
Ig I
or O
submitogenic O
concentrations O
of O
Fab B
' I
2 I
anti I
- I
Ig I
. O

Identification O
of O
a O
novel O
cyclosporin B
- I
sensitive I
element I
in O
the O
human B
tumor I
necrosis I
factor I
alpha I
gene I
promoter I
. O

We O
have O
identified O
a O
human B
TNF I
- I
alpha I
promoter I
element I
, O
kappa O
3 O
, O
which O
plays O
a O
key O
role O
in O
the O
calcium O
- O
mediated O
inducibility O
and O
CsA O
sensitivity O
of O
the O
gene O
. O

Thus O
, O
the O
TNF O
- O
alpha O
gene O
is O
an O
immediate O
early O
gene O
in O
activated O
T O
cells O
and O
provides O
a O
new O
model O
system O
in O
which O
to O
study O
CsA B
- I
sensitive I
gene I
induction O
in O
activated O
T O
cells O
. O

Furthermore O
, O
addition O
of O
sodium O
butyrate O
or O
1 O
alpha O
, O
25 O
- O
dihydroxyvitamin O
D3 O
to O
HL O
- O
60 O
cells O
induced O
the O
expression O
of O
c B
- I
fos I
, I
c I
- I
jun I
, I
jun I
B I
and I
jun I
D I
proto I
- I
oncogenes I
. O

In O
contrast O
, O
when O
HL O
- O
60 O
cells O
were O
treated O
with O
retinoic O
acid O
, O
a O
granulocytic O
differentiation O
inducer O
, O
no O
enhanced O
AP O
- O
1 O
binding O
activity O
was O
observed O
, O
and O
only O
a O
weak O
increase O
in O
jun B
D I
mRNA I
level O
was O
detected O
. O

' B
Activation I
- I
labile I
' I
glucocorticoid I
- I
receptor I
complexes I
of O
a O
steroid O
- O
resistant O
variant O
of O
CEM O
- O
C7 O
human O
lymphoid O
cells O
. O

For O
cytoplasmic B
glucocorticoid I
- I
receptor I
complexes I
to O
enter O
and O
accumulate O
in O
the O
nucleus O
a O
temperature O
- O
dependent O
event O
, O
' O
activation O
' O
is O
required O
. O

Activation O
can O
be O
achieved O
in O
vitro O
by O
increased O
ionic O
strength O
, O
dilution O
or O
gel O
filtration O
and O
is O
manifested O
by O
an O
increased O
affinity O
of O
steroid B
- I
receptor I
complex I
for O
DNA O
and O
an O
altered O
elution O
profile O
from O
ion O
- O
exchange O
resins O
. O

Munck O
and O
Foley O
have O
shown O
that O
activated B
complexes I
isolated O
from O
thymocytes O
elute O
from O
DEAE O
- O
cellulose O
in O
a O
manner O
identical O
to O
complexes O
activated O
in O
vitro O
. O

We O
report O
here O
that O
DEAE O
- O
cellulose O
chromatography O
of O
steroid B
- I
receptor I
complexes I
from O
CEM O
- O
C7 O
, O
a O
cloned O
human O
leukaemic O
T O
- O
cell O
line O
sensitive O
to O
the O
cytolytic O
action O
of O
glucocorticoids O
, O
and O
its O
steroid O
- O
resistant O
subclone O
4R4 O
demonstrated O
that O
steroid O
receptors O
of O
clone O
4R4 O
can O
not O
form O
stable O
activated O
complexes O
. O

The O
mononuclear O
phagocytes O
contained O
approximately O
equal O
to O
4 O
- O
- O
10 O
X O
10 O
( O
3 O
) O
high B
affinity I
receptor I
sites I
per O
cell O
, O
with O
dissociation O
constants O
of O
approximately O
equal O
to O
2 O
- O
- O
8 O
nM O
dexamethasone O
. O

The O
binding O
to O
the O
saturable B
sites I
was O
specific O
for O
steroids O
with O
glucocorticoid O
or O
antiglucocorticoid O
activity O
. O

At O
37 O
degrees O
C O
the O
predominant O
form O
of O
the O
hormone B
- I
receptor I
complex I
was O
nuclear O
. O

We O
describe O
a O
novel O
and O
potentially O
important O
mechanism O
of O
nitric O
oxide O
signaling O
- O
through O
direct O
activation O
of O
guanine B
nucleotide I
- I
binding I
proteins I
( O
G O
proteins O
) O
. O

Furthermore O
, O
the O
GTPase O
activity O
of O
pure O
, O
recombinant O
Gs O
alpha O
, O
Gi B
alpha I
1 I
, O
and O
p21ras O
was O
greatly O
enhanced O
by O
nitric O
oxide O
. O

In O
addition O
, O
nitric O
oxide O
greatly O
reduced O
the O
pertussis O
toxin O
- O
mediated O
ADP O
- O
ribosylation O
of O
45 B
- I
and I
41 I
- I
kDa I
proteins I
in O
membranes O
of O
these O
cells O
. O

The O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
promoter I
cis I
- I
acting I
element I
CLE0 O
mediates O
induction O
signals O
in O
T O
cells O
and O
is O
recognized O
by O
factors O
related O
to O
AP1 O
and O
NFAT O
. O

We O
have O
previously O
shown O
that O
a O
fragment O
containing O
bp B
- I
95 I
to I
+ I
27 I
of O
the O
mouse O
GM O
- O
CSF O
promoter O
can O
confer O
inducibility O
to O
reporter O
genes O
in O
the O
human O
Jurkat O
T O
- O
cell O
line O
. O

Here O
we O
use O
an O
in O
vitro O
transcription O
system O
to O
demonstrate O
that O
a O
cis O
- O
acting O
element O
( O
positions B
- I
54 I
to I
- I
40 I
) O
, O
referred O
to O
as O
CLE0 O
, O
is O
a O
target O
for O
the O
induction O
signals O
. O

We O
observed O
induction O
with O
templates O
containing O
intact O
CLE0 O
but O
not O
with O
templates O
with O
deleted B
or I
mutated I
CLE0 I
. O

Stimulation O
probably O
was O
mediated O
by O
CLE0 B
- I
binding I
proteins I
because O
depletion O
of O
these O
proteins O
specifically O
reduced O
GM O
- O
CSF O
transcription O
. O

One O
of O
the O
binding O
factors O
possessed O
biochemical O
and O
immunological O
features O
identical O
to O
those O
of O
the O
transcription B
factor I
AP1 I
. O

Another O
factor O
resembled O
the O
T B
- I
cell I
- I
specific I
factor I
NFAT I
. O

The O
presence O
of O
CLE0 B
- I
like I
elements I
in O
the O
promoters O
of O
interleukin B
- I
3 I
( I
IL I
- I
3 I
) I
, I
IL I
- I
4 I
, I
IL I
- I
5 I
, I
GM I
- I
CSF I
, I
and I
NFAT I
sites I
in O
the O
IL O
- O
2 O
promoter O
suggests O
that O
the O
factors O
we O
detected O
, O
or O
related O
factors O
that O
recognize O
these O
sites O
, O
may O
account O
for O
the O
coordinate O
induction O
of O
these O
genes O
during O
T O
- O
cell O
activation O
. O

Identification O
and O
characterization O
of O
an O
Alu B
- I
containing I
, I
T I
- I
cell I
- I
specific I
enhancer I
located O
in O
the O
last O
intron O
of O
the O
human B
CD8 I
alpha I
gene I
. O

Expression O
of O
the O
human B
CD8 I
alpha I
gene I
is O
restricted O
to O
cells O
of O
the O
lymphoid O
lineage O
and O
developmentally O
regulated O
during O
thymopoiesis O
. O

As O
an O
initial O
step O
towards O
understanding O
the O
molecular O
basis O
for O
tissue O
- O
specific O
expression O
of O
this O
gene O
, O
we O
surveyed O
the O
surrounding O
chromatin O
structure O
for O
potential O
cis B
- I
acting I
regulatory I
regions I
by O
DNase O
I O
hypersensitivity O
mapping O
and O
found O
four O
hypersensitive O
sites O
, O
three O
of O
which O
were O
T O
cell O
restricted O
. O

By O
using O
a O
reporter O
- O
based O
expression O
approach O
, O
a O
T O
- O
cell O
- O
specific O
enhancer O
was O
identified O
by O
its O
close O
association O
with O
a O
prominent O
T B
- I
cell I
- I
restricted I
hypersensitive I
sites I
in O
the O
last O
intron O
of O
the O
CD8 B
alpha I
gene I
. O

DNA O
sequence O
analysis O
of O
the O
minimal B
enhancer I
revealed O
a O
striking O
cluster O
of O
consensus O
binding O
sites O
for O
Ets B
- I
1 I
, I
TCF I
- I
1 I
, I
CRE I
, I
GATA I
- I
3 I
, I
LyF I
- I
1 I
, I
and I
bHLH I
proteins I
which O
were O
verified O
by O
electrophoretic O
mobility O
shift O
assays O
. O

In O
addition O
, O
the O
5 O
' O
end O
of O
the O
enhancer O
was O
composed O
of O
an O
Alu O
repeat O
which O
contained O
the O
GATA B
- I
3 I
, I
bHLH I
, I
and I
LyF I
- I
1 I
binding I
sites I
. O

Site O
- O
directed O
mutation O
of O
the O
Ets B
- I
1 I
and I
GATA I
- I
3 I
sites I
dramatically O
reduced O
enhancer O
activity O
. O

Taken O
together O
, O
these O
results O
suggest O
that O
the O
human B
CD8 I
alpha I
gene I
is O
regulated O
by O
the O
interaction O
of O
multiple O
T B
- I
cell I
nuclear I
proteins I
with O
a O
transcriptional O
enhancer O
located O
in O
the O
last O
intron O
of O
the O
gene O
. O

Comparison O
of O
the O
CD8 B
alpha I
enhancer I
with O
other O
recently O
identified O
T B
- I
cell I
- I
specific I
regulatory I
elements I
suggests O
that O
a O
common O
set O
of O
transcription O
factors O
regulates O
several O
T O
- O
cell O
genes O
. O

Molecular O
regulation O
of O
the O
human B
IL I
- I
3 I
gene I
: O
inducible O
T O
cell O
- O
restricted O
expression O
requires O
intact O
AP B
- I
1 I
and I
Elf I
- I
1 I
nuclear I
protein I
binding I
sites I
. O

Interleukin O
3 O
( O
IL O
- O
3 O
) O
is O
a O
hematopoietic B
stem I
- I
cell I
growth I
and I
differentiation I
factor I
that O
is O
expressed O
solely O
in O
activated O
T O
and O
NK O
cells O
. O

Studies O
to O
date O
have O
identified O
elements O
5 O
' O
to O
the O
IL B
- I
3 I
coding I
sequences I
that O
regulate O
its O
transcription O
, O
but O
the O
sequences O
that O
confer O
T O
cell O
- O
specific O
expression O
remain O
to O
be O
clearly O
defined O
. O

A O
series O
of O
transient O
transfections O
performed O
with O
human B
IL I
- I
3 I
- I
chloramphenicol I
acetyltransferase I
( I
CAT I
) I
reporter I
plasmids I
in O
T O
and O
non O
- O
T O
cells O
revealed O
that O
a O
plasmid O
containing O
319 O
bp O
of O
5 O
' O
flanking O
sequences O
was O
active O
exclusively O
in O
T O
cells O
. O

Deletion O
analysis O
revealed O
that O
T O
cell O
specificity O
was O
conferred O
by O
a O
49 B
- I
bp I
fragment I
( O
bp B
- I
319 I
to I
- I
270 I
) O
that O
included O
a O
potential B
binding I
site I
for O
AP O
- O
1 O
transcription O
factors O
6 O
bp O
upstream O
of O
a O
binding B
site I
for I
Elf I
- I
1 I
, O
a O
member O
of O
the O
Ets O
family O
of O
transcription O
factors O
. O

DNaseI O
footprint O
and O
electrophoretic O
mobility O
shift O
assay O
analyses O
performed O
with O
MLA O
- O
144 O
T O
cell O
nuclear O
extracts O
demonstrated O
that O
this O
49 B
- I
bp I
region I
contains O
a O
nuclear B
protein I
binding I
region I
that O
includes O
consensus B
AP I
- I
1 I
and I
Elf I
- I
1 I
binding I
sites I
. O

In O
addition O
, O
extracts O
prepared O
from O
purified O
human O
T O
cells O
contained O
proteins O
that O
bound O
to O
synthetic O
oligonucleotides O
corresponding O
to O
the O
AP B
- I
1 I
and I
Elf I
- I
1 I
binding I
sites I
. O

In O
vitro O
- O
transcribed O
and O
- O
translated O
Elf B
- I
1 I
protein I
bound O
specifically O
to O
the O
Elf B
- I
1 I
site I
, O
and O
Elf O
- O
1 O
antisera O
competed O
and O
super O
shifted O
nuclear O
protein O
complexes O
present O
in O
MLA O
- O
144 O
nuclear O
extracts O
. O

Moreover O
, O
addition O
of O
anti O
- O
Jun O
family O
antiserum O
in O
electrophoretic O
mobility O
shift O
assay O
reactions O
completely O
blocked O
formation O
of O
the O
AP B
- I
1 I
- I
related I
complexes I
. O

Transient O
transfection O
studies O
in O
MLA O
- O
144 O
T O
cells O
revealed O
that O
constructs O
containing O
mutations O
in O
the O
AP O
- O
1 O
site O
almost O
completely O
abolished O
CAT O
activity O
while O
mutation O
of O
the O
Elf B
- I
1 I
site I
or O
the O
NF B
- I
IL I
- I
3 I
site I
, O
a O
previously O
described O
nuclear B
protein I
binding I
site I
( O
bp B
. I
- I
155 I
to I
- I
148 I
) O
in O
the O
IL O
- O
3 O
promoter O
, O
reduced O
CAT O
activity O
to O
< O
25 O
% O
of O
the O
activity O
given O
by O
wild O
- O
type O
constructs O
. O

We O
conclude O
that O
expression O
of O
the O
human B
IL I
- I
3 I
gene I
requires O
the O
AP B
- I
1 I
and I
Elf I
- I
1 I
binding I
sites I
; O
however O
, O
unlike O
other O
previously O
characterized O
cytokine O
genes O
such O
as O
IL O
- O
2 O
, O
the O
AP B
- I
1 I
and I
Elf I
- I
1 I
factors I
can O
bind O
independently O
in O
the O
IL O
- O
3 O
gene O
. O

Characterization O
of O
the O
human B
CD4 I
gene I
promoter I
: O
transcription O
from O
the O
CD4 B
gene I
core I
promoter I
is O
tissue O
- O
specific O
and O
is O
activated O
by O
Ets O
proteins O
. O

We O
analyzed O
the O
5 B
' I
transcription I
control I
sequences I
of O
the O
human O
CD4 O
gene O
. O

We O
located O
the O
transcription O
initiation O
site O
and O
showed O
that O
the O
CD4 B
core I
promoter I
( O
positions B
- I
40 I
to I
+ I
16 I
) O
lacks O
a O
classical O
` O
` O
TATA O
' O
' O
or O
initiator B
positioning I
consensus I
sequence I
but O
directs O
precise O
and O
efficient O
transcription O
when O
coupled O
to O
the O
ubiquitously O
active O
simian O
virus O
40 O
enhancer O
. O

The O
transcriptional O
activity O
of O
the O
CD4 B
gene I
promoter I
correlated O
with O
CD4 O
expression O
in O
various O
cell O
types O
. O

Interestingly O
, O
the O
CD4 B
core I
promoter I
also O
displayed O
a O
tissue O
- O
specific O
transcriptional O
activity O
. O

Within O
this O
fragment O
, O
three O
nucleic O
acid O
sequences O
are O
completely O
conserved O
in O
the O
murine B
CD4 I
gene I
. O

One O
of O
these O
sequences O
contains O
a O
perfect B
ETS I
consensus I
sequence I
. O

These O
data O
indicate O
that O
Ets O
transcription O
factors O
play O
a O
central O
role O
in O
controlling O
CD4 O
gene O
expression O
, O
by O
binding O
to O
both O
a O
classical B
remote I
site I
and O
an O
unusual O
proximal O
activator O
sequence O

Although O
glucocorticoids O
are O
not O
cytolytic O
for O
and O
do O
not O
inhibit O
the O
growth O
of O
the O
IM O
- O
9 O
line O
of O
cultured O
human O
lymphoblasts O
, O
these O
cells O
have O
a O
high O
steroid O
- O
binding O
capacity O
. O

We O
have O
used O
IM O
- O
9 O
cells O
in O
order O
to O
examine O
whether O
unoccupied B
glucocorticoid I
receptors I
are O
inactivated O
and O
activated O
in O
intact O
cells O
. O

The O
leukocyte O
migration O
inhibition O
response O
to O
certain O
breast B
cancer I
- I
related I
antigens I
( O
MCF B
- I
7 I
and O
MuMTV B
) O
: O
their O
potential O
as O
discriminants O
. O

We O
have O
used O
the O
leukocyte O
migration O
inhibition O
( O
LMI O
) O
response O
to O
assay O
the O
response O
to O
several O
potential O
breast O
cancer O
- O
related O
antigens O
, O
including O
MuMTV B
, O
MPMV B
, O
and O
a O
breast O
cancer O
cultured O
cell O
line O
, O
MCF O
- O
7 O
, O
in O
96 O
breast O
cancer O
patients O
, O
in O
32 O
women O
with O
benign O
breast O
disease O
, O
and O
in O
67 O
normal O
women O
. O

Breast O
cancer O
patients O
showed O
significant O
responses O
to O
MuMTV B
( O
49 O
% O
and O
to O
MCF O
- O
7 O
( O
50 O
% O
) O
, O
but O
not O
to O
MPMV B
( O
29 O
% O
) O
. O

In O
a O
paired O
- O
antigen O
study O
using O
MuMTV B
and O
MCF B
- I
7 I
, O
75 O
% O
of O
the O
breast O
cancer O
patients O
responded O
, O
versus O
18 O
% O
of O
the O
normal O
women O
( O
P O
less O
than O
0 O
. O
0050 O
) O
. O

The O
overall O
responses O
to O
MuMTV B
and O
MCF B
- I
7 I
were O
analyzed O
with O
reference O
to O
certain O
prognostic O
factors O
, O
but O
showed O
no O
relation O
to O
age O
, O
menstrual O
status O
, O
estrogen O
receptor O
status O
, O
or O
stage O
of O
disease O
. O

The O
above O
reactions O
suggest O
that O
a O
large O
proportion O
of O
breast O
cancer O
patients O
exhibit O
presensitization O
to O
antigenfs O
found O
in O
MuMTV B
and O
MCF B
- I
7 I
, O
which O
may O
be O
cross O
- O
reactive O
with O
antigens O
in O
the O
primary O
cancer O
. O

The O
human O
TNF O
promoter O
contains O
four O
potential O
nuclear B
factor I
- I
kappa I
B I
( I
NF I
- I
kappa I
B I
) I
- I
binding I
sites I
, O
with O
the O
strongest O
binding O
seen O
for O
the O
- O
605 O
motif O
. O

Nuclear O
extracts O
from O
unstimulated O
cells O
of O
the O
human O
monocytic O
cell O
line O
, O
Mono O
Mac O
6 O
, O
contain O
one O
specific B
binding I
protein I
( O
complex O
II O
) O
, O
consistent O
with O
a O
constitutive B
p50 I
homodimer I
. O

Stimulation O
of O
Mono O
Mac O
6 O
cells O
with O
LPS O
will O
increase O
complex O
II O
and O
will O
strongly O
induce O
a O
second O
specific O
complex O
( O
complex O
I O
) O
, O
which O
represents O
the O
p50 B
/ I
65 I
heterodimer I
. O

Treatment O
of O
Mono O
Mac O
6 O
cells O
with O
pyrrolidine O
- O
dithiocarbamate O
( O
PDTC O
) O
at O
300 O
microM O
will O
block O
the O
LPS B
- I
induced I
complex I
I I
almost O
completely O
and O
will O
reduce O
complex O
II O
to O
the O
constitutive O
level O
. O

Northern O
blot O
analysis O
demonstrates O
that O
PDTC O
treatment O
will O
strongly O
reduce O
LPS B
- I
induced I
TNF I
transcripts I
. O

Secreted O
TNF B
protein I
as O
detected O
in O
the O
Wehi O
164S O
/ O
ActD O
bioassay O
and O
in O
a O
sandwich O
immunoassay O
was O
similarly O
reduced O
by O
PDTC O
. O

Kinetic O
analyses O
show O
that O
after O
LPS O
stimulation O
, O
NF O
- O
kappa O
B O
will O
peak O
at O
1 O
h O
, O
TNF O
transcript O
prevalence O
at O
2 O
h O
, O
and O
TNF B
protein I
at O
4 O
h O
. O

PDTC O
did O
not O
shift O
this O
response O
to O
LPS O
to O
a O
later O
time O
, O
but O
suppressed O
NF O
- O
kappa O
B O
mobilization O
, O
TNF O
transcripts O
, O
and O
TNF B
protein I
over O
the O
entire O
8 O
- O
h O
observation O
period O
. O

Furthermore O
, O
in O
these O
primary O
cells O
, O
induction O
of O
TNF O
transcripts O
, O
as O
determined O
by O
Northern O
blot O
analysis O
and O
by O
quantitative O
polymerase O
chain O
reaction O
, O
was O
prevented O
by O
PDTC O
as O
was O
TNF B
protein I
production O
. O

Comparing O
regions O
of O
the O
Epstein O
- O
Barr O
virus O
ZEBRA O
protein O
which O
function O
as O
transcriptional B
activating I
sequences I
in O
Saccharomyces O
cerevisiae O
and O
in O
B O
cells O
. O

The O
ZEBRA O
protein O
activates O
expression O
of O
Epstein O
- O
Barr O
virus O
early B
- I
lytic I
- I
cycle I
genes I
in O
human O
B O
lymphocytes O
. O

Here O
it O
is O
shown O
that O
ZEBRA O
also O
behaves O
as O
a O
sequence B
- I
specific I
transcriptional I
activator I
in O
Saccharomyces O
cerevisiae O
. O

These O
regions O
are O
designated O
YI B
( O
amino B
acids I
[ I
aa I
] I
1 I
to I
25 I
) O
, O
YII B
( O
aa B
51 I
to I
102 I
) O
, O
and O
YIII B
( O
aa B
228 I
to I
245 I
) O
. O

However O
, O
when O
fused O
to O
the O
DNA O
binding O
domain O
of O
GAL B
4 O
and O
assayed O
on O
GAL4 B
binding I
sites I
, O
regions B
YII I
and I
YIII I
were O
each O
sufficient O
to O
confer O
activation O
in O
S O
. O
cerevisiae O
. O

The O
amino O
- O
terminal O
region O
of O
ZEBRA O
( O
aa B
1 I
to I
98 I
) O
was O
required O
for O
activation O
both O
in O
S O
. O
cerevisiae O
and O
in O
human O
B O
cells O
; O
deletion O
of O
the O
carboxy B
- I
terminal I
18 I
aa I
also O
significantly O
reduced O
activation O
in O
both O
cell O
types O
. O

Thus O
, O
the O
behavior O
of O
ZEBRA O
in O
human O
B O
cells O
and O
S O
. O
cerevisiae O
suggests O
that O
the O
protein O
contains O
universal B
activation I
motifs I
that O
interact O
with O
conserved O
components O
of O
the O
transcription O
machinery O
. O

For O
example O
, O
deletion O
of O
ZEBRA B
aa I
26 I
to I
51 I
impaired O
activation O
to O
a O
great O
extent O
in O
B O
cells O
but O
had O
little O
or O
no O
effect O
in O
S O
. O
cerevisiae O
. O

The O
discordant O
mutants O
may O
reflect O
interactions O
with O
a O
variable B
domain I
of O
a O
conserved O
component O
or O
unique O
interactions O
with O
specialized O
components O
of O
the O
basal O
transcription O
apparatus O
in O
different O
cells O
. O

Functional O
interaction O
of O
the O
v B
- I
Rel I
and I
c I
- I
Rel I
oncoproteins I
with O
the O
TATA O
- O
binding O
protein O
and O
association O
with O
transcription B
factor I
IIB I
. O

We O
have O
investigated O
the O
ability O
of O
the O
v B
- I
Rel I
and I
c I
- I
Rel I
oncoproteins I
to O
interact O
with O
components O
of O
the O
basal O
transcription O
machinery O
. O

Here O
we O
report O
that O
both O
the O
acidic O
transcription O
activation O
domain O
mapping O
to O
the O
unique O
C O
terminus O
of O
chicken B
c I
- I
Rel I
and O
the O
F9 B
cell I
- I
specific I
activation I
region I
common O
to O
both O
v B
- I
Rel I
and O
c O
- O
Rel O
interact O
with O
the O
TATA O
- O
binding O
protein O
( O
TBP O
) O
and O
transcription B
factor I
IIB I
( O
TFIIB B
) O
in O
vitro O
and O
in O
vivo O
. O

We O
also O
demonstrate O
that O
TPB B
interaction O
with O
Rel B
activation I
regions I
leads O
to O
synergistic O
activation O
of O
transcription O
of O
a O
kappa B
B I
- I
linked I
reporter I
gene I
. O

Combined O
with O
the O
observation O
that O
the O
mouse B
c I
- I
Rel I
and I
human I
RelA I
proteins I
also O
interact O
with O
TBP O
and O
TFIIB B
in O
vitro O
, O
these O
results O
suggest O
that O
association O
with O
basal B
transcription I
factors I
is O
important O
for O
the O
transcriptional O
activities O
of O
Rel O
family O
proteins O
. O

Expression O
of O
the O
chicken B
GATA I
factor I
family I
during O
early O
erythroid O
development O
and O
differentiation O
. O

The O
DNA O
motif O
WGATAR O
has O
been O
identified O
within O
transcriptional B
regulatory I
domains I
of O
globin O
and O
other O
erythroid O
- O
specific O
genes O
and O
the O
activator B
proteins I
that O
bind O
to O
this O
regulatory O
element O
, O
the O
GATA O
factors O
, O
belong O
to O
a O
multi B
- I
gene I
family I
that O
is O
expressed O
in O
chicken O
erythroid O
cells O
. O

Here O
we O
show O
that O
, O
as O
in O
chickens O
, O
multiple O
members O
of O
the O
GATA B
factor I
family I
are O
expressed O
in O
human O
and O
murine O
erythroid O
cells O
. O

During O
the O
early O
stages O
of O
chicken O
embryogenesis O
( O
well O
before O
blood O
island O
formation O
) O
, O
each O
of O
the O
GATA B
family I
members I
is O
transcribed O
with O
a O
unique O
temporal O
and O
spatial O
pattern O
. O

In O
the O
primitive O
erythroid O
lineage O
, O
transcription O
of O
the O
embryonic B
epsilon I
- I
globin I
gene I
parallels O
GATA O
- O
1 O
expression O
while O
the O
switch O
to O
beta O
- O
globin O
transcription O
in O
definitive O
erythroid O
cells O
is O
directly O
preceded O
by O
a O
pronounced O
increase O
in O
GATA O
- O
3 O
accumulation O
. O

Molecular O
regulation O
of O
human B
interleukin I
2 I
and O
T O
- O
cell O
function O
by O
interleukin O
4 O
. O

IL O
- O
4 O
pretreatment O
of O
Jurkat O
cells O
prior O
to O
stimulation O
resulted O
in O
a O
decrease O
in O
transcription O
of O
the O
IL2 B
gene I
. O

Using O
enhancer B
- I
reporter I
constructs I
, O
IL O
- O
4 O
specifically O
down O
- O
regulated O
the O
NFIL B
- I
2B I
element I
. O

Electrophoretic O
mobility O
shift O
assays O
using O
a O
DNA O
oligomer O
containing O
the O
NFIL B
- I
2B I
binding I
site I
indicated O
that O
IL O
- O
4 O
inhibited O
the O
NFIL B
- I
2B I
complex I
and O
that O
the O
NFIL B
- I
2B I
DNA I
binding I
factor I
is O
distinct O
from O
AP B
- I
1 O
. O

These O
results O
suggest O
that O
IL O
- O
4 O
may O
regulate O
development O
and O
function O
of O
T O
- O
cell O
subsets O
involved O
in O
cell O
- O
mediated O
immunity O
in O
part O
by O
inhibiting B
factors I
required O
for O
transcription O
of O
the O
IL2 O
gene O

Immunochemical O
differences O
between O
glucocorticoid B
receptors I
from O
corticoid O
- O
sensitive O
and O
- O
resistant O
malignant O
lymphocytes O
. O

For O
this O
purpose O
, O
purified B
immune I
immunoglobulin I
G I
was O
covalently O
linked O
to O
Sepharose B
CL I
- I
4B I
. O

We O
then O
examined O
the O
ability O
of O
the O
affinity O
gel O
to O
recognize O
cytosolic B
[ I
3H I
] I
triamcinolone I
acetonide I
- I
receptor I
complexes I
from O
the O
corticoid O
- O
sensitive O
( O
CS O
) O
and O
- O
resistant O
strains O
of O
mouse O
lymphoma O
P1798 O
, O
from O
CS O
lymphocytes O
of O
patients O
with O
chronic O
lymphatic O
leukemia O
, O
and O
from O
a O
CS O
clone O
of O
human O
leukemic O
lymphoblasts O
in O
tissue O
culture O
( O
CH6 O
) O
. O

Whereas O
the O
immunoaffinity O
column O
retained O
70 O
to O
84 O
% O
of O
the O
58 O
- O
to O
62 O
- O
A O
( O
Stokes O
radius O
) O
[ B
3H I
] I
triamcinolone I
acetonide I
- I
receptor I
complexes I
characteristic O
of O
the O
CS O
mouse O
and O
human O
lymphocytes O
, O
it O
failed O
to O
recognize O
the O
27 O
- O
to O
28 O
- O
A O
( O
Stokes O
radius O
) O
glucocorticoid O
receptor O
present O
in O
corticoid O
- O
resistant O
mouse O
lymphoma O
P1798 O
cells O
. O

Therefore O
, O
under O
appropriate O
experimental O
conditions O
, O
it O
was O
possible O
to O
demonstrate O
cross O
- O
reactivity O
between O
the O
antiserum O
against O
rat B
liver I
glucocorticoid I
receptor I
and O
the O
58 O
- O
to O
62 O
- O
A O
( O
Stokes O
radius O
) O
glucocorticoid O
receptor O
from O
species O
as O
diverse O
as O
mouse O
and O
humans O
. O

The O
cytoplasmic B
cortisol I
binding I
protein I
has O
a O
molecular O
weight O
95 O
000 O
and O
the O
soluble B
nuclear I
binding I
protein I
50 O
000 O
. O

The O
apparent O
paradox O
of O
heightened O
adrenal O
corticosteroid O
levels O
associated O
with O
reduction O
in O
the O
competence O
of O
the O
body O
' O
s O
defensive O
apparatus O
to O
cope O
with O
exposure O
to O
new O
microbial B
antigens I
is O
considered O
. O

In O
contrast O
, O
LPS O
did O
not O
increase O
leukemia B
inhibitory I
factor I
mRNA I
, O
which O
was O
constitutively O
expressed O
and O
not O
significantly O
reduced O
by O
these O
inhibitors O
. O

The O
transcription O
factor O
NF O
- O
kappa O
B O
is O
stored O
in O
the O
cytoplasm O
in O
complexes O
with O
the O
inhibitor B
protein I
I I
kappa I
B I
alpha I
. O

It O
has O
been O
shown O
in O
vitro O
that O
dissociation O
of O
I O
kappa O
B O
alpha O
from O
these O
complexes O
results O
in O
active B
NF I
- I
kappa I
B I
. O

Many O
liberated O
NF B
- I
kappa I
B I
dimers I
reached O
the O
nucleus O
, O
where O
increased O
c O
- O
rel O
, O
p65 O
and O
p50 O
were O
detected O
by O
immunoblotting O
and O
by O
DNA O
binding O
assays O
. O

Some O
liberated B
dimers I
were O
retained O
in O
the O
cytoplasm O
, O
however O
, O
through O
binding O
to O
newly O
synthesized O
I O
kappa O
B O
alpha O
, O
a O
finding O
which O
strongly O
suggests O
( O
i O
) O
that O
the O
LPS O
- O
induced O
signal O
causes O
dissociation O
of O
complexes O
rather O
than O
preventing O
their O
association O
and O
( O
ii O
) O
that O
dissociation O
results O
from O
modification O
of O
I O
kappa O
B O
alpha O
and O
not O
of O
c O
- O
rel O
or O
p65 O
. O

No O
effect O
of O
LPS O
treatment O
was O
detected O
on O
p105 O
or O
p100 O
, O
which O
also O
retain O
rel B
family I
members I
in O
the O
cytoplasm O
. O

Quite O
unexpectedly O
, O
we O
also O
found O
that O
in O
unstimulated O
cells O
there O
is O
a O
constant O
ongoing O
process O
of O
degradation O
and O
replacement O
of O
complexed B
I I
kappa I
B I
alpha I
. O

We O
propose O
that O
this O
turnover O
results O
in O
the O
low O
level O
of O
active B
NF I
- I
kappa I
B I
presumably O
necessary O
even O
in O
the O
unstimulated O
cell O
, O
and O
that O
the O
high O
rate O
of O
synthesis O
of O
I O
kappa O
B O
alpha O
provides O
the O
ability O
to O
turn O
off O
NF O
- O
kappa O
B O
activity O
rapidly O
as O
soon O
as O
the O
activating O
signal O
ceases O
. O

Identification O
of O
a O
killer B
cell I
- I
specific I
regulatory I
element I
of O
the O
mouse O
perforin O
gene O
: O
an O
Ets O
- O
binding O
site O
- O
homologous O
motif O
that O
interacts O
with O
Ets O
- O
related O
proteins O
. O

The O
gene O
encoding O
the O
cytolytic B
protein I
perforin O
is O
selectively O
expressed O
by O
activated O
killer O
lymphocytes O
. O

To O
understand O
the O
mechanisms O
underlying O
the O
cell O
- O
type O
- O
specific O
expression O
of O
this O
gene O
, O
we O
have O
characterized O
the O
regulatory O
functions O
and O
the O
DNA O
- O
protein O
interactions O
of O
the O
5 O
' O
- O
flanking O
region O
of O
the O
mouse O
perforin O
gene O
( O
Pfp B
) O
. O

A O
region O
extending O
from O
residues B
+ I
62 I
through I
- I
141 I
, O
which O
possesses O
the O
essential O
promoter O
activity O
, O
and O
regions O
further O
upstream O
, O
which O
are O
able O
to O
either O
enhance O
or O
suppress O
gene O
expression O
, O
were O
identified O
. O

The O
region O
between O
residues B
- I
411 I
and I
- I
566 I
was O
chosen O
for O
further O
characterization O
, O
since O
it O
contains O
an O
enhancer O
- O
like O
activity O
. O

We O
have O
identified O
a O
32 O
- O
mer O
sequence O
( O
residues B
- I
491 I
to I
- I
522 I
) O
which O
appeared O
to O
be O
capable O
of O
enhancing O
gene O
expression O
in O
a O
killer O
cell O
- O
specific O
manner O
. O

Within O
this O
segment O
, O
a O
9 O
- O
mer O
motif O
( O
5 O
' O
- O
ACAGGAAGT O
- O
3 O
' O
, O
residues B
- I
505 I
to I
- I
497 I
; O
designated O
NF O
- O
P O
motif O
) O
, O
which O
is O
highly O
homologous O
to O
the O
Ets B
proto I
- I
oncoprotein I
- I
binding I
site I
, O
was O
found O
to O
interact O
with O
two O
proteins O
, O
NF B
- I
P1 I
and O
NF B
- I
P2 I
. O

NF B
- I
P2 I
appears O
to O
be O
induced O
by O
reagents O
known O
to O
up O
- O
regulate O
the O
perforin O
message O
level O
and O
is O
present O
exclusively O
in O
killer O
cells O
. O

Electrophoretic O
mobility O
shift O
assay O
and O
UV O
cross O
- O
linking O
experiments O
revealed O
that O
NF B
- I
P1 I
and O
NF B
- I
P2 I
may O
possess O
common O
DNA O
- O
binding O
subunits O
. O

However O
, O
the O
larger O
native O
molecular O
mass O
of O
NF B
- I
P1 I
suggests O
that O
NF B
- I
P1 I
contains O
an O
additional O
non B
- I
DNA I
- I
binding I
subunit I
( O
s O
) O
. O

In O
view O
of O
the O
homology O
between O
the O
NF B
- I
P I
motif I
and O
other O
Ets B
proto I
- I
oncoprotein I
- I
binding I
sites I
, O
it O
is O
postulated O
that O
NF B
- I
P1 I
and O
NF B
- I
P2 I
belong O
to O
the O
Ets O
protein O
family O
. O

Results O
obtained O
from O
the O
binding O
competition O
assay O
, O
nevertheless O
, O
suggest O
that O
NF B
- I
P1 I
and O
NF B
- I
P2 I
are O
related O
to O
but O
distinct O
from O
Ets O
proteins O
, O
e O
. O
g O
. O
, O
Ets O
- O
1 O
, O
Ets O
- O
2 O
, O
and O
NF B
- I
AT I
/ I
Elf I
- I
1 I
, O
known O
to O
be O
expressed O
in O
T O
cells O
. O

The O
role O
of O
NF B
- I
kappa I
B1 I
( I
p50 I
/ I
p105 I
) I
gene I
expression O
in O
activation O
of O
human O
blood O
T O
- O
lymphocytes O
via O
CD2 O
and O
CD28 O
adhesion O
molecules O
. O

This O
potent O
activation O
does O
not O
require O
accessory O
cells O
, O
such O
as O
monocytes O
, O
but O
depends O
on O
persistent O
interleukin O
2 O
( O
IL O
- O
2 O
) O
secretion O
and O
receptivity O
, O
which O
is O
associated O
with O
high O
and O
prolonged O
expression O
of O
the O
inducible O
CD25 B
/ I
IL I
- I
2 I
receptor I
alpha I
( I
IL I
- I
2R I
alpha I
) I
chain I
gene I
. O

The O
transcription O
factor O
NF O
- O
kappa O
B O
participates O
in O
the O
regulation O
of O
both O
IL B
- I
2 I
and I
IL I
- I
2R I
alpha I
genes I
, O
as O
well O
as O
multiple B
cellular I
genes I
involved O
in O
T O
- O
cell O
proliferation O
. O

To O
evaluate O
the O
role O
of O
NF O
- O
kappa O
B O
in O
human O
peripheral O
blood O
T O
- O
lymphocytes O
, O
we O
previously O
analyzed O
the O
activation O
of O
NF B
- I
kappa I
B I
- I
related I
complexes I
in O
response O
to O
CD2 O
+ O
CD28 O
costimulation O
. O

We O
demonstrated O
a O
long O
- O
term O
induction O
of O
p50 O
/ O
p65 O
heterodimer O
, O
a O
putative B
p65 I
/ I
c I
- I
Rel I
heterodimer I
, O
and O
a O
constitutive O
nuclear O
expression O
of O
KBF1 O
/ O
p50 O
homodimers O
. O

As O
the O
role O
of O
p50 B
remains O
unclear O
, O
we O
focused O
our O
present O
study O
on O
NF O
- O
kappa O
B1 O
( O
p50 B
/ I
p105 I
) O
gene O
regulation O
. O

Using O
electrophoretic O
mobility O
shift O
assays O
and O
Western O
and O
Northern O
blot O
analyses O
, O
we O
studied O
NF O
- O
kappa O
B1 O
gene O
expression O
during O
T O
- O
cell O
stimulation O
via O
CD2 B
+ I
CD28 I
. O

Partial O
inhibition O
of O
p50 O
and O
p105 O
expression O
by O
NF O
- O
kappa O
B1 O
antisense O
oligonucleotides O
significantly O
reduced O
T O
- O
cell O
proliferation O
and O
CD25 B
/ I
IL I
- I
2R I
alpha I
cell O
surface O
expression O
. O

Reactive O
oxygen O
intermediates O
activate O
NF O
- O
kappa O
B O
in O
a O
tyrosine O
kinase O
- O
dependent O
mechanism O
and O
in O
combination O
with O
vanadate O
activate O
the O
p56lck B
and I
p59fyn I
tyrosine I
kinases I
in O
human O
lymphocytes O
. O

H2O2 O
was O
found O
to O
stimulate O
Ins B
- I
1 I
, I
4 I
, I
5 I
- I
P3 I
production O
in O
a O
tyrosine O
kinase O
- O
dependent O
manner O
and O
to O
induce O
calcium O
signals O
that O
were O
greatly O
augmented O
by O
vanadate O
. O

The O
synergistic O
induction O
of O
tyrosine O
phosphorylation O
by O
H2O2 O
plus O
vanadate O
included O
physiologically O
relevant O
proteins O
such O
as O
PLC B
gamma I
1 I
. O

Although O
treatment O
of O
cells O
with O
H2O2 O
alone O
did O
not O
affect O
the O
activity O
of O
src O
family O
kinases O
, O
treatment O
with O
H2O2 O
plus O
vanadate O
led O
to O
activation O
of O
the O
p56lck B
and I
p59fyn I
tyrosine I
kinases I
. O

Induction O
of O
tyrosine O
phosphorylation O
by O
ROI O
may O
thus O
lead O
to O
many O
of O
the O
pleiotropic O
effects O
of O
ROI O
in O
lymphoid O
cells O
, O
including O
downstream O
activation O
of O
PLC B
gamma I
1 I
and O
NF O
- O
kappa O
B O

Influence O
of O
sex B
hormone I
binding I
globulin I
and O
serum B
albumin I
on O
the O
conversion O
of O
androstenedione O
to O
testosterone O
by O
human O
erythrocytes O
. O

The O
influence O
of O
human B
serum I
albumin I
and O
sex B
hormone I
binding I
globulin I
( O
SHBG O
) O
on O
the O
enzymic O
conversion O
of O
androstenedione O
to O
testosterone O
in O
human O
erythrocytes O
was O
investigated O
in O
vitro O
. O

ATP O
- O
depletion O
experiments O
suggest O
the O
existence O
of O
a O
nonbinding O
form O
of O
the O
receptor O
; O
` O
` O
chase O
' O
' O
experiments O
suggest O
reaction O
of O
hormone O
directly O
with O
nuclear O
- O
bound O
receptor O
; O
experiments O
on O
depletion O
and O
replenishment O
of O
cytoplasmic O
receptor O
using O
cortisol O
and O
dexamethasone O
suggest O
the O
existence O
of O
at O
least O
two O
subpopulations O
of O
nuclear B
- I
bound I
hormone I
- I
receptor I
complex I
. O

Contrary O
to O
the O
widely O
held O
view O
that O
mitogen O
- O
stimulated O
cells O
become O
insensitive O
to O
glucocorticoids O
, O
our O
experiments O
show O
that O
with O
respect O
to O
inhibition O
of O
thymidine O
and O
uridine O
incorporation O
and O
glucose O
uptake O
, O
the O
cells O
are O
highly O
sensitive O
to O
dexamethasone O
at O
24 O
, O
48 O
, O
and O
72 O
h O
after O
stimulation O
with O
concanavalin B
A I
. O

A O
reliable O
procedure O
is O
described O
for O
isolating O
3H B
- I
triamcinolone I
acetonide I
( I
3H I
- I
TA I
) I
receptor I
complexes I
from O
purified O
chronic O
lymphatic O
leukemia O
( O
CLL O
) O
lymphocyte O
nuclei O
, O
based O
on O
the O
use O
of O
carbobenzoxy O
- O
L O
- O
phenylalanine O
( O
CBZ O
- O
L O
- O
phe O
) O
to O
prevent O
breakdown O
of O
hormone B
- I
receptor I
complexes I
during O
extraction O
of O
nuclei O
with O
0 O
. O
6M O
KCl O
. O

Multiple O
closely O
- O
linked O
NFAT B
/ I
octamer I
and O
HMG B
I I
( I
Y I
) I
binding I
sites I
are O
part O
of O
the O
interleukin O
- O
4 O
promoter O
. O

We O
show O
here O
that O
the O
immediate B
upstream I
region I
( O
from O
position O
- O
12 O
to O
- O
270 O
) O
of O
the O
murine B
interleukin I
4 I
( I
Il I
- I
4 I
) I
gene I
harbors O
a O
strong O
cell O
- O
type O
specific O
transcriptional O
enhancer O
. O

In O
T O
lymphoma O
cells O
, O
the O
activity O
of O
the O
Il B
- I
4 I
promoter I
/ I
enhancer I
is O
stimulated O
by O
phorbol O
esters O
, O
Ca O
+ O
+ O
ionophores O
and O
agonists O
of O
protein O
kinase O
A O
and O
inhibited O
by O
low O
doses O
of O
the O
immunosuppressant O
cyclosporin O
A O
. O

The O
Il B
- I
4 I
promoter I
/ I
enhancer I
is O
transcriptionally O
inactive O
in O
B O
lymphoma O
cells O
and O
HeLa O
cells O
. O

DNase O
I O
footprint O
protection O
experiments O
revealed O
six O
sites O
of O
the O
Il B
- I
4 I
promoter I
/ I
enhancer I
to O
be O
bound O
by O
nuclear O
proteins O
from O
lymphoid O
and O
myeloid O
cells O
. O

They O
contain O
the O
motif O
GGAAA O
and O
are O
recognized O
by O
the O
inducible B
and I
cyclosporin I
A I
- I
sensitive I
transcription I
factor I
NFAT I
- I
1 I
. O

Three O
of O
the O
Il B
- I
4 I
NFAT I
- I
1 I
sites I
are O
closely O
linked O
to O
weak O
binding O
sites O
of O
Octamer O
factors O
. O

Several O
purine O
boxes O
and O
an O
AT B
- I
rich I
protein I
- I
binding I
site I
of O
the O
Il O
- O
4 O
promoter O
are O
also O
recognized O
by O
the O
high O
mobility O
group O
protein O
HMG O
I O
( O
Y O
) O
. O

Analysis O
of O
de O
novo O
gene O
activation O
in O
multinucleated O
heterokaryons O
has O
shown O
that O
the O
differentiated O
state O
, O
although O
stable O
, O
is O
not O
irreversible O
, O
and O
can O
be O
reprogrammed O
in O
the O
presence O
of O
appropriate O
combinations O
of O
trans B
- I
acting I
regulatory I
molecules I
. O

We O
have O
tested O
whether O
breakdown O
of O
phosphatidylcholine O
( O
PC O
) O
initiated O
by O
exogenous O
addition O
of O
a O
PC B
- I
specific I
phospholipase I
C I
( O
PC B
- I
PLC I
) O
from O
Bacillus O
cereus O
or O
by O
endogenous O
overexpression O
of O
PC B
- I
PLC I
induces O
functional O
activation O
of O
NF O
- O
kappa O
B O
and O
increases O
human O
immunodeficiency O
virus O
( O
HIV O
) O
enhancer O
activity O
. O

PC O
- O
PLC O
- O
activated O
hydrolysis O
of O
PC O
was O
found O
to O
induce O
bona O
fide O
p50 B
/ I
p65 I
NF I
- I
kappa I
B I
binding O
activity O
in O
three O
different O
cell O
lines O
of O
human O
or O
murine O
origin O
. O

Induction O
of O
NF O
- O
kappa O
B O
by O
PC B
- I
PLC I
did O
not O
depend O
on O
de O
novo O
synthesis O
of O
proteins O
or O
autocrine O
secretion O
of O
either O
tumor O
necrosis O
factor O
or O
interleukin O
1 O
. O

In O
human O
monocytic O
and O
lymphoblastoid O
T O
- O
cell O
lines O
, O
induction O
of O
NF O
- O
kappa O
B O
by O
PC B
- I
PLC I
resulted O
in O
clear O
induction O
of O
luciferase O
expression O
vectors O
placed O
under O
the O
control O
of O
synthetic B
kappa I
B I
enhancers I
or O
wild O
type O
, O
but O
not O
kappa O
B O
- O
mutated O
, O
HIV B
long I
terminal I
repeat I
constructs I
. O

HIV O
replication O
was O
increased O
by O
PC B
- I
PLC I
in O
chronically O
infected O
monocytes O
and O
T O
lymphocytes O
. O

NF O
- O
kappa O
B O
activation O
promoted O
by O
addition O
of O
exogenous B
PC I
- I
PLC I
correlated O
with O
an O
intense O
production O
of O
diacylglycerol O
. O

However O
, O
addition O
of O
a O
phosphatidylinositol B
- I
specific I
PLC I
from O
B O
. O
cereus O
also O
induced O
diacylglycerol O
but O
did O
not O
activate O
kappa B
B I
enhancer I
- I
directed I
vectors I
. O

PC O
- O
PLC O
- O
induced O
NF O
- O
kappa O
B O
activation O
could O
not O
be O
blocked O
by O
a O
specific O
inhibitor O
of O
phorbol B
ester I
- I
inducible I
protein I
kinases I
C I
. O

Interaction O
of O
IL O
- O
2 O
with O
its O
high B
affinity I
membrane I
receptor I
complex I
( O
IL O
- O
2R O
) O
present O
on O
activated O
T O
lymphocytes O
induces O
cell O
proliferation O
and O
mediates O
effector O
functions O
. O

Cell O
surface O
expression O
of O
IL B
- I
2R I
alpha I
- I
and I
beta I
- I
chains I
as O
determined O
by O
immunofluorescence O
analysis O
was O
not O
affected O
by O
Dex O
. O

In O
addition O
, O
Scatchard O
plot O
analysis O
of O
125I B
- I
labeled I
IL I
- I
2 I
showed O
that O
Dex O
did O
not O
affect O
the O
binding O
of O
IL O
- O
2 O
, O
thus O
suggesting O
that O
inhibition O
is O
due O
to O
a O
postreceptor O
effect O
. O

Inhibition O
of O
T O
cell O
proliferation O
by O
Dex O
was O
associated O
with O
decreased O
IL O
- O
2 O
- O
dependent O
tyrosine O
phosphorylation O
of O
several O
intracellular O
proteins O
and O
decreased O
phosphorylation O
of O
the O
retinoblastoma B
gene I
product I
Rb I
, O
a O
protein O
essential O
for O
controlling O
the O
progression O
of O
cells O
through O
the O
cell O
cycle O
. O

This O
unique O
DNA O
binding O
activity O
consisted O
of O
proteins O
of O
70 B
, I
90 I
, I
and I
100 I
kDa I
with O
a O
high O
degree O
of O
binding O
specificity O
for O
the O
NF O
- O
kappa O
B O
site O
within O
the O
PRDII O
domain O
of O
beta O
interferon O
. O

The O
70 B
- I
kDa I
protein I
corresponds O
to O
the O
NF B
- I
kappa I
B I
RelA I
( I
p65 I
) I
subunit I
, O
which O
is O
activated O
in O
response O
to O
an O
acute O
paramyxovirus O
infection O
or O
a O
chronic O
HIV O
- O
1 O
infection O
. O

The O
virally O
induced O
90 B
- I
to I
100 I
- I
kDa I
proteins I
have O
a O
distinct O
binding O
specificity O
for O
the O
PRDII O
domain O
and O
an O
AT B
- I
rich I
sequence I
but O
do O
not O
cross O
- O
react O
with O
NF O
- O
kappa O
B O
subunit O
- O
specific O
antisera O
directed O
against O
NFKB1 O
( O
p105 O
or O
p50 O
) O
, O
NFKB2 O
( O
p100 O
or O
p52 O
) O
, O
RelA O
( O
p65 O
) O
, O
or O
c O
- O
rel O
. O

DNA O
binding O
of O
the O
90 B
- I
to I
100 I
- I
kDa I
proteins I
was O
not O
inhibited O
by O
recombinant B
I I
kappa I
B I
alpha I
/ I
MAD I
- I
3 I
and O
was O
resistant O
to O
tryptic O
digestion O
, O
suggesting O
that O
these O
proteins O
may O
not O
be O
NF B
- I
kappa I
B I
related I
. O

Transient O
cotransfection O
experiments O
demonstrated O
that O
RelA O
and O
NFKB1 O
expression O
maximally O
stimulated O
HIV B
- I
1 I
LTR I
- I
and I
NF I
- I
kappa I
B I
- I
dependent I
reporter I
genes I
; O
differences O
in O
NF O
- O
kappa O
B O
- O
like O
binding O
activity O
were O
also O
reflected O
in O
higher O
constitutive O
levels O
of O
NF O
- O
kappa O
B O
- O
regulated O
gene O
expression O
in O
HIV O
- O
1 O
- O
infected O
myeloid O
cells O
. O

To O
determine O
what O
type O
of O
synovial O
cell O
was O
positive O
for O
EBS O
, O
cryosections O
of O
synovial O
tissues O
were O
immunostained O
with O
a O
specific O
monoclonal B
anti I
- I
estrogen I
receptor I
antibody I
( O
anti B
- I
ER I
MAb I
) O
using O
both O
immunofluorescence O
and O
immunoperoxidase O
techniques O
. O

Double O
immunostaining O
with O
the O
anti B
- I
ER I
MAb I
and O
with O
specific B
MAb I
to O
detect O
different O
macrophage B
antigens I
( O
Ber B
- I
MAC3 I
, O
MAC387 B
, O
CD68 O
) O
and O
CD8 O
+ O
T O
cell O
subsets O
( O
CD29 O
+ O
, O
CD45RO O
+ O
and O
CD29 O
- O
, O
CD45RO O
- O
) O
was O
performed O
. O

